<SEC-DOCUMENT>0001267602-17-000037.txt : 20170511
<SEC-HEADER>0001267602-17-000037.hdr.sgml : 20170511
<ACCEPTANCE-DATETIME>20170511091120
ACCESSION NUMBER:		0001267602-17-000037
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20170331
FILED AS OF DATE:		20170511
DATE AS OF CHANGE:		20170511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALIMERA SCIENCES INC
		CENTRAL INDEX KEY:			0001267602
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34703
		FILM NUMBER:		17832689

	BUSINESS ADDRESS:	
		STREET 1:		6120 WINDWARD PARKWAY
		STREET 2:		STE 290
		CITY:			ALPHARETTA
		STATE:			GA
		ZIP:			30005
		BUSINESS PHONE:		6789905740

	MAIL ADDRESS:	
		STREET 1:		6120 WINDWARD PARKWAY
		STREET 2:		STE 290
		CITY:			ALPHARETTA
		STATE:			GA
		ZIP:			30005
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>alim-3311710q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7EA4F07D1D596455A5FD48DE13EEF465"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:32%;"></td><td style="width:35%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">FORM 10-Q</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Mark One)</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">or</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commission File Number: 001-34703</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:236px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:236px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">Alimera Sciences, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20-0028718</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6120 Windward Parkway, Suite 290</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Alpharetta, GA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">30005</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(678) 990-5740</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:236px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:236px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule&#160;12b-2 of the Exchange Act. (Check one):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:21%;"></td><td style="width:4%;"></td><td style="width:47%;"></td><td style="width:24%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a)(2)(B) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of May 10, 2017 there were </font><font style="font-family:inherit;font-size:10pt;">64,901,636</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the registrant&#8217;s Common Stock issued and outstanding.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s9897417507EA6A73B08948DE1A827938"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">QUARTERLY REPORT ON FORM 10-Q</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:96%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:228px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sE03A3FDB910531CC0C7C48DE1ACEBD12"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I. FINANCIAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6514F224D089B2BF348C48DE1B003F86"><font style="font-family:inherit;font-size:10pt;">Item 1. Interim Condensed Consolidated Financial Statements (unaudited)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s6514F224D089B2BF348C48DE1B003F86">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBACB5B1DC2253EDD4C1C48DE136C4170"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets as of March 31, 2017 and December 31, 2016</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sBACB5B1DC2253EDD4C1C48DE136C4170">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2A8CB087A2056F805E2548DE13BC7405"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations for the three months ended March 31, 2017 and 2016</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s2A8CB087A2056F805E2548DE13BC7405">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCF3580289D92FCAD2A3A48DE132C86F5"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2017 and 2016</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sCF3580289D92FCAD2A3A48DE132C86F5">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8E3030BEA488F7BF58EB48DE13C9CAC6"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows for the three months ended March 31, 2017 and 2016</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s8E3030BEA488F7BF58EB48DE13C9CAC6">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA1810FE9DBCC40B37CC748DE1BFA39F4"><font style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sA1810FE9DBCC40B37CC748DE1BFA39F4">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s98D02BA82206DE2A674A48DE1EEAF21A"><font style="font-family:inherit;font-size:10pt;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s98D02BA82206DE2A674A48DE1EEAF21A">24</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEC449BE9B9CEBFCFBDA648DE2037FB12"><font style="font-family:inherit;font-size:10pt;">Item 3. Quantitative and Qualitative Disclosures about Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sEC449BE9B9CEBFCFBDA648DE2037FB12">36</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF1F761071C6BCA04F6F848DE205FABBB"><font style="font-family:inherit;font-size:10pt;">Item 4. Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sF1F761071C6BCA04F6F848DE205FABBB">37</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:240px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s2348C9D9918B61D92C6C48DE15CA9511"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II. OTHER INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCDEF2D5904AC0E4E6A4048DE20AB0447"><font style="font-family:inherit;font-size:10pt;">Item 1. Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sCDEF2D5904AC0E4E6A4048DE20AB0447">38</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA89B2DEB5E8C1876EE1248DE20DED4C2"><font style="font-family:inherit;font-size:10pt;">Item 1A. Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sA89B2DEB5E8C1876EE1248DE20DED4C2">38</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s303A509E3132BC1CB2DA48DE20FED975"><font style="font-family:inherit;font-size:10pt;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s303A509E3132BC1CB2DA48DE20FED975">39</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF75B0517A3995B18280648DE2131967E"><font style="font-family:inherit;font-size:10pt;">Item 3. Defaults Upon Senior Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sF75B0517A3995B18280648DE2131967E">39</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEBC4D8DD8ABA185B665948DE2159CFAA"><font style="font-family:inherit;font-size:10pt;">Item 4. Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sEBC4D8DD8ABA185B665948DE2159CFAA">39</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC27745637C23FE716A4048DE15CBB90E"><font style="font-family:inherit;font-size:10pt;">Item 5. Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sC27745637C23FE716A4048DE15CBB90E">39</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sACC376DE355D0B272BA348DE15CC8053"><font style="font-family:inherit;font-size:10pt;">Item 6. Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sACC376DE355D0B272BA348DE15CC8053">40</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See the Exhibit Index immediately following the signature page of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.</font></div><div style="text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s6F6D92263166F7CEDF4348DE1AB4D159"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND PROJECTIONS</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various statements in this report are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this report regarding Alimera Sciences, Inc.&#8217;s (we, our, Alimera or the Company) strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. These statements are subject to risks and uncertainties and are based on information currently available to our management. Words such as, but not limited to, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;contemplates,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;likely,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; or the negative of these terms and similar expressions or words, identify forward-looking statements. The events and circumstances reflected in our forward-looking statements may not occur and actual results could differ materially from those projected in our forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">uncertainty as to our ability to achieve profitability and positive cash flow through the commercialization of ILUVIEN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;in the European Economic Area (EEA), the United States (U.S.) and other regions of the world where we sell ILUVIEN;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to operate our business in compliance with the covenants and restrictions that we are subject to under our credit facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">dependence on third-party manufacturers to manufacture ILUVIEN or any future products or product candidates in sufficient quantities and quality.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to raise sufficient additional funding and our need to raise such funds;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">uncertainty as to the pricing and reimbursement guidelines for ILUVIEN or any future products or product candidates, including ILUVIEN;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to successfully commercialize ILUVIEN following regulatory approval in additional markets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delay in or failure to obtain regulatory approval of ILUVIEN in additional countries or any future products or product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our expectation that we will be cash flow positive in late 2017, if at all; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent of government regulations.</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All written and verbal forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We caution investors not to rely too heavily on the forward-looking statements we make or that are made on our behalf. We undertake no obligation and specifically decline any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in any annual, quarterly or current reports that we may file with the Securities and Exchange Commission.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We encourage you to read the discussion and analysis of our financial condition and our unaudited interim financial statements contained in this report. We also encourage you to read Item 1A of Part II of this Quarterly Report on Form 10-Q entitled &#8220;Risk Factors&#8221; and Item 1A of Part I of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, which contains a more complete discussion of the risks and uncertainties associated with our business. In addition to the risks described above, other unknown or unpredictable factors also could affect our results. There can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="sE03A3FDB910531CC0C7C48DE1ACEBD12"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I. FINANCIAL INFORMATION</font></div><div><a name="s6514F224D089B2BF348C48DE1B003F86"></a></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interim Condensed Consolidated Financial Statements (unaudited)</font></div><div><a name="sBACB5B1DC2253EDD4C1C48DE136C4170"></a></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160;thousands,&#160;except&#160;share&#160;and&#160;per share data)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CURRENT ASSETS:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,737</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,979</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,768</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,839</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory, net (Note 5)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">802</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">446</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,450</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,402</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NON-CURRENT ASSETS:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,572</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,787</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible asset, net (Note 6)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,125</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,604</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax asset</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">443</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">436</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TOTAL ASSETS</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,590</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CURRENT LIABILITIES:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,963</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,986</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses (Note 7)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,758</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital lease obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,777</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,123</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NON-CURRENT LIABILITIES:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Note payable (Note 9)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,409</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,084</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital lease obligations &#8212; less current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other non-current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,154</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,162</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">COMMITMENTS AND CONTINGENCIES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">STOCKHOLDERS&#8217; EQUITY:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock, $.01 par value &#8212; 10,000,000 shares authorized at March 31, 2017 and December 31, 2016:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A Convertible Preferred Stock, 1,300,000 authorized and 600,000 issued and outstanding at March 31, 2017 and December 31, 2016; liquidation preference of $24,000 at March 31, 2017 and December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B Convertible Preferred Stock, 8,417 authorized and 8,416.251 issued and outstanding at March 31, 2017 and December 31, 2016; liquidation preference of $50,750 at March 31, 2016 and December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $.01 par value &#8212; 150,000,000 shares authorized, 64,862,904 shares issued and outstanding at March 31, 2017 and December&#160;31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">649</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">649</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331,947</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330,781</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,707</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,707</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(383,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(377,074</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,223</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TOTAL STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,066</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,586</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,590</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Notes to Consolidated Financial Statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s2A8CB087A2056F805E2548DE13BC7405"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FOR THE THREE MONTHS ENDED </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">MARCH&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;AND </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands, except share and per share data)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET REVENUE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(587</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(378</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GROSS PROFIT</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,110</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GENERAL AND ADMINISTRATIVE EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,264</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,395</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SALES AND MARKETING EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DEPRECIATION AND AMORTIZATION</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">666</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">689</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPERATING EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET LOSS FROM OPERATIONS</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,511</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,790</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INTEREST EXPENSE, NET AND OTHER</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,337</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,335</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UNREALIZED FOREIGN CURRENCY (LOSS) GAIN, NET</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CHANGE IN FAIR VALUE OF DERIVATIVE WARRANT LIABILITY</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,519</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LOSS ON EARLY EXTINGUISHMENT OF DEBT</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,564</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET LOSS BEFORE TAXES</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,709</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,136</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PROVISION FOR TAXES</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET LOSS</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,735</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,145</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET LOSS PER SHARE &#8212; Basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WEIGHTED AVERAGE SHARES OUTSTANDING &#8212; Basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,862,904</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,005,833</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Notes to Consolidated Financial Statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="sCF3580289D92FCAD2A3A48DE132C86F5"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FOR THE THREE MONTHS ENDED </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">MARCH&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;AND </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET LOSS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OTHER COMPREHENSIVE INCOME</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TOTAL OTHER COMPREHENSIVE INCOME</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">COMPREHENSIVE LOSS</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,686</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,026</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Notes to Consolidated Financial Statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><a name="s8E3030BEA488F7BF58EB48DE13C9CAC6"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FOR THE THREE MONTHS ENDED </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">MARCH&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;AND </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">2016</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended <br>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">CASH FLOWS FROM OPERATING ACTIVITIES:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(6,735</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(11,145</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">689</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Inventory reserve</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Unrealized foreign currency transaction loss (gain)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Loss on early extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">2,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Amortization of debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">343</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">337</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Stock-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">1,166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">1,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Change in fair value of derivative warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(167</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(1,519</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Changes in assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">3,090</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">761</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(361</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">164</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(1,053</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(1,522</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(1,147</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">1,704</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(4,169</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(6,735</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">CASH FLOWS FROM INVESTING ACTIVITIES:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(57</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(75</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">CASH FLOWS FROM FINANCING ACTIVITIES:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Payment of issuance cost of common stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Payment of debt costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(350</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Payment of capital lease obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Net cash used in financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(38</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(466</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">NET DECREASE IN CASH AND CASH EQUIVALENTS</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(4,242</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">(7,135</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">CASH AND CASH EQUIVALENTS &#8212; Beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">30,979</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">31,075</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">CASH AND CASH EQUIVALENTS &#8212; End of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">26,737</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">23,940</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">SUPPLEMENTAL DISCLOSURES:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">985</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">996</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Cash paid for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Supplemental schedule of non-cash investing and financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Property and equipment acquired under capital leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">Note payable end of term payment accrued but unpaid</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">1,400</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9.7pt;"><font style="font-family:inherit;font-size:9.7pt;">1,400</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;dividend payments made during the three months ended March 31, 2017 and 2016.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Notes to Consolidated Financial Statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><a name="sA1810FE9DBCC40B37CC748DE1BFA39F4"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sF5FECA0BE3429E28262848DE135D59B0"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NATURE OF OPERATIONS</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alimera Sciences, Inc., together with its wholly-owned subsidiaries (the Company), is a pharmaceutical company that specializes in the commercialization, research and development of prescription ophthalmic pharmaceuticals. The Company was formed on June&#160;4, 2003 under the laws of the State of Delaware.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is presently focused on diseases affecting the back of the eye, or retina, because the Company&#8217;s management believes these diseases are not well treated with current therapies and represent a significant market opportunity. The Company&#8217;s only commercial product is ILUVIEN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, which has received marketing authorization in the United States (U.S.), Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the&#160;United Kingdom. In the U.S., ILUVIEN is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries in which ILUVIEN has received marketing authorization, it is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies. As part of the approval process in the EEA, the Company committed to conduct a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year, post-authorization, open label registry study in </font><font style="font-family:inherit;font-size:10pt;">800</font><font style="font-family:inherit;font-size:10pt;">&#32;patients treated with ILUVIEN per the labeled indication. In the fourth quarter of 2016, the Company requested approval to modify its protocol to cap enrollment in the study due to its post market safety surveillance not showing any unexpected safety signals. Although the Company has not received formal regulatory approval, the Medicines &amp; Healthcare products Regulatory Agency (MHRA) has agreed to allow the Company to suspend enrollment, pending approval of the Company&#8217;s protocol amendment.&#160;As of March 31, 2017, </font><font style="font-family:inherit;font-size:10pt;">560</font><font style="font-family:inherit;font-size:10pt;">&#32;patients were enrolled in this study.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company launched ILUVIEN in Germany and the United Kingdom in the second quarter of 2013, in the U.S. and Portugal in the first quarter of 2015 and in Austria in the first quarter of 2017.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the Company has entered into various agreements under which distributors will provide regulatory, reimbursement or sales and marketing support for future commercialization of ILUVIEN in numerous countries in the Middle East, Italy, Spain, Australia, New Zealand and Canada.</font></div><div><a name="s3B2D1744D525C17B2E9048DE13129F40"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2. BASIS OF PRESENTATION</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has prepared the accompanying unaudited interim condensed consolidated financial statements and notes thereto (Interim Financial Statements) in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for interim financial information and the instructions to Form 10-Q and Article&#160;10-01 of Regulation&#160;S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of the Company&#8217;s management, the accompanying interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary to present fairly the Company&#8217;s interim financial information.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying interim financial statements and related notes should be read in conjunction with the Company&#8217;s audited financial statements for the year ended December&#160;31, 2016 and related notes included in the Company&#8217;s Annual Report on Form 10-K, which was filed with the SEC on March&#160;3, 2017. The financial results for any interim period are not necessarily indicative of the expected financial results for the full year.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Modification of Segment Footnote</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company modified its segment footnote for the three months ended March 31, 2016 for an immaterial change&#160;and removed, within the segment footnote, certain non-cash expenses including </font><font style="font-family:inherit;font-size:10pt;">$1,296,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of stock-based compensation expense and </font><font style="font-family:inherit;font-size:10pt;">$689,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of depreciation and amortization from the Company&#8217;s U.S. and International segments.&#160;These amounts are appropriately classified as Other within the segment footnote of these interim unaudited condensed consolidated financial statements.&#160;Additionally, in the Company&#8217;s Annual Report on Form 10-K filing for the year ended December 31, 2016, the Company disclosed that the Company&#8217;s chief operating decision maker separately managed and evaluated each segment primarily upon net loss from operations.&#160;The modification made in these financial statements clarifies that the chief operating decision maker manages and evaluates each segment based on net loss from operations adjusted for certain non-cash items, such as stock-based compensation expense and depreciation and amortization.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><a name="sFC6A11D8B49546BAFDA248DE13765DB3"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accounting policies followed for quarterly financial reporting are the same as those disclosed in the Notes to Financial Statements included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2016. </font></div><div style="line-height:174%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:174%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses were </font><font style="font-family:inherit;font-size:10pt;">$350,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$561,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended March 31, 2017 and 2016, respectively.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Adoption of New Accounting Standards</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued Accounting Standards Update (ASU) 2014-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</font><font style="font-family:inherit;font-size:10pt;">. ASU 2014-15 requires management to perform interim and annual assessments of an entity&#8217;s ability to continue as a going concern within one year of the date the financial statements are issued and provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. ASU 2014-15 applies to all entities and is effective for annual and interim reporting periods ending after December 15, 2016, with early adoption permitted. The adoption of this guidance did not have a material impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory (Topic 330): Simplifying the Measurement of Inventory</font><font style="font-family:inherit;font-size:10pt;">. This update requires entities to measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. This ASU is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those years. The adoption of this guidance did not have a material impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718)</font><font style="font-family:inherit;font-size:10pt;">. This standard makes several modifications to Topic 718 related to the accounting for forfeitures, employer tax withholding on share-based compensation and the financial statement presentation of excess tax benefits or deficiencies. ASU 2016-09 also clarifies the statement of cash flows presentation for certain components of share-based awards. The standard is effective for interim and annual reporting periods beginning after December 15, 2016, although early adoption is permitted. The adoption of this guidance did not have a material impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Standards Issued but Not Yet Effective</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">, as subsequently amended. ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. The revenue guidance contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The standard is effective for the first interim period within annual reporting periods beginning after December 15, 2017 for public entities, with early adoption permitted in the annual reporting period beginning after December 15, 2016. The Company has begun its evaluation of the new guidance on its business and, at this time, do not believe there will be a material impact on the Company&#8217;s current direct product sales in international markets. For the U.S. business, the Company continues to evaluate the variable consideration provisions of the new guidance and the impact it will have specifically on the Company&#8217;s gross to net revenue adjustments, including chargebacks and rebates. The Company anticipates adopting the new revenue standard using the modified retrospective transition method.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">. This standard requires all leases with durations greater than twelve months to be recognized on the balance sheet and is effective for interim and annual reporting periods </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">beginning after December 15, 2018, although early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption on its financial statements.</font></div><div><a name="sCF47190D36D5F7F47F1848DE136383FF"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4. GOING CONCERN</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, the Company has incurred recurring losses, negative cash flow from operations and has accumulated a deficit of </font><font style="font-family:inherit;font-size:10pt;">$383,809,000</font><font style="font-family:inherit;font-size:10pt;">&#32;from inception through </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had approximately </font><font style="font-family:inherit;font-size:10pt;">$26,737,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash and cash equivalents. The Company&#8217;s ability to achieve profitability and positive cash flow is dependent upon its ability to increase revenue and contain its expenses. Further, the Company must maintain compliance with the debt covenants of its debt agreement (see Note 9). In 2016, in order to continue to fund its operations and meet its debt covenants, the Company raised additional equity and amended its debt agreement. In management&#8217;s opinion, the uncertainty regarding future revenues raises substantial doubt about the Company&#8217;s ability to continue as a going concern without access to additional debt or equity financing, over the course of the next twelve months.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to meet the Company&#8217;s working capital needs through the next twelve months and maintain compliance with its debt covenants, the Company may need to raise additional debt or equity financing. The Company may be able to access capital under the Company&#8217;s current at-the-market offering facility, which has approximately </font><font style="font-family:inherit;font-size:10pt;">$21,504,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of remaining availability. The Company implemented a cost savings program in late 2016 that the Company believes will help decrease cash burn over the next twelve months. While the Company has historically been able to raise additional capital through issuance of equity and/or debt financing, and while the Company has a plan in place to reduce spending in order to satisfy its obligations due within one year from the date of issuance of these financial statements, there can be no guarantees on the Company&#8217;s ability to maintain debt compliance, raise additional equity, or successfully implement its cost reduction plans. Accordingly, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after these financial statements are issued.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><a name="s99632BFABFF0A4F92A6348DE1349C465"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5. INVENTORY</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory consisted of the following: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Component parts (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process (2)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">389</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total inventory</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">850</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">486</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory reserve </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory &#8212; net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">802</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">446</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Component parts inventory consists of manufactured components of the ILUVIEN applicator.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) Work-in-process primarily consists of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing or stability testing as required by regulatory authorities in Europe and the U.S.</font></div><div><a name="sCE98CE5E605830BEE32D48DE13350B22"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6. INTANGIBLE ASSET</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the U.S. Food and Drug Administration&#8217;s (FDA) approval of the New Drug Application (NDA) for ILUVIEN in September 2014, the Company was required to pay pSivida US, Inc. (pSivida) a milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$25,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;(the pSivida Milestone Payment) in October 2014 (see Note 8 License Agreements). The Company had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;intangible assets prior to September 2014. </font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The gross carrying amount of the intangible asset was </font><font style="font-family:inherit;font-size:10pt;">$25,000,000</font><font style="font-family:inherit;font-size:10pt;">, which is being amortized over approximately </font><font style="font-family:inherit;font-size:10pt;">13 years</font><font style="font-family:inherit;font-size:10pt;">&#32;from the payment date. The amortization expense related to the intangible asset was </font><font style="font-family:inherit;font-size:10pt;">$478,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$483,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended March 31, 2017 and 2016, respectively. The net book value of the intangible asset was </font><font style="font-family:inherit;font-size:10pt;">$20,125,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$20,604,000</font><font style="font-family:inherit;font-size:10pt;">&#32;as of March 31, 2017 and December 31, 2016, respectively.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated future amortization expense as of March 31, 2017 for the remaining periods in the next five years and thereafter is as follows: </font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:84%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Years Ending December&#160;31</font></div></td><td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,940</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,940</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,946</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,940</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,897</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,125</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><a name="s52CF21530ABC6C45BAE748DE13071E9E"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7. ACCRUED EXPENSES</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consisted of the following: </font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued clinical investigator expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">402</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,020</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued rebate, chargeback and other revenue reserves</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">767</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">807</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accrued expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,636</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,758</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sAF0D62AEEB6A355A06EA48DE1316937E"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8. LICENSE AGREEMENTS</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into an agreement with pSivida for the use of fluocinolone acetonide (FAc) in pSivida&#8217;s proprietary delivery device in February 2005, which was subsequently amended in 2008 (the pSivida Agreement). The pSivida Agreement provides the Company with a worldwide exclusive license to utilize certain underlying technology used in the development and commercialization of ILUVIEN.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s license rights to pSivida&#8217;s proprietary delivery device could revert to pSivida if the Company were to (i)&#160;fail twice to cure its breach of an obligation to make certain payments to pSivida following receipt of written notice thereof; (ii)&#160;fail to cure other breaches of material terms of the pSivida Agreement within </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">30</font><font style="font-family:inherit;font-size:10pt;">&#32;days after notice of such breaches or such longer period (up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">90 days</font><font style="font-family:inherit;font-size:10pt;">) as may be reasonably necessary if the breach cannot be cured within such </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">30</font><font style="font-family:inherit;font-size:10pt;">-day period; (iii)&#160;file for protection under the bankruptcy laws, make an assignment for the benefit of creditors, appoint or suffer appointment of a receiver or trustee over its property, file a petition under any bankruptcy or insolvency act or have any such petition filed against it and such proceeding remains undismissed or unstayed for a period of more than </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60 days</font><font style="font-family:inherit;font-size:10pt;">; or (iv)&#160;notify pSivida in writing of its decision to abandon its license with respect to a certain product using pSivida&#8217;s proprietary delivery device.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company must share </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the net profits of ILUVIEN, determined on a cash basis and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">33%</font><font style="font-family:inherit;font-size:10pt;">&#32;of any lump sum milestone payments received from a sub-licensee of ILUVIEN, as defined by the pSivida Agreement. In connection with this arrangement, the Company is entitled to recover </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20%</font><font style="font-family:inherit;font-size:10pt;">&#32;of commercialization costs of ILUVIEN, as defined in the pSivida Agreement, incurred prior to product profitability out of pSivida&#8217;s share of net profits. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company can reduce future net profit payments to pSivida, as defined in the pSivida Agreement, in the amounts of </font><font style="font-family:inherit;font-size:10pt;">$24,909,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$24,475,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. Due to the uncertainty of future net profits, the Company has fully reserved these amounts in the accompanying Interim Financial Statements. As a result of the FDA&#8217;s approval of the NDA for ILUVIEN in September 2014, the Company made the pSivida Milestone Payment of </font><font style="font-family:inherit;font-size:10pt;">$25,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in October 2014.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the second quarter of 2016, pSivida disputed portions of the Company&#8217;s claimed commercialization costs for the year ended December 31, 2014. On May 3, 2017, the Company and pSivida settled this dispute and amended and clarified certain definitions and clauses of the pSivida Agreement. As part of this settlement, the Company and pSivida agreed no additional amounts would be due for the years ended December 31, 2014, 2015 and 2016 and no audits will take place related to the amounts reported for the years ended December 31, 2015 and 2016. As a result of this settlement and amendment, the amount available for the reduction of future net profit payments was reduced from </font><font style="font-family:inherit;font-size:10pt;">$25,828,000</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$24,475,000</font><font style="font-family:inherit;font-size:10pt;">&#32;as of December 31, 2016. Since these amounts are fully reserved, there was no impact to the statements of operations for any period as a result of this settlement and amendment.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><a name="s9FD74F81FB171FE036C048DE135A37E1"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9. LOAN AGREEMENTS</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hercules Loan Agreement</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2014 Loan Agreement</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, Alimera Sciences Limited (Limited), a subsidiary of the Company, entered into a loan and security agreement (2014 Loan Agreement) with Hercules Capital, Inc. (Hercules) providing for a term loan of up to </font><font style="font-family:inherit;font-size:10pt;">$35,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;(2014 Term Loan), which Limited and Hercules amended in November 2015 (the First Loan Amendment), March 2016 (the Second Loan Amendment), May 2016 (the Third Loan Amendment) and October 2016 (the Fourth Loan Amendment and, collectively with the 2014 Loan Agreement, the First Loan Amendment, the Second Loan Amendment and the Third Loan Amendment, the Term Loan Agreement). Under the 2014 Loan Agreement, Hercules made an advance in the initial principal amount of&#160;</font><font style="font-family:inherit;font-size:10pt;">$10,000,000</font><font style="font-family:inherit;font-size:10pt;">&#160;to Limited at closing to provide Limited with additional working capital for general corporate purposes and to repay a 2013 term loan with Silicon Valley Bank. Hercules made an additional advance of </font><font style="font-family:inherit;font-size:10pt;">$25,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;to Limited in September 2014, following the approval of ILUVIEN by the FDA to fund the pSivida Milestone Payment. The 2014 Loan Agreement provided for interest only payments through November 2015. Interest on the 2014 Term Loan accrued at a floating per annum rate equal to the greater of (i) </font><font style="font-family:inherit;font-size:10pt;">10.90%</font><font style="font-family:inherit;font-size:10pt;">, or (ii) the sum of (A) </font><font style="font-family:inherit;font-size:10pt;">7.65%</font><font style="font-family:inherit;font-size:10pt;">, plus (B) the prime rate. Following the interest only period the 2014 Term Loan was due and payable to Hercules in equal monthly payments of principal and interest through May 1, 2018. The interest rate on the Term Loan Agreement was </font><font style="font-family:inherit;font-size:10pt;">11.25%</font><font style="font-family:inherit;font-size:10pt;">&#32;as of December 31, 2016.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">First Loan Amendment</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, Limited and Hercules amended the 2014 Loan Agreement to extend the interest only payments through May 2017. In connection with the First Loan Amendment, Limited paid to Hercules an amendment fee of </font><font style="font-family:inherit;font-size:10pt;">$262,500</font><font style="font-family:inherit;font-size:10pt;">&#32;and agreed to make an additional payment of </font><font style="font-family:inherit;font-size:10pt;">$1,050,000</font><font style="font-family:inherit;font-size:10pt;">, equal to </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the 2014 Term Loan at the time of the final payment (End of Term Payment).</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Limited and the Company, on a consolidated basis with the Company&#8217;s other subsidiaries (the Consolidated Group), agreed to customary affirmative and negative covenants and events of default in connection with these arrangements. The occurrence of an event of default could result in the acceleration of Limited&#8217;s obligations under the Term Loan Agreement and an increase to the applicable interest rate and would permit Hercules to exercise remedies with respect to the collateral under the Term Loan Agreement. In connection with the First Loan Amendment, Limited agreed to covenants regarding certain revenue thresholds and a liquidity threshold.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Second Loan Amendment</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the revenue threshold covenant was not met by the Consolidated Group and as a result, in March 2016, Limited and Hercules entered into the Second Loan Amendment, which further amended certain terms of the 2014 Loan Agreement. In conjunction with the Second Loan Amendment, Hercules waived this covenant violation.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Second Loan Amendment adjusted the revenue covenant to a rolling three-month calculation, first measured for the three months ended May 31, 2016. In addition, the Second Loan Amendment increased the liquidity covenant. Upon execution of the Second Loan Amendment, Limited paid Hercules an amendment fee of </font><font style="font-family:inherit;font-size:10pt;">$350,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and agreed to increase the End of Term Payment to </font><font style="font-family:inherit;font-size:10pt;">$1,400,000</font><font style="font-family:inherit;font-size:10pt;">&#32;from </font><font style="font-family:inherit;font-size:10pt;">$1,050,000</font><font style="font-family:inherit;font-size:10pt;">, which is payable in May 2018.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company concluded that the Second Loan Amendment resulted in a substantial modification of the terms of debt when considered with the First Loan Amendment in accordance with the guidance in ASC 470-50, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt</font><font style="font-family:inherit;font-size:10pt;">. As a result, the Company accounted for the Second Loan Amendment as an extinguishment and recognized a loss on early extinguishment of debt of approximately </font><font style="font-family:inherit;font-size:10pt;">$2,564,000</font><font style="font-family:inherit;font-size:10pt;">&#32;within the consolidated statement of operations for the year ended December 31, 2016. The loss on early extinguishment consisted primarily of the unamortized debt discount associated with the warrant and debt issuance costs incurred prior to the Second Loan Amendment, the incremental fair value of the warrant as a result of modifying the terms of the warrant and the debt issuance costs of </font><font style="font-family:inherit;font-size:10pt;">$360,000</font><font style="font-family:inherit;font-size:10pt;">&#32;paid to Hercules for the Second Loan Amendment.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Third Loan Amendment and July 2016 Waiver</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016, Limited and Hercules entered into the Third Loan Amendment to expand the definition of liquidity to allow for the inclusion of cash of up to </font><font style="font-family:inherit;font-size:10pt;">$2,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in bank accounts outside of the U.S. and the United Kingdom.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2016, Limited obtained a waiver of the requirements of the liquidity covenant (the Waiver) because the Consolidated Group was not in compliance with the liquidity covenant as of June 30, 2016. The Waiver cured the default of the liquidity covenant then existing under the Term Loan Agreement and decreased the liquidity requirement. In addition, the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Waiver modified the three-month revenue covenant so that it was not measured at July 31, 2016 and reduced the three-month revenue target to be measured at August 31, 2016. Following execution of the Waiver, Limited incurred a weekly ticking fee equal to </font><font style="font-family:inherit;font-size:10pt;">0.05%</font><font style="font-family:inherit;font-size:10pt;">&#32;multiplied by the outstanding principal amount through the closing of the Company&#8217;s public offering in August 2016 (see Note 12 Common Stock), totaling </font><font style="font-family:inherit;font-size:10pt;">$65,000</font><font style="font-family:inherit;font-size:10pt;">. Further, Limited paid Hercules a fee of </font><font style="font-family:inherit;font-size:10pt;">$350,000</font><font style="font-family:inherit;font-size:10pt;">&#32;associated with the Waiver.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Fourth Loan Amendment</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, Limited entered into the Fourth Loan Amendment with Hercules, which further amended certain terms of the Term Loan Agreement. Pursuant to the terms of the Fourth Loan Amendment, Hercules agreed to provide up to an additional </font><font style="font-family:inherit;font-size:10pt;">$10,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;to Limited with (i) the first </font><font style="font-family:inherit;font-size:10pt;">$5,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;available at Limited&#8217;s option through June 30, 2017 subject to (A) the Consolidated Group&#8217;s achievement of </font><font style="font-family:inherit;font-size:10pt;">$12,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in trailing three month net product revenue and (B) no event of default having occurred since October 20, 2016 (the Effective Date) and (ii) the second </font><font style="font-family:inherit;font-size:10pt;">$5,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;available at Limited&#8217;s option through December 31, 2017 subject to (A) the Consolidated Group&#8217;s achievement of </font><font style="font-family:inherit;font-size:10pt;">$15,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in trailing three month net product revenue, (B) no event of default having occurred since the Effective Date and (C) the prior </font><font style="font-family:inherit;font-size:10pt;">$5,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;having been advanced to Limited (the Additional Advances and, together with the 2014 Term Loan, the Term Loan). The Fourth Loan Amendment provides for interest only payments through November 30, 2018 (the Interest-Only Period). Pursuant to the Fourth Loan Amendment, interest on the Term Loan accrues at a floating per annum rate equal the greater of (i) </font><font style="font-family:inherit;font-size:10pt;">11.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;and (ii) the sum of (A) </font><font style="font-family:inherit;font-size:10pt;">11.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;plus (B) the prime rate as reported in The Wall Street Journal, or if not reported, the prime rate most recently reported in The Wall Street Journal, minus </font><font style="font-family:inherit;font-size:10pt;">3.5%</font><font style="font-family:inherit;font-size:10pt;">. In addition to the interest described above, the principal balance of the Term Loan will bear &#8220;payment-in kind&#8221; interest at the rate of </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;(PIK Interest), which PIK Interest will be added to the outstanding principal balance of the Term Loan so as to increase the outstanding principal balance of the Term Loan on each payment date for the Term Loan and which amount will be payable when the aggregate outstanding principal amount of the Term Loan is payable. The Term Loan will be due and payable to Hercules in </font><font style="font-family:inherit;font-size:10pt;">24</font><font style="font-family:inherit;font-size:10pt;">&#32;equal monthly payments of principal and interest following the Interest-Only Period beginning on December 1, 2018 and matures in full on November 1, 2020.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Limited paid Hercules a facility charge of </font><font style="font-family:inherit;font-size:10pt;">$337,500</font><font style="font-family:inherit;font-size:10pt;">&#32;and reimbursed Hercules for legal and diligence fees incurred in connection with the Fourth Loan Amendment. If Limited prepays the Term Loan, it will pay Hercules a prepayment penalty (i) if such amounts are prepaid in any of the first 12 months following the Effective Date, equal to </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the principal amount of the Term Loan being repaid, (ii) if such amounts are prepaid after 12 months but prior to 24 months following the Effective Date, equal to </font><font style="font-family:inherit;font-size:10pt;">2.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the principal amount of the Term Loan being repaid, and (iii) if such amounts are prepaid at any time thereafter, equal to </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the principal amount of the Term Loan being repaid.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Consolidated Group also agreed to customary affirmative and negative covenants, including, without limitation, covenants relating to minimum liquidity, minimum trailing six-month net revenue and adjusted EBITDA and events of default in connection with these arrangements. The occurrence of an event of default could result in the acceleration of Limited&#8217;s obligations under the Term Loan Agreement, as amended by the Fourth Loan Amendment and an increase to the applicable interest rate and would permit Hercules to exercise remedies with respect to the collateral under the Term Loan Agreement, as amended by the Fourth Loan Amendment. In the event that the Company maintains </font><font style="font-family:inherit;font-size:10pt;">$35,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in liquidity, including cash and eligible accounts receivable, at the end of the month and has not been and is not in breach of the amended debt facility, the six-month trailing revenue covenant is waived for such month. As of March 31, 2017, the Company was in compliance with its debt covenants.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">General Discussion of the Term Loan Agreement</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Term Loan Agreement, Limited&#8217;s obligations to Hercules are secured by a first-priority security interest in substantially all of Limited&#8217;s assets, excluding intellectual property. Hercules does, however, maintain a negative pledge on Limited&#8217;s intellectual property requiring Hercules&#8217; consent prior to the sale of such intellectual property. The Company and certain of the Company&#8217;s other subsidiaries are guarantors of the obligations of Limited to Hercules under the Term Loan Agreement pursuant to separate guaranty agreements between Hercules and each of Limited and such subsidiaries (Guaranties). Pursuant to the Guaranties, the Company and these subsidiaries granted Hercules a first-priority security interest in substantially all of their respective assets excluding intellectual property. The Term Loan Agreement also places limitations on the Company&#8217;s ability to declare or pay any dividend or distribution on any shares of capital stock.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2014 Warrant</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with Limited entering into the 2014 Loan Agreement, the Company issued a warrant to Hercules to purchase up to </font><font style="font-family:inherit;font-size:10pt;">285,016</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company&#8217;s common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$6.14</font><font style="font-family:inherit;font-size:10pt;">&#32;per share (the 2014 Warrant). </font><font style="font-family:inherit;font-size:10pt;">Sixty percent</font><font style="font-family:inherit;font-size:10pt;">&#32;of the 2014 Warrant was exercisable at the closing in April 2014 and the remaining </font><font style="font-family:inherit;font-size:10pt;">forty percent</font><font style="font-family:inherit;font-size:10pt;">&#32;became exercisable upon the funding of the additional </font><font style="font-family:inherit;font-size:10pt;">$25,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;to Limited in September 2014.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company agreed to amend the 2014 Warrant in connection with the First Loan Amendment to increase the number of shares issuable upon exercise to </font><font style="font-family:inherit;font-size:10pt;">660,377</font><font style="font-family:inherit;font-size:10pt;">&#32;and decrease the exercise price to </font><font style="font-family:inherit;font-size:10pt;">$2.65</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. Upon entering into the Second Loan Amendment, the Company agreed to further amend the 2014 Warrant to increase the number of shares issuable upon exercise to </font><font style="font-family:inherit;font-size:10pt;">862,069</font><font style="font-family:inherit;font-size:10pt;">&#32;and decrease the exercise price to </font><font style="font-family:inherit;font-size:10pt;">$2.03</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. In connection with the July 2016 Waiver, the Company agreed to further amend the 2014 Warrant to increase the number of shares issuable upon exercise to </font><font style="font-family:inherit;font-size:10pt;">1,258,993</font><font style="font-family:inherit;font-size:10pt;">&#32;and decrease the exercise price to </font><font style="font-family:inherit;font-size:10pt;">$1.39</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. </font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016 Warrant</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with Limited entering into the Fourth Loan Amendment, the Company agreed to issue a new warrant to Hercules (the 2016 Warrant) to purchase up to </font><font style="font-family:inherit;font-size:10pt;">458,716</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company&#8217;s common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.09</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, which was equal to </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;divided by the lowest volume-weighted average sale price for a share of the Company&#8217;s common stock reported over any ten consecutive trading days during the period commencing on and including September 23, 2016 and ending on the earlier to occur of (i) December 30, 2016 (inclusive of such date), and (ii) the second trading day immediately preceding the date of closing of a merger event (as defined in the 2016 Warrant).</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Debt</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average interest rates of the Company&#8217;s notes payable approximate the rate at which the Company could obtain alternative financing and the fair value of the warrants that were issued in connection with the Company&#8217;s notes payable are immaterial. Therefore, the carrying amount of the notes approximated their fair value at March 31, 2017 and December 31, 2016.</font></div><div><a name="s6E22834F8F81958851DF48DE1358D54D"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10. LOSS PER SHARE (EPS)</font></div><div style="line-height:120%;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic EPS is calculated in accordance with ASC 260, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings per Share</font><font style="font-family:inherit;font-size:10pt;">, by dividing net income or loss attributable to common stockholders by the weighted average common stock outstanding. Diluted EPS is calculated in accordance with ASC 260 by adjusting weighted average common shares outstanding for the dilutive effect of common stock options, warrants and convertible preferred stock. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be anti-dilutive. Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because to do so would have been anti-dilutive, were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,022,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,022,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,416,251</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,416,251</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,511,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,511,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,795,663</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">940,023</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,696,269</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,626,077</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,442,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,516,186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><a name="sCF529674537DA0E6386E48DE139E7289"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11. PREFERRED STOCK</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Series A Convertible Preferred Stock</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October&#160;2, 2012, the Company closed its preferred stock financing in which it sold units consisting of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series A Convertible Preferred Stock and warrants to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">300,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series A Convertible Preferred Stock for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$40,000,000</font><font style="font-family:inherit;font-size:10pt;">, prior to the payment of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$560,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of related issuance costs. The powers, preferences and rights of the Series A Convertible Preferred Stock are set forth in the certificate of designation filed by the Company with the Secretary of State of the State of Delaware on October&#160;1, 2012. Each share of Series A Convertible Preferred Stock, including any shares of Series A Convertible Preferred Stock issued upon exercise of the warrants, is convertible into shares of the Company&#8217;s common stock at any time at the option of the holder at the rate equal to </font><font style="font-family:inherit;font-size:10pt;">$40.00</font><font style="font-family:inherit;font-size:10pt;">&#32;divided by </font><font style="font-family:inherit;font-size:10pt;">$2.66</font><font style="font-family:inherit;font-size:10pt;">&#32;(Conversion Price). The initial Conversion Price was subject to adjustment based on certain customary price based anti-dilution adjustments. These adjustment features lapsed in September 2014. Each share of Series A Convertible Preferred Stock shall automatically be converted into shares of common stock at the then-effective Conversion Price upon the occurrence of the later to occur of both (i)&#160;the Company receives and publicly announces the approval by the FDA of the Company&#8217;s NDA for ILUVIEN and (ii)&#160;the date on which the Company consummates an equity financing transaction pursuant to which the Company sells to one or more third party investors either (a)&#160;shares of common stock or (b)&#160;other equity securities that are convertible into shares of common stock and that have rights, preference or privileges, senior to or on a parity with, the Series A Convertible Preferred Stock, in each case having an as-converted per share of common stock price of not less than </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$10.00</font><font style="font-family:inherit;font-size:10pt;">&#32;and that results in total gross proceeds to the Company of at least </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$30,000,000</font><font style="font-family:inherit;font-size:10pt;">. The rights and preferences of Series A Convertible Preferred Stock also place limitations on the Company&#8217;s ability to declare or pay any dividend or distribution on any shares of capital stock.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each unit sold in the preferred stock financing included a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.30</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series A Convertible Preferred Stock at an exercise price equal to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$44.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. At the election of the holder of a warrant, the warrant may be exercised for the number of shares of common stock then issuable upon conversion of the Series A Convertible Preferred Stock that would otherwise be issued upon such exercise at the then-effective Conversion Price. </font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants are considered derivative instruments because the agreements provide for settlement in Series A Convertible Preferred Stock shares or common stock shares at the option of the holder, an adjustment to the warrant exercise price for common shares at some point in the future and contain anti-dilution provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants are subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. Therefore the warrants were recorded as a liability at issuance. The warrant anti-dilution provisions lapsed in September 2014. At </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the fair market value of the warrants was estimated to be </font><font style="font-family:inherit;font-size:10pt;">$21,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$188,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. During the three months ended March 31, 2017 and 2016, the Company recorded gains of </font><font style="font-family:inherit;font-size:10pt;">$167,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1,519,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, as a result of the change in fair value of the warrants. The rights to exercise these warrants expire on October 1, 2017.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, </font><font style="font-family:inherit;font-size:10pt;">2,255,639</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock were issued pursuant to the conversion of </font><font style="font-family:inherit;font-size:10pt;">150,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series A Convertible Preferred Stock held by an investor. In September 2014, </font><font style="font-family:inherit;font-size:10pt;">3,759,398</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock were issued pursuant to the conversion of </font><font style="font-family:inherit;font-size:10pt;">250,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series A Convertible Preferred Stock held by another investor. As of March 31, 2017, there were </font><font style="font-family:inherit;font-size:10pt;">600,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series A Convertible Preferred Stock issued and outstanding.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Series B Convertible Preferred Stock</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December&#160;12, 2014, the Company closed a preferred stock financing in which it sold </font><font style="font-family:inherit;font-size:10pt;">8,291.873</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series B Convertible Preferred Stock for a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$6,030</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, or an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$50,000,000</font><font style="font-family:inherit;font-size:10pt;">, prior to the payment of approximately </font><font style="font-family:inherit;font-size:10pt;">$432,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of related issuance costs. The Company issued an additional </font><font style="font-family:inherit;font-size:10pt;">124.378</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series B Convertible Preferred Stock as a subscription premium to the purchasers. The powers, preferences and rights of the Series B Convertible Preferred Stock are set forth in the certificate of designation filed by the Company with the Secretary of State of the State of Delaware. Each share of Series B Convertible Preferred Stock is convertible into </font><font style="font-family:inherit;font-size:10pt;">1,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company&#8217;s common stock at any time at the option of the holder, provided that the holder will be prohibited from converting Series B Convertible Preferred Stock into shares of the Company&#8217;s common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than </font><font style="font-family:inherit;font-size:10pt;">9.98%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the total number of shares of the Company&#8217;s common stock then issued and outstanding. The Series B Convertible Preferred Stock ranks junior to the Company&#8217;s existing Series A Convertible Preferred Stock and senior to the Company&#8217;s common stock, with respect to rights upon liquidation. The Series B Convertible Preferred Stock ranks junior to all existing and future indebtedness. Except as otherwise required by law (or with respect to approval of certain actions), the Series B Convertible Preferred Stock do not have voting rights. The Series B Convertible Preferred Stock is not redeemable at the option of the holder. The Series B Convertible Preferred Stock is not subject to any price-based or other anti-dilution protections and does not provide for any accruing dividends.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the conversion option of the Series B Convertible Preferred Stock represented a beneficial conversion feature, as the conversion feature had intrinsic value to the holder on the commitment date as a result of the subscription premium. Therefore, the Company recorded a beneficial conversion feature of </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;">&#32;as an increase in additional paid in capital. Because the Series B Convertible Preferred Stock was immediately convertible into common stock at the option of the holder at issuance, the Company immediately accreted the full value of the beneficial conversion feature to the carrying value of the Series B Convertible Preferred Stock on that date.</font></div><div><a name="s9BD4A5DBBEA1806C19FD48DE13B3A57D"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12. COMMON STOCK</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2014, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen) to offer shares of its common stock from time to time through Cowen for the offer and sale of the shares up to an aggregate offering price of </font><font style="font-family:inherit;font-size:10pt;">$35,000,000</font><font style="font-family:inherit;font-size:10pt;">. In 2016, the Company sold a total of </font><font style="font-family:inherit;font-size:10pt;">662,779</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of its common stock at a weighted average purchase price of </font><font style="font-family:inherit;font-size:10pt;">$1.83</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, resulting in gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$1,211,000</font><font style="font-family:inherit;font-size:10pt;">, prior to the payment of approximately </font><font style="font-family:inherit;font-size:10pt;">$62,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of underwriter discounts and commissions and related issuance costs. Proceeds from the offering were used for general corporate and working capital purposes. The Company did not sell shares during the three months ended March 31, 2017. As of March 31, 2017, the Company can sell up to approximately </font><font style="font-family:inherit;font-size:10pt;">$21,504,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of its common stock under the terms of the sales agreement with Cowen.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, in August, 2016, pursuant to an underwriting agreement with Cowen, as representative of the several underwriters named therein, the Company closed a public offering in which it sold </font><font style="font-family:inherit;font-size:10pt;">18,900,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of its common stock at a price to the public of&#160;</font><font style="font-family:inherit;font-size:10pt;">$1.40</font><font style="font-family:inherit;font-size:10pt;">&#160;per share. The offering resulted in gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$26,460,000</font><font style="font-family:inherit;font-size:10pt;">, prior to the payment of approximately </font><font style="font-family:inherit;font-size:10pt;">$1,309,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of underwriter discounts and commissions and related issuance costs.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><a name="s14E7D64A2F4AE96F06F348DE133B7C52"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13. STOCK INCENTIVE PLANS</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Option Plans</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended March 31, 2017 and 2016, the Company recorded compensation expense related to stock options of approximately </font><font style="font-family:inherit;font-size:10pt;">$972,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1,264,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of March 31, 2017, the total unrecognized compensation cost related to non-vested stock options granted was </font><font style="font-family:inherit;font-size:10pt;">$7,877,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and is expected to be recognized over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">2.40 years</font><font style="font-family:inherit;font-size:10pt;">. The following table presents a summary of stock option activity for the three months ended March 31, 2017 and 2016:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding at beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,804,412</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,475,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,312,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,228,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.46</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeitures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(420,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77,813</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding at period end</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,696,269</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,626,077</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable at period end</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,527,392</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,310,239</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.27</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average per share fair value of options granted during the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.86</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides additional information related to outstanding stock options, exercisable stock options and stock options expected to vest as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:41%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,696,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.71 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">289</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,527,392</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.52 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, vested and expected to vest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,131,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.58 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides additional information related to outstanding stock options, exercisable stock options and stock options expected to vest as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:41%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,804,412</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.45 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,363,400</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.42 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, vested and expected to vest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,374,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.35 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended March 31, 2017 and 2016, the Company recorded compensation expense related to its employee stock purchase plan of approximately </font><font style="font-family:inherit;font-size:10pt;">$13,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$32,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Units</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the Company granted </font><font style="font-family:inherit;font-size:10pt;">873,900</font><font style="font-family:inherit;font-size:10pt;">&#32;restricted stock units (RSUs) to its employees in lieu of a cash bonus program for 2017. As of March 31, 2017, </font><font style="font-family:inherit;font-size:10pt;">815,700</font><font style="font-family:inherit;font-size:10pt;">&#32;RSUs were outstanding. During the three months ended March 31, 2017, the Company recorded compensation expense related these RSUs of </font><font style="font-family:inherit;font-size:10pt;">$182,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><a name="s90368AE975A963BDC52D48DE135B6A72"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14. INCOME TAXES</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC 740, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes,</font><font style="font-family:inherit;font-size:10pt;">&#32;the Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities at the enacted tax rates in effect for the year in which the differences are expected to reverse. The Company records a valuation allowance against its net deferred tax asset to reduce the net carrying value to an amount that is more likely than not to be realized.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the end of each interim period, the Company makes its best estimate of the effective tax rate expected to be applicable for the full fiscal year. This estimate reflects, among other items, the Company&#8217;s best estimate of operating results and foreign currency exchange rates. The Company&#8217;s quarterly income tax rate may differ from its estimated annual effective tax rate because accounting standards require the Company to exclude the actual results of certain entities expected to generate a pretax loss when applying the estimated annual effective tax rate to the Company&#8217;s consolidated pretax results in interim periods. In estimating the annual effective tax rate, the Company does not include the estimated impact of unusual and/or infrequent items, including the reversal of valuation allowances, which may cause significant variations in the customary relationship between income tax expense (benefit) and pretax income (loss) in quarterly periods. The income tax expense (benefit) for such unusual and/or infrequent items is recorded in the quarterly period such items are incurred.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s income tax expense and resulting effective tax rate are based upon the respective estimated annual effective tax rates applicable for the respective periods adjusted for the effects of items required to be treated as discrete to the period, including changes in tax laws, changes in estimated exposures for uncertain tax positions and other items. The Company&#8217;s effective tax rate for the three months ended March 31, 2017 properly excluded tax benefits associated with year-to-date pre-tax losses generated in the U.S. and the Netherlands. Income tax positions are considered for uncertainty in accordance with ASC 740-10. The Company has recorded unrecognized tax benefits related to research and development tax credits. In accordance with ASC 740-10, such attributes are reduced to the amount that is expected to be recognized in the future. The Company has not accrued interest or penalties as no research and development credits have been utilized due to significant net operating losses (NOLs) available. The Company does not expect any decreases to the unrecognized tax benefits within the next twelve months due to any lapses in statute of limitations. Tax years since 2003 remain subject to examination in Georgia, Tennessee and at the federal level. The time period is longer than the standard statutory 3-year period due to NOLs from 2003 being available for utilization. The statute of limitations on these years will close when the NOLs expire or when the statute closes on the years in which the NOLs are utilized. Tax years since 2012 remain subject to examination in the United Kingdom and the Netherlands. Tax years since 2013 remain subject to examination in Germany.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant management judgment is involved in determining the provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. Due to uncertainties with respect to the realization of deferred tax assets due to the history of operating losses, a valuation allowance has been established against the net deferred tax asset balance in the U.S. and the Netherlands. The valuation allowance is based on management&#8217;s estimates of taxable income in the jurisdictions in which the Company operates and the period over which deferred tax assets will be recoverable. In the event that actual results differ from these estimates or the Company adjusts these estimates in future periods, a change in the valuation allowance may be needed, which could materially impact its financial position and results of operations.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, 2016, the Company had federal NOL carry-forwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$104,944,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and state NOL carry-forwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$83,270,000</font><font style="font-family:inherit;font-size:10pt;">&#32;available to reduce future taxable income. The Company&#8217;s federal NOL carry-forwards remain fully reserved as of March 31, 2017. If not utilized, the federal NOL carry-forwards will expire at various dates between 2029 and 2035 and the state NOL carry-forwards will expire at various dates between 2020 and 2035. </font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NOL carry-forwards may be subject to annual limitations under Internal Revenue Code (IRC) Section&#160;382 (Section 382) (or comparable provisions of state law) in the event that certain changes in ownership of the Company were to occur. The Company periodically evaluates its NOL carry-forwards and whether certain changes in ownership have occurred that would limit the Company&#8217;s ability to utilize a portion of its NOL carry-forwards. If it is determined that significant ownership changes have occurred since the Company generated its NOL carry-forwards, it may be subject to annual limitations on the use of these NOL carry-forwards under Section&#160;382 (or comparable provisions of state law). The Company has determined that a Section 382 change in ownership occurred in late 2015.&#160;Therefore, the annual utilization of the Company&#8217;s NOLs are subject to certain limitations under Section 382 and other limitations under state tax laws.&#160;The Company is currently in the process of calculating these limitations. Any reduction to the Company&#8217;s NOL deferred tax asset due to the annual Section 382 limitation and the NOL carryforward period would result in an offsetting reduction in valuation allowance recorded against the NOL deferred tax asset. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Therefore, any limitation would not have an impact on the statements of operations for the periods presented. The results of the analysis on the impact to the Company&#8217;s NOLs will be disclosed at a later date.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2016, the Company had cumulative book losses in foreign subsidiaries of </font><font style="font-family:inherit;font-size:10pt;">$92,939,000</font><font style="font-family:inherit;font-size:10pt;">. The Company has not recorded a deferred tax asset for the excess of tax over book basis in the stock of its foreign subsidiaries. The Company anticipates that its foreign subsidiaries will be profitable and have earnings in the future. Once the foreign subsidiaries do have earnings, the Company intends to indefinitely reinvest in its foreign subsidiaries all undistributed earnings of and original investments in such subsidiaries. As a result, the Company has not recorded a deferred tax liability related to excess of book over tax basis in the stock of its foreign subsidiaries in accordance with ASC 740-30-25.</font></div><div><a name="sD4F9F4EE93129D446DE948DE1361CBF8"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15. FAIR VALUE</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company applies ASC 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:inherit;font-size:10pt;">, in determining the fair value of certain assets and liabilities. Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining fair value, the Company uses various valuation approaches. The hierarchy of those valuation approaches is broken down into three levels based on the reliability of inputs as follows:</font></div><div style="line-height:120%;padding-top:10px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. The valuation under this approach does not entail a significant degree of judgment.</font></div><div style="line-height:120%;padding-top:10px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets, inputs other than quoted prices that are observable for the asset or liability, (e.g., interest rates and yield curves observable at commonly quoted intervals or current market) and contractual prices for the underlying financial instrument, as well as other relevant economic measures.</font></div><div style="line-height:120%;padding-top:10px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no changes in the methodologies used at March 31, 2017 and December 31, 2016.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following fair value table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents (1)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative warrant liability (2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents (1)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative warrant liability (2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-2px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-2px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><a name="s996F6F2FE037C128CAC548DE13512AE4"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16. SEGMENT INFORMATION</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended March 31, 2017 and 2016, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;customers within the U.S. segment accounted for </font><font style="font-family:inherit;font-size:10pt;">67%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">71%</font><font style="font-family:inherit;font-size:10pt;">, respectively, of the Company&#8217;s consolidated revenues as a result of our sales to large pharmaceutical distributors in the U.S. These </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;customers within the U.S. segment accounted for approximately </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">90%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Company&#8217;s consolidated accounts receivable at March 31, 2017 and December 31, 2016, respectively. The Company&#8217;s chief operating decision maker is the Chief Executive Officer (CEO). While the CEO is apprised of a variety of financial metrics and information, the business is principally managed and organized based upon geographic and regulatory environment. Each segment is separately managed and is evaluated primarily upon segment loss from operations. Non-cash items including stock-based compensation expense and depreciation and amortization are categorized as Other within the table below.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents a summary of the Company&#8217;s reporting segments for the three months ended March 31, 2017 and 2016:</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"></td></tr><tr><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br>March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br>March 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">International</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Consolidated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">International</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Consolidated</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="31" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NET REVENUE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,445</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(448</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(139</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(587</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(156</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(378</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">GROSS PROFIT</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,110</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">GENERAL AND ADMINISTRATIVE EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,705</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">918</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">641</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,264</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,921</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">714</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">760</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,395</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">SALES AND MARKETING EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,045</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">DEPRECIATION AND AMORTIZATION</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">666</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">666</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">689</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">689</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">OPERATING EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,908</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,802</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,832</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,542</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8,939</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,289</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,985</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,213</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">SEGMENT LOSS FROM OPERATIONS</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,911</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(768</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,832</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5,511</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5,042</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,763</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,985</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8,790</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">OTHER INCOME AND EXPENSES, NET</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NET LOSS BEFORE TAXES</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(11,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr></table></div></div><div><a name="s7a8ca0ba28ca424db1627bfcb5ee2673"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">17. SUBSEQUENT EVENT</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As disclosed in Note 8 License Agreements, the Company and pSivida settled their dispute and amended and clarified certain definitions and clauses of the pSivida Agreement on May 3, 2017. The specific terms of the settlement and amendment are described in detail within Note 8 License Agreements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><a name="s98D02BA82206DE2A674A48DE1EEAF21A"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div><a name="sF54BD9FBC0D560E85CF248DE1F0BC8E8"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alimera Sciences, Inc., and its subsidiaries (we, Alimera or the Company) is a pharmaceutical company that specializes in the commercialization, research and development of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because we believe these diseases are not well treated with current therapies and represent a significant market opportunity.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our only commercial product is ILUVIEN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, which has been developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN has received marketing authorization in the United States (U.S.), Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the&#160;United Kingdom. In the U.S., ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries in which ILUVIEN has received marketing authorization, it is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies. As part of the approval process in Europe, we committed to conduct a five-year, post-authorization, open label registry study in 800 patients treated with ILUVIEN. In the fourth quarter of 2016, we requested approval to modify our protocol to cap enrollment in the study due to our post market safety surveillance not showing any unexpected safety signals.&#160;Although we have not received formal regulatory approval, the Medicines &amp; Healthcare products Regulatory Agency (MHRA) has agreed to allow us to suspend enrollment, pending approval of our protocol amendment.&#160;As of March 31, 2017, 560 patients were enrolled in this study.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We launched ILUVIEN in Germany and the United Kingdom in the second quarter of 2013, in the U.S. and Portugal in the first quarter of 2015 and in Austria in the first quarter of 2017.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we have entered into various agreements under which distributors will provide regulatory, reimbursement or sales and marketing support for future commercialization of ILUVIEN in numerous countries in the Middle East, Italy, Spain, Australia, New Zealand and Canada. In the third quarter of 2016, our Middle East distributor launched ILUVIEN and initiated named patient sales in the United Arab Emirates.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We commenced operations in June 2003. Since our inception we have incurred significant losses. As of March 31, 2017, we have accumulated a deficit of $383.8 million. We expect to continue to incur losses as we:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue the commercialization of ILUVIEN in the U.S. and the EEA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue to seek regulatory approval of ILUVIEN in other jurisdictions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">evaluate the use of ILUVIEN for the treatment of other diseases; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">advance the clinical development of any future products or product candidates either currently in our pipeline, or that we may license or acquire in the future.</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of March 31, 2017, we had approximately $26.7 million in cash and cash equivalents. </font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the limited revenue generated by ILUVIEN to date, our negative cash flow from operations and accumulated deficit raise substantial doubt about our ability to continue as a going concern. Our Interim Financial Statements do not include any adjustments that might result from the outcome of this uncertainty. We believe that we have sufficient funds to allow us to become cash flow positive. However, it is possible that we may determine that we may need to raise additional funds in the future in order to support our business in these countries, to expand ILUVIEN into new geographies, to allow us to expand the indication of ILUVIEN, to maintain compliance with our debt covenants or other business development activities. We cannot be sure that additional financing will be available when needed or that, if available, the additional financing will be obtained on terms favorable to us or our stockholders.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><a name="sA8570B158C2D36C2701E48DE1F3E7302"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Agreement with pSivida</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into an agreement with pSivida US, Inc. (pSivida) for the use of fluocinolone acetonide (FAc) in pSivida&#8217;s proprietary delivery device in February 2005, which was subsequently amended and restated in 2008 (the pSivida Agreement). The pSivida Agreement provides us with a worldwide exclusive license to utilize certain underlying technology used in the development and commercialization of ILUVIEN. ILUVIEN consists of a tiny polyimide tube with a permeable membrane cap on one end and an impermeable silicone cap on the other end that is filled with FAc in a polyvinyl alcohol matrix for delivery to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis). The pSivida Agreement also provides us with a worldwide non-exclusive license to utilize pSivida&#8217;s proprietary delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to treat DME by delivering a compound to the back of the eye through a direct delivery method through an incision required for a 25-gauge or larger needle. We do not have the right to utilize pSivida&#8217;s proprietary delivery device in connection with indications for diseases outside of the eye or for the treatment of uveitis. Further, the pSivida Agreement permits pSivida to grant to any other party the right to use its intellectual property (i)&#160;to treat DME through an incision smaller than that required for a 25-gauge needle, unless using a corticosteroid delivered to the back of the eye, (ii)&#160;to deliver any compound outside the back of the eye unless it is to treat DME through an incision required for a 25-gauge or larger needle, or (iii)&#160;to deliver non-corticosteroids to the back of the eye, unless it is to treat DME through an incision required for a 25-gauge or larger needle.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the U.S. Food and Drug Administration (FDA) approval of ILUVIEN in September 2014, we paid pSivida a milestone payment of $25.0 million (the pSivida Milestone Payment) in October 2014.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pSivida Agreement provides that after commercialization of ILUVIEN, pSivida will be entitled to 20% of our net profits determined on a cash basis, in each country where we sell ILUVIEN directly or through our distributors or sub-distributors and </font><font style="font-family:inherit;font-size:10pt;">33%</font><font style="font-family:inherit;font-size:10pt;">&#32;of any lump sum milestone payments received from a sub-licensee of ILUVIEN, as defined in the pSivida Agreement. In connection with this arrangement we are entitled to recover 20% of commercialization costs of ILUVIEN, as defined in the agreement, incurred prior to product profitability out of pSivida&#8217;s share of net profits. As of March 31, 2017 and December 31, 2016, we can reduce future net profit payments to pSivida, as defined in the pSivida Agreement, in the amounts of $24.9 million and $24.5 million, respectively. Due to the uncertainty of future profits from ILUVIEN, we have fully reserved these amounts in the accompanying consolidated financial statements.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the second quarter of 2016, pSivida disputed portions of our claimed commercialization costs for the year ended December 31, 2014.&#160;On May 3, 2017, we and pSivida settled this dispute and amended and clarified certain definitions and clauses of the pSivida Agreement. As part of this settlement, we and pSivida agreed no additional amounts would be due for the years ended December 31, 2014, 2015 and 2016 and no audits will take place related to the amounts reported for the years ended December 31, 2015 and 2016. As a result of this settlement and amendment, the amount available for the reduction of future net profit payments was reduced from $25.8 million to $24.5 million as of December 31, 2016. Since these amounts are fully reserved, there was no impact to our statements of operations for any period as a result of this settlement and amendment.</font></div><div><a name="sAC87029984AD9EDBB06748DE1F65058D"></a></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Credit Facility</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Hercules Loan Agreement</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2014 Loan Agreement</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, Alimera Sciences Limited (Limited), our subsidiary, entered into a loan and security agreement (2014 Loan Agreement) with Hercules Capital, Inc. (Hercules) providing for a term loan of up to $35.0 million (2014 Term Loan), which Limited and Hercules amended in November 2015 (the First Loan Amendment), March 2016 (the Second Loan Amendment), May 2016 (the Third Loan Amendment) and October 2016 (the Fourth Loan Amendment and, collectively with the 2014 Loan Agreement, the First Loan Amendment, the Second Loan Amendment and the Third Loan Amendment, the Term Loan Agreement). Under the 2014 Loan Agreement, Hercules made an advance in the initial principal amount of&#160;$10.0 million&#160;to Limited at closing to provide Limited with additional working capital for general corporate purposes and to repay a 2013 term loan with Silicon Valley Bank. Hercules made an additional advance of $25.0 million to Limited in September 2014, following the approval of ILUVIEN by the FDA to fund the pSivida Milestone Payment. The 2014 Loan Agreement provided for interest only payments through November 2015. Interest on the 2014 Term Loan accrued at a floating per annum rate equal to the greater of (i) 10.90%, or (ii) the sum of (A) 7.65%, plus (B) the prime rate. Following the interest only period, the 2014 Term Loan was due and payable to Hercules in equal monthly payments of principal and interest through May 1, 2018. The interest rate on the Term Loan Agreement was 11.25% as of December 31, 2016.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">First Loan Amendment</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, Limited and Hercules amended the 2014 Loan Agreement to extend the interest only payments through May 2017. In connection with the First Loan Amendment, Limited paid to Hercules an amendment fee of $262,500 and agreed to make an additional payment of $1,050,000, equal to 3% of the 2014 Term Loan at the time of the final payment on May 1, 2018 (End of Term Payment).</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and Limited, on a consolidated basis with our other subsidiaries (the Consolidated Group), agreed to customary affirmative and negative covenants and events of default in connection with these arrangements. The occurrence of an event of default could result in the acceleration of Limited&#8217;s obligations under the Term Loan Agreement and an increase to the applicable interest rate and would permit Hercules to exercise remedies with respect to the collateral under the Term Loan Agreement. In connection with the First Loan Amendment, Limited agreed to covenants regarding certain revenue thresholds and a liquidity threshold.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Second Loan Amendment</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the revenue threshold covenant was not met by the Consolidated Group and as a result, in March 2016, Limited and Hercules entered into the Second Loan Amendment, which further amended certain terms of the 2014 Loan Agreement. In conjunction with the Second Loan Amendment, Hercules waived this covenant violation.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Second Loan Amendment adjusted the revenue covenant to a rolling three-month calculation, first measured for the three months ended May 31, 2016. In addition, the Second Loan Amendment increased the liquidity covenant. Upon execution of the Second Loan Amendment, Limited paid Hercules an amendment fee of $350,000 and agreed to increase the End of Term Payment to $1,400,000 from $1,050,000, which was payable on the date that the 2014 Term Loan was to be paid in full. </font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We concluded that the Second Loan Amendment resulted in a substantial modification of the terms of debt when considered with the First Loan Amendment in accordance with the guidance in Accounting Standard Codification (ASC) 470-50, Debt. As a result, we accounted for the Second Loan Amendment as an extinguishment and recognized a loss on early extinguishment of debt of approximately $2,564,000 within the consolidated statement of operations for the year ended December 31, 2016. The loss on early extinguishment consisted primarily of the unamortized debt discount associated with the warrant and debt issuance costs incurred prior to the Second Loan Amendment, the incremental fair value of the warrant as a result of modifying the terms of the warrant and the debt issuance costs of $360,000 paid to Hercules for the Second Loan Amendment.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Third Loan Amendment and July 2016 Waiver</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016, Limited and Hercules entered into the Third Loan Amendment to expand the definition of liquidity to allow for the inclusion of cash of up to $2.0 million in bank accounts outside of the U.S. and the United Kingdom.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2016, Limited obtained a waiver of the requirements of the liquidity covenant (the Waiver) because the Consolidated Group was not in compliance with the liquidity covenant as of June 30, 2016. The Waiver cured the default of the liquidity covenant then existing under the Term Loan Agreement and decreased the liquidity requirement. In addition, the Waiver modified the three-month revenue covenant so that it was not measured at July 31, 2016 and reduced the three-month revenue target to be measured at August 31, 2016. Following execution of the Waiver, Limited incurred a weekly ticking fee equal to 0.05% multiplied by the outstanding principal amount through the closing of our public offering in August 2016 (see Note 12 Common Stock), totaling $65,000. Further, Limited paid Hercules a fee of $350,000 associated with the Waiver.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Fourth Loan Amendment</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, Limited entered into the Fourth Loan Amendment with Hercules, which further amended certain terms of the Term Loan Agreement. Pursuant to the terms of the Fourth Loan Amendment, Hercules agreed to provide up to an additional $10.0 million to Limited with (i) the first $5.0 million available at Limited&#8217;s option through June 30, 2017 subject to (A) the Consolidated Group&#8217;s achievement of $12.0 million in trailing three month net product revenue and (B) no event of default having occurred since October 20, 2016 (the Effective Date) and (ii) the second $5.0 million available at Limited&#8217;s option through December 31, 2017 subject to (A) the Consolidated Group&#8217;s achievement of $15.0 million in trailing three month net product revenue, (B) no event of default having occurred since the Effective Date and (C) the prior $5.0 million having been advanced to Limited (the Additional Advances and, together with the 2014 Term Loan, the Term Loan). The Fourth Loan Amendment provides for interest only payments through November 30, 2018 (the Interest-Only Period). Pursuant to the Fourth Loan Amendment, interest on the Term Loan accrues at a floating per annum rate equal to the greater of (i) 11.0% and (ii) the sum of (A) 11.0% plus (B) the prime rate as reported in The Wall Street Journal, or if not reported, the prime rate most recently reported in The Wall Street Journal, minus 3.5%. In addition to the interest described above, the principal balance of the Term Loan will bear &#8220;payment-in kind&#8221; interest at the rate of 1.0% (PIK Interest), which PIK Interest will be added to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the outstanding principal balance of the Term Loan so as to increase the outstanding principal balance of the Term Loan on each payment date for the Term Loan and which amount will be payable when the aggregate outstanding principal amount of the Term Loan is payable. The Term Loan will be due and payable to Hercules in 24 equal monthly payments of principal and interest following the Interest-Only Period beginning on December 1, 2018 and matures in full on November 1, 2020.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Limited paid Hercules a facility charge of $337,500 and reimbursed Hercules for legal and diligence fees incurred in connection with the Fourth Loan Amendment. If Limited prepays the Term Loan, it will pay Hercules a prepayment penalty (i) if such amounts are prepaid in any of the first 12 months following the Effective Date, equal to 3.0% of the principal amount of the Term Loan being repaid, (ii) if such amounts are prepaid after 12 months but prior to 24 months following the Effective Date, equal to 2.0% of the principal amount of the Term Loan being repaid, and (iii) if such amounts are prepaid at any time thereafter, equal to 1.0% of the principal amount of the Term Loan being repaid.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Consolidated Group also agreed to customary affirmative and negative covenants, including, without limitation, covenants relating to minimum liquidity, minimum trailing six-month net revenue and adjusted EBITDA, and events of default in connection with these arrangements. The occurrence of an event of default could result in the acceleration of Limited&#8217;s obligations under the Term Loan Agreement, as amended by the Fourth Loan Amendment and an increase to the applicable interest rate, and would permit Hercules to exercise remedies with respect to the collateral under the Term Loan Agreement, as amended by the Fourth Loan Amendment. In the event that we maintain $35.0 million in liquidity, including cash and eligible accounts receivable, at the end of the month and have not been and are not in breach of the amended debt facility, the six-month trailing revenue covenant is effectively waived for such month. As of March 31, 2017, we were in compliance with our debt covenants.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">General Discussion of the Term Loan Agreement</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Term Loan Agreement, Limited&#8217;s obligations to Hercules are secured by a first-priority security interest in substantially all of Limited&#8217;s assets, excluding intellectual property. Hercules does, however, maintain a negative pledge on Limited&#8217;s intellectual property requiring Hercules&#8217; consent prior to the sale of such intellectual property. We and certain of our other subsidiaries are guarantors of the obligations of Limited to Hercules under the Term Loan Agreement pursuant to separate guaranty agreements between Hercules and each of Limited and such subsidiaries (Guaranties). Pursuant to the Guaranties, we and our subsidiaries granted Hercules a first-priority security interest in substantially all of their respective assets excluding intellectual property. The Term Loan Agreement also places limitations on our ability to declare or pay any dividend or distribution on any shares of capital stock.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2014 Warrant</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with Limited entering into the 2014 Loan Agreement, we issued a warrant to Hercules to purchase up to 285,016 shares of our common stock at an exercise price of $6.14 per share (the 2014 Warrant). Sixty percent of the 2014 Warrant was exercisable at the closing in April 2014 and the remaining&#160;forty percent became exercisable upon the funding of the additional $25.0 million to Limited in September 2014.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We agreed to amend the 2014 Warrant in connection with the First Loan Amendment to increase the number of shares issuable upon exercise to 660,377 and decrease the exercise price to $2.65 per share. Upon entering into the Second Loan Amendment, we agreed to further amend the 2014 Warrant to increase the number of shares issuable upon exercise to 862,069 and decrease the exercise price to $2.03 per share. In connection with the July 2016 Waiver, we agreed to further amend the 2014 Warrant to increase the number of shares issuable upon exercise to 1,258,993 and decrease the exercise price to $1.39 per share. </font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016 Warrant</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with Limited entering into the Fourth Loan Amendment, we agreed to issue a new warrant to Hercules (the 2016 Warrant) to purchase up to 458,716 shares of our common stock at an exercise price of $1.09 per share which was equal to $500,000 divided by the lowest volume-weighted average sale price for a share of our common stock reported over any ten consecutive trading days during the period commencing on and including September 23, 2016 and ending on the earlier to occur of (i) December 30, 2016 (inclusive of such date), and (ii) the second trading day immediately preceding the date of closing of a merger event (as defined in the 2016 Warrant).</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Debt</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average interest rates of our notes payable approximate the rate at which we could obtain alternative financing and the fair value of the warrants that were issued in connection with our notes payable are immaterial. Therefore, the carrying amount of the notes approximated their fair value at March 31, 2017 and December 31, 2016.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><a name="sC0A26ED72108BF9E503848DE190EB3F8"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Operations Overview</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET REVENUE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GROSS PROFIT</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,031</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,423</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPERATING EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET LOSS FROM OPERATIONS</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,511</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,790</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET LOSS</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We began generating revenue from ILUVIEN in the second quarter of 2013, but do not expect positive cash flow from operations until late 2017, if at all. In addition to generating revenue from product sales, we intend to seek to generate revenue from other sources such as upfront fees, milestone payments in connection with collaborative or strategic relationships and royalties resulting from the licensing of ILUVIEN or any future product candidates and other intellectual property. We expect any revenue we generate will fluctuate from quarter to quarter as a result of the nature, timing and amount of any milestone payments we may receive from potential collaborative and strategic relationships, as well as revenue we may receive upon the sale of our products to the extent any are successfully commercialized.</font></div><div style="line-height:120%;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenue increased by approximately $800,000, or 14%, to approximately $6.6 million for the three months ended March 31, 2017. The increase was primarily attributable to increased sales volume in the U.S. and all the markets in Europe offset by changes in exchange rates of the Euro and the British pound sterling.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Expenses</font></div><div style="line-height:120%;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses decreased by approximately $2.7 million, or 19%, to approximately $11.5 million for the three months ended March 31, 2017, primarily as a result of decreases in sales and marketing expenses of approximately $1.6 million and in research, development and medical affairs expenses of approximately $860,000.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research, Development and Medical Affairs Expenses</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Substantially all of our research, development and medical affairs expenses incurred to date related to our continuing operations have been related to the development of ILUVIEN. We anticipate that we will incur additional research, development and medical affairs expenses in the future as we expand the availability of ILUVIEN in additional geographies, evaluate and possibly pursue the regulatory approval of ILUVIEN in additional jurisdictions, the development of ILUVIEN for additional indications, or develop additional products or product candidates. We recognize research, development and medical affairs expenses as they are incurred. Our research, development and medical affairs expenses consist primarily of:</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">salaries and related expenses for personnel, including medical sales liaisons;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs related to the provision of medical affairs support, including symposia development for physician education;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs related to compliance with FDA, EEA or other regulatory requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fees paid to consultants and contract research organizations (CRO) in conjunction with independently monitoring clinical trials and acquiring and evaluating data in conjunction with clinical trials, including all related fees such as investigator grants, patient screening, lab work and data compilation and statistical analysis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs incurred with third parties related to the establishment of a commercially viable manufacturing process for products or product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs related to production of clinical materials, including fees paid to contract manufacturers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs related to post marketing authorization studies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">consulting fees paid to third-parties involved in research, development and medical affairs activities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs related to stock options or other stock-based compensation granted to personnel in research, development and medical affairs functions.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expense both internal and external development costs as they are incurred.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currently, our research, development and medical affairs expenses are primarily focused on activities that support ILUVIEN. Until we reach profitability, if at all, we do not expect to change the focus of these activities. However, once we reach profitability we expect that a large percentage of our research, development and medical affairs expenses in the future will be incurred in support of our current and future technical, preclinical and clinical development programs. These expenditures are subject to numerous uncertainties in terms of both their timing and total cost to completion. Assuming we reach profitability, we expect to continue to develop stable formulations of ILUVIEN or any future products or product candidates, test such formulations in preclinical studies for toxicology, safety and efficacy and to conduct clinical trials for each future product candidate. We anticipate funding these clinical trials ourselves, but we may engage collaboration partners at certain stages of clinical development. As we obtain results from these clinical trials, we may elect to discontinue or delay them for certain products or product candidates or programs in order to focus our resources on more promising products or product candidates or programs. Completion of these clinical trials by us or our future collaborators may take several years or more, the length of time generally varying with the type, complexity, novelty and intended use of a product candidate.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our only commercial product is ILUVIEN, which has received marketing authorization in the U.S., Austria, Belgium, the Czech Republic, Denmark, Finland, Germany, France, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the United Kingdom. In the U.S., ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP. In the EEA countries in which ILUVIEN has received marketing authorization, it is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies. ILUVIEN has not been approved in any jurisdiction other than as set forth above. In order to grant marketing approval, a health authority such as the FDA or foreign regulatory agencies must conclude that clinical and preclinical data establish the safety and efficacy of ILUVIEN or any future products or product candidates with an appropriate benefit to risk profile relevant to a particular indication and that the product can be manufactured under current Good Manufacturing Practice in a reproducible manner to deliver the product&#8217;s intended performance in terms of its stability, quality, purity and potency. Until our submissions are reviewed by health authorities, there is no way to predict the outcome of their review. Even if the clinical studies meet their predetermined primary endpoints and a registration dossier is accepted for filing, a health authority could still determine that an appropriate benefit to risk relationship does not exist for the indication that we are seeking. We cannot forecast with any degree of certainty whether ILUVIEN or any future products or product candidates will be subject to future collaborations or how such arrangements would affect our development plan or capital requirements. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our development projects or when and to what extent we will receive cash inflows from the commercialization and sale of an approved product candidate.</font></div><div style="line-height:120%;padding-top:10px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expenses</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses consist primarily of compensation for employees in executive and administrative functions, including finance, accounting, information technology and human resources. Other significant costs include facilities costs and professional fees for accounting and legal services, including legal services associated with obtaining and maintaining patents. We expect to continue to incur significant costs to comply with the corporate governance, internal control and similar requirements applicable to public companies.</font></div><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sales and Marketing Expenses</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and marketing expenses consist primarily of professional fees and compensation for employees for the commercial promotion of, the development of market awareness for, the pursuit of reimbursement for and the execution of launch plans for ILUVIEN. Other costs include professional fees associated with developing plans for ILUVIEN and maintaining public relations.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We launched ILUVIEN in Germany and the United Kingdom in the second quarter of 2013, in the U.S. and Portugal in the first quarter of 2015 and in Austria in the first quarter of 2017.</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a European marketing and sales team, including local management and sales teams in France, Germany, Portugal and the United Kingdom, totaling 22 persons as of March 31, 2017. We also have a U.S. marketing and field force, including sales personnel, reimbursement specialists and payor relations directors, totaling 39 persons as of March 31, 2017.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2016, after unsuccessfully negotiating with the French government to obtain an appropriate price, we decided to close operations in France. We expect the closing of operations to be completed in 2017. We are continuing to evaluate our options to enter the French market, including potential distributor relationships.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Critical Accounting Policies and Estimates</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our discussion and analysis of our financial condition and results of operations are based on our unaudited interim condensed consolidated financial statements and notes (Interim Financial Statements) which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these interim financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate these estimates and judgments, including those described below. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results and experiences may differ materially from these estimates. We discuss our critical accounting policies in the Management&#8217;s Discussion and Analysis section of our Annual Report on Form 10-K. There have been no significant changes in our critical accounting policies.</font></div><div><a name="sB63E13E47EA53E85FA6448DE169CEE66"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations - Segment Review</font></div><div style="line-height:120%;padding-bottom:9px;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following selected unaudited financial and operating data are derived from our interim financial statements and should be read in conjunction with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements. The results and discussions that follow are reflective of how our executive management monitors the performance of our reporting segments. Our chief operating decision maker is our Chief Executive Officer (CEO). While the CEO is apprised of a variety of financial metrics and information, the business is principally managed and organized based upon geographic and regulatory environment. Each segment is separately managed and is evaluated primarily upon segment loss from operations. The tables below exclude non-cash items including stock-based compensation expense and depreciation and amortization.</font></div><div style="line-height:120%;padding-bottom:9px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">U.S. Segment</font></div><div style="line-height:120%;padding-top:10px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET REVENUE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,445</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(448</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GROSS PROFIT</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GENERAL AND ADMINISTRATIVE EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,705</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,921</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SALES AND MARKETING EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,045</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DEPRECIATION AND AMORTIZATION</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPERATING EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,908</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,939</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SEGMENT LOSS FROM OPERATIONS</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,911</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,042</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Three months ended March 31, 2017 compared to the three months ended March 31, 2016</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Revenue. </font><font style="font-family:inherit;font-size:10pt;">Net revenue increased by approximately $300,000, or 7%, to approximately $4.4 million for the three months ended March 31, 2017 compared to approximately $4.1 million for the three months ended March 31, 2016. The increase was primarily attributable to an increase in end user unit demand of 34% offset by fluctuations in the timing of orders by our two U.S. distributors.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of goods sold, excluding depreciation and amortization. </font><font style="font-family:inherit;font-size:10pt;">Cost of goods sold, excluding depreciation and amortization increased by approximately $230,000, or 105%, to approximately $450,000 for the three months ended March 31, 2017 compared to approximately $220,000 for the three months ended March 31, 2016, primarily as a result of an increase in net profit amounts owed to pSivida, as defined in the pSivida Agreement, for the three months ended March 31, 2017. </font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research, development and medical affairs expenses</font><font style="font-family:inherit;font-size:10pt;">. Research, development and medical affairs expenses decreased by approximately $500,000, or 29%, to approximately $1.2&#160;million for the three months ended March 31, 2017 compared to approximately $1.7 million for the three months ended March 31, 2016. The decrease was primarily attributable to decreases of $210,000 in personnel costs and $110,000 in FDA registration costs.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and administrative expenses. </font><font style="font-family:inherit;font-size:10pt;">General and administrative expenses decreased by approximately $200,000, or 11%, to approximately $1.7 million for the three months ended March 31, 2017 compared to approximately $1.9 million for the three months ended March 31, 2016. The decrease was primarily attributable to decreases in bonus expense as we granted restricted stock unit awards to our non-field personnel in lieu of a cash bonus program in 2017.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Sales and Marketing expenses</font><font style="font-family:inherit;font-size:10pt;">. Sales and marketing expenses decreased by approximately $1.3 million, or 25%, to approximately $4.0 million for the three months ended March 31, 2017 compared to approximately $5.3 million for the three months ended March 31, 2016. The decrease was primarily attributable to decreases of $760,000 for personnel costs, $310,000 in marketing cost and $140,000 in travel and entertainment costs in connection with the cost savings program we implemented in late 2016.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">International Segment</font></div><div style="line-height:120%;padding-top:10px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET REVENUE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(139</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(156</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GROSS PROFIT</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GENERAL AND ADMINISTRATIVE EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">918</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SALES AND MARKETING EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DEPRECIATION AND AMORTIZATION</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPERATING EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,289</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SEGMENT LOSS FROM OPERATIONS</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,763</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Three months ended March 31, 2017 compared to the three months ended March 31, 2016</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Revenue. </font><font style="font-family:inherit;font-size:10pt;">Net revenue increased by approximately $500,000, or 29%, to approximately $2.2 million for the three months ended March 31, 2017 compared to approximately $1.7 million for the three months ended March 31, 2016. The increase was primarily attributable to increased sales volume in all the markets in Europe offset by changes in exchange rates of the Euro and the British pound sterling. </font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of goods sold, excluding depreciation and amortization. </font><font style="font-family:inherit;font-size:10pt;">Cost of goods sold, excluding depreciation and amortization decreased by approximately $20,000, or 13%, to approximately $140,000 for the three months ended March 31, 2017 compared to approximately $160,000 for the three months ended March 31, 2016. During the three months ended March 31, 2016 we reserved $50,000 for potentially expiring inventory, offset by increases in our supplier costs and increased sales volume during the three months ended March 31, 2017.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research, development and medical affairs expenses</font><font style="font-family:inherit;font-size:10pt;">. Research, development and medical affairs expenses decreased by approximately $360,000, or 33%, to approximately $740,000 for the three months ended March 31, 2017 compared to approximately $1.1&#160;million for the three months ended March 31, 2016. The decrease was primarily attributable to decreases of $210,000 in costs associated with our five-year, post-authorization, open label registry study.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and administrative expenses. </font><font style="font-family:inherit;font-size:10pt;">General and administrative expenses increased by approximately $200,000, or 28%, to approximately $920,000 for the three months ended March 31, 2017 compared to approximately $720,000 for the three months ended March 31, 2016.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Sales and Marketing expenses</font><font style="font-family:inherit;font-size:10pt;">. Sales and marketing expenses decreased by approximately $400,000, or 27%, to approximately $1.1&#160;million for the three months ended March 31, 2017 compared to approximately $1.5 million for the three months ended March 31, 2016. The decrease was primarily attributable to decreases of $250,000 in market access costs in the United Kingdom and Germany and $120,000 in personnel costs. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><a name="s3FE816E5E7CC3A912E5048DE1FE38F9D"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Consolidated other income and expense</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following selected unaudited financial and operating data are derived from our consolidated financial statements and should be read in conjunction with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our interim condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:10px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET LOSS FROM OPERATIONS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,511</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INTEREST EXPENSE, NET AND OTHER</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UNREALIZED FOREIGN CURRENCY (LOSS) GAIN, NET</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CHANGE IN FAIR VALUE OF DERIVATIVE WARRANT LIABILITY</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,519</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LOSS ON EARLY EXTINGUISHMENT OF DEBT</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,564</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET LOSS BEFORE TAXES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PROVISION FOR TAXES</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET LOSS</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,735</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,145</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense, net and other. </font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net and other was approximately $1.3 million for the three months ended March 31, 2017 and 2016. Interest incurred in both periods was related to the 2014 Term Loan and related amendments with Hercules. </font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Unrealized foreign currency loss, net. </font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recorded a non-cash unrealized foreign currency loss of approximately $30,000 for the three months ended March 31, 2017 compared to a gain of approximately $30,000 for the three months ended March 31, 2016. The unrealized foreign currency loss and gain were primarily attributable to the changing values of the Euro and the British pound sterling during the three months ended March 31, 2017 and 2016.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Change in fair value of derivative warrant liability. </font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A decrease in the fair value of our derivative warrant liability resulted in a non-cash gains of approximately $170,000 and $1.5 million for the three months ended March 31, 2017 and 2016, respectively. The change in fair value was primarily attributable to decreases in the fair market value of our underlying common stock during both the three-month periods ended March 31, 2017 and 2016 and the decreasing time remaining to exercise the warrants.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loss on early extinguishment of debt. </font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recorded a loss on early extinguishment of debt of approximately $2.6 million for the three months ended March 31, 2016, as a result of the Second Loan Amendment to our 2014 Term Loan with Hercules. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><a name="s741336A197D2422413B048DE200409B7"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, we have incurred negative cash flow from operations and have accumulated a deficit of $383.8 million from our inception through March 31, 2017. </font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of March 31, 2017, we had approximately $26.7 million in cash and cash equivalents. </font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We launched ILUVIEN in Germany and the United Kingdom in the second quarter of 2013, in the U.S. and Portugal in the first quarter of 2015 and in Austria in the first quarter of 2017. </font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, Limited entered into the Fourth Loan Amendment. Under the Fourth Loan Amendment, Hercules agreed to provide up to an additional $10.0 million to Limited with (i) the first $5.0 million available at Limited&#8217;s option through June 30, 2017 subject to (A) the achievement of $12.0 million in trailing three month net product revenue and (B) no event of default having occurred since the Effective Date and (ii) the second $5.0 million available at Limited&#8217;s option through December 31, 2017 subject to (A) the achievement of $15.0 million in trailing three month net product revenue, (B) no event of default having occurred since the Effective Date and (C) the prior $5.0 million having been advanced to Limited.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Term Loan Agreement requires that we maintain at least $25.0 million in liquid assets, with a minimum of $12.5 million in cash. Additionally, in any month in which we have $35.0 million in liquidity, including cash and eligible accounts receivable, the revenue and adjusted EBITDA covenants requirement will be waived.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the limited revenue generated by ILUVIEN to date, our negative cash flow from operations and accumulated deficit raise substantial doubt about our ability to continue as a going concern. Our Interim Financial Statements do not include any adjustments that might result from the outcome of this uncertainty. We believe that we have sufficient funds to allow us to become cash flow positive in the countries in which we sell ILUVIEN. However, in order to meet the Company&#8217;s working capital needs through the next twelve months and maintain compliance with its debt covenants, the Company may need to raise additional debt or equity financing.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We cannot be sure that alternative or additional financing will be available when needed or that, if available, the additional financing will be obtained on terms favorable to us or our stockholders. If we raise additional funds by issuing equity securities, substantial dilution to existing stockholders would likely result and the terms of any new equity securities may have a preference over our common stock. If we attempt to raise additional funds through strategic collaboration agreements and debt financing, we may not be successful in obtaining collaboration agreements, or in receiving milestone or royalty payments under those agreements, or the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to commercialize ILUVIEN or any future products or product candidates or operate our business.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended March 31, 2017, cash used by our operations of $4.2&#160;million was primarily due to our net loss of $6.7&#160;million offset by non-cash items, including $1.2 million of stock-based compensation expense, $670,000 for depreciation and amortization and $340,000 for non-cash interest expense associated with our debt discount. Further offsetting cash used in operations was a decrease in accounts receivable of approximately $3.1 million, offset by a decrease in accounts payable, accrued expenses and other current liabilities of approximately $2.2 million and an increase in inventory of approximately $360,000. Accounts receivable decreased primarily due to lower sales volume in the U.S. in the first quarter of 2017 compared to the fourth quarter of 2016. Accounts payable, accrued expenses and other current liabilities decreased primarily due to decreases of approximately $1.0 million of general accounts payable as our operating expenses during the three months ended March 31, 2017 were significantly reduced compared to the three months ended December 31, 2016 as a result of a cost savings program we implemented in late 2016, $740,000 of accrued 2016 bonuses and commissions that were paid in the first quarter of 2017 and $460,000 of accrued rebate, chargeback and other revenue reserves.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended March 31, 2016, cash used by our operations of $6.7&#160;million was primarily due to our net loss of $11.1&#160;million and a non-cash gain of $1.5 million for the change in our derivative warrant liability offset by non-cash items, including $2.6 million loss on early debt extinguishment, $1.3 million of stock-based compensation expense, $690,000 for depreciation and amortization and $340,000 for non-cash interest expense associated with our debt discount. Further decreasing cash used in operations were decreases in accounts receivable of approximately $760,000 and in inventory of approximately $160,000 and an increase in accounts payable, accrued expenses and other current liabilities of approximately $180,000. Accounts receivable decreased primarily due to collections in the U.S. and Portugal. </font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended March 31, 2017, net cash used in our investing activities was approximately $60,000, which was due to the purchase of property and equipment, primarily the purchase of software that our sales force will use in the field.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended March 31, 2016, net cash used in our investing activities was approximately $80,000, which was due to the purchase of property and equipment, primarily the purchase of accounts payable software and leasehold improvements.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended March 31, 2017, net cash used in our financing activities was approximately $40,000 due to payments on capital leases.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended March 31, 2016, net cash used in our financing activities was approximately $470,000 due to the payment of debt issuance costs of approximately $350,000 associated with the second amendment of our Hercules Term Loan Agreement and approximately $60,000 in payments on capital leases.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contractual Obligations and Commitments</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no other material changes to our contractual obligations and commitments outside the ordinary course of business from those disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2016, filed with the SEC on March&#160;3, 2017.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, that would have been established for the purpose of facilitating off-balance sheet arrangements (as that term is defined in Item&#160;303(a)(4)(ii) of Regulation S-K) or other contractually narrow or limited purposes. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in those types of relationships. We enter into guarantees in the ordinary course of business related to the guarantee of our own performance and the performance of our subsidiaries.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Adoption of New Accounting Standards</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</font><font style="font-family:inherit;font-size:10pt;">. ASU 2014-15 requires management to perform interim and annual assessments of an entity&#8217;s ability to continue as a going concern within one year of the date the financial statements are issued and provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. ASU 2014-15 applies to all entities and is effective for annual and interim reporting periods ending after December 15, 2016, with early adoption permitted. The adoption of this guidance did not have a material impact on our financial statements.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory (Topic 330): Simplifying the Measurement of Inventory</font><font style="font-family:inherit;font-size:10pt;">. This update requires entities to measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. This ASU is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those years. The adoption of this guidance did not have a material impact on our financial statements.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718)</font><font style="font-family:inherit;font-size:10pt;">. This standard makes several modifications to Topic 718 related to the accounting for forfeitures, employer tax withholding on share-based compensation and the financial statement presentation of excess tax benefits or deficiencies. ASU 2016-09 also clarifies the statement of cash flows presentation for certain components of share-based awards. The standard is effective for interim and annual reporting periods beginning after December 15, 2016, although early adoption is permitted. The adoption of this guidance did not have a material impact on our financial statements.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Standards Issued but Not Yet Effective</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">.&#160;ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. The revenue guidance contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017 for public entities, with early adoption permitted in the annual reporting period beginning after December 15, 2016. We have begun our evaluation of the new guidance on our business and, at this time, do not believe there will be a material impact on our current direct product sales in international markets. For the U.S. business, we continue to evaluate the variable consideration provisions of the new guidance and the impact it will have specifically on our gross to net revenue adjustments, including chargebacks and rebates. We anticipate adopting the new revenue standard using the modified retrospective transition method.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">. This standard requires all leases with durations greater than twelve months to be recognized on the balance sheet and is effective for interim and annual reporting periods beginning after December 15, 2018, although early adoption is permitted. We are currently in the process of evaluating the impact of the adoption on our financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><a name="sEC449BE9B9CEBFCFBDA648DE2037FB12"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;3.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See the &#8220;Liquidity and Capital Resources&#8221; section of this Quarterly Report on Form 10-Q for additional discussion of liquidity and related risks. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest Rate Risk</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our earnings and cash flows are subject to fluctuations due to changes in interest rates, principally in connection with our loan agreement with Hercules. We do not believe we are materially exposed to changes in interest rates. We do not currently use interest rate derivative instruments to manage exposure to interest rate changes. We estimate that a 100 basis point, or 1%, unfavorable change in interest rates would have resulted in approximately a $88,000 increase in interest expense for the three months ended March 31, 2017. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Credit Quality Risk</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to credit risk in connection with accounts receivable from our product sales of ILUVIEN. We have contractual payment terms with each of our customers and we monitor our customers&#8217; financial performance and credit worthiness so that we can properly assess and respond to any changes in their credit profile. During the three months ended March 31, 2017 and 2016, we did not recognize any charges for write-offs of accounts receivable. As of March 31, 2017 and December 31, 2016, two U.S.-based distributors accounted for 85% and 90%, respectively, of our accounts receivable balances.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Exchange Risk </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As discussed further above, we market ILUVIEN outside the U.S. Therefore, significant changes in foreign exchange rates of the countries outside the U.S. where our product is sold can impact our operating results and financial condition. As sales outside the U.S. continue to grow and as we expand our international operations, we will continue to assess potential steps, including foreign currency hedging and other strategies, to mitigate our foreign exchange risk. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><a name="sF1F761071C6BCA04F6F848DE205FABBB"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;4.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Controls and Procedures</font></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2017. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2017, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</font></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the three months ended March 31, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><a name="s2348C9D9918B61D92C6C48DE15CA9511"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II. OTHER INFORMATION</font></div><div><a name="sCDEF2D5904AC0E4E6A4048DE20AB0447"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2016, Cantor Fitzgerald &amp; Co. (Cantor Fitzgerald) filed a complaint in the Supreme Court of the State of New York, County of New York against us. This complaint mirrored a complaint that Cantor Fitzgerald filed against us in November 2016 in the United States District Court for the Southern District of New York and then voluntarily dismissed.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the operative complaint, Cantor Fitzgerald alleges breach of a letter agreement pursuant to which we had engaged Cantor Fitzgerald to assist us in obtaining bank or loan financing. Cantor Fitzgerald alleges that our agreement in October 2016 with Hercules Capital, Inc. (Hercules) to restructure and amend our existing $35.0 million debt facility with Hercules and to secure an additional $10.0 million in debt financing requires the payment to Cantor Fitzgerald of an advisory fee of 2% of $45 million, or $900,000, plus expenses of $24,890. Cantor Fitzgerald seeks compensatory and punitive damages, pre- and post-judgment interest, plus attorneys&#8217; fees and costs.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 12, 2017, we filed a counterclaim against Cantor Fitzgerald for breach of contract. We allege in the counterclaim, among other things, that Cantor Fitzgerald failed to meet its obligations to provide services to us as required under the letter agreement. We seek compensatory and other damages, arising from, among other things, our additional out-of-pocket costs incurred as a result of Cantor Fitzgerald&#8217;s breach.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Both parties have answered each other&#8217;s complaint and counterclaims and denied liability. This lawsuit is in its earliest stages, no date has been set for trial and we are not able to predict the outcome.</font></div><div><a name="sA89B2DEB5E8C1876EE1248DE20DED4C2"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1A.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risk Factors</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2016, filed with the SEC on March&#160;3, 2017, we identify under Item&#160;1A of Part I important factors which could affect our business, financial condition, results of operations and future operations and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Quarterly Report on Form 10-Q. There have been no material changes in our risk factors subsequent to the filing of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016. However, the risks described in our Form 10-K are not the only risks we face. Additional risks and uncertainties that we currently deem to be immaterial or not currently known to us, as well as other risks reported from time to time in our reports to the SEC, also could cause our actual results to differ materially from our anticipated results or other expectations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><a name="s303A509E3132BC1CB2DA48DE20FED975"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;2.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Unregistered Sales of Equity Securities and Use of Proceeds</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="sF75B0517A3995B18280648DE2131967E"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;3.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Defaults Upon Senior Securities</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="sEBC4D8DD8ABA185B665948DE2159CFAA"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;4.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Mine Safety Disclosures</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div><a name="sC27745637C23FE716A4048DE15CBB90E"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;5.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Information</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><a name="sACC376DE355D0B272BA348DE15CC8053"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;6.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Exhibits</font></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:10%;"></td><td style="width:2%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restated Certificate of Incorporation of Registrant, as amended on various dates (filed as Exhibit 3.2 to Amendment No. 4 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-162782), as filed on April 6, 2010 and incorporated herein by reference).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amended and Restated Bylaws of the Registrant, as amended (filed as Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, as filed on November 5, 2015 and incorporated herein by reference).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Certificate of Designation of Series A Convertible Preferred Stock (filed as Exhibit 3.5 to the Registrant&#8217;s Current Report on Form 8-K, as filed on October 2, 2012 and incorporated herein by reference).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (filed as Exhibit 3.6 to the Registrant&#8217;s Current Report on Form 8-K, as filed on December 15, 2014 and incorporated herein by reference).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Certification of the Principal Executive Officer, as required by Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Certification of the Principal Financial Officer, as required by Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Certification of the Chief Executive Officer and Chief Financial Officer, as required by Section&#160;906 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101.INS+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">XBRL Instance Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101.SCH+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">XBRL Taxonomy Extension Schema Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101.CAL+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101.DEF+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">XBRL Taxonomy Extension Definition Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101.LAB+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">XBRL Taxonomy Extension Label Link Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101.PRE+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">XBRL Taxonomy Extension Presentation Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">+</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Users of this data are advised pursuant to Rule 406T of Regulation S-T that this interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and otherwise is not subject to liability under these sections.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The certification attached as Exhibit&#160;32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Alimera Sciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><a name="sB4C25C00D019E09E8F6248DE21D8A637"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Signatures</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:43%;"></td><td style="width:4%;"></td><td style="width:53%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALIMERA SCIENCES, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;11, 2017</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ C. Daniel Myers</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C. Daniel Myers</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;11, 2017</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Richard S. Eiswirth, Jr.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Richard S. Eiswirth, Jr.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">President and Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><a name="sA54B15B752AA0A844B6048DE21FA2D64"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9897417507EA6A73B08948DE1A827938"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:10%;"></td><td style="width:2%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restated Certificate of Incorporation of Registrant, as amended on various dates (filed as Exhibit 3.2 to Amendment No. 4 to the Registrant&#8217;s Registration Statement on Form S-1 (SEC File No. 333-162782), as filed on April 6, 2010 and incorporated herein by reference).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amended and Restated Bylaws of the Registrant, as amended (filed as Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, as filed on November 5, 2015 and incorporated herein by reference).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Certificate of Designation of Series A Convertible Preferred Stock (filed as Exhibit 3.5 to the Registrant&#8217;s Current Report on Form 8-K, as filed on October 2, 2012 and incorporated herein by reference).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (filed as Exhibit 3.6 to the Registrant&#8217;s Current Report on Form 8-K, as filed on December 15, 2014 and incorporated herein by reference).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Certification of the Principal Executive Officer, as required by Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Certification of the Principal Financial Officer, as required by Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Certification of the Chief Executive Officer and Chief Financial Officer, as required by Section&#160;906 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101.INS+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">XBRL Instance Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101.SCH+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">XBRL Taxonomy Extension Schema Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101.CAL+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101.DEF+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">XBRL Taxonomy Extension Definition Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101.LAB+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">XBRL Taxonomy Extension Label Link Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101.PRE+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">XBRL Taxonomy Extension Presentation Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">+</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Users of this data are advised pursuant to Rule 406T of Regulation S-T that this interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and otherwise is not subject to liability under these sections.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The certification attached as Exhibit&#160;32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Alimera Sciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>alim-ex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9EC7EA3CEF459D72CF3148DE2B4E5B33"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:right;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.1</font></div><div style="line-height:120%;padding-top:13px;text-align:center;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;padding-top:13px;text-align:left;padding-left:24px;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, C. Daniel Myers, certify that:</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.24305555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:95%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Alimera Sciences, Inc.;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.06944444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:5%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:91%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision; to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.24305555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:95%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.24305555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:6%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:41%;"></td><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:36%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 11, 2017</font></div></td><td colspan="4" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ C. Daniel Myers</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C. Daniel Myers</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chief Executive Officer<br>(Principal Executive Officer)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>alim-ex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s2FC5795324B9720C010F48DE2BEED67F"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:right;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.2</font></div><div style="line-height:120%;padding-top:13px;text-align:center;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;padding-top:13px;text-align:left;padding-left:24px;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Richard S. Eiswirth, Jr., certify that:</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.24305555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:95%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Alimera Sciences, Inc.;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.06944444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:5%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:91%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision; to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.24305555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:95%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.24305555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:5%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:41%;"></td><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 11, 2017</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Richard S. Eiswirth, Jr.</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Richard S. Eiswirth, Jr.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">President and Chief Financial Officer <br>(Principal Financial and Accounting Officer)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>alim-ex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sAA36946AE91239473A7348DE2C94774B"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:right;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32.1</font></div><div style="line-height:120%;padding-top:13px;text-align:center;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification</font></div><div style="line-height:120%;padding-top:13px;text-align:center;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;padding-top:13px;text-align:center;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Subsections (a)&#160;and (b)&#160;of Section&#160;1350, Chapter&#160;63 of Title 18, United States Code)</font></div><div style="line-height:120%;padding-top:13px;text-align:left;padding-left:24px;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Alimera Sciences, Inc. (the Company), does hereby certify, to the best of such officer&#8217;s knowledge, that:</font></div><div style="line-height:120%;padding-top:13px;text-align:left;padding-left:24px;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 (the Form 10-Q) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.24305555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:32%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 11, 2017</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ C. Daniel Myers</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C. Daniel Myers</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chief Executive Officer <br>(Principal Executive Officer)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 11, 2017</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Richard S. Eiswirth, Jr.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Richard S. Eiswirth, Jr.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">President and Chief Financial Officer <br>(Principal Financial and Accounting Officer)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-align:left;padding-left:24px;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. This certification &#8220;accompanies&#8221; the Form 10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>alim-20170331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:3c4ee0e9c6bb4839ae47428794a30d82,x:fe662f9255284ea988b4496f17b41c19-->
<xbrli:xbrl xmlns:alim="http://www.alimerasciences.com/20170331" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="alim-20170331.xsd" xlink:type="simple" />
	<xbrli:context id="FD2017Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2SharesOutstanding">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_ProductOrServiceAxis_alim_IluvienMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">alim:IluvienMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_alim_IluvienMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">alim:IluvienMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q3Aug31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Oct1-31_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementCopromotionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-10-01</xbrli:startDate>
			<xbrli:endDate>2014-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementCopromotionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementCopromotionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementCopromotionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4No30_dei_LegalEntityAxis_alim_AlimeraSciencesIncCompanyMember_us-gaap_CreditFacilityAxis_alim_FirstLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesIncCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:FirstLoanAmendmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-11-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q2Apr30_dei_LegalEntityAxis_alim_AlimeraSciencesIncCompanyMember_us-gaap_CreditFacilityAxis_alim_TwentyFourteenTermLoanMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesIncCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:TwentyFourteenTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Jul31_dei_LegalEntityAxis_alim_AlimeraSciencesIncCompanyMember_us-gaap_CreditFacilityAxis_alim_July2016WaiverMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesIncCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:July2016WaiverMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_SecondLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesLimitedLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:SecondLoanAmendmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct1-31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesLimitedLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:FourthLoanAmendmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesLimitedLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:FourthLoanAmendmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_SecondLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesLimitedLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:SecondLoanAmendmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Jul31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_July2016WaiverMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesLimitedLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:July2016WaiverMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q3_dei_LegalEntityAxis_alim_AlimeraSciencesIncCompanyMember_us-gaap_CreditFacilityAxis_alim_TwentyFourteenTermLoanMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesIncCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:TwentyFourteenTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Aug1-31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_July2016WaiverMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesLimitedLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:July2016WaiverMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-08-01</xbrli:startDate>
			<xbrli:endDate>2016-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct1-31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_DebtInstrumentAxis_alim_TrancheOneMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesLimitedLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:FourthLoanAmendmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alim:TrancheOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct1-31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesLimitedLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:FourthLoanAmendmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_ThirdLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesLimitedLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:ThirdLoanAmendmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Nov1-30_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FirstLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesLimitedLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:FirstLoanAmendmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-11-01</xbrli:startDate>
			<xbrli:endDate>2015-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct1-31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_DebtInstrumentAxis_alim_TrancheTwoMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesLimitedLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:FourthLoanAmendmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alim:TrancheTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4No30_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FirstLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesLimitedLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:FirstLoanAmendmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-11-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_dei_LegalEntityAxis_alim_AlimeraSciencesIncCompanyMember_us-gaap_CreditFacilityAxis_alim_SecondLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesIncCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:SecondLoanAmendmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_TwentyFourteenTermLoanMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesLimitedLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:TwentyFourteenTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q2Apr30_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_TwentyFourteenTermLoanMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesLimitedLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:TwentyFourteenTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q2Apr1-30_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_TwentyFourteenTermLoanMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesLimitedLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:TwentyFourteenTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q3_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_TwentyFourteenTermLoanMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">alim:AlimeraSciencesLimitedLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alim:TwentyFourteenTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alim:HerculesTechnologyGrowthCapitalInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alim_PreferredStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alim:PreferredStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alim_PreferredStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alim:PreferredStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q4SeriesAstock_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-10-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Dec12_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Dec12_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-12-12</xbrli:startDate>
			<xbrli:endDate>2014-12-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q4Oct1-2_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-10-01</xbrli:startDate>
			<xbrli:endDate>2012-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Dec12_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-12-12</xbrli:startDate>
			<xbrli:endDate>2014-12-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q2Apr1-30_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q2Apr1-30_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q3Sep1-30_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-09-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q3Sep1-30_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-09-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Aug1-31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_alim_PublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alim:PublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-08-01</xbrli:startDate>
			<xbrli:endDate>2016-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Aug31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_alim_PublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alim:PublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Jan_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alim:InternationalSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alim:InternationalSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alim:UnitedStatesSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001267602</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">alim:UnitedStatesSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="Patient">
		<xbrli:measure>alim:Patient</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="payment">
		<xbrli:measure>alim:payment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="customer">
		<xbrli:measure>alim:customer</xbrli:measure>
	</xbrli:unit>
	<alim:AccruedClinicalInvestigatorExpenses contextRef="FI2016Q4" decimals="-3" id="Fact-BBF0C709FC3DB3E8827448DE14986DDC" unitRef="usd">1122000</alim:AccruedClinicalInvestigatorExpenses>
	<alim:AccruedClinicalInvestigatorExpenses contextRef="FI2017Q1" decimals="-3" id="Fact-80E4AB1B1726CBFA631848DE1499C391" unitRef="usd">1119000</alim:AccruedClinicalInvestigatorExpenses>
	<alim:AdditionalMilestonePayment contextRef="D2014Q4Oct1-31_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember" decimals="INF" id="Fact-95A6B8D352DB96C2A86348DE14839982" unitRef="usd">25000000</alim:AdditionalMilestonePayment>
	<alim:AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature contextRef="D2014Q4Dec12_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact-6A59228D5CF719C3CFE048DE1514D2A3" unitRef="usd">750000</alim:AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature>
	<alim:BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled contextRef="FD2017Q1YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember" id="Fact-CC97C54D1024A409E2FA48DE14A425C4">P60D</alim:BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled>
	<alim:ClassofWarrantorRightExercisablePercentage contextRef="I2014Q2Apr30_dei_LegalEntityAxis_alim_AlimeraSciencesIncCompanyMember_us-gaap_CreditFacilityAxis_alim_TwentyFourteenTermLoanMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-4623C9681E7B7F2D6604880CA505F0A1" unitRef="number">0.6</alim:ClassofWarrantorRightExercisablePercentage>
	<alim:ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage contextRef="I2014Q2Apr30_dei_LegalEntityAxis_alim_AlimeraSciencesIncCompanyMember_us-gaap_CreditFacilityAxis_alim_TwentyFourteenTermLoanMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-DDD0CF5E5FC238197578880CDB59BBE1" unitRef="number">0.4</alim:ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage>
	<alim:CommercializationCosts contextRef="FI2016Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember" decimals="-3" id="Fact-1F82AA50E5467903292D48DE14A4B563" unitRef="usd">24475000</alim:CommercializationCosts>
	<alim:CommercializationCosts contextRef="FI2017Q1_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember" decimals="-3" id="Fact-0F346C28CCB5681D183F48DE14A57EA2" unitRef="usd">24909000</alim:CommercializationCosts>
	<alim:CommercializationCostsReceivable contextRef="FI2016Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember" decimals="-3" id="Fact-E2BC5F8194E9A51BF884D54625AFD20D" unitRef="usd">25828000</alim:CommercializationCostsReceivable>
	<alim:CommercializationCostsReceivablePostAdjustment contextRef="FI2016Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember" decimals="-3" id="Fact-63DC5DAE8A4AC669321CD5465EF44A3E" unitRef="usd">24475000</alim:CommercializationCostsReceivablePostAdjustment>
	<alim:CommonStocktobeIssuedValueMaximum contextRef="FI2014Q3" decimals="-3" id="Fact-65733D27FA881E443EA548DE15214386" unitRef="usd">35000000</alim:CommonStocktobeIssuedValueMaximum>
	<alim:CommonStocktobeIssuedValueMaximum contextRef="FI2016Q1" decimals="-3" id="Fact-6A6D1C11369FA9E26BDD48DE1474462F" unitRef="usd">21504000</alim:CommonStocktobeIssuedValueMaximum>
	<alim:CommonStocktobeIssuedValueMaximum contextRef="FI2017Q1" decimals="-3" id="Fact-3C3DBAD6CD60EF922ED148DE15215E84" unitRef="usd">21504000</alim:CommonStocktobeIssuedValueMaximum>
	<alim:ConcentrationRiskNumberofCustomers contextRef="FD2016Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="INF" id="Fact-E2923BDC94420A16C5B048DE15CA94B7" unitRef="customer">2</alim:ConcentrationRiskNumberofCustomers>
	<alim:ConcentrationRiskNumberofCustomers contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="INF" id="Fact-FAD47FFE5F901172965448DE15CAE60F" unitRef="customer">2</alim:ConcentrationRiskNumberofCustomers>
	<alim:ConcentrationRiskNumberofCustomers contextRef="FD2017Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="INF" id="Fact-B2C56321BDAD630C022048DE15C2B32A" unitRef="customer">2</alim:ConcentrationRiskNumberofCustomers>
	<alim:ConcentrationRiskNumberofCustomers contextRef="FD2017Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="INF" id="Fact-7FB8D4D077811E6C44A748DE15C20CFA" unitRef="customer">2</alim:ConcentrationRiskNumberofCustomers>
	<alim:ConvertiblePreferredStockOwnershipInterestAfterConversionPercent contextRef="D2014Q4Dec12_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="4" id="Fact-A35FFF200905B7C10E4348DE1515888E" unitRef="number">0.0998</alim:ConvertiblePreferredStockOwnershipInterestAfterConversionPercent>
	<alim:CumulativeIncomeLossFromForeignOperations contextRef="FI2016Q4" decimals="-3" id="Fact-0B2A73F5A57A60D8107F48DE1558753F" unitRef="usd">-92939000</alim:CumulativeIncomeLossFromForeignOperations>
	<alim:DebitInstrumentPaymentinKindInterestRate contextRef="D2016Q4Oct1-31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-36D4B3EC833D20EC2547B02BB5C0E2D2" unitRef="number">0.01</alim:DebitInstrumentPaymentinKindInterestRate>
	<alim:DebtInstrumentBasisSpreadonVariableRateReduction contextRef="D2016Q4Oct1-31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember" decimals="INF" id="Fact-7A4CFD30CE9267E235E2B02B96904BB0" unitRef="number">0.035</alim:DebtInstrumentBasisSpreadonVariableRateReduction>
	<alim:DebtInstrumentCovenantLiquidityThreshold contextRef="I2016Q4Oct31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-184FFDD953AC93858225B02CBAB12487" unitRef="usd">35000000</alim:DebtInstrumentCovenantLiquidityThreshold>
	<alim:DebtInstrumentCovenantMinimumCashBalance contextRef="I2016Q2May31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_ThirdLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-B7FB6C6CE0488FA165BBB029CFC69FA1" unitRef="usd">2000000</alim:DebtInstrumentCovenantMinimumCashBalance>
	<alim:DebtInstrumentEndofTermPaymentAccrued contextRef="FD2016Q1QTD" decimals="-3" id="Fact-E6A688F45B3E8B83854848DE1457B890" unitRef="usd">1400000</alim:DebtInstrumentEndofTermPaymentAccrued>
	<alim:DebtInstrumentEndofTermPaymentAccrued contextRef="FD2017Q1YTD" decimals="-3" id="Fact-084A16E2786CE641B1DA48DE145649DC" unitRef="usd">1400000</alim:DebtInstrumentEndofTermPaymentAccrued>
	<alim:DebtInstrumentPaymentTermsNumberofPayments contextRef="D2016Q4Oct1-31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-15A1717E0620D668F00AB02BD6DCE591" unitRef="payment">24</alim:DebtInstrumentPaymentTermsNumberofPayments>
	<alim:DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal contextRef="D2015Q4Nov1-30_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FirstLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-258BA10097659CA627708809AD373DF8" unitRef="number">0.03</alim:DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal>
	<alim:DebtInstrumentPrepaymentFeePercentageFirst12Months contextRef="D2016Q4Oct1-31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="3" id="Fact-60A7E254A81689D0DFA5B02C4D8FCAEB" unitRef="number">0.030</alim:DebtInstrumentPrepaymentFeePercentageFirst12Months>
	<alim:DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months contextRef="D2016Q4Oct1-31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="3" id="Fact-17CAC06B7CE0FD96F589B02C7B978721" unitRef="number">0.020</alim:DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months>
	<alim:DebtInstrumentPrepaymentFeePercentageGreaterthan24Months contextRef="D2016Q4Oct1-31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="3" id="Fact-C25684828CADC396B894B02C9D88690F" unitRef="number">0.010</alim:DebtInstrumentPrepaymentFeePercentageGreaterthan24Months>
	<alim:DebtInstrumentRevenueRequirement contextRef="D2016Q4Oct1-31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_DebtInstrumentAxis_alim_TrancheOneMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-E4A2BA086C360A41E523B02AE9DA9121" unitRef="usd">12000000</alim:DebtInstrumentRevenueRequirement>
	<alim:DebtInstrumentRevenueRequirement contextRef="D2016Q4Oct1-31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_DebtInstrumentAxis_alim_TrancheTwoMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-CA74DDC3AD18D7EFA2B6B02B295E7807" unitRef="usd">15000000</alim:DebtInstrumentRevenueRequirement>
	<alim:DebtInstrumentTickingFee contextRef="D2016Q3Aug1-31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_July2016WaiverMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="-3" id="Fact-FEF3449D2DCDDDF24898B02A695B51C6" unitRef="usd">65000</alim:DebtInstrumentTickingFee>
	<alim:DebtInstrumentTickingFeePercent contextRef="I2016Q3Jul31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_July2016WaiverMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-F5A3E198693EC255E3CEB02A01E2C417" unitRef="number">0.0005</alim:DebtInstrumentTickingFeePercent>
	<alim:DerivativeWarrantLiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A8BD8924A4C189C4AC9348DE15851906" unitRef="usd">0</alim:DerivativeWarrantLiabilitiesFairValueDisclosure>
	<alim:DerivativeWarrantLiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-8A5371781CC9EE99B0AB48DE15858DA4" unitRef="usd">188000</alim:DerivativeWarrantLiabilitiesFairValueDisclosure>
	<alim:DerivativeWarrantLiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-F91C2A3BED4519D2022348DE15860514" unitRef="usd">0</alim:DerivativeWarrantLiabilitiesFairValueDisclosure>
	<alim:DerivativeWarrantLiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-332AEB304DCC812844D348DE158623F0" unitRef="usd">188000</alim:DerivativeWarrantLiabilitiesFairValueDisclosure>
	<alim:DerivativeWarrantLiabilitiesFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-F3755A91997EF2FF104248DE156FA30A" unitRef="usd">0</alim:DerivativeWarrantLiabilitiesFairValueDisclosure>
	<alim:DerivativeWarrantLiabilitiesFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-2AB1C1970644FC11422948DE156E379E" unitRef="usd">21000</alim:DerivativeWarrantLiabilitiesFairValueDisclosure>
	<alim:DerivativeWarrantLiabilitiesFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-680C43DC2BEFDDFF0B9948DE156ECEA3" unitRef="usd">0</alim:DerivativeWarrantLiabilitiesFairValueDisclosure>
	<alim:DerivativeWarrantLiabilitiesFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-7EF1586023463DD019AF48DE156E8762" unitRef="usd">21000</alim:DerivativeWarrantLiabilitiesFairValueDisclosure>
	<alim:EstimatedTotalStockIssuanceCost contextRef="D2012Q4Oct1-2_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-3" id="Fact-AAAB15D2B107C9C4C96D48DE1515B89A" unitRef="usd">560000</alim:EstimatedTotalStockIssuanceCost>
	<alim:ExercisePriceOfWarrants contextRef="I2012Q4SeriesAstock_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-0A8BF180A965ADFE191548DE1515E376" unitRef="usdPerShare">44.00</alim:ExercisePriceOfWarrants>
	<alim:GrossProceedsUnderSecuritiesPurchaseAgreement contextRef="I2012Q4SeriesAstock_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-6" id="Fact-0BA5C6F31F89A5FDCA2648DE15163ED7" unitRef="usd">40000000</alim:GrossProceedsUnderSecuritiesPurchaseAgreement>
	<alim:GrossProceedsUnderSecuritiesPurchaseAgreementPerValue contextRef="I2012Q4SeriesAstock_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-A2C0DFF000CA60CDEF6048DE15149E41" unitRef="usdPerShare">40.00</alim:GrossProceedsUnderSecuritiesPurchaseAgreementPerValue>
	<alim:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities contextRef="FD2016Q1QTD" decimals="-3" id="Fact-1C5A4488BDC9D3B4F62348DE145B1F38" unitRef="usd">1704000</alim:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
	<alim:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities contextRef="FD2017Q1YTD" decimals="-3" id="Fact-DF18D1C6BCC4726A1E2F48DE1458761B" unitRef="usd">-1147000</alim:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
	<alim:IncreaseDecreaseInFairValueOfPreferredStockConversionFeature contextRef="FD2016Q1QTD" decimals="-3" id="Fact-29A21F3344A2A4B9BE1C48DE14311A7B" unitRef="usd">1519000</alim:IncreaseDecreaseInFairValueOfPreferredStockConversionFeature>
	<alim:IncreaseDecreaseInFairValueOfPreferredStockConversionFeature contextRef="FD2017Q1YTD" decimals="-3" id="Fact-624CFF743CC23630F92948DE14312742" unitRef="usd">167000</alim:IncreaseDecreaseInFairValueOfPreferredStockConversionFeature>
	<alim:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets contextRef="FD2016Q1QTD" decimals="-3" id="Fact-E1113FA0A90D370F272548DE145703B8" unitRef="usd">67000</alim:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
	<alim:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets contextRef="FD2017Q1YTD" decimals="-3" id="Fact-D0964774D83683E965B348DE1456FA30" unitRef="usd">-8000</alim:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
	<alim:InventoryComponent contextRef="FI2016Q4" decimals="-3" id="Fact-C2D1CC8B523D52A36F2248DE1477E044" unitRef="usd">115000</alim:InventoryComponent>
	<alim:InventoryComponent contextRef="FI2017Q1" decimals="-3" id="Fact-1E28BB63A2C6B0B867B448DE14775443" unitRef="usd">334000</alim:InventoryComponent>
	<alim:LineofCreditFacilityIncreaseinBorrowingCapacity contextRef="D2016Q4Oct1-31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_DebtInstrumentAxis_alim_TrancheOneMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-8DDB39B120405B53935BB02AC531012A" unitRef="usd">5000000</alim:LineofCreditFacilityIncreaseinBorrowingCapacity>
	<alim:LineofCreditFacilityIncreaseinBorrowingCapacity contextRef="D2016Q4Oct1-31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_DebtInstrumentAxis_alim_TrancheTwoMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-E0B1E188FAABC81A0CE4B02B0AE62926" unitRef="usd">5000000</alim:LineofCreditFacilityIncreaseinBorrowingCapacity>
	<alim:LineofCreditFacilityIncreaseinBorrowingCapacity contextRef="D2016Q4Oct1-31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-C58ECFC518F2031E48F2B02AA5D87044" unitRef="usd">10000000</alim:LineofCreditFacilityIncreaseinBorrowingCapacity>
	<alim:MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract contextRef="FD2017Q1YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember" id="Fact-332DC7CFDE9DC5A682E448DE14A4EBAC">P90D</alim:MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract>
	<alim:MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract contextRef="FD2017Q1YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember" id="Fact-CD5938224FA611F6D7AA48DE14A45755">P30D</alim:MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract>
	<alim:NumberOfPreferredStockAndWarrants contextRef="I2012Q4SeriesAstock_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-54C24D646AC4CAB6D5B248DE15155838" unitRef="shares">1000000</alim:NumberOfPreferredStockAndWarrants>
	<alim:PercentageOfRecoveryOfCommercializationCost contextRef="FD2017Q1YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember" decimals="INF" id="Fact-69C48901CFE17A6160F248DE14A444B8" unitRef="number">0.2</alim:PercentageOfRecoveryOfCommercializationCost>
	<alim:PlannedDrugStudyNumberofPatients contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_alim_IluvienMember" decimals="INF" id="Fact-6CC9630425145E967E1C48DE1467E908" unitRef="Patient">800</alim:PlannedDrugStudyNumberofPatients>
	<alim:PlannedStudyNumberofPatients contextRef="FI2017Q1_us-gaap_ProductOrServiceAxis_alim_IluvienMember" decimals="0" id="Fact-8655BFF3FAD7EDD4F0ADB01BB7CD6B70" unitRef="Patient">560</alim:PlannedStudyNumberofPatients>
	<alim:PostAuthorizationOpenStudyPeriod contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_alim_IluvienMember" id="Fact-29437A4096AA034E473C48DE146761EC">P5Y</alim:PostAuthorizationOpenStudyPeriod>
	<alim:PreferredStockConvertedToCommonStockPerShare contextRef="D2012Q4Oct1-2_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-BB028DFE4CD7B7182DC948DE15140EA8" unitRef="usdPerShare">10.00</alim:PreferredStockConvertedToCommonStockPerShare>
	<alim:ProportionOfEachUnitOfShares contextRef="I2012Q4SeriesAstock_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-6D87DF58F008A88BB47848DE1516F796" unitRef="shares">0.30</alim:ProportionOfEachUnitOfShares>
	<alim:ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien contextRef="FD2017Q1YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember" decimals="INF" id="Fact-4A2DA366525F1C20843F48DE14A412B1" unitRef="number">0.33</alim:ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien>
	<alim:ShareOfNetProfits contextRef="FD2017Q1YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember" decimals="INF" id="Fact-93C9D16D55734E11F2A348DE14A462C9" unitRef="number">0.2</alim:ShareOfNetProfits>
	<alim:WarrantsToPurchaseAdditionalShares contextRef="I2012Q4SeriesAstock_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-E92395049316AC49AC2F48DE1515FDA1" unitRef="shares">300000</alim:WarrantsToPurchaseAdditionalShares>
	<dei:AmendmentFlag contextRef="FD2017Q1YTD" id="Fact-14A283FD9432997A312548DE13F9E9A0">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2017Q1YTD" id="Fact-3A063ACE3A075E4CB45548DE13F951C3">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2017Q1YTD" id="Fact-629D420B9DD1C179AEFB48DE13F9EBDF">Q1</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2017Q1YTD" id="Fact-79FBB7181CB6C37F605848DE13FA6FAB">2017</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2017Q1YTD" id="Fact-349A883F6E05800D6C4448DE13FA13A3">2017-03-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2017Q1YTD" id="Fact-E45E8124D14E9CD2445948DE13FA3903">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2017Q1YTD" id="Fact-5D812D8A94C49D4281A948DE13F9FE1E">0001267602</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2017Q2SharesOutstanding" decimals="INF" id="Fact-108BD70C5C47B24468FB48DE13F9CC60" unitRef="shares">64901636</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2017Q1YTD" id="Fact-C0E915C8E5C0ECA3C89148DE13F9B927">Smaller Reporting Company</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2017Q1YTD" id="Fact-F56E8562F86B0FFACD7148DE13FABD80">ALIMERA SCIENCES INC</dei:EntityRegistrantName>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-067FE4719346056C99BB48DE14081EC4" unitRef="usd">4986000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-A6228B00EC8970B6861648DE140E5E63" unitRef="usd">3963000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-C53CB64DF156AF7DD17648DE140EB1B7" unitRef="usd">13839000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-652C27F743C0BDACD56448DE140B4451" unitRef="usd">10768000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-41EFE709722FE30B9C8F48DE1409B068" unitRef="usd">3758000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-89F5EDD1CD5B7F8E79C548DE140D6ACE" unitRef="usd">2636000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4" decimals="-3" id="Fact-C40F29AE87EBD1415A6648DE140C10C9" unitRef="usd">-1272000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q1" decimals="-3" id="Fact-D35AC0D2AFA2E67732FB48DE140A7865" unitRef="usd">-1223000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2016Q4" decimals="-3" id="Fact-DBEA5F22329F58F7A91848DE1408CC36" unitRef="usd">330781000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2017Q1" decimals="-3" id="Fact-F0C37B5377E90D79572E48DE140C2814" unitRef="usd">331947000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="-3" id="Fact-70567FE685243D5E81AB48DE154FCDAF" unitRef="usd">32000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-28D7B1C65DB29384AB8548DE154F3EA8" unitRef="usd">1264000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="-3" id="Fact-A3C424DA8F1FD60537B148DE154F8149" unitRef="usd">13000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-BD39B6F7EECE9E9CF9D648DE1550D1A4" unitRef="usd">972000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-3E03B69065DDC9F5CDFDE8BFBFA9F1BF" unitRef="usd">182000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2016Q1QTD" decimals="-3" id="Fact-9C71C2847009FF0236B048DE145AFEFE" unitRef="usd">337000</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2017Q1YTD" decimals="-3" id="Fact-A64635911CB816347DDC48DE145CC8A6" unitRef="usd">343000</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2016Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" decimals="-3" id="Fact-BE3056753BF5323D977F48DE148320DB" unitRef="usd">483000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q1QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" decimals="-3" id="Fact-6FCF5FE26B68A46F186A48DE1484185C" unitRef="usd">478000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q1QTD" decimals="0" id="Fact-D6DAE6075571F3E4833648DE14F9707D" unitRef="shares">33516186</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alim_PreferredStockWarrantsMember" decimals="0" id="Fact-37053FF311C928B523DA48DE14F82387" unitRef="shares">4511279</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-3440BFF5BA947C5849E448DE14F8EC96" unitRef="shares">10626077</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_SeriesAPreferredStockMember" decimals="0" id="Fact-0C03788545687223991448DE14F826C7" unitRef="shares">9022556</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_SeriesBPreferredStockMember" decimals="0" id="Fact-58E4B624D63E6B83BD7C48DE14F940F3" unitRef="shares">8416251</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-758D13B96FF192B8420648DE14F83967" unitRef="shares">940023</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alim_PreferredStockWarrantsMember" decimals="0" id="Fact-C44E0AC8A1B4ECE339A948DE14F81F60" unitRef="shares">4511279</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-D4F336BC118AF845EB0948DE14F971BA" unitRef="shares">11696269</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_SeriesAPreferredStockMember" decimals="0" id="Fact-1AA9DFDCF6DC1A650C0B48DE14F906CA" unitRef="shares">9022556</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_SeriesBPreferredStockMember" decimals="0" id="Fact-6775071225C4EBD45B9C48DE14F8F788" unitRef="shares">8416251</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-7F5C9091812506F3458A48DE14F81B24" unitRef="shares">1795663</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1YTD" decimals="0" id="Fact-2CD2198A1BDA6E02FCB048DE14F9CEFE" unitRef="shares">35442018</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-3" id="Fact-8584176B1264A4A94ACF48DE1408C6B0" unitRef="usd">70229000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2017Q1" decimals="-3" id="Fact-C72A8437E3033B83483748DE1408D163" unitRef="usd">62590000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-3406D550FF6365A1027C48DE140B8FB0" unitRef="usd">47402000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-0DF5702D7C068FA2AA6648DE140A6F83" unitRef="usd">40450000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-64559BFE4EA75CE0D9F548DE1585C862" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A1C2B8A2C4926D1A43C648DE1586B5F1" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C7EAF1E5294A4410477148DE158788F3" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A01A28F882E3F0A1FF8848DE1586DE29" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-83252BFA0E21FDD2FC2648DE156D7A3D" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E88FE79E92AEA1C1315348DE156DD1F0" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-874C67B2AE269A0E0B9A48DE156F4FBE" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-644EB7B3BE12690DE40D48DE156F4E61" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:CapitalLeaseObligationsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-EC226919542BB9B8A8E848DE140BB72B" unitRef="usd">191000</us-gaap:CapitalLeaseObligationsCurrent>
	<us-gaap:CapitalLeaseObligationsCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-6BA85CEE7F21A9B848E348DE140D509E" unitRef="usd">157000</us-gaap:CapitalLeaseObligationsCurrent>
	<us-gaap:CapitalLeaseObligationsIncurred contextRef="FD2016Q1QTD" decimals="-3" id="Fact-6ABD8D8A7577AB8A04CF48DE14582684" unitRef="usd">56000</us-gaap:CapitalLeaseObligationsIncurred>
	<us-gaap:CapitalLeaseObligationsIncurred contextRef="FD2017Q1YTD" decimals="-3" id="Fact-26E9E71D3B8E38EF8E4348DE145669D7" unitRef="usd">0</us-gaap:CapitalLeaseObligationsIncurred>
	<us-gaap:CapitalLeaseObligationsNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-131E33948CB5B3C05C1A48DE140DD514" unitRef="usd">274000</us-gaap:CapitalLeaseObligationsNoncurrent>
	<us-gaap:CapitalLeaseObligationsNoncurrent contextRef="FI2017Q1" decimals="-3" id="Fact-18D9E8D0EC3A1803CDA948DE1409EA7C" unitRef="usd">184000</us-gaap:CapitalLeaseObligationsNoncurrent>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-97701CB6020FAB22795E48DE145ADD16" unitRef="usd">31075000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q1" decimals="-3" id="Fact-ED63A8AF5B2D585A524F48DE1455209D" unitRef="usd">23940000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-D569A83CBC6DC014E60148DE140ED568" unitRef="usd">30979000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q1" decimals="-3" id="Fact-DB7E1F62418B60A47E8648DE140E4536" unitRef="usd">26737000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-D7E82A484631FB87349F48DE1586B6C8" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-57AD4EAD36B1E6BFC31A48DE1585271B" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E0D34C799374A86BB2ED48DE15868120" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-4B7677504102C0EC1E4D48DE15840D53" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1741FDFF27C98D86D25E48DE156D937E" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E294F1762FCECE4A99F948DE156EC52B" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-399DD46FC48063CE39F948DE156F922D" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-F488D944869EDF733E4048DE156FB056" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q1QTD" decimals="-3" id="Fact-6DF5CF48D73C48204FF848DE145AD94E" unitRef="usd">-7135000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q1YTD" decimals="-3" id="Fact-958164CF8663773E234848DE14569A52" unitRef="usd">-4242000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2016Q1_dei_LegalEntityAxis_alim_AlimeraSciencesIncCompanyMember_us-gaap_CreditFacilityAxis_alim_SecondLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="2" id="Fact-45B119398A5CFD783FB4880E04CBE6D1" unitRef="usdPerShare">2.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2014Q2Apr30_dei_LegalEntityAxis_alim_AlimeraSciencesIncCompanyMember_us-gaap_CreditFacilityAxis_alim_TwentyFourteenTermLoanMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-0206DF89395A29B9B352880C6D774980" unitRef="usdPerShare">6.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2015Q4No30_dei_LegalEntityAxis_alim_AlimeraSciencesIncCompanyMember_us-gaap_CreditFacilityAxis_alim_FirstLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-65064620F792C8D7C24C880D95262329" unitRef="usdPerShare">2.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q3Jul31_dei_LegalEntityAxis_alim_AlimeraSciencesIncCompanyMember_us-gaap_CreditFacilityAxis_alim_July2016WaiverMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-9606F3555169619150D9B02DD807F421" unitRef="usdPerShare">1.39</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q4Oct31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-CE01E0BB70A28FD1D972B02E2FB85AD1" unitRef="usdPerShare">1.09</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2016Q1_dei_LegalEntityAxis_alim_AlimeraSciencesIncCompanyMember_us-gaap_CreditFacilityAxis_alim_SecondLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-CE6C6E37A10132ADDED5880DC92548C5" unitRef="shares">862069</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2014Q2Apr30_dei_LegalEntityAxis_alim_AlimeraSciencesIncCompanyMember_us-gaap_CreditFacilityAxis_alim_TwentyFourteenTermLoanMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-7AF0DD974825B4D6A51F880C31231097" unitRef="shares">285016</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2015Q4No30_dei_LegalEntityAxis_alim_AlimeraSciencesIncCompanyMember_us-gaap_CreditFacilityAxis_alim_FirstLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-14581C0088FFF4245B66880D60F7CA90" unitRef="shares">660377</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2016Q3Jul31_dei_LegalEntityAxis_alim_AlimeraSciencesIncCompanyMember_us-gaap_CreditFacilityAxis_alim_July2016WaiverMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-C45985849C0401B4B3C5B02DA99E7AB1" unitRef="shares">1258993</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2016Q4Oct31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-55CF7DB38295B6A20151B02E0F7B9263" unitRef="shares">458716</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2016Q4" id="Fact-F47AF95E8F1274A2EFFA48DE140EF521" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q1" id="Fact-0D7C20B2A78152B6598648DE140AB8BD" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-625E8BED12CC14233FDF48DE1421A5C0" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q1" decimals="INF" id="Fact-B154B74B25F80C7CB77348DE14217D0D" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-5F257049DB36EA27033748DE1420C7AF" unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q1" decimals="INF" id="Fact-89512F434D262B966A4C48DE141EAF25" unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-45533FD4FF5F1F6FD5A448DE141F977C" unitRef="shares">64862904</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q1" decimals="INF" id="Fact-10AAC1A079B335B190BE48DE141E6AE6" unitRef="shares">64862904</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-B5D1B93A70C5D325DF1B48DE141FB665" unitRef="shares">64862904</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q1" decimals="INF" id="Fact-86BF758059887029ACE948DE141F901E" unitRef="shares">64862904</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-315CDA95258EF695C33148DE140CED84" unitRef="usd">649000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2017Q1" decimals="-3" id="Fact-32898741F4B7AE3558D048DE140BBFE2" unitRef="usd">649000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q1QTD" decimals="-3" id="Fact-24F41F16E7C99E54A46348DE14403117" unitRef="usd">-11026000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q1YTD" decimals="-3" id="Fact-ED260FD20F144120B1EF48DE1440125B" unitRef="usd">-6686000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-275F983A4EE5D6A49D8848DE15C25096" unitRef="number">0.71</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-55088B701044272662E148DE15C13CFA" unitRef="number">0.90</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-740763811559D078EED948DE15C1C3AF" unitRef="number">0.85</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-3F5A4469B678759D625C48DE15C10C5D" unitRef="number">0.67</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2014Q2Apr1-30_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-50C14F5E9AA156B1577E48DE1515E374" unitRef="shares">150000</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2014Q3Sep1-30_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-567DCEC8EEC884589F1348DE15141BCD" unitRef="shares">250000</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="I2014Q4Dec12_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-156B2FB66D4C48FA762048DE1517F0CD" unitRef="shares">1000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
	<us-gaap:CostOfGoodsSold contextRef="FD2016Q1QTD" decimals="-3" id="Fact-0973C25AE9E59998F3F448DE1435E824" unitRef="usd">378000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember" decimals="-3" id="Fact-4046A108F6C306F72FDC48DE15B47EA8" unitRef="usd">156000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember" decimals="-3" id="Fact-3E412702E3CF28C4FDF248DE15B477C5" unitRef="usd">222000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-8543CC67B22892E7A82AF30314EBD487" unitRef="usd">0</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember" decimals="-3" id="Fact-10CAF71CA11143CF191548DE15B181A1" unitRef="usd">139000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember" decimals="-3" id="Fact-225B61D89C15CF86C5E248DE15B0832E" unitRef="usd">448000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-A4496D00909A67F90454F302518B8D51" unitRef="usd">0</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q1YTD" decimals="-3" id="Fact-37A5F060062EA7E9701148DE14339AB0" unitRef="usd">587000</us-gaap:CostOfGoodsSold>
	<us-gaap:CustomerRefundLiabilityCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-47A7049600537799F9A248DE14995BDB" unitRef="usd">809000</us-gaap:CustomerRefundLiabilityCurrent>
	<us-gaap:CustomerRefundLiabilityCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-A3063F226C424837B17B48DE1498DBA2" unitRef="usd">348000</us-gaap:CustomerRefundLiabilityCurrent>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="D2014Q2Apr1-30_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_TwentyFourteenTermLoanMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember" decimals="INF" id="Fact-18E380109B1C092DC75B8808E8C3E46B" unitRef="number">0.0765</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="D2016Q4Oct1-31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember" decimals="INF" id="Fact-443240E24D1D444B0C72B02B77D58E49" unitRef="number">0.11</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="I2012Q4SeriesAstock_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-9D4810D48FE0512E273B48DE15172BC3" unitRef="usdPerShare">2.66</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2014Q3_dei_LegalEntityAxis_alim_AlimeraSciencesIncCompanyMember_us-gaap_CreditFacilityAxis_alim_TwentyFourteenTermLoanMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-76A226BD5D95737505CF880D1BB57804" unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2014Q3_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_TwentyFourteenTermLoanMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-4B0C0D1905A8BC2DD94C880867F5DF7B" unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2014Q2Apr30_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_TwentyFourteenTermLoanMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-10DB551E57218060114B8808294DBFD7" unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFeeAmount contextRef="FI2016Q1_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_SecondLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="-3" id="Fact-D439E135FC7D030708AF880AA5B43E97" unitRef="usd">350000</us-gaap:DebtInstrumentFeeAmount>
	<us-gaap:DebtInstrumentFeeAmount contextRef="I2015Q4No30_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FirstLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="-3" id="Fact-20247435E069136D20DD8809F72A1B59" unitRef="usd">263000</us-gaap:DebtInstrumentFeeAmount>
	<us-gaap:DebtInstrumentFeeAmount contextRef="I2016Q3Jul31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_July2016WaiverMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="-3" id="Fact-DEDCC638600E80A87FE4B02A853BA9B9" unitRef="usd">350000</us-gaap:DebtInstrumentFeeAmount>
	<us-gaap:DebtInstrumentFeeAmount contextRef="I2016Q4Oct31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="-3" id="Fact-1C1FD4B5025DFBF35A28B02C273DAF66" unitRef="usd">338000</us-gaap:DebtInstrumentFeeAmount>
	<us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="FI2016Q4_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_TwentyFourteenTermLoanMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="4" id="Fact-6B5578FF29A893F3C53988091ED9ECF0" unitRef="number">0.1125</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2014Q2Apr30_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_TwentyFourteenTermLoanMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-14CE1B9894A68EAD4DF68808A7BE419C" unitRef="number">0.109</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2016Q4Oct31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-71CBBD5BF33A09D34F71B02BF681EFD8" unitRef="number">0.11</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="FI2016Q1_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_SecondLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="-3" id="Fact-BEB63053172F944E930A880A6717791F" unitRef="usd">1400000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
	<us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="I2015Q4No30_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FirstLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="-3" id="Fact-60B544ED2937BFAC9A5A88097553E337" unitRef="usd">1050000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
	<us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-1BE20C25FE67C5F6FC6448DE14099C26" unitRef="usd">436000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
	<us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="FI2017Q1" decimals="-3" id="Fact-A288D0D3C4ACFD13B04348DE140BE14E" unitRef="usd">443000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
	<us-gaap:DepreciationAmortizationAndAccretionNet contextRef="FD2016Q1QTD" decimals="-3" id="Fact-771189D3761A14DB0A5C48DE1434289D" unitRef="usd">689000</us-gaap:DepreciationAmortizationAndAccretionNet>
	<us-gaap:DepreciationAmortizationAndAccretionNet contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember" decimals="-3" id="Fact-B481E04EAB5CDD66E23448DE15B47D21" unitRef="usd">0</us-gaap:DepreciationAmortizationAndAccretionNet>
	<us-gaap:DepreciationAmortizationAndAccretionNet contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember" decimals="-3" id="Fact-08A342BF9E94F93DA80C48DE15B1050B" unitRef="usd">0</us-gaap:DepreciationAmortizationAndAccretionNet>
	<us-gaap:DepreciationAmortizationAndAccretionNet contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-C031DC1F5272CFE6E566F3031D541D4B" unitRef="usd">689000</us-gaap:DepreciationAmortizationAndAccretionNet>
	<us-gaap:DepreciationAmortizationAndAccretionNet contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember" decimals="-3" id="Fact-A2B2858F617400E7CD5E48DE15BB932F" unitRef="usd">0</us-gaap:DepreciationAmortizationAndAccretionNet>
	<us-gaap:DepreciationAmortizationAndAccretionNet contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember" decimals="-3" id="Fact-4C1A9E3E20F5AF79856F48DE15B356A5" unitRef="usd">0</us-gaap:DepreciationAmortizationAndAccretionNet>
	<us-gaap:DepreciationAmortizationAndAccretionNet contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-581934571214591B13B2F30258C50D18" unitRef="usd">666000</us-gaap:DepreciationAmortizationAndAccretionNet>
	<us-gaap:DepreciationAmortizationAndAccretionNet contextRef="FD2017Q1YTD" decimals="-3" id="Fact-E247DC08ABB1EF64FDE848DE14345B5D" unitRef="usd">666000</us-gaap:DepreciationAmortizationAndAccretionNet>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q1QTD" decimals="-3" id="Fact-E8C0AD0A775BDB73AC5648DE1459649E" unitRef="usd">689000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q1YTD" decimals="-3" id="Fact-DB2339961CA1432E069148DE14579292" unitRef="usd">666000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral contextRef="FI2016Q4" decimals="-3" id="Fact-6B07F310374AB46523B648DE1515C740" unitRef="usd">188000</us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral>
	<us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral contextRef="FI2017Q1" decimals="-3" id="Fact-CF92058B8892385FF66148DE15148B55" unitRef="usd">21000</us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral>
	<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="FD2016Q1QTD" decimals="-3" id="Fact-3B16548D4BEA1FF191FF48DE1516CD95" unitRef="usd">1519000</us-gaap:DerivativeGainLossOnDerivativeNet>
	<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="FD2017Q1YTD" decimals="-3" id="Fact-D0CF7EC75BAC94D3B1AF48DE15147FFB" unitRef="usd">167000</us-gaap:DerivativeGainLossOnDerivativeNet>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-B4FF6CE42CA8AF4D284F5928AB152099" unitRef="usd">188000</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-7E1756C1003D04153AD55928AB249C48" unitRef="usd">21000</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q1QTD" decimals="2" id="Fact-C5C0E2440895EA2A910848DE1433887D" unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q1YTD" decimals="2" id="Fact-139D5F7B6518AE3AC92D48DE1431ABDD" unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2016Q1QTD" decimals="-3" id="Fact-C48B25E99A10DF7010F448DE1455C39B" unitRef="usd">141000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2017Q1YTD" decimals="-3" id="Fact-DAA5E16D1ED7DFA5D77C48DE145B2824" unitRef="usd">22000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="FI2016Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-265438C18DFACBCACF9148DE1550D844" unitRef="usd">7877000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q1QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" id="Fact-E89546D813E73F892D6A48DE1484EF72">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" decimals="-3" id="Fact-9F79471BBA769300AEE448DE148EF9C4" unitRef="usd">10897000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" decimals="-3" id="Fact-63E564919619761A577F48DE148D9982" unitRef="usd">1462000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" decimals="-3" id="Fact-A91D4B104DD848EF8DDAB01E8BC173F5" unitRef="usd">1940000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" decimals="-3" id="Fact-3D71750808368078538248DE148D18D9" unitRef="usd">1946000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" decimals="-3" id="Fact-DC6081FA93A076F119E148DE148DA600" unitRef="usd">1940000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" decimals="-3" id="Fact-E4EC43EC86D25A8AF80848DE148D1D31" unitRef="usd">1940000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" decimals="-6" id="Fact-8F5EB5AE262BD5505AB148DE1483DF36" unitRef="usd">25000000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q4" decimals="-3" id="Fact-BE37C0D9911D6A4CEB9C48DE140B7676" unitRef="usd">20604000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" decimals="-3" id="Fact-5D4E355C82EC1AC6C85A48DE1484939C" unitRef="usd">20604000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q1" decimals="-3" id="Fact-7D95E7D446A54921985648DE140BDC6C" unitRef="usd">20125000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" decimals="-3" id="Fact-B7A87C3C1B0FB602AD9248DE148D9958" unitRef="usd">20125000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="I2014Q3Aug31" decimals="INF" id="Fact-F581109446C797AC729048DE1483C9C2" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="FD2016Q1QTD" decimals="-3" id="Fact-ABCE635C44F0B581BC0548DE1434E210" unitRef="usd">34000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
	<us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="FD2017Q1YTD" decimals="-3" id="Fact-2707B42AC77A71B93BAA48DE1433531E" unitRef="usd">-28000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2016Q1QTD" decimals="-3" id="Fact-44197F0436FE5E6A673B48DE1435886C" unitRef="usd">-2564000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2016Q4YTD_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_SecondLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="-3" id="Fact-33BF1A6DF337F8E652A4880B2E5D51BC" unitRef="usd">-2564000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2017Q1YTD" decimals="-3" id="Fact-5E0CA2F0E6A5EED3868F48DE14351873" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q1QTD" decimals="-3" id="Fact-5A3ED5A3DC5782E79E5948DE1434A02A" unitRef="usd">3395000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember" decimals="-3" id="Fact-506F4D70607BD71D74B648DE15B2FCDB" unitRef="usd">714000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember" decimals="-3" id="Fact-276CDC3C6B598DD45ECB48DE15B3F932" unitRef="usd">1921000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-FB3E81EC57492E93A92BF3031A0EB6E7" unitRef="usd">760000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember" decimals="-3" id="Fact-C6A9F44BD9DE4F53763548DE15B3D50C" unitRef="usd">918000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember" decimals="-3" id="Fact-F2E3D045997678D9449D48DE15B5F376" unitRef="usd">1705000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-B1FF8BA4EAB264B9954BF3025675C2D3" unitRef="usd">641000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q1YTD" decimals="-3" id="Fact-142A453671AD6DFEAC6848DE14311375" unitRef="usd">3264000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GrossProfit contextRef="FD2016Q1QTD" decimals="-3" id="Fact-4FC0F12B2BE26493BA9A48DE1432A94A" unitRef="usd">5423000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember" decimals="-3" id="Fact-8AE2BC5508D4D5CC9E8548DE15B15E60" unitRef="usd">1526000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember" decimals="-3" id="Fact-6B24E4AE05C103FE314248DE15BB8922" unitRef="usd">3897000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-E0192648A32D32295684F30316386727" unitRef="usd">0</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember" decimals="-3" id="Fact-1993FC012527208B9C4748DE15B4D5DF" unitRef="usd">2034000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember" decimals="-3" id="Fact-2B8A0B0B71B6AD9F827748DE15B20A3A" unitRef="usd">3997000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-DFBCDC4AAC9F1234269CF302530C4FF1" unitRef="usd">0</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q1YTD" decimals="-3" id="Fact-0541EE29A0B597DDFB4A48DE143514A0" unitRef="usd">6031000</us-gaap:GrossProfit>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2016Q1QTD" decimals="-3" id="Fact-A6C14E018946CFCCA13748DE143561F4" unitRef="usd">-11136000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2017Q1YTD" decimals="-3" id="Fact-22820090123C0059880848DE14349BCE" unitRef="usd">-6709000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q1QTD" decimals="-3" id="Fact-963436C3C88A8734E53648DE14335DF9" unitRef="usd">9000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q1YTD" decimals="-3" id="Fact-41755C6C306B21E226C548DE143363CE" unitRef="usd">26000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxesPaid contextRef="FD2016Q1QTD" decimals="-3" id="Fact-880AF35000E513D8DABE48DE14598207" unitRef="usd">13000</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncomeTaxesPaid contextRef="FD2017Q1YTD" decimals="-3" id="Fact-7BFC79A583EE211C5D7648DE145A3313" unitRef="usd">11000</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2016Q1QTD" decimals="-3" id="Fact-97C403ABAFA5F12BB85B48DE145A6CC6" unitRef="usd">-1522000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2017Q1YTD" decimals="-3" id="Fact-DC087FECD83E2FC9FC7248DE14580751" unitRef="usd">-1053000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2016Q1QTD" decimals="-3" id="Fact-20D377B29DC31CFBD1CF48DE145B16CA" unitRef="usd">-761000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2017Q1YTD" decimals="-3" id="Fact-8BE491ED88950707EFA048DE1455A909" unitRef="usd">-3090000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2016Q1QTD" decimals="-3" id="Fact-EC1B332FA30BDE66CCB648DE145720B3" unitRef="usd">-164000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2017Q1YTD" decimals="-3" id="Fact-E2F1C976DFB671C3EC0448DE145622CE" unitRef="usd">361000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2016Q1QTD" decimals="-3" id="Fact-0C90863C0D3E9923DAB848DE145A3AD9" unitRef="usd">-13000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2017Q1YTD" decimals="-3" id="Fact-6CDE1CDDA38C7695441648DE145741BD" unitRef="usd">-15000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:InterestExpense contextRef="FD2016Q1QTD" decimals="-3" id="Fact-90F3E743ADDB520295DB48DE14317ED5" unitRef="usd">1335000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q1YTD" decimals="-3" id="Fact-027BA26F47607C64BB1F48DE1431226A" unitRef="usd">1337000</us-gaap:InterestExpense>
	<us-gaap:InterestPaid contextRef="FD2016Q1QTD" decimals="-3" id="Fact-5DD812AA4F2A9B14477A48DE145AC029" unitRef="usd">996000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2017Q1YTD" decimals="-3" id="Fact-E98FCADDC9B5B1F12DAB48DE1458C893" unitRef="usd">985000</us-gaap:InterestPaid>
	<us-gaap:InventoryFinishedGoods contextRef="FI2016Q4" decimals="-3" id="Fact-03D40581678C7771C64548DE14776E17" unitRef="usd">353000</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryFinishedGoods contextRef="FI2017Q1" decimals="-3" id="Fact-B5926D7D80FC5DAAEEE248DE1477C1AD" unitRef="usd">127000</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryGross contextRef="FI2016Q4" decimals="-3" id="Fact-939F20E03E295EC1B07548DE1477E7DF" unitRef="usd">486000</us-gaap:InventoryGross>
	<us-gaap:InventoryGross contextRef="FI2017Q1" decimals="-3" id="Fact-39EB9067A72D05125A1648DE1477DC13" unitRef="usd">850000</us-gaap:InventoryGross>
	<us-gaap:InventoryNet contextRef="FI2016Q4" decimals="-3" id="Fact-0AA75B38A7DE2A2C424648DE140E324D" unitRef="usd">446000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2017Q1" decimals="-3" id="Fact-DB1C5B3632EBEB91512948DE140DCB8F" unitRef="usd">802000</us-gaap:InventoryNet>
	<us-gaap:InventoryValuationReserves contextRef="FI2016Q4" decimals="-3" id="Fact-495123ED2CBDF27EF07048DE1477F51C" unitRef="usd">40000</us-gaap:InventoryValuationReserves>
	<us-gaap:InventoryValuationReserves contextRef="FI2017Q1" decimals="-3" id="Fact-13773B37BC1CD10F55FA48DE1476254B" unitRef="usd">48000</us-gaap:InventoryValuationReserves>
	<us-gaap:InventoryWorkInProcess contextRef="FI2016Q4" decimals="-3" id="Fact-45BA7E21FC25BA8AFE2348DE14778800" unitRef="usd">18000</us-gaap:InventoryWorkInProcess>
	<us-gaap:InventoryWorkInProcess contextRef="FI2017Q1" decimals="-3" id="Fact-A76357E29F36D3C64CD948DE1478A00F" unitRef="usd">389000</us-gaap:InventoryWorkInProcess>
	<us-gaap:InventoryWriteDown contextRef="FD2016Q1QTD" decimals="-3" id="Fact-9F26C135823777C0B9F048DE1458D15B" unitRef="usd">50000</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown contextRef="FD2017Q1YTD" decimals="-3" id="Fact-8AA0BD8DE30B66D598F148DE1457FC69" unitRef="usd">8000</us-gaap:InventoryWriteDown>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-DF81A7D2CD298C1DF50D48DE140CA5D8" unitRef="usd">70229000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q1" decimals="-3" id="Fact-3636689BAFD8C901640A48DE14081C8F" unitRef="usd">62590000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-F71771C6BC196C85328D48DE140B8A6D" unitRef="usd">9123000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-3A2B93D521BE98EC5CFE48DE140C09A9" unitRef="usd">6777000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-9245EED59584E7A207C948DE15861A57" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-354AD79B736469F0089448DE1586A7FC" unitRef="usd">188000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-08B84AFFA97ECA49A4CF48DE1586B2BD" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B1972D066682E7A8674E48DE157FA662" unitRef="usd">188000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-458D579DB67821D3769C48DE156E6B99" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-F514E4290B2E87A2BA5A48DE156D9733" unitRef="usd">21000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0972192173015618614148DE156ED119" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-903325C0646238B8908748DE156E8EFE" unitRef="usd">21000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2014Q2Apr30_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_TwentyFourteenTermLoanMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="INF" id="Fact-2E9FA8557946E922C8BF8807CF29CDAE" unitRef="usd">35000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LongTermNotesPayable contextRef="FI2016Q4" decimals="-3" id="Fact-8ADF574B87E884E3DB235929594CDA0A" unitRef="usd">33084000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2017Q1" decimals="-3" id="Fact-D716C13A4E34D5E216925929594EA50C" unitRef="usd">33409000</us-gaap:LongTermNotesPayable>
	<us-gaap:MarketingExpense contextRef="FD2016Q1QTD" decimals="-3" id="Fact-A4392026BE500EA24A1648DE14348093" unitRef="usd">7109000</us-gaap:MarketingExpense>
	<us-gaap:MarketingExpense contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember" decimals="-3" id="Fact-472A3F15BC3208135B7E48DE15B146A9" unitRef="usd">1489000</us-gaap:MarketingExpense>
	<us-gaap:MarketingExpense contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember" decimals="-3" id="Fact-3BC125DED777EE7E327E48DE15B0CFEE" unitRef="usd">5310000</us-gaap:MarketingExpense>
	<us-gaap:MarketingExpense contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-D31A2E8BD81077DCE849F3031BB0D75A" unitRef="usd">310000</us-gaap:MarketingExpense>
	<us-gaap:MarketingExpense contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember" decimals="-3" id="Fact-92E9B3518B11D74E122348DE15B10094" unitRef="usd">1143000</us-gaap:MarketingExpense>
	<us-gaap:MarketingExpense contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember" decimals="-3" id="Fact-ECC1CF059CA1E61016C148DE15B46860" unitRef="usd">4045000</us-gaap:MarketingExpense>
	<us-gaap:MarketingExpense contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-CFF0172966D95ADCFBD9F30257BDEB28" unitRef="usd">314000</us-gaap:MarketingExpense>
	<us-gaap:MarketingExpense contextRef="FD2017Q1YTD" decimals="-3" id="Fact-E2C361AD2089A1FAF12B48DE143261DA" unitRef="usd">5502000</us-gaap:MarketingExpense>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q1QTD" decimals="-3" id="Fact-37B1C8D19BB005B077DC48DE145B3B18" unitRef="usd">-466000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q1YTD" decimals="-3" id="Fact-CC278F633AA79989807A48DE145BCA7D" unitRef="usd">-38000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q1QTD" decimals="-3" id="Fact-D0D567C3467B3181D02148DE145C2C3C" unitRef="usd">-75000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q1YTD" decimals="-3" id="Fact-667AC51F77446B1F285C48DE145623FF" unitRef="usd">-57000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q1QTD" decimals="-3" id="Fact-9E350B1AD0615CC2C2E148DE145AF997" unitRef="usd">-6735000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q1YTD" decimals="-3" id="Fact-DC0F32A9B6AC0BE5F70F48DE14591C6E" unitRef="usd">-4169000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q1QTD" decimals="-3" id="Fact-653997BFE4127A5F379748DE1431693E" unitRef="usd">-11145000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q1YTD" decimals="-3" id="Fact-BA3D9D70E7FA097441A648DE143289F6" unitRef="usd">-6735000</us-gaap:NetIncomeLoss>
	<us-gaap:OperatingExpenses contextRef="FD2016Q1QTD" decimals="-3" id="Fact-62C19151DFA97C5B37CA48DE143213DF" unitRef="usd">14213000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember" decimals="-3" id="Fact-5D7E7A495DD43595798148DE15BC422A" unitRef="usd">3289000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember" decimals="-3" id="Fact-2833837A946E59F64FA048DE15B1EABE" unitRef="usd">8939000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-06809E688138E600F45DF3031EF02389" unitRef="usd">1985000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember" decimals="-3" id="Fact-B3DEF6A501FCD340062F48DE15B01BF6" unitRef="usd">2802000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember" decimals="-3" id="Fact-20A83687C95D8B757EDD48DE15B2D9E7" unitRef="usd">6908000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-645A11DCD160E1572A08F30259AF6506" unitRef="usd">1832000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q1YTD" decimals="-3" id="Fact-9728305FD4BBF0FD3AC948DE1433213B" unitRef="usd">11542000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q1QTD" decimals="-3" id="Fact-DA5A4E737798E591ED4E48DE143272F8" unitRef="usd">-8790000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember" decimals="-3" id="Fact-6753AF9E59D30F8179DA48DE15B3646B" unitRef="usd">-1763000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember" decimals="-3" id="Fact-8358A614BFA3FC60834348DE15BB9DD3" unitRef="usd">-5042000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-CC9E6B8415C3E9BBEA2AF30320254748" unitRef="usd">-1985000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember" decimals="-3" id="Fact-4283F0D631B3841DA49548DE15B3C18B" unitRef="usd">-768000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember" decimals="-3" id="Fact-47B4AC3E409CDAED677C48DE15B4B11C" unitRef="usd">-2911000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-545690206D0F8BCE1E83F3025B1A740D" unitRef="usd">-1832000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q1YTD" decimals="-3" id="Fact-AA14DE4FBAD5EDE2C65A48DE1435B207" unitRef="usd">-5511000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-3" id="Fact-04D666994178BA679C6E48DE1558C42C" unitRef="usd">104944000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-3" id="Fact-BB0C30583B12CD59224048DE1559AC11" unitRef="usd">83270000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-9B07939D96625B4BC44648DE14981EAD" unitRef="usd">807000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-7D2A6999069ED14998EF48DE14989F86" unitRef="usd">767000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="FD2016Q1QTD" decimals="-3" id="Fact-E165426CD45D2B1A8ECD48DE143F1041" unitRef="usd">119000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="FD2017Q1YTD" decimals="-3" id="Fact-E65B0D087222F26735EF48DE143F5BE9" unitRef="usd">49000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q1QTD" decimals="-3" id="Fact-3BBED95F5CC197576FF448DE143FC0F0" unitRef="usd">119000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2017Q1YTD" decimals="-3" id="Fact-8AC39556C1D53D02E28148DE144017D0" unitRef="usd">49000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-1E2ED3E0CF41B8731DAE48DE1498C120" unitRef="usd">1020000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent>
	<us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="FI2017Q1" decimals="-3" id="Fact-4EF98A8165A04231075A48DE1499F38F" unitRef="usd">402000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-041011DC559B5D23BA6148DE140EA2D4" unitRef="usd">2162000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q1" decimals="-3" id="Fact-FB5441BF0117BB71389448DE1408EE39" unitRef="usd">2154000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2016Q1QTD" decimals="-3" id="Fact-5F79B17290C5ECE4BD5648DE15B1A23A" unitRef="usd">-2346000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-BA20B3A4BA533E65AF34F44843EC41CD" unitRef="usd">-2346000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-573661B6F81C32BD46EEF44819DA6AA6" unitRef="usd">-1198000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2017Q1YTD" decimals="-3" id="Fact-FBC0654D659B1BAE01CF48DE15B38F0A" unitRef="usd">-1198000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2016Q1QTD" decimals="-3" id="Fact-67B1BD13D1C726F97DCC48DE14556AA7" unitRef="usd">350000</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2016Q4YTD_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_SecondLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="-3" id="Fact-CD6B0795646F5281B431880B72BCCFBC" unitRef="usd">360000</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2017Q1YTD" decimals="-3" id="Fact-7846783630F7B6934D6148DE145B2ADD" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfDividends contextRef="FD2016Q1QTD" decimals="INF" id="Fact-71D919467D35972BCA066CE490BF0C49" unitRef="usd">0</us-gaap:PaymentsOfDividends>
	<us-gaap:PaymentsOfDividends contextRef="FD2017Q1YTD" decimals="INF" id="Fact-71751460CF26342069966CE46395B6DB" unitRef="usd">0</us-gaap:PaymentsOfDividends>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2014Q4Dec12_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact-3E4BC9A2562A5CB651BF48DE1517A330" unitRef="usd">432000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2016Q3Aug1-31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_alim_PublicOfferingMember" decimals="-3" id="Fact-8CF05FA7D0019308D384D8D50F8AF961" unitRef="usd">1309000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2016Q1QTD" decimals="-3" id="Fact-A575963004DDFE3DC27448DE14557D78" unitRef="usd">52000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="-3" id="Fact-F852AF2766EFBB88A338C9DA3471BC4B" unitRef="usd">62000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2017Q1YTD" decimals="-3" id="Fact-6388E91674693C27545448DE14578F85" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q1QTD" decimals="-3" id="Fact-8115D67833CF045CF3A848DE145C423F" unitRef="usd">75000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q1YTD" decimals="-3" id="Fact-46A6E6FD10C9C1077EB848DE14589C94" unitRef="usd">57000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockLiquidationPreferenceValue contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-B7158B5253BB6C2CEFE448DE1421159F" unitRef="usd">24000000</us-gaap:PreferredStockLiquidationPreferenceValue>
	<us-gaap:PreferredStockLiquidationPreferenceValue contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-19E8F691936F74B47B2248DE141F9142" unitRef="usd">50750000</us-gaap:PreferredStockLiquidationPreferenceValue>
	<us-gaap:PreferredStockLiquidationPreferenceValue contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-7D6B2E187EF7F307986148DE141E3296" unitRef="usd">24000000</us-gaap:PreferredStockLiquidationPreferenceValue>
	<us-gaap:PreferredStockLiquidationPreferenceValue contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-006546BD4BF44B67B29A48DE14206C6E" unitRef="usd">50750000</us-gaap:PreferredStockLiquidationPreferenceValue>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-C96354A8C427CABF326948DE141F3E52" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q1" decimals="INF" id="Fact-03AA52D4ADC815EDF75F48DE141ECEC3" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-66D649324780EC16256748DE141E5A9A" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-5F20F0468A4B59C8781948DE14204165" unitRef="shares">1300000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-F099696EC0B9CF18EDE848DE1421021E" unitRef="shares">8417</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q1" decimals="INF" id="Fact-2D6E5D3262020A67AC9048DE14204884" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-8B1F036906919216680248DE142073EA" unitRef="shares">1300000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-57B0DCEFFB038A1DB01648DE14208FB1" unitRef="shares">8417</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-527B0C8195E8E51FD70D48DE1516242A" unitRef="shares">600000</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-C1F6C2EB7E543EAED8E548DE14208A3B" unitRef="shares">600000</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="3" id="Fact-7F844F1A2EACDEEB9D2148DE1420827F" unitRef="shares">8416.251</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-DE3FEFC1C76B6094401C48DE1420C031" unitRef="shares">600000</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="3" id="Fact-A89CC055309C0DC2742C48DE1420C76B" unitRef="shares">8416.251</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-6B557B1CD366371696FC498AF83EEA8F" unitRef="shares">600000</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-F9C43CF6DE73CED606BE48DE1421546B" unitRef="shares">600000</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="3" id="Fact-9DCAC26B5DFEEAD815DB48DE1420D3A9" unitRef="shares">8416.251</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-D5BB0DD8EE8427C0F9F748DE1420588D" unitRef="shares">600000</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="3" id="Fact-D141EC28688303895ED648DE141E9427" unitRef="shares">8416.251</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2016Q4" id="Fact-B68E4F7926FFA28BDA1248DE14092450" unitRef="usd" xsi:nil="true" />
	<us-gaap:PreferredStockValue contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-3" id="Fact-C30DE6BAE27D9BF2FF3048DE140BEA3E" unitRef="usd">19227000</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact-A831D9593F5A2C2CFCE548DE140AA631" unitRef="usd">49568000</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2017Q1" id="Fact-3ACA5CE626D7051314C448DE140E8A5D" unitRef="usd" xsi:nil="true" />
	<us-gaap:PreferredStockValue contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-3" id="Fact-85DF42ACC75700DFA34648DE140A47F2" unitRef="usd">19227000</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact-059147B3CB280623E77B48DE14096227" unitRef="usd">49568000</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-DCCC6A5611ABA251199B48DE140B0994" unitRef="usd">2107000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-8F8C20E6DF08ECC4AE9248DE140A3316" unitRef="usd">2112000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2016Q3Aug1-31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_alim_PublicOfferingMember" decimals="-3" id="Fact-998B982607FD610E7EEED8D4EA130C3C" unitRef="usd">26460000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="-3" id="Fact-9D4DCA1CA324C4250ACBC9DA1317632E" unitRef="usd">1211000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="D2012Q4Oct1-2_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-6" id="Fact-F1F83474D745626F625148DE15140927" unitRef="usd">30000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-3" id="Fact-40D0C8EBD9DAD8F6D4BF48DE140BC8F8" unitRef="usd">1787000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q1" decimals="-3" id="Fact-5DEA8DD8350ED7C890B348DE140E9CBE" unitRef="usd">1572000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="FD2016Q1QTD" decimals="-3" id="Fact-3833EB9C1E9E6B8738A748DE145B6609" unitRef="usd">64000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
	<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="FD2017Q1YTD" decimals="-3" id="Fact-A8455F48AC637EAC9F5048DE145B9E63" unitRef="usd">38000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q1QTD" decimals="-3" id="Fact-3861384A12401742CCD148DE14349520" unitRef="usd">3020000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember" decimals="-3" id="Fact-BA3B875A8E2B652617D048DE15BBCCB9" unitRef="usd">1086000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember" decimals="-3" id="Fact-6C9A49314AEBFF7E92A148DE15B2AA5D" unitRef="usd">1708000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-4C96B0ADE2DAC67BC40BF303184D646D" unitRef="usd">226000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember" decimals="-3" id="Fact-93CB6673E2FD877E4F3748DE15B2FEEE" unitRef="usd">741000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember" decimals="-3" id="Fact-DD16907801A5BEAB549748DE15B32F4A" unitRef="usd">1158000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-9780DB51206BCADC6F40F30254E4E770" unitRef="usd">211000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q1YTD" decimals="-3" id="Fact-A48D230537B93B464B0E48DE1435DD2F" unitRef="usd">2110000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q1QTD" decimals="-3" id="Fact-958159389BD6B900D9F6E8BA7635832D" unitRef="usd">561000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q1YTD" decimals="-3" id="Fact-C64F1B06806D7084DEC3E8BA76388346" unitRef="usd">350000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-CA7001C1F8ECBEE3472748DE140C55B7" unitRef="usd">31000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q1" decimals="-3" id="Fact-5F4447733D860722639448DE1409B838" unitRef="usd">31000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-3" id="Fact-0B4F53F3F28DD07B044D48DE1408FF2D" unitRef="usd">-377074000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q1" decimals="-3" id="Fact-6FC2BD13C6D2C0AA713F48DE140D7767" unitRef="usd">-383809000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:Revenues contextRef="FD2016Q1QTD" decimals="-3" id="Fact-28F7CA8616841E58279D48DE143415DD" unitRef="usd">5801000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember" decimals="-3" id="Fact-B217EFA99D50A8203C2548DE15B07970" unitRef="usd">1682000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember" decimals="-3" id="Fact-4527CE1E38AF6D721B8148DE15B2E877" unitRef="usd">4119000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-57A558CEB1FF18BEBA85F30313189DF3" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_InternationalSegmentMember" decimals="-3" id="Fact-BB69BC176882EB3EFDF648DE15B49CE7" unitRef="usd">2173000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_alim_UnitedStatesSegmentMember" decimals="-3" id="Fact-1699B6DF2BFC07F1FF4F48DE15B4CBCB" unitRef="usd">4445000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q1QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" decimals="-3" id="Fact-0BB01AED389D4E24F3DBF3024F54D34D" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q1YTD" decimals="-3" id="Fact-54D3D2596768928E753348DE14347AEF" unitRef="usd">6618000</us-gaap:Revenues>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q1QTD" decimals="-3" id="Fact-31208DF731D95D1882C348DE145B2967" unitRef="usd">1296000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q1YTD" decimals="-3" id="Fact-B53BE574F908DEE456B848DE145AAC2D" unitRef="usd">1166000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="D2017Q1Jan_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-85020A9F0F6412BE3F08E8C0F0D60D98" unitRef="shares">873900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-28FE6EED662E1180D7B8E8C321F00739" unitRef="shares">815700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2016Q1" decimals="INF" id="Fact-5FE38ECD9E4D8028DB4848DE154025A9" unitRef="shares">6310239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2016Q4" decimals="INF" id="Fact-9B86D27522B92DCD30E448DE15249E1A" unitRef="shares">7363400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2017Q1" decimals="INF" id="Fact-A6FD7EE6141F7402112748DE152FDE0C" unitRef="shares">7527392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2016Q1" decimals="2" id="Fact-D44297A4C7570FFC9C4148DE15406BBC" unitRef="usdPerShare">3.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2016Q4" decimals="2" id="Fact-4B5DC7F931D44B672C6848DE15241368" unitRef="usdPerShare">3.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2017Q1" decimals="2" id="Fact-45DEC432A9EE3496C3AC48DE152FF4E7" unitRef="usdPerShare">3.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2016Q1QTD" decimals="INF" id="Fact-D58B1D8D2D06149BDCB548DE153FD402" unitRef="shares">77813</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2017Q1YTD" decimals="INF" id="Fact-120DD7128F2FEB447C0848DE153F95D9" unitRef="shares">420643</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2016Q1QTD" decimals="INF" id="Fact-C3DF685B77E446F21D7048DE1540879E" unitRef="shares">1228000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2017Q1YTD" decimals="INF" id="Fact-2D26D97694E2BF91AEED48DE154189E0" unitRef="shares">1312500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q1QTD" decimals="2" id="Fact-5635CFABCA6FFECBE6AE48DE1541D6FD" unitRef="usdPerShare">1.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q1YTD" decimals="2" id="Fact-2303C3A0262FF78AF05348DE1541DEB8" unitRef="usdPerShare">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2016Q4" decimals="-3" id="Fact-93C3D3C6A41D46AFF56048DE15257075" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2017Q1" decimals="-3" id="Fact-C9A4D50F612A460758BF48DE152F2C42" unitRef="usd">289000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4" decimals="INF" id="Fact-45AEDF425B8AB528A47948DE153F299D" unitRef="shares">9475890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q1" decimals="INF" id="Fact-2D843225EC3D880F122A48DE15401152" unitRef="shares">10626077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4" decimals="INF" id="Fact-D6DC231B56CBE9FC991D48DE1540A81E" unitRef="shares">10804412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q1" decimals="INF" id="Fact-AC00246698DC9A47D0C148DE152F7D94" unitRef="shares">11696269</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4" decimals="2" id="Fact-A7C5B6867B50FC95BA1848DE1541E175" unitRef="usdPerShare">3.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q1" decimals="2" id="Fact-132A5435C7009967972448DE1540BCCE" unitRef="usdPerShare">3.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4" decimals="2" id="Fact-643D5C271C2EB864556548DE15414246" unitRef="usdPerShare">3.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q1" decimals="2" id="Fact-AEE9171B9161345564F548DE152F2C35" unitRef="usdPerShare">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2016Q4" decimals="-3" id="Fact-F1780728924EF1A5C1A548DE1524EDA7" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2017Q1" decimals="-3" id="Fact-0AD4360F2AAD524CB06148DE152FB020" unitRef="usd">240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2016Q4" decimals="INF" id="Fact-9B0724570B157C8E587A48DE152571A4" unitRef="shares">10374846</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2017Q1" decimals="INF" id="Fact-5E2E7BCFA4EA64FC1E0B48DE152FA1B4" unitRef="shares">11131410</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4" decimals="2" id="Fact-043885C94FA7741703DB48DE1525DF43" unitRef="usdPerShare">3.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2017Q1" decimals="2" id="Fact-F143263C39FDF7000D2348DE152EF5D2" unitRef="usdPerShare">3.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2016Q1QTD" decimals="2" id="Fact-81FF886D894DEDBD8CC248DE15407CE1" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2017Q1YTD" decimals="2" id="Fact-72553C4C2A8DDCFCC7A148DE153FB661" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2016Q1QTD" decimals="2" id="Fact-3F97391A7344BEE8AC5C48DE153F488E" unitRef="usdPerShare">3.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2017Q1YTD" decimals="2" id="Fact-862C2074DE3A73724D9848DE154070D1" unitRef="usdPerShare">2.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2016Q1QTD" decimals="2" id="Fact-06BBD932F5AF1F7C5C3F48DE15402FD9" unitRef="usdPerShare">2.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q1YTD" decimals="2" id="Fact-A095662142ACA5E8482348DE15426176" unitRef="usdPerShare">1.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2016Q4" decimals="-3" id="Fact-099B75B3DA6329B4CF3048DE152410D6" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2017Q1" decimals="-3" id="Fact-DD19ACC42566D096908E48DE152F3D7A" unitRef="usd">12000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2016Q4YTD" id="Fact-425EE499654DAF70C2FC48DE1525E638">P5Y5M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2017Q1YTD" id="Fact-A067BA3B93D4E9EA91AB48DE152F51EC">P5Y6M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-962C2F80A3B4C5F5451F48DE1550E115">P2Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2016Q4YTD" id="Fact-8A0D4A4C074F31E6088648DE1525F1CF">P6Y5M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2017Q1YTD" id="Fact-5BF4B54EE9A5C3A5AEF048DE152E52A1">P6Y8M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="FD2016Q4YTD" id="Fact-2BDE320360E68F92AFAF48DE152419DA">P6Y4M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="FD2017Q1YTD" id="Fact-021EC3E48F5974A4C7E648DE152F75EC">P6Y6M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharesIssuedPricePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="2" id="Fact-F54B0BEEF81393459BF0C9DA5F26E598" unitRef="usdPerShare">1.83</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:SharesIssuedPricePerShare contextRef="I2014Q4Dec12_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-CF1BD2BD9DBA6F26462348DE1515F3CA" unitRef="usdPerShare">6030.00</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:SharesIssuedPricePerShare contextRef="I2016Q3Aug31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_alim_PublicOfferingMember" decimals="INF" id="Fact-A852D3DA08087523E78BD8D4BBA26E21" unitRef="usdPerShare">1.40</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="D2014Q2Apr1-30_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-84F8DBE9BB62D996829748DE15171808" unitRef="shares">2255639</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="D2014Q3Sep1-30_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-89E7504FEA2796A376E348DE15153A72" unitRef="shares">3759398</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2014Q4Dec12_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="3" id="Fact-6F566DCB3BC2839C915A48DE15175A16" unitRef="shares">8291.873</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2014Q4Dec12_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="3" id="Fact-3F0C11AB97F054207A4748DE15166807" unitRef="shares">124.378</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2016Q3Aug1-31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_alim_PublicOfferingMember" decimals="INF" id="Fact-C57AC383C1EDCF12D427D8D48D906369" unitRef="shares">18900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-87F396470783F4F8189EC9DA82A41752" unitRef="shares">662779</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q1QTD" decimals="INF" id="Fact-A205E553AF15354CDCA348DE15427A0D" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q1YTD" decimals="INF" id="Fact-E4041D885382E35F48F148DE1541760C" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="D2014Q4Dec12_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="-6" id="Fact-1AC597542545D0EE748948DE15170163" unitRef="usd">50000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-CD605ED0569D94399F9448DE140D1C63" unitRef="usd">25586000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q1" decimals="-3" id="Fact-B2E5091E69E23D3EE4B648DE140A734D" unitRef="usd">20066000</us-gaap:StockholdersEquity>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2016Q4" decimals="-3" id="Fact-5DF8042BB97F88AE070A48DE140F7A7B" unitRef="usd">3707000</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2017Q1" decimals="-3" id="Fact-21E4D2D720BF80AF53B048DE140B8929" unitRef="usd">3707000</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="I2016Q4Oct31_dei_LegalEntityAxis_alim_AlimeraSciencesLimitedLimitedMember_us-gaap_CreditFacilityAxis_alim_FourthLoanAmendmentMember_us-gaap_LineOfCreditFacilityAxis_alim_HerculesTechnologyGrowthCapitalInc.Member" decimals="-3" id="Fact-614D0C87E4A1B9AF75BED0CA192FA9B4" unitRef="usd">500000</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q1QTD" decimals="0" id="Fact-11083A3D9C54B9E8645648DE1434BF86" unitRef="shares">45005833</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q1YTD" decimals="0" id="Fact-605025A4879AAF87D66548DE14331DCB" unitRef="shares">64862904</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<alim:AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2017Q1YTD" id="Fact-FCBE3B394095B081CB0448DE154FF781">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table provides additional information related to outstanding stock options, exercisable stock options and stock options expected to vest as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Remaining Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In&amp;#160;thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,696,269&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.71 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;289&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,527,392&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.52 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, vested and expected to vest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,131,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.58 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;240&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table provides additional information related to outstanding stock options, exercisable stock options and stock options expected to vest as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Remaining Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In&amp;#160;thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,804,412&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.45 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,363,400&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.42 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, vested and expected to vest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,374,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.35 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</alim:AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-63773E74462597AC499148DE148F14BC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;ACCRUED EXPENSES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses consisted of the following: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March 31, &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued clinical investigator expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;402&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued rebate, chargeback and other revenue reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;348&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;767&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;807&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,758&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
	<us-gaap:BasisOfAccounting contextRef="FD2017Q1YTD" id="Fact-FD1F4DA610F2BF977CC248DE1469B0F9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;BASIS OF PRESENTATION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has prepared the accompanying unaudited interim condensed consolidated financial statements and notes thereto (Interim Financial Statements) in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for interim financial information and the instructions to Form 10-Q and Article&amp;#160;10-01 of Regulation&amp;#160;S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of the Company&amp;#8217;s management, the accompanying interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary to present fairly the Company&amp;#8217;s interim financial information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying interim financial statements and related notes should be read in conjunction with the Company&amp;#8217;s audited financial statements for the year ended December&amp;#160;31, 2016 and related notes included in the Company&amp;#8217;s Annual Report on Form 10-K, which was filed with the SEC on March&amp;#160;3, 2017. The financial results for any interim period are not necessarily indicative of the expected financial results for the full year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Modification of Segment Footnote&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company modified its segment footnote for the three months ended March 31, 2016 for an immaterial change&amp;#160;and removed, within the segment footnote, certain non-cash expenses including &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,296,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of stock-based compensation expense and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$689,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of depreciation and amortization from the Company&amp;#8217;s U.S. and International segments.&amp;#160;These amounts are appropriately classified as Other within the segment footnote of these interim unaudited condensed consolidated financial statements.&amp;#160;Additionally, in the Company&amp;#8217;s Annual Report on Form 10-K filing for the year ended December 31, 2016, the Company disclosed that the Company&amp;#8217;s chief operating decision maker separately managed and evaluated each segment primarily upon net loss from operations.&amp;#160;The modification made in these financial statements clarifies that the chief operating decision maker manages and evaluates each segment based on net loss from operations adjusted for certain non-cash items, such as stock-based compensation expense and depreciation and amortization.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-2FBC895A2EB7D758CE9648DE1469EA28">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;BASIS OF PRESENTATION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has prepared the accompanying unaudited interim condensed consolidated financial statements and notes thereto (Interim Financial Statements) in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for interim financial information and the instructions to Form 10-Q and Article&amp;#160;10-01 of Regulation&amp;#160;S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of the Company&amp;#8217;s management, the accompanying interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary to present fairly the Company&amp;#8217;s interim financial information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying interim financial statements and related notes should be read in conjunction with the Company&amp;#8217;s audited financial statements for the year ended December&amp;#160;31, 2016 and related notes included in the Company&amp;#8217;s Annual Report on Form 10-K, which was filed with the SEC on March&amp;#160;3, 2017. The financial results for any interim period are not necessarily indicative of the expected financial results for the full year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Modification of Segment Footnote&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company modified its segment footnote for the three months ended March 31, 2016 for an immaterial change&amp;#160;and removed, within the segment footnote, certain non-cash expenses including &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,296,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of stock-based compensation expense and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$689,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of depreciation and amortization from the Company&amp;#8217;s U.S. and International segments.&amp;#160;These amounts are appropriately classified as Other within the segment footnote of these interim unaudited condensed consolidated financial statements.&amp;#160;Additionally, in the Company&amp;#8217;s Annual Report on Form 10-K filing for the year ended December 31, 2016, the Company disclosed that the Company&amp;#8217;s chief operating decision maker separately managed and evaluated each segment primarily upon net loss from operations.&amp;#160;The modification made in these financial statements clarifies that the chief operating decision maker manages and evaluates each segment based on net loss from operations adjusted for certain non-cash items, such as stock-based compensation expense and depreciation and amortization.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-535BCF3812A3B889B9E648DE14A54AEC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;LICENSE AGREEMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company entered into an agreement with pSivida for the use of fluocinolone acetonide (FAc) in pSivida&amp;#8217;s proprietary delivery device in February 2005, which was subsequently amended in 2008 (the pSivida Agreement). The pSivida Agreement provides the Company with a worldwide exclusive license to utilize certain underlying technology used in the development and commercialization of ILUVIEN.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s license rights to pSivida&amp;#8217;s proprietary delivery device could revert to pSivida if the Company were to (i)&amp;#160;fail twice to cure its breach of an obligation to make certain payments to pSivida following receipt of written notice thereof; (ii)&amp;#160;fail to cure other breaches of material terms of the pSivida Agreement within &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; days after notice of such breaches or such longer period (up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;90 days&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) as may be reasonably necessary if the breach cannot be cured within such &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-day period; (iii)&amp;#160;file for protection under the bankruptcy laws, make an assignment for the benefit of creditors, appoint or suffer appointment of a receiver or trustee over its property, file a petition under any bankruptcy or insolvency act or have any such petition filed against it and such proceeding remains undismissed or unstayed for a period of more than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;60 days&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; or (iv)&amp;#160;notify pSivida in writing of its decision to abandon its license with respect to a certain product using pSivida&amp;#8217;s proprietary delivery device.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company must share &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;20%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the net profits of ILUVIEN, determined on a cash basis and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;33%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of any lump sum milestone payments received from a sub-licensee of ILUVIEN, as defined by the pSivida Agreement. In connection with this arrangement, the Company is entitled to recover &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;20%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of commercialization costs of ILUVIEN, as defined in the pSivida Agreement, incurred prior to product profitability out of pSivida&amp;#8217;s share of net profits. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company can reduce future net profit payments to pSivida, as defined in the pSivida Agreement, in the amounts of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$24,909,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$24,475,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. Due to the uncertainty of future net profits, the Company has fully reserved these amounts in the accompanying Interim Financial Statements. As a result of the FDA&amp;#8217;s approval of the NDA for ILUVIEN in September 2014, the Company made the pSivida Milestone Payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$25,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in October 2014.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In the second quarter of 2016, pSivida disputed portions of the Company&amp;#8217;s claimed commercialization costs for the year ended December 31, 2014. On May 3, 2017, the Company and pSivida settled this dispute and amended and clarified certain definitions and clauses of the pSivida Agreement. As part of this settlement, the Company and pSivida agreed no additional amounts would be due for the years ended December 31, 2014, 2015 and 2016 and no audits will take place related to the amounts reported for the years ended December 31, 2015 and 2016. As a result of this settlement and amendment, the amount available for the reduction of future net profit payments was reduced from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$25,828,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$24,475,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of December 31, 2016. Since these amounts are fully reserved, there was no impact to the statements of operations for any period as a result of this settlement and amendment.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-FC5EC15F8FFC4BEE39E948DE14DE582D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;LOAN AGREEMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hercules Loan Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;2014 Loan Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2014, Alimera Sciences Limited (Limited), a subsidiary of the Company, entered into a loan and security agreement (2014 Loan Agreement) with Hercules Capital, Inc. (Hercules) providing for a term loan of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$35,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2014 Term Loan), which Limited and Hercules amended in November 2015 (the First Loan Amendment), March 2016 (the Second Loan Amendment), May 2016 (the Third Loan Amendment) and October 2016 (the Fourth Loan Amendment and, collectively with the 2014 Loan Agreement, the First Loan Amendment, the Second Loan Amendment and the Third Loan Amendment, the Term Loan Agreement). Under the 2014 Loan Agreement, Hercules made an advance in the initial principal amount of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;to Limited at closing to provide Limited with additional working capital for general corporate purposes and to repay a 2013 term loan with Silicon Valley Bank. Hercules made an additional advance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$25,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to Limited in September 2014, following the approval of ILUVIEN by the FDA to fund the pSivida Milestone Payment. The 2014 Loan Agreement provided for interest only payments through November 2015. Interest on the 2014 Term Loan accrued at a floating per annum rate equal to the greater of (i) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.90%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, or (ii) the sum of (A) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.65%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, plus (B) the prime rate. Following the interest only period the 2014 Term Loan was due and payable to Hercules in equal monthly payments of principal and interest through May 1, 2018. The interest rate on the Term Loan Agreement was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;First Loan Amendment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2015, Limited and Hercules amended the 2014 Loan Agreement to extend the interest only payments through May 2017. In connection with the First Loan Amendment, Limited paid to Hercules an amendment fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$262,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and agreed to make an additional payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,050,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the 2014 Term Loan at the time of the final payment (End of Term Payment).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Limited and the Company, on a consolidated basis with the Company&amp;#8217;s other subsidiaries (the Consolidated Group), agreed to customary affirmative and negative covenants and events of default in connection with these arrangements. The occurrence of an event of default could result in the acceleration of Limited&amp;#8217;s obligations under the Term Loan Agreement and an increase to the applicable interest rate and would permit Hercules to exercise remedies with respect to the collateral under the Term Loan Agreement. In connection with the First Loan Amendment, Limited agreed to covenants regarding certain revenue thresholds and a liquidity threshold.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Second Loan Amendment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2016, the revenue threshold covenant was not met by the Consolidated Group and as a result, in March 2016, Limited and Hercules entered into the Second Loan Amendment, which further amended certain terms of the 2014 Loan Agreement. In conjunction with the Second Loan Amendment, Hercules waived this covenant violation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Second Loan Amendment adjusted the revenue covenant to a rolling three-month calculation, first measured for the three months ended May 31, 2016. In addition, the Second Loan Amendment increased the liquidity covenant. Upon execution of the Second Loan Amendment, Limited paid Hercules an amendment fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$350,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and agreed to increase the End of Term Payment to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,400,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,050,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which is payable in May 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company concluded that the Second Loan Amendment resulted in a substantial modification of the terms of debt when considered with the First Loan Amendment in accordance with the guidance in ASC 470-50, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Debt&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As a result, the Company accounted for the Second Loan Amendment as an extinguishment and recognized a loss on early extinguishment of debt of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2,564,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; within the consolidated statement of operations for the year ended December 31, 2016. The loss on early extinguishment consisted primarily of the unamortized debt discount associated with the warrant and debt issuance costs incurred prior to the Second Loan Amendment, the incremental fair value of the warrant as a result of modifying the terms of the warrant and the debt issuance costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$360,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; paid to Hercules for the Second Loan Amendment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Third Loan Amendment and July 2016 Waiver&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2016, Limited and Hercules entered into the Third Loan Amendment to expand the definition of liquidity to allow for the inclusion of cash of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in bank accounts outside of the U.S. and the United Kingdom.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2016, Limited obtained a waiver of the requirements of the liquidity covenant (the Waiver) because the Consolidated Group was not in compliance with the liquidity covenant as of June 30, 2016. The Waiver cured the default of the liquidity covenant then existing under the Term Loan Agreement and decreased the liquidity requirement. In addition, the Waiver modified the three-month revenue covenant so that it was not measured at July 31, 2016 and reduced the three-month revenue target to be measured at August 31, 2016. Following execution of the Waiver, Limited incurred a weekly ticking fee equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.05%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; multiplied by the outstanding principal amount through the closing of the Company&amp;#8217;s public offering in August 2016 (see Note 12 Common Stock), totaling &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$65,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Further, Limited paid Hercules a fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$350,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; associated with the Waiver.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Fourth Loan Amendment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2016, Limited entered into the Fourth Loan Amendment with Hercules, which further amended certain terms of the Term Loan Agreement. Pursuant to the terms of the Fourth Loan Amendment, Hercules agreed to provide up to an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to Limited with (i) the first &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; available at Limited&amp;#8217;s option through June 30, 2017 subject to (A) the Consolidated Group&amp;#8217;s achievement of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in trailing three month net product revenue and (B) no event of default having occurred since October 20, 2016 (the Effective Date) and (ii) the second &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; available at Limited&amp;#8217;s option through December 31, 2017 subject to (A) the Consolidated Group&amp;#8217;s achievement of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in trailing three month net product revenue, (B) no event of default having occurred since the Effective Date and (C) the prior &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; having been advanced to Limited (the Additional Advances and, together with the 2014 Term Loan, the Term Loan). The Fourth Loan Amendment provides for interest only payments through November 30, 2018 (the Interest-Only Period). Pursuant to the Fourth Loan Amendment, interest on the Term Loan accrues at a floating per annum rate equal the greater of (i) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and (ii) the sum of (A) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; plus (B) the prime rate as reported in The Wall Street Journal, or if not reported, the prime rate most recently reported in The Wall Street Journal, minus &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In addition to the interest described above, the principal balance of the Term Loan will bear &amp;#8220;payment-in kind&amp;#8221; interest at the rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (PIK Interest), which PIK Interest will be added to the outstanding principal balance of the Term Loan so as to increase the outstanding principal balance of the Term Loan on each payment date for the Term Loan and which amount will be payable when the aggregate outstanding principal amount of the Term Loan is payable. The Term Loan will be due and payable to Hercules in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; equal monthly payments of principal and interest following the Interest-Only Period beginning on December 1, 2018 and matures in full on November 1, 2020.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Limited paid Hercules a facility charge of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$337,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and reimbursed Hercules for legal and diligence fees incurred in connection with the Fourth Loan Amendment. If Limited prepays the Term Loan, it will pay Hercules a prepayment penalty (i) if such amounts are prepaid in any of the first 12 months following the Effective Date, equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the principal amount of the Term Loan being repaid, (ii) if such amounts are prepaid after 12 months but prior to 24 months following the Effective Date, equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the principal amount of the Term Loan being repaid, and (iii) if such amounts are prepaid at any time thereafter, equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the principal amount of the Term Loan being repaid.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Consolidated Group also agreed to customary affirmative and negative covenants, including, without limitation, covenants relating to minimum liquidity, minimum trailing six-month net revenue and adjusted EBITDA and events of default in connection with these arrangements. The occurrence of an event of default could result in the acceleration of Limited&amp;#8217;s obligations under the Term Loan Agreement, as amended by the Fourth Loan Amendment and an increase to the applicable interest rate and would permit Hercules to exercise remedies with respect to the collateral under the Term Loan Agreement, as amended by the Fourth Loan Amendment. In the event that the Company maintains &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$35,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in liquidity, including cash and eligible accounts receivable, at the end of the month and has not been and is not in breach of the amended debt facility, the six-month trailing revenue covenant is waived for such month. As of March 31, 2017, the Company was in compliance with its debt covenants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;General Discussion of the Term Loan Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pursuant to the Term Loan Agreement, Limited&amp;#8217;s obligations to Hercules are secured by a first-priority security interest in substantially all of Limited&amp;#8217;s assets, excluding intellectual property. Hercules does, however, maintain a negative pledge on Limited&amp;#8217;s intellectual property requiring Hercules&amp;#8217; consent prior to the sale of such intellectual property. The Company and certain of the Company&amp;#8217;s other subsidiaries are guarantors of the obligations of Limited to Hercules under the Term Loan Agreement pursuant to separate guaranty agreements between Hercules and each of Limited and such subsidiaries (Guaranties). Pursuant to the Guaranties, the Company and these subsidiaries granted Hercules a first-priority security interest in substantially all of their respective assets excluding intellectual property. The Term Loan Agreement also places limitations on the Company&amp;#8217;s ability to declare or pay any dividend or distribution on any shares of capital stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;2014 Warrant&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with Limited entering into the 2014 Loan Agreement, the Company issued a warrant to Hercules to purchase up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;285,016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.14&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share (the 2014 Warrant). &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Sixty percent&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the 2014 Warrant was exercisable at the closing in April 2014 and the remaining &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;forty percent&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; became exercisable upon the funding of the additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$25,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to Limited in September 2014.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company agreed to amend the 2014 Warrant in connection with the First Loan Amendment to increase the number of shares issuable upon exercise to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;660,377&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and decrease the exercise price to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.65&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. Upon entering into the Second Loan Amendment, the Company agreed to further amend the 2014 Warrant to increase the number of shares issuable upon exercise to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;862,069&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and decrease the exercise price to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.03&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. In connection with the July 2016 Waiver, the Company agreed to further amend the 2014 Warrant to increase the number of shares issuable upon exercise to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,258,993&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and decrease the exercise price to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.39&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;2016 Warrant&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with Limited entering into the Fourth Loan Amendment, the Company agreed to issue a new warrant to Hercules (the 2016 Warrant) to purchase up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;458,716&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.09&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, which was equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; divided by the lowest volume-weighted average sale price for a share of the Company&amp;#8217;s common stock reported over any ten consecutive trading days during the period commencing on and including September 23, 2016 and ending on the earlier to occur of (i) December 30, 2016 (inclusive of such date), and (ii) the second trading day immediately preceding the date of closing of a merger event (as defined in the 2016 Warrant).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value of Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted average interest rates of the Company&amp;#8217;s notes payable approximate the rate at which the Company could obtain alternative financing and the fair value of the warrants that were issued in connection with the Company&amp;#8217;s notes payable are immaterial. Therefore, the carrying amount of the notes approximated their fair value at March 31, 2017 and December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2017Q1YTD" id="Fact-337FDD057BB1E5DA557E48DE154FBAD7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;STOCK INCENTIVE PLANS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock Option Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the three months ended March 31, 2017 and 2016, the Company recorded compensation expense related to stock options of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$972,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,264,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. As of March 31, 2017, the total unrecognized compensation cost related to non-vested stock options granted was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7,877,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and is expected to be recognized over a weighted average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.40 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The following table presents a summary of stock option activity for the three months ended March 31, 2017 and 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three Months Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,804,412&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,475,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Grants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,312,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,228,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeitures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(420,643&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(77,813&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at period end&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,696,269&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,626,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercisable at period end&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,527,392&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,310,239&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average per share fair value of options granted during the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table provides additional information related to outstanding stock options, exercisable stock options and stock options expected to vest as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Remaining Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In&amp;#160;thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,696,269&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.71 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;289&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,527,392&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.52 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, vested and expected to vest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,131,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.58 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;240&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table provides additional information related to outstanding stock options, exercisable stock options and stock options expected to vest as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Remaining Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In&amp;#160;thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,804,412&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.45 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,363,400&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.42 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, vested and expected to vest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,374,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.35 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the three months ended March 31, 2017 and 2016, the Company recorded compensation expense related to its employee stock purchase plan of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$32,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restricted Stock Units&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2017, the Company granted &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;873,900&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; restricted stock units (RSUs) to its employees in lieu of a cash bonus program for 2017. As of March 31, 2017, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;815,700&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; RSUs were outstanding. During the three months ended March 31, 2017, the Company recorded compensation expense related these RSUs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$182,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2017Q1YTD" id="Fact-0E6CF5141A34607A48F348DE150159FC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;LOSS PER SHARE (EPS)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic EPS is calculated in accordance with ASC 260, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Earnings per Share&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, by dividing net income or loss attributable to common stockholders by the weighted average common stock outstanding. Diluted EPS is calculated in accordance with ASC 260 by adjusting weighted average common shares outstanding for the dilutive effect of common stock options, warrants and convertible preferred stock. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be anti-dilutive. Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because to do so would have been anti-dilutive, were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three Months Ended &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series A convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,022,556&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,022,556&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series B convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,416,251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,416,251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series A convertible preferred stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,511,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,511,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,795,663&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;940,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,696,269&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,626,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,442,018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,516,186&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="FD2017Q1YTD" id="Fact-0ADED21512ABC4439D2D48DE1588352E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following fair value table presents information about the Company&amp;#8217;s assets and liabilities measured at fair value on a recurring basis:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets measured at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Derivative warrant liability (2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities measured at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets measured at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Derivative warrant liability (2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities measured at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:40px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:-2px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:40px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:-2px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2017Q1YTD" id="Fact-184EAD33F1044BD58A1C48DE15884F21">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;FAIR VALUE&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company applies ASC 820, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, in determining the fair value of certain assets and liabilities. Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &amp;#8220;exit price&amp;#8221;) in an orderly transaction between market participants at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In determining fair value, the Company uses various valuation approaches. The hierarchy of those valuation approaches is broken down into three levels based on the reliability of inputs as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. The valuation under this approach does not entail a significant degree of judgment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets, inputs other than quoted prices that are observable for the asset or liability, (e.g., interest rates and yield curves observable at commonly quoted intervals or current market) and contractual prices for the underlying financial instrument, as well as other relevant economic measures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There have been no changes in the methodologies used at March 31, 2017 and December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following fair value table presents information about the Company&amp;#8217;s assets and liabilities measured at fair value on a recurring basis:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets measured at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Derivative warrant liability (2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities measured at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets measured at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Derivative warrant liability (2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities measured at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:40px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:-2px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:40px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:-2px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-554CE63895C6423CBC8C48DE155946EA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;INCOME TAXES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In accordance with ASC 740, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; the Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities at the enacted tax rates in effect for the year in which the differences are expected to reverse. The Company records a valuation allowance against its net deferred tax asset to reduce the net carrying value to an amount that is more likely than not to be realized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At the end of each interim period, the Company makes its best estimate of the effective tax rate expected to be applicable for the full fiscal year. This estimate reflects, among other items, the Company&amp;#8217;s best estimate of operating results and foreign currency exchange rates. The Company&amp;#8217;s quarterly income tax rate may differ from its estimated annual effective tax rate because accounting standards require the Company to exclude the actual results of certain entities expected to generate a pretax loss when applying the estimated annual effective tax rate to the Company&amp;#8217;s consolidated pretax results in interim periods. In estimating the annual effective tax rate, the Company does not include the estimated impact of unusual and/or infrequent items, including the reversal of valuation allowances, which may cause significant variations in the customary relationship between income tax expense (benefit) and pretax income (loss) in quarterly periods. The income tax expense (benefit) for such unusual and/or infrequent items is recorded in the quarterly period such items are incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s income tax expense and resulting effective tax rate are based upon the respective estimated annual effective tax rates applicable for the respective periods adjusted for the effects of items required to be treated as discrete to the period, including changes in tax laws, changes in estimated exposures for uncertain tax positions and other items. The Company&amp;#8217;s effective tax rate for the three months ended March 31, 2017 properly excluded tax benefits associated with year-to-date pre-tax losses generated in the U.S. and the Netherlands. Income tax positions are considered for uncertainty in accordance with ASC 740-10. The Company has recorded unrecognized tax benefits related to research and development tax credits. In accordance with ASC 740-10, such attributes are reduced to the amount that is expected to be recognized in the future. The Company has not accrued interest or penalties as no research and development credits have been utilized due to significant net operating losses (NOLs) available. The Company does not expect any decreases to the unrecognized tax benefits within the next twelve months due to any lapses in statute of limitations. Tax years since 2003 remain subject to examination in Georgia, Tennessee and at the federal level. The time period is longer than the standard statutory 3-year period due to NOLs from 2003 being available for utilization. The statute of limitations on these years will close when the NOLs expire or when the statute closes on the years in which the NOLs are utilized. Tax years since 2012 remain subject to examination in the United Kingdom and the Netherlands. Tax years since 2013 remain subject to examination in Germany.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Significant management judgment is involved in determining the provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. Due to uncertainties with respect to the realization of deferred tax assets due to the history of operating losses, a valuation allowance has been established against the net deferred tax asset balance in the U.S. and the Netherlands. The valuation allowance is based on management&amp;#8217;s estimates of taxable income in the jurisdictions in which the Company operates and the period over which deferred tax assets will be recoverable. In the event that actual results differ from these estimates or the Company adjusts these estimates in future periods, a change in the valuation allowance may be needed, which could materially impact its financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At December&amp;#160;31, 2016, the Company had federal NOL carry-forwards of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$104,944,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and state NOL carry-forwards of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$83,270,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; available to reduce future taxable income. The Company&amp;#8217;s federal NOL carry-forwards remain fully reserved as of March 31, 2017. If not utilized, the federal NOL carry-forwards will expire at various dates between 2029 and 2035 and the state NOL carry-forwards will expire at various dates between 2020 and 2035. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;NOL carry-forwards may be subject to annual limitations under Internal Revenue Code (IRC) Section&amp;#160;382 (Section 382) (or comparable provisions of state law) in the event that certain changes in ownership of the Company were to occur. The Company periodically evaluates its NOL carry-forwards and whether certain changes in ownership have occurred that would limit the Company&amp;#8217;s ability to utilize a portion of its NOL carry-forwards. If it is determined that significant ownership changes have occurred since the Company generated its NOL carry-forwards, it may be subject to annual limitations on the use of these NOL carry-forwards under Section&amp;#160;382 (or comparable provisions of state law). The Company has determined that a Section 382 change in ownership occurred in late 2015.&amp;#160;Therefore, the annual utilization of the Company&amp;#8217;s NOLs are subject to certain limitations under Section 382 and other limitations under state tax laws.&amp;#160;The Company is currently in the process of calculating these limitations. Any reduction to the Company&amp;#8217;s NOL deferred tax asset due to the annual Section 382 limitation and the NOL carryforward period would result in an offsetting reduction in valuation allowance recorded against the NOL deferred tax asset. Therefore, any limitation would not have an impact on the statements of operations for the periods presented. The results of the analysis on the impact to the Company&amp;#8217;s NOLs will be disclosed at a later date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of December 31, 2016, the Company had cumulative book losses in foreign subsidiaries of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$92,939,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company has not recorded a deferred tax asset for the excess of tax over book basis in the stock of its foreign subsidiaries. The Company anticipates that its foreign subsidiaries will be profitable and have earnings in the future. Once the foreign subsidiaries do have earnings, the Company intends to indefinitely reinvest in its foreign subsidiaries all undistributed earnings of and original investments in such subsidiaries. As a result, the Company has not recorded a deferred tax liability related to excess of book over tax basis in the stock of its foreign subsidiaries in accordance with ASC 740-30-25.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-B75069BF760DF8402BF248DE1483467B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;INTANGIBLE ASSET&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As a result of the U.S. Food and Drug Administration&amp;#8217;s (FDA) approval of the New Drug Application (NDA) for ILUVIEN in September 2014, the Company was required to pay pSivida US, Inc. (pSivida) a milestone payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$25,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (the pSivida Milestone Payment) in October 2014 (see Note 8 License Agreements). The Company had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; intangible assets prior to September 2014. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The gross carrying amount of the intangible asset was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$25,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which is being amortized over approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from the payment date. The amortization expense related to the intangible asset was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$478,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$483,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the three months ended March 31, 2017 and 2016, respectively. The net book value of the intangible asset was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20,125,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20,604,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of March 31, 2017 and December 31, 2016, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The estimated future amortization expense as of March 31, 2017 for the remaining periods in the next five years and thereafter is as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Years Ending December&amp;#160;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In&amp;#160;thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,462&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,940&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,940&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,946&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,940&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-FBB617207E1357A5FA0148DE147E9E5B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;INVENTORY&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory consisted of the following: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March 31, &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Component parts (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Work-in-process (2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;389&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;486&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory reserve &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory &amp;#8212; net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;446&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1) Component parts inventory consists of manufactured components of the ILUVIEN applicator.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2) Work-in-process primarily consists of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing or stability testing as required by regulatory authorities in Europe and the U.S.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:NatureOfOperations contextRef="FD2017Q1YTD" id="Fact-6ED32D84E2F7CFA4AF0748DE1467A2C1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;NATURE OF OPERATIONS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Alimera Sciences, Inc., together with its wholly-owned subsidiaries (the Company), is a pharmaceutical company that specializes in the commercialization, research and development of prescription ophthalmic pharmaceuticals. The Company was formed on June&amp;#160;4, 2003 under the laws of the State of Delaware.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is presently focused on diseases affecting the back of the eye, or retina, because the Company&amp;#8217;s management believes these diseases are not well treated with current therapies and represent a significant market opportunity. The Company&amp;#8217;s only commercial product is ILUVIEN&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which has received marketing authorization in the United States (U.S.), Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the&amp;#160;United Kingdom. In the U.S., ILUVIEN is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries in which ILUVIEN has received marketing authorization, it is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies. As part of the approval process in the EEA, the Company committed to conduct a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year, post-authorization, open label registry study in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;800&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; patients treated with ILUVIEN per the labeled indication. In the fourth quarter of 2016, the Company requested approval to modify its protocol to cap enrollment in the study due to its post market safety surveillance not showing any unexpected safety signals. Although the Company has not received formal regulatory approval, the Medicines &amp;amp; Healthcare products Regulatory Agency (MHRA) has agreed to allow the Company to suspend enrollment, pending approval of the Company&amp;#8217;s protocol amendment.&amp;#160;As of March 31, 2017, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;560&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; patients were enrolled in this study.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company launched ILUVIEN in Germany and the United Kingdom in the second quarter of 2013, in the U.S. and Portugal in the first quarter of 2015 and in Austria in the first quarter of 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition, the Company has entered into various agreements under which distributors will provide regulatory, reimbursement or sales and marketing support for future commercialization of ILUVIEN in numerous countries in the Middle East, Italy, Spain, Australia, New Zealand and Canada.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-3B444D80B354C7029B9648DE146B86F1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Adoption of New Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2014, the FASB issued Accounting Standards Update (ASU) 2014-15, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. ASU 2014-15 requires management to perform interim and annual assessments of an entity&amp;#8217;s ability to continue as a going concern within one year of the date the financial statements are issued and provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. ASU 2014-15 applies to all entities and is effective for annual and interim reporting periods ending after December 15, 2016, with early adoption permitted. The adoption of this guidance did not have a material impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2015, the FASB issued ASU 2015-11, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventory (Topic 330): Simplifying the Measurement of Inventory&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. This update requires entities to measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. This ASU is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those years. The adoption of this guidance did not have a material impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued ASU 2016-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation (Topic 718)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. This standard makes several modifications to Topic 718 related to the accounting for forfeitures, employer tax withholding on share-based compensation and the financial statement presentation of excess tax benefits or deficiencies. ASU 2016-09 also clarifies the statement of cash flows presentation for certain components of share-based awards. The standard is effective for interim and annual reporting periods beginning after December 15, 2016, although early adoption is permitted. The adoption of this guidance did not have a material impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounting Standards Issued but Not Yet Effective&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued ASU 2014-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, as subsequently amended. ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. The revenue guidance contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The standard is effective for the first interim period within annual reporting periods beginning after December 15, 2017 for public entities, with early adoption permitted in the annual reporting period beginning after December 15, 2016. The Company has begun its evaluation of the new guidance on its business and, at this time, do not believe there will be a material impact on the Company&amp;#8217;s current direct product sales in international markets. For the U.S. business, the Company continues to evaluate the variable consideration provisions of the new guidance and the impact it will have specifically on the Company&amp;#8217;s gross to net revenue adjustments, including chargebacks and rebates. The Company anticipates adopting the new revenue standard using the modified retrospective transition method.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. This standard requires all leases with durations greater than twelve months to be recognized on the balance sheet and is effective for interim and annual reporting periods beginning after December 15, 2018, although early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:PreferredStockTextBlock contextRef="FD2017Q1YTD" id="Fact-C40584ACE64B40360B9548DE1516265E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;PREFERRED STOCK&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Series A Convertible Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On October&amp;#160;2, 2012, the Company closed its preferred stock financing in which it sold units consisting of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series A Convertible Preferred Stock and warrants to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;300,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series A Convertible Preferred Stock for gross proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$40,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, prior to the payment of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$560,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of related issuance costs. The powers, preferences and rights of the Series A Convertible Preferred Stock are set forth in the certificate of designation filed by the Company with the Secretary of State of the State of Delaware on October&amp;#160;1, 2012. Each share of Series A Convertible Preferred Stock, including any shares of Series A Convertible Preferred Stock issued upon exercise of the warrants, is convertible into shares of the Company&amp;#8217;s common stock at any time at the option of the holder at the rate equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$40.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; divided by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.66&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (Conversion Price). The initial Conversion Price was subject to adjustment based on certain customary price based anti-dilution adjustments. These adjustment features lapsed in September 2014. Each share of Series A Convertible Preferred Stock shall automatically be converted into shares of common stock at the then-effective Conversion Price upon the occurrence of the later to occur of both (i)&amp;#160;the Company receives and publicly announces the approval by the FDA of the Company&amp;#8217;s NDA for ILUVIEN and (ii)&amp;#160;the date on which the Company consummates an equity financing transaction pursuant to which the Company sells to one or more third party investors either (a)&amp;#160;shares of common stock or (b)&amp;#160;other equity securities that are convertible into shares of common stock and that have rights, preference or privileges, senior to or on a parity with, the Series A Convertible Preferred Stock, in each case having an as-converted per share of common stock price of not less than &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"&gt;$10.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and that results in total gross proceeds to the Company of at least &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"&gt;$30,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The rights and preferences of Series A Convertible Preferred Stock also place limitations on the Company&amp;#8217;s ability to declare or pay any dividend or distribution on any shares of capital stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Each unit sold in the preferred stock financing included a warrant to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;0.30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series A Convertible Preferred Stock at an exercise price equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$44.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. At the election of the holder of a warrant, the warrant may be exercised for the number of shares of common stock then issuable upon conversion of the Series A Convertible Preferred Stock that would otherwise be issued upon such exercise at the then-effective Conversion Price. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants are considered derivative instruments because the agreements provide for settlement in Series A Convertible Preferred Stock shares or common stock shares at the option of the holder, an adjustment to the warrant exercise price for common shares at some point in the future and contain anti-dilution provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants are subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. Therefore the warrants were recorded as a liability at issuance. The warrant anti-dilution provisions lapsed in September 2014. At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the fair market value of the warrants was estimated to be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$21,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$188,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. During the three months ended March 31, 2017 and 2016, the Company recorded gains of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$167,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,519,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, as a result of the change in fair value of the warrants. The rights to exercise these warrants expire on October 1, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2014, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,255,639&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock were issued pursuant to the conversion of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;150,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series A Convertible Preferred Stock held by an investor. In September 2014, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,759,398&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock were issued pursuant to the conversion of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;250,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series A Convertible Preferred Stock held by another investor. As of March 31, 2017, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;600,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series A Convertible Preferred Stock issued and outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Series B Convertible Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December&amp;#160;12, 2014, the Company closed a preferred stock financing in which it sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,291.873&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series B Convertible Preferred Stock for a purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6,030&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, or an aggregate purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, prior to the payment of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$432,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of related issuance costs. The Company issued an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;124.378&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series B Convertible Preferred Stock as a subscription premium to the purchasers. The powers, preferences and rights of the Series B Convertible Preferred Stock are set forth in the certificate of designation filed by the Company with the Secretary of State of the State of Delaware. Each share of Series B Convertible Preferred Stock is convertible into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock at any time at the option of the holder, provided that the holder will be prohibited from converting Series B Convertible Preferred Stock into shares of the Company&amp;#8217;s common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.98%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the total number of shares of the Company&amp;#8217;s common stock then issued and outstanding. The Series B Convertible Preferred Stock ranks junior to the Company&amp;#8217;s existing Series A Convertible Preferred Stock and senior to the Company&amp;#8217;s common stock, with respect to rights upon liquidation. The Series B Convertible Preferred Stock ranks junior to all existing and future indebtedness. Except as otherwise required by law (or with respect to approval of certain actions), the Series B Convertible Preferred Stock do not have voting rights. The Series B Convertible Preferred Stock is not redeemable at the option of the holder. The Series B Convertible Preferred Stock is not subject to any price-based or other anti-dilution protections and does not provide for any accruing dividends.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determined that the conversion option of the Series B Convertible Preferred Stock represented a beneficial conversion feature, as the conversion feature had intrinsic value to the holder on the commitment date as a result of the subscription premium. Therefore, the Company recorded a beneficial conversion feature of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$750,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as an increase in additional paid in capital. Because the Series B Convertible Preferred Stock was immediately convertible into common stock at the option of the holder at issuance, the Company immediately accreted the full value of the beneficial conversion feature to the carrying value of the Series B Convertible Preferred Stock on that date.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PreferredStockTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2017Q1YTD" id="Fact-3A3E1408D677B390801B48DE148F6550">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses consisted of the following: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March 31, &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued clinical investigator expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;402&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued rebate, chargeback and other revenue reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;348&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;767&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;807&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,758&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2017Q1YTD" id="Fact-C7C7CE047B388E5044C148DE15013B40">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because to do so would have been anti-dilutive, were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three Months Ended &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series A convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,022,556&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,022,556&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series B convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,416,251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,416,251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series A convertible preferred stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,511,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,511,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,795,663&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;940,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,696,269&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,626,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,442,018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,516,186&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2017Q1YTD" id="Fact-17224F2FFF26922A91B548DE147EE2C4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory consisted of the following: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March 31, &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Component parts (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Work-in-process (2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;389&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;486&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory reserve &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory &amp;#8212; net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;446&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1) Component parts inventory consists of manufactured components of the ILUVIEN applicator.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2) Work-in-process primarily consists of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing or stability testing as required by regulatory authorities in Europe and the U.S.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="FD2017Q1YTD" id="Fact-C82EBFB5DBAFA90D689148DE15C184E8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents a summary of the Company&amp;#8217;s reporting segments for the three months ended March 31, 2017 and 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="32" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended &lt;br clear="none"/&gt;March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended &lt;br clear="none"/&gt;March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;International&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Consolidated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;International&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Consolidated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;NET REVENUE&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;4,445&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;6,618&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;4,119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;5,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(139&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(587&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(156&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;GROSS PROFIT&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,997&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2,034&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;6,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;5,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,158&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;741&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;211&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2,110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,708&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,086&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;226&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;GENERAL AND ADMINISTRATIVE EXPENSES&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,705&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;918&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;641&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,921&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;714&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;760&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;SALES AND MARKETING EXPENSES&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;4,045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;5,502&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;5,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;7,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;DEPRECIATION AND AMORTIZATION&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;689&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;689&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;OPERATING EXPENSES&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;6,908&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,832&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;11,542&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;8,939&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,289&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,985&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;14,213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;SEGMENT LOSS FROM OPERATIONS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(2,911&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(768&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1,832&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(5,511&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(5,042&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1,763&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1,985&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(8,790&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;OTHER INCOME AND EXPENSES, NET&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(2,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(2,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;NET LOSS BEFORE TAXES&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(6,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(11,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2017Q1YTD" id="Fact-0450A8416923EA2A0F7048DE154FF767">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents a summary of stock option activity for the three months ended March 31, 2017 and 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three Months Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,804,412&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,475,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Grants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,312,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,228,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeitures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(420,643&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(77,813&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at period end&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,696,269&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,626,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercisable at period end&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,527,392&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,310,239&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average per share fair value of options granted during the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="FD2017Q1YTD" id="Fact-15DDE6622D29F402C2B048DE14831293">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The estimated future amortization expense as of March 31, 2017 for the remaining periods in the next five years and thereafter is as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Years Ending December&amp;#160;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In&amp;#160;thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,462&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,940&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,940&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,946&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,940&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
	<us-gaap:SegmentReportingDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-0752FD845F684A47FBD648DE15C2288F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;SEGMENT INFORMATION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the three months ended March 31, 2017 and 2016, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; customers within the U.S. segment accounted for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, of the Company&amp;#8217;s consolidated revenues as a result of our sales to large pharmaceutical distributors in the U.S. These &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; customers within the U.S. segment accounted for approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the Company&amp;#8217;s consolidated accounts receivable at March 31, 2017 and December 31, 2016, respectively. The Company&amp;#8217;s chief operating decision maker is the Chief Executive Officer (CEO). While the CEO is apprised of a variety of financial metrics and information, the business is principally managed and organized based upon geographic and regulatory environment. Each segment is separately managed and is evaluated primarily upon segment loss from operations. Non-cash items including stock-based compensation expense and depreciation and amortization are categorized as Other within the table below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents a summary of the Company&amp;#8217;s reporting segments for the three months ended March 31, 2017 and 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="32" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended &lt;br clear="none"/&gt;March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended &lt;br clear="none"/&gt;March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;International&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Consolidated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;International&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Consolidated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;NET REVENUE&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;4,445&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;6,618&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;4,119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;5,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(139&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(587&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(156&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;GROSS PROFIT&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,997&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2,034&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;6,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;5,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,158&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;741&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;211&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2,110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,708&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,086&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;226&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;GENERAL AND ADMINISTRATIVE EXPENSES&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,705&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;918&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;641&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,921&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;714&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;760&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;SALES AND MARKETING EXPENSES&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;4,045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;5,502&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;5,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;7,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;DEPRECIATION AND AMORTIZATION&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;689&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;689&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;OPERATING EXPENSES&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;6,908&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,832&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;11,542&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;8,939&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,289&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,985&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;14,213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;SEGMENT LOSS FROM OPERATIONS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(2,911&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(768&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1,832&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(5,511&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(5,042&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1,763&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1,985&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(8,790&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;OTHER INCOME AND EXPENSES, NET&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(2,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(2,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;NET LOSS BEFORE TAXES&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(6,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(11,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2017Q1YTD" id="Fact-27D801DC355E37D3696948DE146CB645">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accounting policies followed for quarterly financial reporting are the same as those disclosed in the Notes to Financial Statements included in the Company&amp;#8217;s Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2016. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:174%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:174%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$350,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$561,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the three months ended March 31, 2017 and 2016, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Adoption of New Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2014, the FASB issued Accounting Standards Update (ASU) 2014-15, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. ASU 2014-15 requires management to perform interim and annual assessments of an entity&amp;#8217;s ability to continue as a going concern within one year of the date the financial statements are issued and provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. ASU 2014-15 applies to all entities and is effective for annual and interim reporting periods ending after December 15, 2016, with early adoption permitted. The adoption of this guidance did not have a material impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2015, the FASB issued ASU 2015-11, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventory (Topic 330): Simplifying the Measurement of Inventory&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. This update requires entities to measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. This ASU is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those years. The adoption of this guidance did not have a material impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued ASU 2016-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation (Topic 718)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. This standard makes several modifications to Topic 718 related to the accounting for forfeitures, employer tax withholding on share-based compensation and the financial statement presentation of excess tax benefits or deficiencies. ASU 2016-09 also clarifies the statement of cash flows presentation for certain components of share-based awards. The standard is effective for interim and annual reporting periods beginning after December 15, 2016, although early adoption is permitted. The adoption of this guidance did not have a material impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounting Standards Issued but Not Yet Effective&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued ASU 2014-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, as subsequently amended. ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. The revenue guidance contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The standard is effective for the first interim period within annual reporting periods beginning after December 15, 2017 for public entities, with early adoption permitted in the annual reporting period beginning after December 15, 2016. The Company has begun its evaluation of the new guidance on its business and, at this time, do not believe there will be a material impact on the Company&amp;#8217;s current direct product sales in international markets. For the U.S. business, the Company continues to evaluate the variable consideration provisions of the new guidance and the impact it will have specifically on the Company&amp;#8217;s gross to net revenue adjustments, including chargebacks and rebates. The Company anticipates adopting the new revenue standard using the modified retrospective transition method.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. This standard requires all leases with durations greater than twelve months to be recognized on the balance sheet and is effective for interim and annual reporting periods beginning after December 15, 2018, although early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-E081E3024F171A8FB1F848DE1521157F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;COMMON STOCK&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In September 2014, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen) to offer shares of its common stock from time to time through Cowen for the offer and sale of the shares up to an aggregate offering price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$35,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In 2016, the Company sold a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;662,779&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock at a weighted average purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.83&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, resulting in gross proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,211,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, prior to the payment of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$62,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of underwriter discounts and commissions and related issuance costs. Proceeds from the offering were used for general corporate and working capital purposes. The Company did not sell shares during the three months ended March 31, 2017. As of March 31, 2017, the Company can sell up to approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$21,504,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of its common stock under the terms of the sales agreement with Cowen.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition, in August, 2016, pursuant to an underwriting agreement with Cowen, as representative of the several underwriters named therein, the Company closed a public offering in which it sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,900,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock at a price to the public of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.40&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;per share. The offering resulted in gross proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$26,460,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, prior to the payment of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,309,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of underwriter discounts and commissions and related issuance costs.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2017Q1YTD" id="Fact-EBB1491C9F706CA476C0D5487A835E67">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;SUBSEQUENT EVENT&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As disclosed in Note 8 License Agreements, the Company and pSivida settled their dispute and amended and clarified certain definitions and clauses of the pSivida Agreement on May 3, 2017. The specific terms of the settlement and amendment are described in detail within Note 8 License Agreements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="FD2017Q1YTD" id="Fact-CDDE3AA9DEE105A70ED348DE1474D69D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;GOING CONCERN&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;To date, the Company has incurred recurring losses, negative cash flow from operations and has accumulated a deficit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$383,809,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from inception through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$26,737,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash and cash equivalents. The Company&amp;#8217;s ability to achieve profitability and positive cash flow is dependent upon its ability to increase revenue and contain its expenses. Further, the Company must maintain compliance with the debt covenants of its debt agreement (see Note 9). In 2016, in order to continue to fund its operations and meet its debt covenants, the Company raised additional equity and amended its debt agreement. In management&amp;#8217;s opinion, the uncertainty regarding future revenues raises substantial doubt about the Company&amp;#8217;s ability to continue as a going concern without access to additional debt or equity financing, over the course of the next twelve months.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In order to meet the Company&amp;#8217;s working capital needs through the next twelve months and maintain compliance with its debt covenants, the Company may need to raise additional debt or equity financing. The Company may be able to access capital under the Company&amp;#8217;s current at-the-market offering facility, which has approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$21,504,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of remaining availability. The Company implemented a cost savings program in late 2016 that the Company believes will help decrease cash burn over the next twelve months. While the Company has historically been able to raise additional capital through issuance of equity and/or debt financing, and while the Company has a plan in place to reduce spending in order to satisfy its obligations due within one year from the date of issuance of these financial statements, there can be no guarantees on the Company&amp;#8217;s ability to maintain debt compliance, raise additional equity, or successfully implement its cost reduction plans. Accordingly, there is substantial doubt about the Company&amp;#8217;s ability to continue as a going concern within one year after these financial statements are issued.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
		<link:loc xlink:href="#Fact-1741FDFF27C98D86D25E48DE156D937E" xlink:label="Fact-1741FDFF27C98D86D25E48DE156D937E_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-1E28BB63A2C6B0B867B448DE14775443" xlink:label="Fact-1E28BB63A2C6B0B867B448DE14775443_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2AB1C1970644FC11422948DE156E379E" xlink:label="Fact-2AB1C1970644FC11422948DE156E379E_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-332AEB304DCC812844D348DE158623F0" xlink:label="Fact-332AEB304DCC812844D348DE158623F0_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-399DD46FC48063CE39F948DE156F922D" xlink:label="Fact-399DD46FC48063CE39F948DE156F922D_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-45BA7E21FC25BA8AFE2348DE14778800" xlink:label="Fact-45BA7E21FC25BA8AFE2348DE14778800_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-4B7677504102C0EC1E4D48DE15840D53" xlink:label="Fact-4B7677504102C0EC1E4D48DE15840D53_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-57AD4EAD36B1E6BFC31A48DE1585271B" xlink:label="Fact-57AD4EAD36B1E6BFC31A48DE1585271B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-680C43DC2BEFDDFF0B9948DE156ECEA3" xlink:label="Fact-680C43DC2BEFDDFF0B9948DE156ECEA3_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-7EF1586023463DD019AF48DE156E8762" xlink:label="Fact-7EF1586023463DD019AF48DE156E8762_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-8A5371781CC9EE99B0AB48DE15858DA4" xlink:label="Fact-8A5371781CC9EE99B0AB48DE15858DA4_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-A76357E29F36D3C64CD948DE1478A00F" xlink:label="Fact-A76357E29F36D3C64CD948DE1478A00F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-A8BD8924A4C189C4AC9348DE15851906" xlink:label="Fact-A8BD8924A4C189C4AC9348DE15851906_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-C2D1CC8B523D52A36F2248DE1477E044" xlink:label="Fact-C2D1CC8B523D52A36F2248DE1477E044_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-D7E82A484631FB87349F48DE1586B6C8" xlink:label="Fact-D7E82A484631FB87349F48DE1586B6C8_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-E0D34C799374A86BB2ED48DE15868120" xlink:label="Fact-E0D34C799374A86BB2ED48DE15868120_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-E294F1762FCECE4A99F948DE156EC52B" xlink:label="Fact-E294F1762FCECE4A99F948DE156EC52B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-F3755A91997EF2FF104248DE156FA30A" xlink:label="Fact-F3755A91997EF2FF104248DE156FA30A_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-F488D944869EDF733E4048DE156FB056" xlink:label="Fact-F488D944869EDF733E4048DE156FB056_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-F91C2A3BED4519D2022348DE15860514" xlink:label="Fact-F91C2A3BED4519D2022348DE15860514_lbl" xlink:type="locator" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-1741FDFF27C98D86D25E48DE156D937E_lbl" xlink:to="Footnote-8FD0CFE77AD3F3AFD64648DE15879AD8_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-1E28BB63A2C6B0B867B448DE14775443_lbl" xlink:to="Footnote-2562AED7E98A11A7612A48DE147801C3_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2AB1C1970644FC11422948DE156E379E_lbl" xlink:to="Footnote-43A61193B2018D7D4EAF48DE158738EE_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-332AEB304DCC812844D348DE158623F0_lbl" xlink:to="Footnote-43A61193B2018D7D4EAF48DE158738EE_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-399DD46FC48063CE39F948DE156F922D_lbl" xlink:to="Footnote-8FD0CFE77AD3F3AFD64648DE15879AD8_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-45BA7E21FC25BA8AFE2348DE14778800_lbl" xlink:to="Footnote-85259E157AEE4572901848DE1478593A_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-4B7677504102C0EC1E4D48DE15840D53_lbl" xlink:to="Footnote-8FD0CFE77AD3F3AFD64648DE15879AD8_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-57AD4EAD36B1E6BFC31A48DE1585271B_lbl" xlink:to="Footnote-8FD0CFE77AD3F3AFD64648DE15879AD8_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-680C43DC2BEFDDFF0B9948DE156ECEA3_lbl" xlink:to="Footnote-43A61193B2018D7D4EAF48DE158738EE_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-7EF1586023463DD019AF48DE156E8762_lbl" xlink:to="Footnote-43A61193B2018D7D4EAF48DE158738EE_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-8A5371781CC9EE99B0AB48DE15858DA4_lbl" xlink:to="Footnote-43A61193B2018D7D4EAF48DE158738EE_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-A76357E29F36D3C64CD948DE1478A00F_lbl" xlink:to="Footnote-85259E157AEE4572901848DE1478593A_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-A8BD8924A4C189C4AC9348DE15851906_lbl" xlink:to="Footnote-43A61193B2018D7D4EAF48DE158738EE_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-C2D1CC8B523D52A36F2248DE1477E044_lbl" xlink:to="Footnote-2562AED7E98A11A7612A48DE147801C3_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-D7E82A484631FB87349F48DE1586B6C8_lbl" xlink:to="Footnote-8FD0CFE77AD3F3AFD64648DE15879AD8_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-E0D34C799374A86BB2ED48DE15868120_lbl" xlink:to="Footnote-8FD0CFE77AD3F3AFD64648DE15879AD8_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-E294F1762FCECE4A99F948DE156EC52B_lbl" xlink:to="Footnote-8FD0CFE77AD3F3AFD64648DE15879AD8_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-F3755A91997EF2FF104248DE156FA30A_lbl" xlink:to="Footnote-43A61193B2018D7D4EAF48DE158738EE_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-F488D944869EDF733E4048DE156FB056_lbl" xlink:to="Footnote-8FD0CFE77AD3F3AFD64648DE15879AD8_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-F91C2A3BED4519D2022348DE15860514_lbl" xlink:to="Footnote-43A61193B2018D7D4EAF48DE158738EE_lbl" xlink:type="arc" />
		<link:footnote xlink:label="Footnote-2562AED7E98A11A7612A48DE147801C3_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Component parts inventory consists of manufactured components of the ILUVIEN applicator.</link:footnote>
		<link:footnote xlink:label="Footnote-43A61193B2018D7D4EAF48DE158738EE_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments.</link:footnote>
		<link:footnote xlink:label="Footnote-85259E157AEE4572901848DE1478593A_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Work-in-process primarily consists of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing or stability testing as required by regulatory authorities in Europe and the U.S.</link:footnote>
		<link:footnote xlink:label="Footnote-8FD0CFE77AD3F3AFD64648DE15879AD8_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents.</link:footnote>
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>alim-20170331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.alimerasciences.com/20170331" xmlns:alim="http://www.alimerasciences.com/20170331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alim-20170331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alim-20170331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alim-20170331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alim-20170331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedExpenses" roleURI="http://www.alimerasciences.com/role/AccruedExpenses">
        <link:definition>2112100 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesSummaryOfAccruedExpensesDetail" roleURI="http://www.alimerasciences.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail">
        <link:definition>2412402 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.alimerasciences.com/role/AccruedExpensesTables">
        <link:definition>2312301 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentation" roleURI="http://www.alimerasciences.com/role/BasisOfPresentation">
        <link:definition>2102100 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationBasisOfPresentationPolicies" roleURI="http://www.alimerasciences.com/role/BasisOfPresentationBasisOfPresentationPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationNarrativeDetails" roleURI="http://www.alimerasciences.com/role/BasisOfPresentationNarrativeDetails">
        <link:definition>2402402 - Disclosure - Basis of Presentation Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://www.alimerasciences.com/role/CommonStock">
        <link:definition>2131100 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockDetail" roleURI="http://www.alimerasciences.com/role/CommonStockDetail">
        <link:definition>2431401 - Disclosure - Common Stock (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.alimerasciences.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.alimerasciences.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.alimerasciences.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1005000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.alimerasciences.com/role/ConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>1003000 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperations" roleURI="http://www.alimerasciences.com/role/ConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.alimerasciences.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValue" roleURI="http://www.alimerasciences.com/role/FairValue">
        <link:definition>2134100 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueDetail" roleURI="http://www.alimerasciences.com/role/FairValueDetail">
        <link:definition>2434402 - Disclosure - Fair Value (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueTables" roleURI="http://www.alimerasciences.com/role/FairValueTables">
        <link:definition>2334301 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoingConcern" roleURI="http://www.alimerasciences.com/role/GoingConcern">
        <link:definition>2108100 - Disclosure - Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoingConcernDetail" roleURI="http://www.alimerasciences.com/role/GoingConcernDetail">
        <link:definition>2408401 - Disclosure - Going Concern (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.alimerasciences.com/role/IncomeTaxes">
        <link:definition>2133100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetail" roleURI="http://www.alimerasciences.com/role/IncomeTaxesDetail">
        <link:definition>2433401 - Disclosure - Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAsset" roleURI="http://www.alimerasciences.com/role/IntangibleAsset">
        <link:definition>2111100 - Disclosure - Intangible Asset</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetFutureAmortizationDetails" roleURI="http://www.alimerasciences.com/role/IntangibleAssetFutureAmortizationDetails">
        <link:definition>2411403 - Disclosure - Intangible Asset - Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetNarrativeDetails" roleURI="http://www.alimerasciences.com/role/IntangibleAssetNarrativeDetails">
        <link:definition>2411402 - Disclosure - Intangible Asset - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetTables" roleURI="http://www.alimerasciences.com/role/IntangibleAssetTables">
        <link:definition>2311301 - Disclosure - Intangible Asset (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.alimerasciences.com/role/Inventory">
        <link:definition>2109100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetail" roleURI="http://www.alimerasciences.com/role/InventoryDetail">
        <link:definition>2409402 - Disclosure - Inventory (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.alimerasciences.com/role/InventoryTables">
        <link:definition>2309301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://www.alimerasciences.com/role/LicenseAgreements">
        <link:definition>2117100 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDetail" roleURI="http://www.alimerasciences.com/role/LicenseAgreementsDetail">
        <link:definition>2417401 - Disclosure - License Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanAgreements" roleURI="http://www.alimerasciences.com/role/LoanAgreements">
        <link:definition>2118100 - Disclosure - Loan Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanAgreementsDetail" roleURI="http://www.alimerasciences.com/role/LoanAgreementsDetail">
        <link:definition>2418401 - Disclosure - Loan Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareEps" roleURI="http://www.alimerasciences.com/role/LossPerShareEps">
        <link:definition>2124100 - Disclosure - Loss Per Share (EPS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareEpsAntidilutiveSecuritiesExcludedDetail" roleURI="http://www.alimerasciences.com/role/LossPerShareEpsAntidilutiveSecuritiesExcludedDetail">
        <link:definition>2424402 - Disclosure - Loss Per Share (EPS) - AntiDilutive Securities Excluded (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareEpsTables" roleURI="http://www.alimerasciences.com/role/LossPerShareEpsTables">
        <link:definition>2324301 - Disclosure - Loss Per Share (EPS) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureOfOperations" roleURI="http://www.alimerasciences.com/role/NatureOfOperations">
        <link:definition>2101100 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureOfOperationsDetail" roleURI="http://www.alimerasciences.com/role/NatureOfOperationsDetail">
        <link:definition>2401401 - Disclosure - Nature of Operations (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredStock" roleURI="http://www.alimerasciences.com/role/PreferredStock">
        <link:definition>2128100 - Disclosure - Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredStockDetail" roleURI="http://www.alimerasciences.com/role/PreferredStockDetail">
        <link:definition>2428401 - Disclosure - Preferred Stock (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.alimerasciences.com/role/SegmentInformation">
        <link:definition>2135100 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails" roleURI="http://www.alimerasciences.com/role/SegmentInformationDetails">
        <link:definition>2435402 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.alimerasciences.com/role/SegmentInformationTables">
        <link:definition>2335301 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlans" roleURI="http://www.alimerasciences.com/role/StockIncentivePlans">
        <link:definition>2132100 - Disclosure - Stock Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansAdditionalInformationDetail" roleURI="http://www.alimerasciences.com/role/StockIncentivePlansAdditionalInformationDetail">
        <link:definition>2432402 - Disclosure - Stock Incentive Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansAdditionalStockOptionTransactionsDetail" roleURI="http://www.alimerasciences.com/role/StockIncentivePlansAdditionalStockOptionTransactionsDetail">
        <link:definition>2432404 - Disclosure - Stock Incentive Plans - Additional Stock Option Transactions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansSummaryOfStockOptionTransactionsDetail" roleURI="http://www.alimerasciences.com/role/StockIncentivePlansSummaryOfStockOptionTransactionsDetail">
        <link:definition>2432403 - Disclosure - Stock Incentive Plans - Summary of Stock Option Transactions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansTables" roleURI="http://www.alimerasciences.com/role/StockIncentivePlansTables">
        <link:definition>2332301 - Disclosure - Stock Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventNotes" roleURI="http://www.alimerasciences.com/role/SubsequentEventNotes">
        <link:definition>2136100 - Disclosure - Subsequent Event (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2107100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2407402 - Disclosure - Summary of Significant Accounting Policies Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2207201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="alim_AccruedClinicalInvestigatorExpenses" name="AccruedClinicalInvestigatorExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="alim_AdditionalMilestonePayment" name="AdditionalMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="alim_AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock" name="AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature" name="AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alim_AlimeraSciencesIncCompanyMember" name="AlimeraSciencesIncCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alim_AlimeraSciencesLimitedLimitedMember" name="AlimeraSciencesLimitedLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled" name="BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_ClassofWarrantorRightExercisablePercentage" name="ClassofWarrantorRightExercisablePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage" name="ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="alim_CommercializationCosts" name="CommercializationCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="alim_CommercializationCostsReceivable" name="CommercializationCostsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="alim_CommercializationCostsReceivablePostAdjustment" name="CommercializationCostsReceivablePostAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="alim_CommonStocktobeIssuedValueMaximum" name="CommonStocktobeIssuedValueMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="alim_ConcentrationRiskNumberofCustomers" name="ConcentrationRiskNumberofCustomers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent" name="ConvertiblePreferredStockOwnershipInterestAfterConversionPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_CumulativeIncomeLossFromForeignOperations" name="CumulativeIncomeLossFromForeignOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="alim_DebitInstrumentPaymentinKindInterestRate" name="DebitInstrumentPaymentinKindInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_DebtInstrumentBasisSpreadonVariableRateReduction" name="DebtInstrumentBasisSpreadonVariableRateReduction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_DebtInstrumentCovenantCurrentLiquidity" name="DebtInstrumentCovenantCurrentLiquidity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="alim_DebtInstrumentCovenantLiquidityRelatedtoAccountsReceivable" name="DebtInstrumentCovenantLiquidityRelatedtoAccountsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="alim_DebtInstrumentCovenantLiquidityRelatedtoCashandCashEquivalents" name="DebtInstrumentCovenantLiquidityRelatedtoCashandCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="alim_DebtInstrumentCovenantLiquidityThreshold" name="DebtInstrumentCovenantLiquidityThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="alim_DebtInstrumentCovenantMinimumCashBalance" name="DebtInstrumentCovenantMinimumCashBalance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="alim_DebtInstrumentEndofTermPaymentAccrued" name="DebtInstrumentEndofTermPaymentAccrued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="alim_DebtInstrumentPaymentTermsNumberofPayments" name="DebtInstrumentPaymentTermsNumberofPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal" name="DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_DebtInstrumentPrepaymentFeePercentageFirst12Months" name="DebtInstrumentPrepaymentFeePercentageFirst12Months" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months" name="DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months" name="DebtInstrumentPrepaymentFeePercentageGreaterthan24Months" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_DebtInstrumentRevenueRequirement" name="DebtInstrumentRevenueRequirement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="alim_DebtInstrumentTickingFee" name="DebtInstrumentTickingFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="alim_DebtInstrumentTickingFeePercent" name="DebtInstrumentTickingFeePercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="alim_DerivativeWarrantLiabilitiesFairValueDisclosure" name="DerivativeWarrantLiabilitiesFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="alim_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_EstimatedTotalStockIssuanceCost" name="EstimatedTotalStockIssuanceCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="alim_ExercisePriceOfWarrants" name="ExercisePriceOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="alim_FirstLoanAmendmentMember" name="FirstLoanAmendmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alim_FourthLoanAmendmentMember" name="FourthLoanAmendmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_GrossProceedsUnderSecuritiesPurchaseAgreement" name="GrossProceedsUnderSecuritiesPurchaseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue" name="GrossProceedsUnderSecuritiesPurchaseAgreementPerValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="alim_HerculesTechnologyGrowthCapitalInc.Member" name="HerculesTechnologyGrowthCapitalInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alim_IluvienMember" name="IluvienMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" name="IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" name="IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alim_InternationalSegmentMember" name="InternationalSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_InventoryComponent" name="InventoryComponent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="alim_July2016WaiverMember" name="July2016WaiverMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_LineofCreditFacilityIncreaseinBorrowingCapacity" name="LineofCreditFacilityIncreaseinBorrowingCapacity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract" name="MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract" name="MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alim_NatureOfOperationsLineItems" name="NatureOfOperationsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_NumberOfPreferredStockAndWarrants" name="NumberOfPreferredStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="alim_PercentageOfRecoveryOfCommercializationCost" name="PercentageOfRecoveryOfCommercializationCost" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_PlannedDrugStudyNumberofPatients" name="PlannedDrugStudyNumberofPatients" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_PlannedStudyNumberofPatients" name="PlannedStudyNumberofPatients" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="alim_PostAuthorizationOpenStudyPeriod" name="PostAuthorizationOpenStudyPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_PreferredStockConvertedToCommonStockPerShare" name="PreferredStockConvertedToCommonStockPerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alim_PreferredStockWarrantsMember" name="PreferredStockWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_ProportionOfEachUnitOfShares" name="ProportionOfEachUnitOfShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="alim_PublicOfferingMember" name="PublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alim_ScheduleNatureOfOperationsTable" name="ScheduleNatureOfOperationsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alim_SecondLoanAmendmentMember" name="SecondLoanAmendmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien" name="ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_ShareOfNetProfits" name="ShareOfNetProfits" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alim_ThirdLoanAmendmentMember" name="ThirdLoanAmendmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alim_TrancheOneMember" name="TrancheOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alim_TrancheTwoMember" name="TrancheTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alim_TwentyFourteenTermLoanMember" name="TwentyFourteenTermLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="alim_UnitedStatesSegmentMember" name="UnitedStatesSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="alim_WarrantsToPurchaseAdditionalShares" name="WarrantsToPurchaseAdditionalShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>alim-20170331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.alimerasciences.com/role/AccruedExpenses" xlink:href="alim-20170331.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" xlink:href="alim-20170331.xsd#AccruedExpensesSummaryOfAccruedExpensesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/AccruedExpensesTables" xlink:href="alim-20170331.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/BasisOfPresentation" xlink:href="alim-20170331.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/BasisOfPresentationBasisOfPresentationPolicies" xlink:href="alim-20170331.xsd#BasisOfPresentationBasisOfPresentationPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/BasisOfPresentationNarrativeDetails" xlink:href="alim-20170331.xsd#BasisOfPresentationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/CommonStock" xlink:href="alim-20170331.xsd#CommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/CommonStockDetail" xlink:href="alim-20170331.xsd#CommonStockDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/ConsolidatedBalanceSheets" xlink:href="alim-20170331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="alim-20170331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="alim-20170331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="alim-20170331.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/ConsolidatedStatementsOfOperations" xlink:href="alim-20170331.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/DocumentAndEntityInformation" xlink:href="alim-20170331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/FairValue" xlink:href="alim-20170331.xsd#FairValue" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/FairValueDetail" xlink:href="alim-20170331.xsd#FairValueDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/FairValueTables" xlink:href="alim-20170331.xsd#FairValueTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/GoingConcern" xlink:href="alim-20170331.xsd#GoingConcern" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/GoingConcernDetail" xlink:href="alim-20170331.xsd#GoingConcernDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/IncomeTaxes" xlink:href="alim-20170331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/IncomeTaxesDetail" xlink:href="alim-20170331.xsd#IncomeTaxesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/IntangibleAsset" xlink:href="alim-20170331.xsd#IntangibleAsset" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/IntangibleAssetFutureAmortizationDetails" xlink:href="alim-20170331.xsd#IntangibleAssetFutureAmortizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/IntangibleAssetNarrativeDetails" xlink:href="alim-20170331.xsd#IntangibleAssetNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/IntangibleAssetTables" xlink:href="alim-20170331.xsd#IntangibleAssetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/Inventory" xlink:href="alim-20170331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/InventoryDetail" xlink:href="alim-20170331.xsd#InventoryDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/InventoryTables" xlink:href="alim-20170331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LicenseAgreements" xlink:href="alim-20170331.xsd#LicenseAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LicenseAgreementsDetail" xlink:href="alim-20170331.xsd#LicenseAgreementsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LoanAgreements" xlink:href="alim-20170331.xsd#LoanAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LoanAgreementsDetail" xlink:href="alim-20170331.xsd#LoanAgreementsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LossPerShareEps" xlink:href="alim-20170331.xsd#LossPerShareEps" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LossPerShareEpsAntidilutiveSecuritiesExcludedDetail" xlink:href="alim-20170331.xsd#LossPerShareEpsAntidilutiveSecuritiesExcludedDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LossPerShareEpsTables" xlink:href="alim-20170331.xsd#LossPerShareEpsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/NatureOfOperations" xlink:href="alim-20170331.xsd#NatureOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/NatureOfOperationsDetail" xlink:href="alim-20170331.xsd#NatureOfOperationsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/PreferredStock" xlink:href="alim-20170331.xsd#PreferredStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/PreferredStockDetail" xlink:href="alim-20170331.xsd#PreferredStockDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SegmentInformation" xlink:href="alim-20170331.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SegmentInformationDetails" xlink:href="alim-20170331.xsd#SegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SegmentInformationTables" xlink:href="alim-20170331.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/StockIncentivePlans" xlink:href="alim-20170331.xsd#StockIncentivePlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/StockIncentivePlansAdditionalInformationDetail" xlink:href="alim-20170331.xsd#StockIncentivePlansAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/StockIncentivePlansAdditionalStockOptionTransactionsDetail" xlink:href="alim-20170331.xsd#StockIncentivePlansAdditionalStockOptionTransactionsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/StockIncentivePlansSummaryOfStockOptionTransactionsDetail" xlink:href="alim-20170331.xsd#StockIncentivePlansSummaryOfStockOptionTransactionsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/StockIncentivePlansTables" xlink:href="alim-20170331.xsd#StockIncentivePlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SubsequentEventNotes" xlink:href="alim-20170331.xsd#SubsequentEventNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="alim-20170331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="alim-20170331.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="alim-20170331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/AccruedExpenses" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_a7c5f1a6-0ac0-4022-b42d-3a515759fe19" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_a7c5f1a6-0ac0-4022-b42d-3a515759fe19" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_AccruedClinicalInvestigatorExpenses" xlink:label="loc_alim_AccruedClinicalInvestigatorExpenses_01a62d38-93f9-4acf-8bc6-72f74af1a9d2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_alim_AccruedClinicalInvestigatorExpenses_01a62d38-93f9-4acf-8bc6-72f74af1a9d2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_d0a9389f-d44c-424b-7441-ff0e7fce964d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_d0a9389f-d44c-424b-7441-ff0e7fce964d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/BasisOfPresentation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/BasisOfPresentationBasisOfPresentationPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/BasisOfPresentationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/CommonStock" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/CommonStockDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_d6e62e4f-fa41-c5ac-31c0-f175f0c219a7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_d6e62e4f-fa41-c5ac-31c0-f175f0c219a7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8cc01d89-cd24-22b5-77d4-23f6bae81aca" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8cc01d89-cd24-22b5-77d4-23f6bae81aca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_77f006fd-b727-9e55-3ff1-d8268898b4c7" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_77f006fd-b727-9e55-3ff1-d8268898b4c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_2481d529-2911-4e71-2975-f0b62d3c248e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_2481d529-2911-4e71-2975-f0b62d3c248e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_abb88b5c-ef84-43b7-a075-78b44bb32132" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_abb88b5c-ef84-43b7-a075-78b44bb32132" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent_979060bb-bdba-fd3f-8dd5-05b622a57ee4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_CapitalLeaseObligationsNoncurrent_979060bb-bdba-fd3f-8dd5-05b622a57ee4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1a68b05-ec26-b896-ce8e-937cca99264e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1a68b05-ec26-b896-ce8e-937cca99264e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_fdc0ed61-91fa-946a-6107-cae34d7fdf9d" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_fdc0ed61-91fa-946a-6107-cae34d7fdf9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_1a54c9c9-504a-3600-d358-4e7e40235d41" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_LongTermNotesPayable_1a54c9c9-504a-3600-d358-4e7e40235d41" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a92fcd53-a70b-5961-cbbe-44e0298b332c" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a92fcd53-a70b-5961-cbbe-44e0298b332c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_21041b8b-cf55-3af3-04a5-97303c43edf7" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_21041b8b-cf55-3af3-04a5-97303c43edf7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_24485696-f982-096a-ee6a-f5e510cdb21c" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_24485696-f982-096a-ee6a-f5e510cdb21c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_d54f9058-c80a-50a5-1d83-83d52ae1941f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_InventoryWriteDown_d54f9058-c80a-50a5-1d83-83d52ae1941f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc155cc8-6ee1-5ea7-d824-9c91dc052636" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc155cc8-6ee1-5ea7-d824-9c91dc052636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_721e1a2c-7f31-841f-8094-3b154fa61fcf" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_721e1a2c-7f31-841f-8094-3b154fa61fcf" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="loc_alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_a7ee5766-42c3-b1fc-6f01-72f74af90de6" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_a7ee5766-42c3-b1fc-6f01-72f74af90de6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_503015f3-ea26-0d7a-c655-6d6aff0c5fab" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_503015f3-ea26-0d7a-c655-6d6aff0c5fab" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_6ecb4c75-a1c0-ea23-2c6f-72f74aeff02d" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_6ecb4c75-a1c0-ea23-2c6f-72f74aeff02d" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" xlink:label="loc_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_4bdf8a54-a7c4-341c-89ff-72f74af3f9b6" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_4bdf8a54-a7c4-341c-89ff-72f74af3f9b6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7a016eeb-d472-4272-2fad-97e749a6fbc2" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7a016eeb-d472-4272-2fad-97e749a6fbc2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_fa260602-6369-9a36-3ad2-d6d2d1064552" xlink:type="locator" />
    <link:calculationArc order="14" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_fa260602-6369-9a36-3ad2-d6d2d1064552" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9f72449f-62f6-71b1-0128-c7088f4f3527" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9f72449f-62f6-71b1-0128-c7088f4f3527" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fc027bcf-19a3-7936-be65-3ec1deb94fb4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fc027bcf-19a3-7936-be65-3ec1deb94fb4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5c0eef35-65f3-1f95-6efc-88d329d3a633" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fc027bcf-19a3-7936-be65-3ec1deb94fb4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5c0eef35-65f3-1f95-6efc-88d329d3a633" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:to="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:to="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_758fda00-4ec6-2a1a-3601-b22661c1a7ff" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:to="loc_us-gaap_CostOfGoodsSold_758fda00-4ec6-2a1a-3601-b22661c1a7ff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:to="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_61ca427c-a8f7-736f-ff6b-927d826fc7fa" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_61ca427c-a8f7-736f-ff6b-927d826fc7fa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2b63fac5-7a72-3880-3fd2-630099895af7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2b63fac5-7a72-3880-3fd2-630099895af7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaap_MarketingExpense_bd8f9f20-f80f-7cd1-5674-6c5e423a6fa1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_MarketingExpense_bd8f9f20-f80f-7cd1-5674-6c5e423a6fa1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_31fc303b-1b94-6362-1b8a-157609a23bce" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_31fc303b-1b94-6362-1b8a-157609a23bce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4b6ddf50-6253-3349-fa29-8fc77f744f58" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:to="loc_us-gaap_InterestExpense_4b6ddf50-6253-3349-fa29-8fc77f744f58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_fa260602-6369-9a36-3ad2-d6d2d1064552" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_fa260602-6369-9a36-3ad2-d6d2d1064552" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" xlink:label="loc_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_4bdf8a54-a7c4-341c-89ff-72f74af3f9b6" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:to="loc_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_4bdf8a54-a7c4-341c-89ff-72f74af3f9b6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc155cc8-6ee1-5ea7-d824-9c91dc052636" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc155cc8-6ee1-5ea7-d824-9c91dc052636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:type="arc" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/FairValue" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/FairValueDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1503e99b-7965-ca9e-26eb-ff9af4108a7c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5987d7dd-ab82-bea6-ec65-c10216a0873a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1503e99b-7965-ca9e-26eb-ff9af4108a7c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5987d7dd-ab82-bea6-ec65-c10216a0873a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_4f567ef5-b8d7-6688-bab2-00271c822568" xlink:type="locator" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DerivativeWarrantLiabilitiesFairValueDisclosure" xlink:label="loc_alim_DerivativeWarrantLiabilitiesFairValueDisclosure_34b005c6-869a-97cb-3778-72f74b06c78f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_4f567ef5-b8d7-6688-bab2-00271c822568" xlink:to="loc_alim_DerivativeWarrantLiabilitiesFairValueDisclosure_34b005c6-869a-97cb-3778-72f74b06c78f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/FairValueTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/GoingConcern" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/GoingConcernDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/IncomeTaxesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/IntangibleAsset" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/IntangibleAssetFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_441e5869-bd08-8d9f-f5d3-2febc2ab5a6e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_441e5869-bd08-8d9f-f5d3-2febc2ab5a6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_36b3b152-325b-61f4-d066-1d3685b6c394" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_36b3b152-325b-61f4-d066-1d3685b6c394" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_10c80460-5b5e-7e81-facb-0d1ed91293c2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_10c80460-5b5e-7e81-facb-0d1ed91293c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ad66514d-dce4-49aa-3300-d457a5d4216a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ad66514d-dce4-49aa-3300-d457a5d4216a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_df415662-e392-2016-38c7-6c4ddd8a9714" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_df415662-e392-2016-38c7-6c4ddd8a9714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_e7896482-8d23-a8f9-52eb-54c2c885aa06" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_e7896482-8d23-a8f9-52eb-54c2c885aa06" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/IntangibleAssetNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/IntangibleAssetTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/InventoryDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_614208db-429d-6b0c-c478-94024260bd46" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:to="loc_us-gaap_InventoryGross_614208db-429d-6b0c-c478-94024260bd46" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_InventoryComponent" xlink:label="loc_alim_InventoryComponent_f6ecb43e-96c4-2620-0b67-72f74affeea5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_614208db-429d-6b0c-c478-94024260bd46" xlink:to="loc_alim_InventoryComponent_f6ecb43e-96c4-2620-0b67-72f74affeea5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_6d5597db-4bd4-7d0e-9946-68f22d2ba196" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_614208db-429d-6b0c-c478-94024260bd46" xlink:to="loc_us-gaap_InventoryWorkInProcess_6d5597db-4bd4-7d0e-9946-68f22d2ba196" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_58a767dc-544b-b9e2-38ae-a5daf42f4bd2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_614208db-429d-6b0c-c478-94024260bd46" xlink:to="loc_us-gaap_InventoryFinishedGoods_58a767dc-544b-b9e2-38ae-a5daf42f4bd2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_c22c9884-6890-7a25-f431-8ed2b8c9fadb" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:to="loc_us-gaap_InventoryValuationReserves_c22c9884-6890-7a25-f431-8ed2b8c9fadb" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/LicenseAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/LicenseAgreementsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/LoanAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/LoanAgreementsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/LossPerShareEps" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/LossPerShareEpsAntidilutiveSecuritiesExcludedDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/LossPerShareEpsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/NatureOfOperations" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/NatureOfOperationsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/PreferredStock" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/PreferredStockDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/SegmentInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:to="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_635b5b86-b9ab-e949-79a2-ce2ff4a8c847" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_635b5b86-b9ab-e949-79a2-ce2ff4a8c847" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/SegmentInformationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/StockIncentivePlans" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/StockIncentivePlansAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/StockIncentivePlansAdditionalStockOptionTransactionsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/StockIncentivePlansSummaryOfStockOptionTransactionsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/StockIncentivePlansTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/SubsequentEventNotes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>alim-20170331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.alimerasciences.com/role/AccruedExpenses" xlink:href="alim-20170331.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" xlink:href="alim-20170331.xsd#AccruedExpensesSummaryOfAccruedExpensesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/AccruedExpensesTables" xlink:href="alim-20170331.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/BasisOfPresentation" xlink:href="alim-20170331.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/BasisOfPresentationBasisOfPresentationPolicies" xlink:href="alim-20170331.xsd#BasisOfPresentationBasisOfPresentationPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/BasisOfPresentationNarrativeDetails" xlink:href="alim-20170331.xsd#BasisOfPresentationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/CommonStock" xlink:href="alim-20170331.xsd#CommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/CommonStockDetail" xlink:href="alim-20170331.xsd#CommonStockDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/ConsolidatedBalanceSheets" xlink:href="alim-20170331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="alim-20170331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="alim-20170331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="alim-20170331.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/ConsolidatedStatementsOfOperations" xlink:href="alim-20170331.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/DocumentAndEntityInformation" xlink:href="alim-20170331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/FairValue" xlink:href="alim-20170331.xsd#FairValue" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/FairValueDetail" xlink:href="alim-20170331.xsd#FairValueDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/FairValueTables" xlink:href="alim-20170331.xsd#FairValueTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/GoingConcern" xlink:href="alim-20170331.xsd#GoingConcern" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/GoingConcernDetail" xlink:href="alim-20170331.xsd#GoingConcernDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/IncomeTaxes" xlink:href="alim-20170331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/IncomeTaxesDetail" xlink:href="alim-20170331.xsd#IncomeTaxesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/IntangibleAsset" xlink:href="alim-20170331.xsd#IntangibleAsset" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/IntangibleAssetFutureAmortizationDetails" xlink:href="alim-20170331.xsd#IntangibleAssetFutureAmortizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/IntangibleAssetNarrativeDetails" xlink:href="alim-20170331.xsd#IntangibleAssetNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/IntangibleAssetTables" xlink:href="alim-20170331.xsd#IntangibleAssetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/Inventory" xlink:href="alim-20170331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/InventoryDetail" xlink:href="alim-20170331.xsd#InventoryDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/InventoryTables" xlink:href="alim-20170331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LicenseAgreements" xlink:href="alim-20170331.xsd#LicenseAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LicenseAgreementsDetail" xlink:href="alim-20170331.xsd#LicenseAgreementsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LoanAgreements" xlink:href="alim-20170331.xsd#LoanAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LoanAgreementsDetail" xlink:href="alim-20170331.xsd#LoanAgreementsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LossPerShareEps" xlink:href="alim-20170331.xsd#LossPerShareEps" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LossPerShareEpsAntidilutiveSecuritiesExcludedDetail" xlink:href="alim-20170331.xsd#LossPerShareEpsAntidilutiveSecuritiesExcludedDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LossPerShareEpsTables" xlink:href="alim-20170331.xsd#LossPerShareEpsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/NatureOfOperations" xlink:href="alim-20170331.xsd#NatureOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/NatureOfOperationsDetail" xlink:href="alim-20170331.xsd#NatureOfOperationsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/PreferredStock" xlink:href="alim-20170331.xsd#PreferredStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/PreferredStockDetail" xlink:href="alim-20170331.xsd#PreferredStockDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SegmentInformation" xlink:href="alim-20170331.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SegmentInformationDetails" xlink:href="alim-20170331.xsd#SegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SegmentInformationTables" xlink:href="alim-20170331.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/StockIncentivePlans" xlink:href="alim-20170331.xsd#StockIncentivePlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/StockIncentivePlansAdditionalInformationDetail" xlink:href="alim-20170331.xsd#StockIncentivePlansAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/StockIncentivePlansAdditionalStockOptionTransactionsDetail" xlink:href="alim-20170331.xsd#StockIncentivePlansAdditionalStockOptionTransactionsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/StockIncentivePlansSummaryOfStockOptionTransactionsDetail" xlink:href="alim-20170331.xsd#StockIncentivePlansSummaryOfStockOptionTransactionsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/StockIncentivePlansTables" xlink:href="alim-20170331.xsd#StockIncentivePlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SubsequentEventNotes" xlink:href="alim-20170331.xsd#SubsequentEventNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="alim-20170331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="alim-20170331.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="alim-20170331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/AccruedExpenses" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/BasisOfPresentation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/BasisOfPresentationBasisOfPresentationPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/BasisOfPresentationNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/CommonStock" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/CommonStockDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_924534266FA28A16450CE8B8825E06E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_924534266FA28A16450CE8B8825E06E3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2FC5FEBDB0C7DEE4E447E8B8825E2589" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_924534266FA28A16450CE8B8825E06E3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2FC5FEBDB0C7DEE4E447E8B8825E2589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E41628A22DED3B99C5BBE8B8825E7393_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2FC5FEBDB0C7DEE4E447E8B8825E2589" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E41628A22DED3B99C5BBE8B8825E7393_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E41628A22DED3B99C5BBE8B8825E7393" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2FC5FEBDB0C7DEE4E447E8B8825E2589" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E41628A22DED3B99C5BBE8B8825E7393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_5F58BB967C4C772EE7BDE8B8825ED1F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E41628A22DED3B99C5BBE8B8825E7393" xlink:to="loc_us-gaap_PrivatePlacementMember_5F58BB967C4C772EE7BDE8B8825ED1F8" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_PublicOfferingMember" xlink:label="loc_alim_PublicOfferingMember_CD8B28925474C539DF9BE8BE3EFC923B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E41628A22DED3B99C5BBE8B8825E7393" xlink:to="loc_alim_PublicOfferingMember_CD8B28925474C539DF9BE8BE3EFC923B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A9D62954C8FA4E265D29E8B8825E7BA9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_924534266FA28A16450CE8B8825E06E3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A9D62954C8FA4E265D29E8B8825E7BA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5E6FEFDDBCE4E0791FBEE8B8825E4B7C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A9D62954C8FA4E265D29E8B8825E7BA9" xlink:to="loc_us-gaap_ClassOfStockDomain_5E6FEFDDBCE4E0791FBEE8B8825E4B7C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5E6FEFDDBCE4E0791FBEE8B8825E4B7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A9D62954C8FA4E265D29E8B8825E7BA9" xlink:to="loc_us-gaap_ClassOfStockDomain_5E6FEFDDBCE4E0791FBEE8B8825E4B7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_ECFC23A6CB36F4E5E874E8B8825EA745" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5E6FEFDDBCE4E0791FBEE8B8825E4B7C" xlink:to="loc_us-gaap_CommonStockMember_ECFC23A6CB36F4E5E874E8B8825EA745" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_CommonStocktobeIssuedValueMaximum" xlink:label="loc_alim_CommonStocktobeIssuedValueMaximum_16058BB4D6E58863A3D2E8B8825E7BB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:to="loc_alim_CommonStocktobeIssuedValueMaximum_16058BB4D6E58863A3D2E8B8825E7BB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E1098E0A5A2B152DF046E8B8825E6923" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E1098E0A5A2B152DF046E8B8825E6923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_37B433083D9A1BACA918E8B8825E18A8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_37B433083D9A1BACA918E8B8825E18A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6B66E2794F48CE927F14E8B8825E73FD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6B66E2794F48CE927F14E8B8825E73FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_256BE2E5843EE1FD1160E8B8825E52AD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_256BE2E5843EE1FD1160E8B8825E52AD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_8DDAAB2A2DCF1B756AE5C9CD1C9208F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_StatementTable_8DDAAB2A2DCF1B756AE5C9CD1C9208F3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1203FAE5B547EF230F4AC9CD1C9254DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8DDAAB2A2DCF1B756AE5C9CD1C9208F3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1203FAE5B547EF230F4AC9CD1C9254DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3DB7DF2CFB13066EB004C9CD1C92FBDC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1203FAE5B547EF230F4AC9CD1C9254DD" xlink:to="loc_us-gaap_ClassOfStockDomain_3DB7DF2CFB13066EB004C9CD1C92FBDC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3DB7DF2CFB13066EB004C9CD1C92FBDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1203FAE5B547EF230F4AC9CD1C9254DD" xlink:to="loc_us-gaap_ClassOfStockDomain_3DB7DF2CFB13066EB004C9CD1C92FBDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_897A7AE7CABF415085FDC9CD1C92B3FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3DB7DF2CFB13066EB004C9CD1C92FBDC" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_897A7AE7CABF415085FDC9CD1C92B3FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_2C321560D3D515DAFB24C9CD1C92E39B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3DB7DF2CFB13066EB004C9CD1C92FBDC" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_2C321560D3D515DAFB24C9CD1C92E39B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C12A021F10009024D4E7C9CD1C92D3C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C12A021F10009024D4E7C9CD1C92D3C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_CDC56721589EC5C72A0FC9CD1C921905" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_CDC56721589EC5C72A0FC9CD1C921905" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_896BFCF723EDC4C33220C9CD1C92BAB5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_896BFCF723EDC4C33220C9CD1C92BAB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4203033638040A923828C9CD1C92EDCF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4203033638040A923828C9CD1C92EDCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_8B0B9687FC66722908D8C9CD1C929150" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:to="loc_us-gaap_InventoryNet_8B0B9687FC66722908D8C9CD1C929150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_BB394E1C58DA36EF63FDC9CD1C926703" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:to="loc_us-gaap_AssetsCurrent_BB394E1C58DA36EF63FDC9CD1C926703" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8AA29E37755CE9BE5F0FC9CD1C92D3C2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8AA29E37755CE9BE5F0FC9CD1C92D3C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1473D06CF139A820CA1CC9CD1C925E98" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1473D06CF139A820CA1CC9CD1C925E98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_91D6D0B1C60D17907B78C9CD1C924D6D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_91D6D0B1C60D17907B78C9CD1C924D6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_DF2D5EF62413BACE7D98C9CD1C92BDE4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_Assets_DF2D5EF62413BACE7D98C9CD1C92BDE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_185B9680717D7C84C637C9CD1C9291F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:to="loc_us-gaap_AccountsPayableCurrent_185B9680717D7C84C637C9CD1C9291F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_A43972AFA28B71203473C9CD1C92D600" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_A43972AFA28B71203473C9CD1C92D600" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_0F4834DA9D267A52E4E8C9CD1C928BBD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_0F4834DA9D267A52E4E8C9CD1C928BBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_3C19B4BBE77D52048AD8C9CD1C92CA72" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_3C19B4BBE77D52048AD8C9CD1C92CA72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_D67C531D6B133ADE373BC9CD1C92A23E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:to="loc_us-gaap_LiabilitiesCurrent_D67C531D6B133ADE373BC9CD1C92A23E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_811AAA277DA6C5D75974C9CD1C927E2C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_811AAA277DA6C5D75974C9CD1C927E2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_E075D58C5268F747DD13C9CD1C921C81" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_811AAA277DA6C5D75974C9CD1C927E2C" xlink:to="loc_us-gaap_LongTermNotesPayable_E075D58C5268F747DD13C9CD1C921C81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent_22A5C3F34D5AE574175FC9CD1C92A9ED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_811AAA277DA6C5D75974C9CD1C927E2C" xlink:to="loc_us-gaap_CapitalLeaseObligationsNoncurrent_22A5C3F34D5AE574175FC9CD1C92A9ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_C7D8BAE11C3D9B3EAFFDC9CD1C92FC3A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_811AAA277DA6C5D75974C9CD1C927E2C" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_C7D8BAE11C3D9B3EAFFDC9CD1C92FC3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0055424628E42D295352C9CD1C9245AF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0055424628E42D295352C9CD1C9245AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_2EB4B74630F7B2F3F156C9CD1C9253ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:to="loc_us-gaap_PreferredStockValue_2EB4B74630F7B2F3F156C9CD1C9253ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_939E4A4BAF27B68E8120C9CD1C92C4DA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:to="loc_us-gaap_CommonStockValue_939E4A4BAF27B68E8120C9CD1C92C4DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_F8EC311D9D4637606637C9CD1C92824C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_F8EC311D9D4637606637C9CD1C92824C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_A701D0532A4CDE88A3DCC9CD1C924E41" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_A701D0532A4CDE88A3DCC9CD1C924E41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_446CB8BB3CCBE395BA12C9CD1C92EDCE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_446CB8BB3CCBE395BA12C9CD1C92EDCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6D41AFB0FBCD18321B0C9CD1C92A7AB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6D41AFB0FBCD18321B0C9CD1C92A7AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_24A9C75B810ECC42CCE1C9CD1C92E8DA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:to="loc_us-gaap_StockholdersEquity_24A9C75B810ECC42CCE1C9CD1C92E8DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_775CC71950C7F6D132C6C9CD1C923CA4" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_775CC71950C7F6D132C6C9CD1C923CA4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_5910B0A397DA4AE7375F48DE132671F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_StatementTable_5910B0A397DA4AE7375F48DE132671F7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6AFA87215D5F7C60CB3448DE1326E3E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5910B0A397DA4AE7375F48DE132671F7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6AFA87215D5F7C60CB3448DE1326E3E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A1B3F748D0B02C8C40D348DE13263FE8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6AFA87215D5F7C60CB3448DE1326E3E0" xlink:to="loc_us-gaap_ClassOfStockDomain_A1B3F748D0B02C8C40D348DE13263FE8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A1B3F748D0B02C8C40D348DE13263FE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6AFA87215D5F7C60CB3448DE1326E3E0" xlink:to="loc_us-gaap_ClassOfStockDomain_A1B3F748D0B02C8C40D348DE13263FE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_637F1D73D49D74EA962748DE1326259E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A1B3F748D0B02C8C40D348DE13263FE8" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_637F1D73D49D74EA962748DE1326259E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_DB209E78A51BE82D7B1E48DE1326169A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A1B3F748D0B02C8C40D348DE13263FE8" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_DB209E78A51BE82D7B1E48DE1326169A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0B3D8EB31750282EEC1F48DE1326720E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0B3D8EB31750282EEC1F48DE1326720E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_367F3E2EF9545FAB85E848DE13269E89" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_367F3E2EF9545FAB85E848DE13269E89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_FD40DA17FA6BA964985B48DE13260523" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_PreferredStockSharesIssued_FD40DA17FA6BA964985B48DE13260523" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_634F25A30D684335305E48DE13269265" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_634F25A30D684335305E48DE13269265" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_063BAE6AFF7355FCC74348DE13263EDD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_063BAE6AFF7355FCC74348DE13263EDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_06D2ACE9BEA2D36317EB48DE13268E83" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_06D2ACE9BEA2D36317EB48DE13268E83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0A7D76D2FA16AF3B261748DE13275DC6" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0A7D76D2FA16AF3B261748DE13275DC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_A6EA0FC6771517B0BC7548DE1327E78B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_CommonStockSharesIssued_A6EA0FC6771517B0BC7548DE1327E78B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_92386473E92EC0F4BDE148DE132733F3" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_92386473E92EC0F4BDE148DE132733F3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/FairValue" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/FairValueDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33B2683B017FFAB84F4548DE13AD0EED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2AA3D744E69596DAFF7D48DE13ACE057" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33B2683B017FFAB84F4548DE13AD0EED" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2AA3D744E69596DAFF7D48DE13ACE057" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_858C1CA21D364F51974248DE13AC48B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2AA3D744E69596DAFF7D48DE13ACE057" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_858C1CA21D364F51974248DE13AC48B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0C1092799D16F24A911248DE13ACAC55_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_858C1CA21D364F51974248DE13AC48B3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0C1092799D16F24A911248DE13ACAC55_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0C1092799D16F24A911248DE13ACAC55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_858C1CA21D364F51974248DE13AC48B3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0C1092799D16F24A911248DE13ACAC55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_DA08F051C15AB54E1A8548DE13AC6646" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0C1092799D16F24A911248DE13ACAC55" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_DA08F051C15AB54E1A8548DE13AC6646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1AAB24272BFCE1D2A42948DE13AC7B3F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2AA3D744E69596DAFF7D48DE13ACE057" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1AAB24272BFCE1D2A42948DE13AC7B3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1AAB24272BFCE1D2A42948DE13AC7B3F" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1AAB24272BFCE1D2A42948DE13AC7B3F" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_FD05358DFBF1EA53923948DE13AD2656" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_FD05358DFBF1EA53923948DE13AD2656" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_CF96C3F141558E1D838048DE13ADA1E3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_CF96C3F141558E1D838048DE13ADA1E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_A8399D2E5A34F5AD7C6048DE13AD3C89" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_A8399D2E5A34F5AD7C6048DE13AD3C89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_8C58B517DF8EE742A94D48DE13AD1F1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33B2683B017FFAB84F4548DE13AD0EED" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_8C58B517DF8EE742A94D48DE13AD1F1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6E7F133B0C23991B010E48DE13AD0BEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8C58B517DF8EE742A94D48DE13AD1F1F" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6E7F133B0C23991B010E48DE13AD0BEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_AEEB1A2E6B0BBF9FD06448DE13AD43FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8C58B517DF8EE742A94D48DE13AD1F1F" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_AEEB1A2E6B0BBF9FD06448DE13AD43FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B6D9B67E966D8E1A318848DE13ADC9CD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33B2683B017FFAB84F4548DE13AD0EED" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B6D9B67E966D8E1A318848DE13ADC9CD" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DerivativeWarrantLiabilitiesFairValueDisclosure" xlink:label="loc_alim_DerivativeWarrantLiabilitiesFairValueDisclosure_D284E628CF70DCF6C82A48DE13ADFD71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B6D9B67E966D8E1A318848DE13ADC9CD" xlink:to="loc_alim_DerivativeWarrantLiabilitiesFairValueDisclosure_D284E628CF70DCF6C82A48DE13ADFD71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_1E268DAE28811EC921A248DE13AD88A5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B6D9B67E966D8E1A318848DE13ADC9CD" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_1E268DAE28811EC921A248DE13AD88A5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/FairValueTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/GoingConcern" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/GoingConcernDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/IncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_C46E349AD85B218ACB4CB015E3084F7D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_208CEA5278434B7E899FB015E307FD8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_C46E349AD85B218ACB4CB015E3084F7D" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_208CEA5278434B7E899FB015E307FD8A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_E4263A40940A793DF7D8B015E3086751" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_208CEA5278434B7E899FB015E307FD8A" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_E4263A40940A793DF7D8B015E3086751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_F2C66B71142DEE0F31A0B015E30886D4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_E4263A40940A793DF7D8B015E3086751" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_F2C66B71142DEE0F31A0B015E30886D4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_F2C66B71142DEE0F31A0B015E30886D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_E4263A40940A793DF7D8B015E3086751" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_F2C66B71142DEE0F31A0B015E30886D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_9E387820743B077C5019B015E30872EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_F2C66B71142DEE0F31A0B015E30886D4" xlink:to="loc_us-gaap_DomesticCountryMember_9E387820743B077C5019B015E30872EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_6802DB620D6F4AAF09BCB015E3087066" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_F2C66B71142DEE0F31A0B015E30886D4" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_6802DB620D6F4AAF09BCB015E3087066" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6A38DABA6BDC707147CCB015E308F595" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_C46E349AD85B218ACB4CB015E3084F7D" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6A38DABA6BDC707147CCB015E308F595" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_CumulativeIncomeLossFromForeignOperations" xlink:label="loc_alim_CumulativeIncomeLossFromForeignOperations_98A3DACCFB327311E5F2B087E7BEB55E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_C46E349AD85B218ACB4CB015E3084F7D" xlink:to="loc_alim_CumulativeIncomeLossFromForeignOperations_98A3DACCFB327311E5F2B087E7BEB55E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/IntangibleAsset" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/IntangibleAssetFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A079DEB2077C987EAC8B015E3995744" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EC56B4F0651EE606AE7EB015E3991D98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A079DEB2077C987EAC8B015E3995744" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EC56B4F0651EE606AE7EB015E3991D98" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10F2743B228CCEA1C066B015E3995CA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EC56B4F0651EE606AE7EB015E3991D98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10F2743B228CCEA1C066B015E3995CA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_78512CD547B44296534DB015E399FAF8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10F2743B228CCEA1C066B015E3995CA5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_78512CD547B44296534DB015E399FAF8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_78512CD547B44296534DB015E399FAF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10F2743B228CCEA1C066B015E3995CA5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_78512CD547B44296534DB015E399FAF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_CAE7CCAA38DC76D5B087B015E3998587" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_78512CD547B44296534DB015E399FAF8" xlink:to="loc_us-gaap_LicensingAgreementsMember_CAE7CCAA38DC76D5B087B015E3998587" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A079DEB2077C987EAC8B015E3995744" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2E6B9BAA48E03997AF2CB015E399DEA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2E6B9BAA48E03997AF2CB015E399DEA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F4A81FE91F060E0920C8B015E399F567" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F4A81FE91F060E0920C8B015E399F567" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C6E9AAF9EEDDCB9F18C2B015E3993760" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C6E9AAF9EEDDCB9F18C2B015E3993760" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_32A7E106A5E132F44B74B015E399646C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_32A7E106A5E132F44B74B015E399646C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ECDADBCD13F3CF488DDEB015E39A1872" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ECDADBCD13F3CF488DDEB015E39A1872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_491A73D7283CA274BAC2B015E39A2CC1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_491A73D7283CA274BAC2B015E39A2CC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_72CD7353D600253F1FDAB015E39A9D16" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_72CD7353D600253F1FDAB015E39A9D16" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/IntangibleAssetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66C5D37A0164460EA6AA48DE133553A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66C5D37A0164460EA6AA48DE133553A8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F4A92976164C6EE9D48A48DE13359B5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66C5D37A0164460EA6AA48DE133553A8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F4A92976164C6EE9D48A48DE13359B5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_300AF2A93ED565568C9948DE13350097_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F4A92976164C6EE9D48A48DE13359B5A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_300AF2A93ED565568C9948DE13350097_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_300AF2A93ED565568C9948DE13350097" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F4A92976164C6EE9D48A48DE13359B5A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_300AF2A93ED565568C9948DE13350097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementCopromotionMember" xlink:label="loc_us-gaap_CollaborativeArrangementCopromotionMember_05CF83E61AFFBA9DF7C948DE13363CE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_300AF2A93ED565568C9948DE13350097" xlink:to="loc_us-gaap_CollaborativeArrangementCopromotionMember_05CF83E61AFFBA9DF7C948DE13363CE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C5319055EB446BD6E90C48DE13362783" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66C5D37A0164460EA6AA48DE133553A8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C5319055EB446BD6E90C48DE13362783" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F34D80EF790E93F9E74848DE1336934B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C5319055EB446BD6E90C48DE13362783" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F34D80EF790E93F9E74848DE1336934B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F34D80EF790E93F9E74848DE1336934B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C5319055EB446BD6E90C48DE13362783" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F34D80EF790E93F9E74848DE1336934B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_9D8D5D8910D1AF76F93B48DE13364905" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F34D80EF790E93F9E74848DE1336934B" xlink:to="loc_us-gaap_LicensingAgreementsMember_9D8D5D8910D1AF76F93B48DE13364905" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_AdditionalMilestonePayment" xlink:label="loc_alim_AdditionalMilestonePayment_5A101626C074F00790DF48DE13368DB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:to="loc_alim_AdditionalMilestonePayment_5A101626C074F00790DF48DE13368DB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_FF054DCF2B7E3CCD077148DE13369769" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_FF054DCF2B7E3CCD077148DE13369769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_379444018DB15483528848DE13365980" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_379444018DB15483528848DE13365980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_78FAD7ECB10545E6E90E48DE13377AE9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_78FAD7ECB10545E6E90E48DE13377AE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_E43A99A6CE36AFBF26BE48DE1337E8D6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_E43A99A6CE36AFBF26BE48DE1337E8D6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/IntangibleAssetTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/InventoryDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/LicenseAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/LicenseAgreementsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5388B8A2581C443F5F46D5403003B8A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5388B8A2581C443F5F46D5403003B8A9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E1E8E8B433D25240D4EFD5403004D1ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5388B8A2581C443F5F46D5403003B8A9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_E1E8E8B433D25240D4EFD5403004D1ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6518C085A30D8C0DBCB8D5403004FC83_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E1E8E8B433D25240D4EFD5403004D1ED" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6518C085A30D8C0DBCB8D5403004FC83_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6518C085A30D8C0DBCB8D5403004FC83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E1E8E8B433D25240D4EFD5403004D1ED" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6518C085A30D8C0DBCB8D5403004FC83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementCopromotionMember" xlink:label="loc_us-gaap_CollaborativeArrangementCopromotionMember_027E53BE3A6B0FABD01AD5403004E2EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6518C085A30D8C0DBCB8D5403004FC83" xlink:to="loc_us-gaap_CollaborativeArrangementCopromotionMember_027E53BE3A6B0FABD01AD5403004E2EE" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract" xlink:label="loc_alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_B67A04D6F4B0589DD055D5403004C689" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_B67A04D6F4B0589DD055D5403004C689" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract" xlink:label="loc_alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_F913F6AE0704CFF672FFD5403004CC16" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_F913F6AE0704CFF672FFD5403004CC16" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled" xlink:label="loc_alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled_8BE8E81DCC19B49F80B1D5403004FDEF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled_8BE8E81DCC19B49F80B1D5403004FDEF" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ShareOfNetProfits" xlink:label="loc_alim_ShareOfNetProfits_8B1BAFAE2D438CA6C6D9D54030047F62" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_ShareOfNetProfits_8B1BAFAE2D438CA6C6D9D54030047F62" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien" xlink:label="loc_alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien_44C79A7985384E5D2731D54030050854" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien_44C79A7985384E5D2731D54030050854" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_PercentageOfRecoveryOfCommercializationCost" xlink:label="loc_alim_PercentageOfRecoveryOfCommercializationCost_EB7D3362B0DAA86A973AD5403005DE3A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_PercentageOfRecoveryOfCommercializationCost_EB7D3362B0DAA86A973AD5403005DE3A" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_CommercializationCosts" xlink:label="loc_alim_CommercializationCosts_66BB602101B4DACD43ADD5403005BB04" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_CommercializationCosts_66BB602101B4DACD43ADD5403005BB04" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_AdditionalMilestonePayment" xlink:label="loc_alim_AdditionalMilestonePayment_5DD9C269B26ABD88075FD54030059DAF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_AdditionalMilestonePayment_5DD9C269B26ABD88075FD54030059DAF" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_CommercializationCostsReceivable" xlink:label="loc_alim_CommercializationCostsReceivable_6F046B759D5CCE2735FBD5403005D724" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_CommercializationCostsReceivable_6F046B759D5CCE2735FBD5403005D724" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_CommercializationCostsReceivablePostAdjustment" xlink:label="loc_alim_CommercializationCostsReceivablePostAdjustment_FD22786B8807954A7401D5403005530F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_CommercializationCostsReceivablePostAdjustment_FD22786B8807954A7401D5403005530F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/LoanAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/LoanAgreementsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_C372B3E9AC583313B572D0A03D4D6975" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:to="loc_us-gaap_VariableRateAxis_C372B3E9AC583313B572D0A03D4D6975" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_857E9D77E6699632F4D5D0A03D4DD3DC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_C372B3E9AC583313B572D0A03D4D6975" xlink:to="loc_us-gaap_VariableRateDomain_857E9D77E6699632F4D5D0A03D4DD3DC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_857E9D77E6699632F4D5D0A03D4DD3DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_C372B3E9AC583313B572D0A03D4D6975" xlink:to="loc_us-gaap_VariableRateDomain_857E9D77E6699632F4D5D0A03D4DD3DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_6C19C1299E16764F9015D0A03D4D7185" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_857E9D77E6699632F4D5D0A03D4DD3DC" xlink:to="loc_us-gaap_PrimeRateMember_6C19C1299E16764F9015D0A03D4D7185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_DBB2028ADB4BBA933F5BD0A03D4D75D5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:to="loc_us-gaap_DebtInstrumentAxis_DBB2028ADB4BBA933F5BD0A03D4D75D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D99061EF866BC35EDA41D0A03D4DBF25_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_DBB2028ADB4BBA933F5BD0A03D4D75D5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D99061EF866BC35EDA41D0A03D4DBF25_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D99061EF866BC35EDA41D0A03D4DBF25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_DBB2028ADB4BBA933F5BD0A03D4D75D5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D99061EF866BC35EDA41D0A03D4DBF25" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_TrancheOneMember" xlink:label="loc_alim_TrancheOneMember_F64400775473302E1CCED0A03D4DE894" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D99061EF866BC35EDA41D0A03D4DBF25" xlink:to="loc_alim_TrancheOneMember_F64400775473302E1CCED0A03D4DE894" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_TrancheTwoMember" xlink:label="loc_alim_TrancheTwoMember_0D683E8A120D5A2E9EBFD0A03D4DDE93" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D99061EF866BC35EDA41D0A03D4DBF25" xlink:to="loc_alim_TrancheTwoMember_0D683E8A120D5A2E9EBFD0A03D4DDE93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4D7BD9EA91B89CD98329D0A03D4D42B6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:to="loc_dei_LegalEntityAxis_4D7BD9EA91B89CD98329D0A03D4D42B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_931635576EF6E62A8602D0A03D4DEDD4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4D7BD9EA91B89CD98329D0A03D4D42B6" xlink:to="loc_dei_EntityDomain_931635576EF6E62A8602D0A03D4DEDD4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_931635576EF6E62A8602D0A03D4DEDD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4D7BD9EA91B89CD98329D0A03D4D42B6" xlink:to="loc_dei_EntityDomain_931635576EF6E62A8602D0A03D4DEDD4" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_AlimeraSciencesIncCompanyMember" xlink:label="loc_alim_AlimeraSciencesIncCompanyMember_8346677F50ADBE675777D0A03D4DF98D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_931635576EF6E62A8602D0A03D4DEDD4" xlink:to="loc_alim_AlimeraSciencesIncCompanyMember_8346677F50ADBE675777D0A03D4DF98D" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_AlimeraSciencesLimitedLimitedMember" xlink:label="loc_alim_AlimeraSciencesLimitedLimitedMember_19F017263905C6EC710BD0A03D4DECB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alim_AlimeraSciencesIncCompanyMember_8346677F50ADBE675777D0A03D4DF98D" xlink:to="loc_alim_AlimeraSciencesLimitedLimitedMember_19F017263905C6EC710BD0A03D4DECB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_97CF78E6E442D6CFC615D0A03D4DBF02" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_97CF78E6E442D6CFC615D0A03D4DBF02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_8BF8FC722C062451D4A2D0A03D4D581E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_97CF78E6E442D6CFC615D0A03D4DBF02" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_8BF8FC722C062451D4A2D0A03D4D581E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_8BF8FC722C062451D4A2D0A03D4D581E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_97CF78E6E442D6CFC615D0A03D4DBF02" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_8BF8FC722C062451D4A2D0A03D4D581E" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_HerculesTechnologyGrowthCapitalInc.Member" xlink:label="loc_alim_HerculesTechnologyGrowthCapitalInc.Member_E4ACF7BEE50590DFBA70D0A03D534CBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_8BF8FC722C062451D4A2D0A03D4D581E" xlink:to="loc_alim_HerculesTechnologyGrowthCapitalInc.Member_E4ACF7BEE50590DFBA70D0A03D534CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_BC486F6880CD0B995EB9D0A03D538322" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:to="loc_us-gaap_CreditFacilityAxis_BC486F6880CD0B995EB9D0A03D538322" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_BC486F6880CD0B995EB9D0A03D538322" xlink:to="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_BC486F6880CD0B995EB9D0A03D538322" xlink:to="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_TwentyFourteenTermLoanMember" xlink:label="loc_alim_TwentyFourteenTermLoanMember_641A97B5F66A1490E452D0A03D53DC6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:to="loc_alim_TwentyFourteenTermLoanMember_641A97B5F66A1490E452D0A03D53DC6B" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_FirstLoanAmendmentMember" xlink:label="loc_alim_FirstLoanAmendmentMember_B4E5FD3761A879AF73FED0A03D538606" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:to="loc_alim_FirstLoanAmendmentMember_B4E5FD3761A879AF73FED0A03D538606" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_SecondLoanAmendmentMember" xlink:label="loc_alim_SecondLoanAmendmentMember_F62DD0E7654575D32291D0A03D537135" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:to="loc_alim_SecondLoanAmendmentMember_F62DD0E7654575D32291D0A03D537135" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ThirdLoanAmendmentMember" xlink:label="loc_alim_ThirdLoanAmendmentMember_4C617DB150C2E2B15FF7D0A03D533ECC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:to="loc_alim_ThirdLoanAmendmentMember_4C617DB150C2E2B15FF7D0A03D533ECC" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_July2016WaiverMember" xlink:label="loc_alim_July2016WaiverMember_7C7285237E1241EA3442D0A03D531B39" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:to="loc_alim_July2016WaiverMember_7C7285237E1241EA3442D0A03D531B39" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_FourthLoanAmendmentMember" xlink:label="loc_alim_FourthLoanAmendmentMember_E6C8C1BDCB5B0B18E802D0A03D53462C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:to="loc_alim_FourthLoanAmendmentMember_E6C8C1BDCB5B0B18E802D0A03D53462C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2F91139318E12902EC65D0A03D53F185" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2F91139318E12902EC65D0A03D53F185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_25386C9781535C3F245AD0A03D5395CC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_25386C9781535C3F245AD0A03D5395CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_B5A276BF118FF03CEE98D0A03D53FCA2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_B5A276BF118FF03CEE98D0A03D53FCA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_F1E16C6B0297E63D677AD0A03D538319" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_F1E16C6B0297E63D677AD0A03D538319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9FDF9ACD430CF5C52D7ED0A03D53301A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9FDF9ACD430CF5C52D7ED0A03D53301A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_29DF648A001CD9CAF6E1D0A03D537003" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_29DF648A001CD9CAF6E1D0A03D537003" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_3135E044B1BF3F0CF295D0A03D53BAE3" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_3135E044B1BF3F0CF295D0A03D53BAE3" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal" xlink:label="loc_alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal_7B40471ADE1126C796BDD0A03D536DFC" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal_7B40471ADE1126C796BDD0A03D536DFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_E2FC800A538044BDC1B2D0A03D53340E" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_E2FC800A538044BDC1B2D0A03D53340E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2BC4312706EAB9966713D0A03D533658" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2BC4312706EAB9966713D0A03D533658" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentCovenantMinimumCashBalance" xlink:label="loc_alim_DebtInstrumentCovenantMinimumCashBalance_D3D18BE0A43228DF1EB8D0A03D540FC8" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentCovenantMinimumCashBalance_D3D18BE0A43228DF1EB8D0A03D540FC8" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentTickingFeePercent" xlink:label="loc_alim_DebtInstrumentTickingFeePercent_2363FA43B0C21A54C231D0A03D54F785" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentTickingFeePercent_2363FA43B0C21A54C231D0A03D54F785" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentTickingFee" xlink:label="loc_alim_DebtInstrumentTickingFee_F78DCC5780EFE69306F3D0A03D54289B" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentTickingFee_F78DCC5780EFE69306F3D0A03D54289B" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_LineofCreditFacilityIncreaseinBorrowingCapacity" xlink:label="loc_alim_LineofCreditFacilityIncreaseinBorrowingCapacity_C2971B517BC6002C8C08D0A03D543E46" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_LineofCreditFacilityIncreaseinBorrowingCapacity_C2971B517BC6002C8C08D0A03D543E46" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentRevenueRequirement" xlink:label="loc_alim_DebtInstrumentRevenueRequirement_556E6AB9C1C9132382C8D0A03D546B83" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentRevenueRequirement_556E6AB9C1C9132382C8D0A03D546B83" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentBasisSpreadonVariableRateReduction" xlink:label="loc_alim_DebtInstrumentBasisSpreadonVariableRateReduction_ED2A42019B24FA1CE5FFD0A03D54C550" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentBasisSpreadonVariableRateReduction_ED2A42019B24FA1CE5FFD0A03D54C550" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebitInstrumentPaymentinKindInterestRate" xlink:label="loc_alim_DebitInstrumentPaymentinKindInterestRate_A80ECCDD1B6E4852EF52D0A03D54C40D" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebitInstrumentPaymentinKindInterestRate_A80ECCDD1B6E4852EF52D0A03D54C40D" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentPaymentTermsNumberofPayments" xlink:label="loc_alim_DebtInstrumentPaymentTermsNumberofPayments_E32862D8340405D3F198D0A03D54D9DC" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentPaymentTermsNumberofPayments_E32862D8340405D3F198D0A03D54D9DC" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentPrepaymentFeePercentageFirst12Months" xlink:label="loc_alim_DebtInstrumentPrepaymentFeePercentageFirst12Months_5FAD954C2C3738CF9732D0A03D548D28" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentPrepaymentFeePercentageFirst12Months_5FAD954C2C3738CF9732D0A03D548D28" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months" xlink:label="loc_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months_4E6039E162F9E9F062EFD0A03D54C559" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months_4E6039E162F9E9F062EFD0A03D54C559" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months" xlink:label="loc_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months_E59CE0128FCD2EECABAAD0A03D54CBA3" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months_E59CE0128FCD2EECABAAD0A03D54CBA3" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentCovenantLiquidityThreshold" xlink:label="loc_alim_DebtInstrumentCovenantLiquidityThreshold_8E1D75E61EAF125CE022D0A03D546179" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentCovenantLiquidityThreshold_8E1D75E61EAF125CE022D0A03D546179" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentCovenantCurrentLiquidity" xlink:label="loc_alim_DebtInstrumentCovenantCurrentLiquidity_EB5259E9BE3A10700668D0A03D549ED2" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentCovenantCurrentLiquidity_EB5259E9BE3A10700668D0A03D549ED2" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentCovenantLiquidityRelatedtoCashandCashEquivalents" xlink:label="loc_alim_DebtInstrumentCovenantLiquidityRelatedtoCashandCashEquivalents_CBC6955F23035D086FACD0A03D54BD15" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentCovenantLiquidityRelatedtoCashandCashEquivalents_CBC6955F23035D086FACD0A03D54BD15" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentCovenantLiquidityRelatedtoAccountsReceivable" xlink:label="loc_alim_DebtInstrumentCovenantLiquidityRelatedtoAccountsReceivable_17C011E8AED3A6B173BFD0A03D548DEA" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentCovenantLiquidityRelatedtoAccountsReceivable_17C011E8AED3A6B173BFD0A03D548DEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FEA6E40C2D7975FD43A6D0A03D545303" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FEA6E40C2D7975FD43A6D0A03D545303" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3FE461D56301EA11092BD0A03D54D500" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3FE461D56301EA11092BD0A03D54D500" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ClassofWarrantorRightExercisablePercentage" xlink:label="loc_alim_ClassofWarrantorRightExercisablePercentage_04890CAE64872BB9B068D0A03D54C696" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_ClassofWarrantorRightExercisablePercentage_04890CAE64872BB9B068D0A03D54C696" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage" xlink:label="loc_alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage_E606938B4C18AE34F676D0A03D54CF1C" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage_E606938B4C18AE34F676D0A03D54CF1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_4EF4ED11BE8CCCDB6F52D0CA19049ED7" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_4EF4ED11BE8CCCDB6F52D0CA19049ED7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/LossPerShareEps" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/LossPerShareEpsAntidilutiveSecuritiesExcludedDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E78E48379702E2F2436B48DE13824676" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_580B53CB8223994B766A48DE13814C3A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E78E48379702E2F2436B48DE13824676" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_580B53CB8223994B766A48DE13814C3A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8BB437A3371E225BEF148DE13811963" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_580B53CB8223994B766A48DE13814C3A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8BB437A3371E225BEF148DE13811963" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8BB437A3371E225BEF148DE13811963" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8BB437A3371E225BEF148DE13811963" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_AB5DD40080E58875358E48DE13816821" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_AB5DD40080E58875358E48DE13816821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_D010C17E43ABD85C72F948DE1382C332" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_D010C17E43ABD85C72F948DE1382C332" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_PreferredStockWarrantsMember" xlink:label="loc_alim_PreferredStockWarrantsMember_DB59C729E4008AEBA9BD48DE13825A03" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:to="loc_alim_PreferredStockWarrantsMember_DB59C729E4008AEBA9BD48DE13825A03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_28D77D558F211EB9159348DE1382ABCD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:to="loc_us-gaap_WarrantMember_28D77D558F211EB9159348DE1382ABCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C81F8E6435367F25E0CF48DE13827BF0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C81F8E6435367F25E0CF48DE13827BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3B9CF70C3E363066E93048DE138264F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E78E48379702E2F2436B48DE13824676" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3B9CF70C3E363066E93048DE138264F8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/LossPerShareEpsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/NatureOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/NatureOfOperationsDetail" xlink:type="extended">
    <link:loc xlink:href="alim-20170331.xsd#alim_NatureOfOperationsLineItems" xlink:label="loc_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD" xlink:type="locator" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ScheduleNatureOfOperationsTable" xlink:label="loc_alim_ScheduleNatureOfOperationsTable_966477850E80C2374980D0D38EB289A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD" xlink:to="loc_alim_ScheduleNatureOfOperationsTable_966477850E80C2374980D0D38EB289A0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_7F8E45ABE6D48D4C2EBAD0D38EB38551" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alim_ScheduleNatureOfOperationsTable_966477850E80C2374980D0D38EB289A0" xlink:to="loc_us-gaap_ProductOrServiceAxis_7F8E45ABE6D48D4C2EBAD0D38EB38551" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_74D12FB94A09DC1941E7D0D38EB39EF1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_7F8E45ABE6D48D4C2EBAD0D38EB38551" xlink:to="loc_us-gaap_ProductsAndServicesDomain_74D12FB94A09DC1941E7D0D38EB39EF1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_74D12FB94A09DC1941E7D0D38EB39EF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_7F8E45ABE6D48D4C2EBAD0D38EB38551" xlink:to="loc_us-gaap_ProductsAndServicesDomain_74D12FB94A09DC1941E7D0D38EB39EF1" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_IluvienMember" xlink:label="loc_alim_IluvienMember_08F87BCC806DD243A399D0D38EB397D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_74D12FB94A09DC1941E7D0D38EB39EF1" xlink:to="loc_alim_IluvienMember_08F87BCC806DD243A399D0D38EB397D8" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_PostAuthorizationOpenStudyPeriod" xlink:label="loc_alim_PostAuthorizationOpenStudyPeriod_F7A99C94AC253AB5F7B9D0D38EB3DB6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD" xlink:to="loc_alim_PostAuthorizationOpenStudyPeriod_F7A99C94AC253AB5F7B9D0D38EB3DB6F" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_PlannedDrugStudyNumberofPatients" xlink:label="loc_alim_PlannedDrugStudyNumberofPatients_1884172BADDBC5B4F58DD0D38EB3059D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD" xlink:to="loc_alim_PlannedDrugStudyNumberofPatients_1884172BADDBC5B4F58DD0D38EB3059D" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_PlannedStudyNumberofPatients" xlink:label="loc_alim_PlannedStudyNumberofPatients_B7DF1DC95EEB0BDF2075D0DB455AD02B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD" xlink:to="loc_alim_PlannedStudyNumberofPatients_B7DF1DC95EEB0BDF2075D0DB455AD02B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/PreferredStock" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/PreferredStockDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_us-gaap_ConversionOfStockTable_1B25A705ED56B5A42C2E591B212DA232" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_ConversionOfStockTable_1B25A705ED56B5A42C2E591B212DA232" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0EF278CFEB309C2113E7591B212D2A79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_1B25A705ED56B5A42C2E591B212DA232" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0EF278CFEB309C2113E7591B212D2A79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8B140EB37DBECAA9A50D591B212D012F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0EF278CFEB309C2113E7591B212D2A79" xlink:to="loc_us-gaap_ClassOfStockDomain_8B140EB37DBECAA9A50D591B212D012F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8B140EB37DBECAA9A50D591B212D012F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0EF278CFEB309C2113E7591B212D2A79" xlink:to="loc_us-gaap_ClassOfStockDomain_8B140EB37DBECAA9A50D591B212D012F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_11183F049F3FACCBE2F7591B212DB24B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8B140EB37DBECAA9A50D591B212D012F" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_11183F049F3FACCBE2F7591B212DB24B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2BF7226A27CF88FAEBBF591B212D3BB4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8B140EB37DBECAA9A50D591B212D012F" xlink:to="loc_us-gaap_CommonStockMember_2BF7226A27CF88FAEBBF591B212D3BB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_3C35EC7B0303E6B3BCCA591B212D3362" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8B140EB37DBECAA9A50D591B212D012F" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_3C35EC7B0303E6B3BCCA591B212D3362" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_91A528AB170018D9441C591B212D7610" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_1B25A705ED56B5A42C2E591B212DA232" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_91A528AB170018D9441C591B212D7610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9613EE457881F65C42A6591B212D688E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_91A528AB170018D9441C591B212D7610" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9613EE457881F65C42A6591B212D688E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9613EE457881F65C42A6591B212D688E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_91A528AB170018D9441C591B212D7610" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9613EE457881F65C42A6591B212D688E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_D7314E7C0D39D3E408CF591B212D9D6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9613EE457881F65C42A6591B212D688E" xlink:to="loc_us-gaap_OverAllotmentOptionMember_D7314E7C0D39D3E408CF591B212D9D6C" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_NumberOfPreferredStockAndWarrants" xlink:label="loc_alim_NumberOfPreferredStockAndWarrants_4C99EB07A5E2BA6AC84D591B212ECD50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_NumberOfPreferredStockAndWarrants_4C99EB07A5E2BA6AC84D591B212ECD50" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_WarrantsToPurchaseAdditionalShares" xlink:label="loc_alim_WarrantsToPurchaseAdditionalShares_5658BEC2990679F67A3F591B212E6E1C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_WarrantsToPurchaseAdditionalShares_5658BEC2990679F67A3F591B212E6E1C" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_GrossProceedsUnderSecuritiesPurchaseAgreement" xlink:label="loc_alim_GrossProceedsUnderSecuritiesPurchaseAgreement_39636316BD971BE61872591B212E72F6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_GrossProceedsUnderSecuritiesPurchaseAgreement_39636316BD971BE61872591B212E72F6" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_EstimatedTotalStockIssuanceCost" xlink:label="loc_alim_EstimatedTotalStockIssuanceCost_8D179FEEDE00ACE4664A591B212E044F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_EstimatedTotalStockIssuanceCost_8D179FEEDE00ACE4664A591B212E044F" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue" xlink:label="loc_alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue_5840EA2725D97A606998591B212E95D4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue_5840EA2725D97A606998591B212E95D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_53946E113613A0974E40591B212EC012" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_53946E113613A0974E40591B212EC012" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_PreferredStockConvertedToCommonStockPerShare" xlink:label="loc_alim_PreferredStockConvertedToCommonStockPerShare_001A9DA1D206754EC9F8591B212E7319" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_PreferredStockConvertedToCommonStockPerShare_001A9DA1D206754EC9F8591B212E7319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_A6941D3349929AF35C3B591B212EE647" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_A6941D3349929AF35C3B591B212EE647" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ProportionOfEachUnitOfShares" xlink:label="loc_alim_ProportionOfEachUnitOfShares_9831103A75B019217437591B212ECDED" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_ProportionOfEachUnitOfShares_9831103A75B019217437591B212ECDED" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ExercisePriceOfWarrants" xlink:label="loc_alim_ExercisePriceOfWarrants_C02488C215B82DCC5697591B212EF21B" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_ExercisePriceOfWarrants_C02488C215B82DCC5697591B212EF21B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_F3AA9D84656CC800084D591B212E3FFA" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_F3AA9D84656CC800084D591B212E3FFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_A3C86DD1AD63F57FF9E5591B212EDE0D" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_A3C86DD1AD63F57FF9E5591B212EDE0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_59E046C366E80FA5EB96591B212EDCC1" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_59E046C366E80FA5EB96591B212EDCC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_7945A6E51B149735AB9B591B212EE980" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_7945A6E51B149735AB9B591B212EE980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_CBF13D8C139FEB457394591B21335152" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_PreferredStockSharesIssued_CBF13D8C139FEB457394591B21335152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2C9A4E44512FFFF21154591B21346A3C" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2C9A4E44512FFFF21154591B21346A3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3DD5DD705BB64E352E4D591B21345BD2" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3DD5DD705BB64E352E4D591B21345BD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_0E00EEBE6771911A7A2C591B213462C4" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_0E00EEBE6771911A7A2C591B213462C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2224C0256F1CEDB7AEC591B2134129E" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2224C0256F1CEDB7AEC591B2134129E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_88EDB58AE8F089DFDAC2591B2134FA52" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_88EDB58AE8F089DFDAC2591B2134FA52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_473A215BE740185DB071591B2134620F" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_473A215BE740185DB071591B2134620F" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent" xlink:label="loc_alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent_FEC5F0D04E4BA8D5D190591B213408C3" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent_FEC5F0D04E4BA8D5D190591B213408C3" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature" xlink:label="loc_alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature_A2079E28A0524491D149591B2134BA0A" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature_A2079E28A0524491D149591B2134BA0A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/SegmentInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6119CE2A30FC8023FE05F446051EA098" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6119CE2A30FC8023FE05F446051EA098" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_D61AF0E4E21DDCDF0B0DF446051E42D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6119CE2A30FC8023FE05F446051EA098" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_D61AF0E4E21DDCDF0B0DF446051E42D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_A2A60FE73E0D3DE65C99F446051E80C0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_D61AF0E4E21DDCDF0B0DF446051E42D9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_A2A60FE73E0D3DE65C99F446051E80C0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_A2A60FE73E0D3DE65C99F446051E80C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_D61AF0E4E21DDCDF0B0DF446051E42D9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_A2A60FE73E0D3DE65C99F446051E80C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_C19D169E64C9B47B4DB6F446051E8BDB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_A2A60FE73E0D3DE65C99F446051E80C0" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_C19D169E64C9B47B4DB6F446051E8BDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8D14481FCC9A61FA9C44F446051E4EA5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6119CE2A30FC8023FE05F446051EA098" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8D14481FCC9A61FA9C44F446051E4EA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3CDB716420AAD9F40816F446051E2221_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8D14481FCC9A61FA9C44F446051E4EA5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3CDB716420AAD9F40816F446051E2221_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3CDB716420AAD9F40816F446051E2221" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8D14481FCC9A61FA9C44F446051E4EA5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3CDB716420AAD9F40816F446051E2221" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_E796284D9FF1C4A24839F446051ED12B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3CDB716420AAD9F40816F446051E2221" xlink:to="loc_us-gaap_SalesMember_E796284D9FF1C4A24839F446051ED12B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_FF9A38545D89061EF6A5F446051EE8AE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3CDB716420AAD9F40816F446051E2221" xlink:to="loc_us-gaap_AccountsReceivableMember_FF9A38545D89061EF6A5F446051EE8AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9B86506938475CFF7349F446051EBE75" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6119CE2A30FC8023FE05F446051EA098" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9B86506938475CFF7349F446051EBE75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9B86506938475CFF7349F446051EBE75" xlink:to="loc_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9B86506938475CFF7349F446051EBE75" xlink:to="loc_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_UnitedStatesSegmentMember" xlink:label="loc_alim_UnitedStatesSegmentMember_B3F2F97588FA1CE7DD4FF446051E63E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B" xlink:to="loc_alim_UnitedStatesSegmentMember_B3F2F97588FA1CE7DD4FF446051E63E2" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_InternationalSegmentMember" xlink:label="loc_alim_InternationalSegmentMember_DC439EA1AFF7EE35B5E2F446051E727A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B" xlink:to="loc_alim_InternationalSegmentMember_DC439EA1AFF7EE35B5E2F446051E727A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="loc_us-gaap_AllOtherSegmentsMember_D21185038C6D6E107F72F446051E5962" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B" xlink:to="loc_us-gaap_AllOtherSegmentsMember_D21185038C6D6E107F72F446051E5962" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ConcentrationRiskNumberofCustomers" xlink:label="loc_alim_ConcentrationRiskNumberofCustomers_DA8A9F5319C2421BF230F446051E76DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_alim_ConcentrationRiskNumberofCustomers_DA8A9F5319C2421BF230F446051E76DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_945826C84DDCE124F28FF446051EA8F2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_945826C84DDCE124F28FF446051EA8F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_13B2AEACA8F67EA1926DF446051E1395" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_Revenues_13B2AEACA8F67EA1926DF446051E1395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_E8EDF06E274109035DB3F446051E271D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_CostOfGoodsSold_E8EDF06E274109035DB3F446051E271D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1C4650992C086D179EAEF446051EC55B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_GrossProfit_1C4650992C086D179EAEF446051EC55B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_41715EB32B0AE1420C7EF446051EC071" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_41715EB32B0AE1420C7EF446051EC071" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0C435E24FCFC3BDF9227F446051EF0DE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0C435E24FCFC3BDF9227F446051EF0DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaap_MarketingExpense_6C3E1BAF836D87CBA3D9F446051ECFE7" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_MarketingExpense_6C3E1BAF836D87CBA3D9F446051ECFE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_41F4D2B8EC52B9DE8245F446051E5CE8" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_41F4D2B8EC52B9DE8245F446051E5CE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_D1519612BD3CB70BEE1AF446052F57CA" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_OperatingExpenses_D1519612BD3CB70BEE1AF446052F57CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_198B1E9724A368A7090FF446052F531A" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_OperatingIncomeLoss_198B1E9724A368A7090FF446052F531A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_A4670A833DC3D2C20492F446052F83F1" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_A4670A833DC3D2C20492F446052F83F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_03CB71D2F7EDDADD8472F4460531568D" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_03CB71D2F7EDDADD8472F4460531568D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/SegmentInformationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/StockIncentivePlans" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/StockIncentivePlansAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ACC172FB833E9F9C306E8B8825658D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ACC172FB833E9F9C306E8B8825658D1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6647BE7361AF447F22CBE8B882565E61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ACC172FB833E9F9C306E8B8825658D1" xlink:to="loc_us-gaap_AwardTypeAxis_6647BE7361AF447F22CBE8B882565E61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6647BE7361AF447F22CBE8B882565E61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6647BE7361AF447F22CBE8B882565E61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_928F1F150267C5F50236E8B882569C4D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73" xlink:to="loc_us-gaap_EmployeeStockOptionMember_928F1F150267C5F50236E8B882569C4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_868BC4AC16D57B4480BEE8B882562D4F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73" xlink:to="loc_us-gaap_EmployeeStockMember_868BC4AC16D57B4480BEE8B882562D4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1A48D595BD697281E3ECE8C011B1DBAB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1A48D595BD697281E3ECE8C011B1DBAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2254FA9481D279DBD5ECE8B8825650C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2254FA9481D279DBD5ECE8B8825650C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7F3D41694E07AC638DDAE8B88256C3E7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7F3D41694E07AC638DDAE8B88256C3E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1B7FAA7E316645FD66ABE8B88257390F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1B7FAA7E316645FD66ABE8B88257390F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_404E5F7BA4D4804BF165E8C0F0C5AC06" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_404E5F7BA4D4804BF165E8C0F0C5AC06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_FE3F95A3091A933C2C9BE8C321B94744" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_FE3F95A3091A933C2C9BE8C321B94744" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/StockIncentivePlansAdditionalStockOptionTransactionsDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/StockIncentivePlansSummaryOfStockOptionTransactionsDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/StockIncentivePlansTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/SubsequentEventNotes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>alim-20170331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SegmentReportingAbstract_95276524943EB58D30E948DE135F34D8_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract_95276524943EB58D30E948DE135F34D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_95276524943EB58D30E948DE135F34D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_95276524943EB58D30E948DE135F34D8" xlink:to="lab_us-gaap_SegmentReportingAbstract_95276524943EB58D30E948DE135F34D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_52E5B174B1AAB24626FE48DE135F7ED5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_52E5B174B1AAB24626FE48DE135F7ED5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reporting Segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_52E5B174B1AAB24626FE48DE135F7ED5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_52E5B174B1AAB24626FE48DE135F7ED5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_52E5B174B1AAB24626FE48DE135F7ED5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_52E5B174B1AAB24626FE48DE135F7ED5" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_52E5B174B1AAB24626FE48DE135F7ED5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_64E11556AB1F4311485A48DE1356910E_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_64E11556AB1F4311485A48DE1356910E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_64E11556AB1F4311485A48DE1356910E_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_64E11556AB1F4311485A48DE1356910E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_64E11556AB1F4311485A48DE1356910E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_64E11556AB1F4311485A48DE1356910E" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_64E11556AB1F4311485A48DE1356910E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_BDE4078A183C129429CC48DE13B67983_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_BDE4078A183C129429CC48DE13B67983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_BDE4078A183C129429CC48DE13B67983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_BDE4078A183C129429CC48DE13B67983" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_BDE4078A183C129429CC48DE13B67983" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_AD8E3D8394871EDB898A48DE13B79F00_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_AD8E3D8394871EDB898A48DE13B79F00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_AD8E3D8394871EDB898A48DE13B79F00_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_AD8E3D8394871EDB898A48DE13B79F00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_AD8E3D8394871EDB898A48DE13B79F00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_AD8E3D8394871EDB898A48DE13B79F00" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_AD8E3D8394871EDB898A48DE13B79F00" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_39D901B0341E6F1F190148DE13580D73_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_39D901B0341E6F1F190148DE13580D73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_39D901B0341E6F1F190148DE13580D73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_39D901B0341E6F1F190148DE13580D73" xlink:to="lab_us-gaap_EarningsPerShareAbstract_39D901B0341E6F1F190148DE13580D73" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_190CB2C9AA85B19729D348DE1359D171_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_190CB2C9AA85B19729D348DE1359D171" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_190CB2C9AA85B19729D348DE1359D171_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_190CB2C9AA85B19729D348DE1359D171" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_190CB2C9AA85B19729D348DE1359D171" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_190CB2C9AA85B19729D348DE1359D171" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_190CB2C9AA85B19729D348DE1359D171" xlink:type="arc" />
    <link:label id="lab_alim_DocumentAndEntityInformationAbstract_D1A1BE1880CFDA23AA5D48DE1393C7A9_label_en-US" xlink:label="lab_alim_DocumentAndEntityInformationAbstract_D1A1BE1880CFDA23AA5D48DE1393C7A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_alim_DocumentAndEntityInformationAbstract_D1A1BE1880CFDA23AA5D48DE1393C7A9_documentation_en-US" xlink:label="lab_alim_DocumentAndEntityInformationAbstract_D1A1BE1880CFDA23AA5D48DE1393C7A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_DocumentAndEntityInformationAbstract" xlink:label="loc_alim_DocumentAndEntityInformationAbstract_D1A1BE1880CFDA23AA5D48DE1393C7A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_DocumentAndEntityInformationAbstract_D1A1BE1880CFDA23AA5D48DE1393C7A9" xlink:to="lab_alim_DocumentAndEntityInformationAbstract_D1A1BE1880CFDA23AA5D48DE1393C7A9" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_7C93A436B4C1F3087BB048DE1393553F_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_7C93A436B4C1F3087BB048DE1393553F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_7C93A436B4C1F3087BB048DE1393553F_label_en-US" xlink:label="lab_dei_EntityRegistrantName_7C93A436B4C1F3087BB048DE1393553F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_7C93A436B4C1F3087BB048DE1393553F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_7C93A436B4C1F3087BB048DE1393553F" xlink:to="lab_dei_EntityRegistrantName_7C93A436B4C1F3087BB048DE1393553F" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_6922D9FFAA0C23EBBA3A48DE13934FF5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_6922D9FFAA0C23EBBA3A48DE13934FF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_6922D9FFAA0C23EBBA3A48DE13934FF5_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_6922D9FFAA0C23EBBA3A48DE13934FF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6922D9FFAA0C23EBBA3A48DE13934FF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_6922D9FFAA0C23EBBA3A48DE13934FF5" xlink:to="lab_dei_EntityCentralIndexKey_6922D9FFAA0C23EBBA3A48DE13934FF5" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_3AE65524962872ECB84948DE1393C7AD_terseLabel_en-US" xlink:label="lab_dei_DocumentType_3AE65524962872ECB84948DE1393C7AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_3AE65524962872ECB84948DE1393C7AD_label_en-US" xlink:label="lab_dei_DocumentType_3AE65524962872ECB84948DE1393C7AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_3AE65524962872ECB84948DE1393C7AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_3AE65524962872ECB84948DE1393C7AD" xlink:to="lab_dei_DocumentType_3AE65524962872ECB84948DE1393C7AD" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_6DC7B540A7FD0C15B9A948DE1393B946_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_6DC7B540A7FD0C15B9A948DE1393B946" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_6DC7B540A7FD0C15B9A948DE1393B946_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_6DC7B540A7FD0C15B9A948DE1393B946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_6DC7B540A7FD0C15B9A948DE1393B946" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_6DC7B540A7FD0C15B9A948DE1393B946" xlink:to="lab_dei_DocumentPeriodEndDate_6DC7B540A7FD0C15B9A948DE1393B946" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_15D14C334D8E40AB46DC48DE13938BB5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_15D14C334D8E40AB46DC48DE13938BB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_15D14C334D8E40AB46DC48DE13938BB5_label_en-US" xlink:label="lab_dei_AmendmentFlag_15D14C334D8E40AB46DC48DE13938BB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_15D14C334D8E40AB46DC48DE13938BB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_15D14C334D8E40AB46DC48DE13938BB5" xlink:to="lab_dei_AmendmentFlag_15D14C334D8E40AB46DC48DE13938BB5" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_F10F6FFB940BA504842448DE13943438_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_F10F6FFB940BA504842448DE13943438" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_F10F6FFB940BA504842448DE13943438_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_F10F6FFB940BA504842448DE13943438" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_F10F6FFB940BA504842448DE13943438" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_F10F6FFB940BA504842448DE13943438" xlink:to="lab_dei_DocumentFiscalYearFocus_F10F6FFB940BA504842448DE13943438" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_38D78B2390B2A41E7C2948DE1394E20A_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_38D78B2390B2A41E7C2948DE1394E20A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_38D78B2390B2A41E7C2948DE1394E20A_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_38D78B2390B2A41E7C2948DE1394E20A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_38D78B2390B2A41E7C2948DE1394E20A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_38D78B2390B2A41E7C2948DE1394E20A" xlink:to="lab_dei_DocumentFiscalPeriodFocus_38D78B2390B2A41E7C2948DE1394E20A" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_71C2624A2DA909C481F248DE1394E28B_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_71C2624A2DA909C481F248DE1394E28B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_71C2624A2DA909C481F248DE1394E28B_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_71C2624A2DA909C481F248DE1394E28B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_71C2624A2DA909C481F248DE1394E28B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_71C2624A2DA909C481F248DE1394E28B" xlink:to="lab_dei_CurrentFiscalYearEndDate_71C2624A2DA909C481F248DE1394E28B" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_FDCEC096B3A4C094BE2048DE13949A91_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_FDCEC096B3A4C094BE2048DE13949A91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_FDCEC096B3A4C094BE2048DE13949A91_label_en-US" xlink:label="lab_dei_EntityFilerCategory_FDCEC096B3A4C094BE2048DE13949A91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_FDCEC096B3A4C094BE2048DE13949A91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_FDCEC096B3A4C094BE2048DE13949A91" xlink:to="lab_dei_EntityFilerCategory_FDCEC096B3A4C094BE2048DE13949A91" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7D743C179813541DA96F48DE1394A945_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_7D743C179813541DA96F48DE1394A945" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7D743C179813541DA96F48DE1394A945_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_7D743C179813541DA96F48DE1394A945" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7D743C179813541DA96F48DE1394A945" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_7D743C179813541DA96F48DE1394A945" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_7D743C179813541DA96F48DE1394A945" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06B25301D6F643788EB848DE134B507D_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06B25301D6F643788EB848DE134B507D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06B25301D6F643788EB848DE134B507D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06B25301D6F643788EB848DE134B507D" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06B25301D6F643788EB848DE134B507D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_C60570F163FF388AC6BB48DE134BD4FB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_C60570F163FF388AC6BB48DE134BD4FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of stock option transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_C60570F163FF388AC6BB48DE134BD4FB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_C60570F163FF388AC6BB48DE134BD4FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_C60570F163FF388AC6BB48DE134BD4FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_C60570F163FF388AC6BB48DE134BD4FB" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_C60570F163FF388AC6BB48DE134BD4FB" xlink:type="arc" />
    <link:label id="lab_alim_AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock_08F23C14571D364343A148DE134C4F9A_terseLabel_en-US" xlink:label="lab_alim_AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock_08F23C14571D364343A148DE134C4F9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of additional stock option transactions</link:label>
    <link:label id="lab_alim_AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock_08F23C14571D364343A148DE134C4F9A_label_en-US" xlink:label="lab_alim_AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock_08F23C14571D364343A148DE134C4F9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Schedule Of Share-based Compensation Stock Options Activity [Table Text Block]</link:label>
    <link:label id="lab_alim_AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock_08F23C14571D364343A148DE134C4F9A_documentation_en-US" xlink:label="lab_alim_AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock_08F23C14571D364343A148DE134C4F9A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Schedule Of Share-based Compensation Stock Options Activity [Table Text Block]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_alim_AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock_08F23C14571D364343A148DE134C4F9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock_08F23C14571D364343A148DE134C4F9A" xlink:to="lab_alim_AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock_08F23C14571D364343A148DE134C4F9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_DEBD2BE3255A51F5185648DE137D6607_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_DEBD2BE3255A51F5185648DE137D6607" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Share (EPS)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_DEBD2BE3255A51F5185648DE137D6607_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_DEBD2BE3255A51F5185648DE137D6607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_DEBD2BE3255A51F5185648DE137D6607" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_DEBD2BE3255A51F5185648DE137D6607" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_DEBD2BE3255A51F5185648DE137D6607" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_05F18D664872E2FD4EF048DE135BE77A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_05F18D664872E2FD4EF048DE135BE77A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_05F18D664872E2FD4EF048DE135BE77A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05F18D664872E2FD4EF048DE135BE77A" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_05F18D664872E2FD4EF048DE135BE77A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1EB370342CD5B40A5C8148DE135B540F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_1EB370342CD5B40A5C8148DE135B540F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1EB370342CD5B40A5C8148DE135B540F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_1EB370342CD5B40A5C8148DE135B540F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1EB370342CD5B40A5C8148DE135B540F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_1EB370342CD5B40A5C8148DE135B540F" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_1EB370342CD5B40A5C8148DE135B540F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_39DA93292F33AB77912148DE1378B34F_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_39DA93292F33AB77912148DE1378B34F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_39DA93292F33AB77912148DE1378B34F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_39DA93292F33AB77912148DE1378B34F" xlink:to="lab_us-gaap_EquityAbstract_39DA93292F33AB77912148DE1378B34F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B23B01F065DF26BEE1E948DE1378456F_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B23B01F065DF26BEE1E948DE1378456F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B23B01F065DF26BEE1E948DE1378456F_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B23B01F065DF26BEE1E948DE1378456F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B23B01F065DF26BEE1E948DE1378456F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B23B01F065DF26BEE1E948DE1378456F" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B23B01F065DF26BEE1E948DE1378456F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_1F5F06891E550E16DA4748DE13796061_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_1F5F06891E550E16DA4748DE13796061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1F5F06891E550E16DA4748DE13796061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1F5F06891E550E16DA4748DE13796061" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_1F5F06891E550E16DA4748DE13796061" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A834670DB4109577589D48DE137999B3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A834670DB4109577589D48DE137999B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A834670DB4109577589D48DE137999B3_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A834670DB4109577589D48DE137999B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A834670DB4109577589D48DE137999B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A834670DB4109577589D48DE137999B3" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A834670DB4109577589D48DE137999B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C4EB20B120788F92ECDAD0D38EB2A8B9_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C4EB20B120788F92ECDAD0D38EB2A8B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C4EB20B120788F92ECDAD0D38EB2A8B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C4EB20B120788F92ECDAD0D38EB2A8B9" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C4EB20B120788F92ECDAD0D38EB2A8B9" xlink:type="arc" />
    <link:label id="lab_alim_ScheduleNatureOfOperationsTable_966477850E80C2374980D0D38EB289A0_terseLabel_en-US" xlink:label="lab_alim_ScheduleNatureOfOperationsTable_966477850E80C2374980D0D38EB289A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Nature Of Operations [Table]</link:label>
    <link:label id="lab_alim_ScheduleNatureOfOperationsTable_966477850E80C2374980D0D38EB289A0_label_en-US" xlink:label="lab_alim_ScheduleNatureOfOperationsTable_966477850E80C2374980D0D38EB289A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Nature Of Operations [Table]</link:label>
    <link:label id="lab_alim_ScheduleNatureOfOperationsTable_966477850E80C2374980D0D38EB289A0_documentation_en-US" xlink:label="lab_alim_ScheduleNatureOfOperationsTable_966477850E80C2374980D0D38EB289A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Nature Of Operations [Table]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_ScheduleNatureOfOperationsTable" xlink:label="loc_alim_ScheduleNatureOfOperationsTable_966477850E80C2374980D0D38EB289A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_ScheduleNatureOfOperationsTable_966477850E80C2374980D0D38EB289A0" xlink:to="lab_alim_ScheduleNatureOfOperationsTable_966477850E80C2374980D0D38EB289A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_7F8E45ABE6D48D4C2EBAD0D38EB38551_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_7F8E45ABE6D48D4C2EBAD0D38EB38551" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_7F8E45ABE6D48D4C2EBAD0D38EB38551_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_7F8E45ABE6D48D4C2EBAD0D38EB38551" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_7F8E45ABE6D48D4C2EBAD0D38EB38551" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_7F8E45ABE6D48D4C2EBAD0D38EB38551" xlink:to="lab_us-gaap_ProductOrServiceAxis_7F8E45ABE6D48D4C2EBAD0D38EB38551" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_74D12FB94A09DC1941E7D0D38EB39EF1_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_74D12FB94A09DC1941E7D0D38EB39EF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_74D12FB94A09DC1941E7D0D38EB39EF1_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_74D12FB94A09DC1941E7D0D38EB39EF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_74D12FB94A09DC1941E7D0D38EB39EF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_74D12FB94A09DC1941E7D0D38EB39EF1" xlink:to="lab_us-gaap_ProductsAndServicesDomain_74D12FB94A09DC1941E7D0D38EB39EF1" xlink:type="arc" />
    <link:label id="lab_alim_IluvienMember_08F87BCC806DD243A399D0D38EB397D8_terseLabel_en-US" xlink:label="lab_alim_IluvienMember_08F87BCC806DD243A399D0D38EB397D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ILUVIEN</link:label>
    <link:label id="lab_alim_IluvienMember_08F87BCC806DD243A399D0D38EB397D8_label_en-US" xlink:label="lab_alim_IluvienMember_08F87BCC806DD243A399D0D38EB397D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ILUVIEN [Member]</link:label>
    <link:label id="lab_alim_IluvienMember_08F87BCC806DD243A399D0D38EB397D8_documentation_en-US" xlink:label="lab_alim_IluvienMember_08F87BCC806DD243A399D0D38EB397D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ILUVIEN [Member]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_IluvienMember" xlink:label="loc_alim_IluvienMember_08F87BCC806DD243A399D0D38EB397D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_IluvienMember_08F87BCC806DD243A399D0D38EB397D8" xlink:to="lab_alim_IluvienMember_08F87BCC806DD243A399D0D38EB397D8" xlink:type="arc" />
    <link:label id="lab_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD_terseLabel_en-US" xlink:label="lab_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature Of Operations [Line Items]</link:label>
    <link:label id="lab_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD_label_en-US" xlink:label="lab_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature Of Operations [Line Items]</link:label>
    <link:label id="lab_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD_documentation_en-US" xlink:label="lab_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nature Of Operations [Line Items]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_NatureOfOperationsLineItems" xlink:label="loc_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD" xlink:to="lab_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD" xlink:type="arc" />
    <link:label id="lab_alim_PostAuthorizationOpenStudyPeriod_F7A99C94AC253AB5F7B9D0D38EB3DB6F_terseLabel_en-US" xlink:label="lab_alim_PostAuthorizationOpenStudyPeriod_F7A99C94AC253AB5F7B9D0D38EB3DB6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Post-authorization open study period (in years)</link:label>
    <link:label id="lab_alim_PostAuthorizationOpenStudyPeriod_F7A99C94AC253AB5F7B9D0D38EB3DB6F_label_en-US" xlink:label="lab_alim_PostAuthorizationOpenStudyPeriod_F7A99C94AC253AB5F7B9D0D38EB3DB6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Post-authorization Open Study Period</link:label>
    <link:label id="lab_alim_PostAuthorizationOpenStudyPeriod_F7A99C94AC253AB5F7B9D0D38EB3DB6F_documentation_en-US" xlink:label="lab_alim_PostAuthorizationOpenStudyPeriod_F7A99C94AC253AB5F7B9D0D38EB3DB6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Post-authorization Open Study Period</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_PostAuthorizationOpenStudyPeriod" xlink:label="loc_alim_PostAuthorizationOpenStudyPeriod_F7A99C94AC253AB5F7B9D0D38EB3DB6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_PostAuthorizationOpenStudyPeriod_F7A99C94AC253AB5F7B9D0D38EB3DB6F" xlink:to="lab_alim_PostAuthorizationOpenStudyPeriod_F7A99C94AC253AB5F7B9D0D38EB3DB6F" xlink:type="arc" />
    <link:label id="lab_alim_PlannedDrugStudyNumberofPatients_1884172BADDBC5B4F58DD0D38EB3059D_terseLabel_en-US" xlink:label="lab_alim_PlannedDrugStudyNumberofPatients_1884172BADDBC5B4F58DD0D38EB3059D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Planned drug study, number of patients</link:label>
    <link:label id="lab_alim_PlannedDrugStudyNumberofPatients_1884172BADDBC5B4F58DD0D38EB3059D_label_en-US" xlink:label="lab_alim_PlannedDrugStudyNumberofPatients_1884172BADDBC5B4F58DD0D38EB3059D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Planned Drug Study, Number of Patients</link:label>
    <link:label id="lab_alim_PlannedDrugStudyNumberofPatients_1884172BADDBC5B4F58DD0D38EB3059D_documentation_en-US" xlink:label="lab_alim_PlannedDrugStudyNumberofPatients_1884172BADDBC5B4F58DD0D38EB3059D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Planned Drug Study, Number of Patients</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_PlannedDrugStudyNumberofPatients" xlink:label="loc_alim_PlannedDrugStudyNumberofPatients_1884172BADDBC5B4F58DD0D38EB3059D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_PlannedDrugStudyNumberofPatients_1884172BADDBC5B4F58DD0D38EB3059D" xlink:to="lab_alim_PlannedDrugStudyNumberofPatients_1884172BADDBC5B4F58DD0D38EB3059D" xlink:type="arc" />
    <link:label id="lab_alim_PlannedStudyNumberofPatients_B7DF1DC95EEB0BDF2075D0DB455AD02B_terseLabel_en-US" xlink:label="lab_alim_PlannedStudyNumberofPatients_B7DF1DC95EEB0BDF2075D0DB455AD02B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_alim_PlannedStudyNumberofPatients_B7DF1DC95EEB0BDF2075D0DB455AD02B_label_en-US" xlink:label="lab_alim_PlannedStudyNumberofPatients_B7DF1DC95EEB0BDF2075D0DB455AD02B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Planned Study, Number of Patients</link:label>
    <link:label id="lab_alim_PlannedStudyNumberofPatients_B7DF1DC95EEB0BDF2075D0DB455AD02B_documentation_en-US" xlink:label="lab_alim_PlannedStudyNumberofPatients_B7DF1DC95EEB0BDF2075D0DB455AD02B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of patients in drug study.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_PlannedStudyNumberofPatients" xlink:label="loc_alim_PlannedStudyNumberofPatients_B7DF1DC95EEB0BDF2075D0DB455AD02B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_PlannedStudyNumberofPatients_B7DF1DC95EEB0BDF2075D0DB455AD02B" xlink:to="lab_alim_PlannedStudyNumberofPatients_B7DF1DC95EEB0BDF2075D0DB455AD02B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_208CEA5278434B7E899FB015E307FD8A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_208CEA5278434B7E899FB015E307FD8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_208CEA5278434B7E899FB015E307FD8A_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_208CEA5278434B7E899FB015E307FD8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_208CEA5278434B7E899FB015E307FD8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_208CEA5278434B7E899FB015E307FD8A" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_208CEA5278434B7E899FB015E307FD8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_E4263A40940A793DF7D8B015E3086751_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_E4263A40940A793DF7D8B015E3086751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_E4263A40940A793DF7D8B015E3086751_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_E4263A40940A793DF7D8B015E3086751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_E4263A40940A793DF7D8B015E3086751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_E4263A40940A793DF7D8B015E3086751" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_E4263A40940A793DF7D8B015E3086751" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_F2C66B71142DEE0F31A0B015E30886D4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_F2C66B71142DEE0F31A0B015E30886D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_F2C66B71142DEE0F31A0B015E30886D4_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_F2C66B71142DEE0F31A0B015E30886D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_F2C66B71142DEE0F31A0B015E30886D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_F2C66B71142DEE0F31A0B015E30886D4" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_F2C66B71142DEE0F31A0B015E30886D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_9E387820743B077C5019B015E30872EE_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_9E387820743B077C5019B015E30872EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_9E387820743B077C5019B015E30872EE_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_9E387820743B077C5019B015E30872EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_9E387820743B077C5019B015E30872EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_9E387820743B077C5019B015E30872EE" xlink:to="lab_us-gaap_DomesticCountryMember_9E387820743B077C5019B015E30872EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_6802DB620D6F4AAF09BCB015E3087066_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_6802DB620D6F4AAF09BCB015E3087066" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_6802DB620D6F4AAF09BCB015E3087066_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_6802DB620D6F4AAF09BCB015E3087066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_6802DB620D6F4AAF09BCB015E3087066" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_6802DB620D6F4AAF09BCB015E3087066" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_6802DB620D6F4AAF09BCB015E3087066" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_C46E349AD85B218ACB4CB015E3084F7D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_C46E349AD85B218ACB4CB015E3084F7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_C46E349AD85B218ACB4CB015E3084F7D_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_C46E349AD85B218ACB4CB015E3084F7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_C46E349AD85B218ACB4CB015E3084F7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_C46E349AD85B218ACB4CB015E3084F7D" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_C46E349AD85B218ACB4CB015E3084F7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_6A38DABA6BDC707147CCB015E308F595_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_6A38DABA6BDC707147CCB015E308F595" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carry-forwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_6A38DABA6BDC707147CCB015E308F595_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_6A38DABA6BDC707147CCB015E308F595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6A38DABA6BDC707147CCB015E308F595" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_6A38DABA6BDC707147CCB015E308F595" xlink:to="lab_us-gaap_OperatingLossCarryforwards_6A38DABA6BDC707147CCB015E308F595" xlink:type="arc" />
    <link:label id="lab_alim_CumulativeIncomeLossFromForeignOperations_98A3DACCFB327311E5F2B087E7BEB55E_negatedLabel_en-US" xlink:label="lab_alim_CumulativeIncomeLossFromForeignOperations_98A3DACCFB327311E5F2B087E7BEB55E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cumulative book losses in foreign subsidiaries</link:label>
    <link:label id="lab_alim_CumulativeIncomeLossFromForeignOperations_98A3DACCFB327311E5F2B087E7BEB55E_label_en-US" xlink:label="lab_alim_CumulativeIncomeLossFromForeignOperations_98A3DACCFB327311E5F2B087E7BEB55E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Income (Loss) From Foreign Operations</link:label>
    <link:label id="lab_alim_CumulativeIncomeLossFromForeignOperations_98A3DACCFB327311E5F2B087E7BEB55E_documentation_en-US" xlink:label="lab_alim_CumulativeIncomeLossFromForeignOperations_98A3DACCFB327311E5F2B087E7BEB55E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative Income (Loss) From Foreign Operations</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_CumulativeIncomeLossFromForeignOperations" xlink:label="loc_alim_CumulativeIncomeLossFromForeignOperations_98A3DACCFB327311E5F2B087E7BEB55E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_CumulativeIncomeLossFromForeignOperations_98A3DACCFB327311E5F2B087E7BEB55E" xlink:to="lab_alim_CumulativeIncomeLossFromForeignOperations_98A3DACCFB327311E5F2B087E7BEB55E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockTextBlock_A0DDA76F52B52A50423448DE13AFA8F6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock_A0DDA76F52B52A50423448DE13AFA8F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockTextBlock_A0DDA76F52B52A50423448DE13AFA8F6_label_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock_A0DDA76F52B52A50423448DE13AFA8F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaap_PreferredStockTextBlock_A0DDA76F52B52A50423448DE13AFA8F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockTextBlock_A0DDA76F52B52A50423448DE13AFA8F6" xlink:to="lab_us-gaap_PreferredStockTextBlock_A0DDA76F52B52A50423448DE13AFA8F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_81C4E2226B12DA374E93B015E42115B5_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_81C4E2226B12DA374E93B015E42115B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_81C4E2226B12DA374E93B015E42115B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_81C4E2226B12DA374E93B015E42115B5" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_81C4E2226B12DA374E93B015E42115B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_212E5C26F49C09F09AF6B015E421C9B4_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_212E5C26F49C09F09AF6B015E421C9B4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">NET LOSS</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_212E5C26F49C09F09AF6B015E421C9B4_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_212E5C26F49C09F09AF6B015E421C9B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_212E5C26F49C09F09AF6B015E421C9B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_212E5C26F49C09F09AF6B015E421C9B4" xlink:to="lab_us-gaap_NetIncomeLoss_212E5C26F49C09F09AF6B015E421C9B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_305AEC4DED2C3A7EDFA9B015E421C2D8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_305AEC4DED2C3A7EDFA9B015E421C2D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER COMPREHENSIVE INCOME</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_305AEC4DED2C3A7EDFA9B015E421C2D8_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_305AEC4DED2C3A7EDFA9B015E421C2D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_305AEC4DED2C3A7EDFA9B015E421C2D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_305AEC4DED2C3A7EDFA9B015E421C2D8" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_305AEC4DED2C3A7EDFA9B015E421C2D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_E20894E4E7BE9A656643B015E4210170_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_E20894E4E7BE9A656643B015E4210170" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_E20894E4E7BE9A656643B015E4210170_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_E20894E4E7BE9A656643B015E4210170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_E20894E4E7BE9A656643B015E4210170" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_E20894E4E7BE9A656643B015E4210170" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_E20894E4E7BE9A656643B015E4210170" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_DEF3F7F5987376BF37BCB015E4218FB3_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_DEF3F7F5987376BF37BCB015E4218FB3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL OTHER COMPREHENSIVE INCOME</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_DEF3F7F5987376BF37BCB015E4218FB3_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_DEF3F7F5987376BF37BCB015E4218FB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_DEF3F7F5987376BF37BCB015E4218FB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_DEF3F7F5987376BF37BCB015E4218FB3" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_DEF3F7F5987376BF37BCB015E4218FB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_65168250D1AF6C5066C7B015E421BB75_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_65168250D1AF6C5066C7B015E421BB75" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_65168250D1AF6C5066C7B015E421BB75_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_65168250D1AF6C5066C7B015E421BB75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_65168250D1AF6C5066C7B015E421BB75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_65168250D1AF6C5066C7B015E421BB75" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_65168250D1AF6C5066C7B015E421BB75" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0FA99FC61230287BDC2B48DE13D57B13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0FA99FC61230287BDC2B48DE13D57B13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0FA99FC61230287BDC2B48DE13D57B13_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0FA99FC61230287BDC2B48DE13D57B13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0FA99FC61230287BDC2B48DE13D57B13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0FA99FC61230287BDC2B48DE13D57B13" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0FA99FC61230287BDC2B48DE13D57B13" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_31D4607CD9DDC720812648DE13D500B1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_31D4607CD9DDC720812648DE13D500B1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_31D4607CD9DDC720812648DE13D500B1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_31D4607CD9DDC720812648DE13D500B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_31D4607CD9DDC720812648DE13D500B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_31D4607CD9DDC720812648DE13D500B1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_31D4607CD9DDC720812648DE13D500B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FED887BF47B09ED8E12D48DE13D5CC61_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FED887BF47B09ED8E12D48DE13D5CC61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FED887BF47B09ED8E12D48DE13D5CC61_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FED887BF47B09ED8E12D48DE13D5CC61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FED887BF47B09ED8E12D48DE13D5CC61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FED887BF47B09ED8E12D48DE13D5CC61" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FED887BF47B09ED8E12D48DE13D5CC61" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_933036092485461E719B48DE13D575F8_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_933036092485461E719B48DE13D575F8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_933036092485461E719B48DE13D575F8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_933036092485461E719B48DE13D575F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_933036092485461E719B48DE13D575F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_933036092485461E719B48DE13D575F8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_933036092485461E719B48DE13D575F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C475271B32E06DA2431348DE13D5B9AE_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C475271B32E06DA2431348DE13D5B9AE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C475271B32E06DA2431348DE13D5B9AE_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C475271B32E06DA2431348DE13D5B9AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C475271B32E06DA2431348DE13D5B9AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C475271B32E06DA2431348DE13D5B9AE" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C475271B32E06DA2431348DE13D5B9AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1254AA4FB4BC8014D79248DE13D580B0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1254AA4FB4BC8014D79248DE13D580B0" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at year end (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1254AA4FB4BC8014D79248DE13D580B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1254AA4FB4BC8014D79248DE13D580B0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1254AA4FB4BC8014D79248DE13D580B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7B978F628F53D95B40FA48DE13D5DA19_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7B978F628F53D95B40FA48DE13D5DA19" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable at year end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7B978F628F53D95B40FA48DE13D5DA19_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7B978F628F53D95B40FA48DE13D5DA19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7B978F628F53D95B40FA48DE13D5DA19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7B978F628F53D95B40FA48DE13D5DA19" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7B978F628F53D95B40FA48DE13D5DA19" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EBBB23CCF17E83C655BE48DE13D57D32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EBBB23CCF17E83C655BE48DE13D57D32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average per share fair value of options granted during the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EBBB23CCF17E83C655BE48DE13D57D32_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EBBB23CCF17E83C655BE48DE13D57D32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EBBB23CCF17E83C655BE48DE13D57D32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EBBB23CCF17E83C655BE48DE13D57D32" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EBBB23CCF17E83C655BE48DE13D57D32" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_BF25ACBADC78EE9AAA1348DE13D50E4F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_BF25ACBADC78EE9AAA1348DE13D50E4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_BF25ACBADC78EE9AAA1348DE13D50E4F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_BF25ACBADC78EE9AAA1348DE13D50E4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_BF25ACBADC78EE9AAA1348DE13D50E4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_BF25ACBADC78EE9AAA1348DE13D50E4F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_BF25ACBADC78EE9AAA1348DE13D50E4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_232100121516D0A5EA5448DE13D5885E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_232100121516D0A5EA5448DE13D5885E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_232100121516D0A5EA5448DE13D5885E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_232100121516D0A5EA5448DE13D5885E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_232100121516D0A5EA5448DE13D5885E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_232100121516D0A5EA5448DE13D5885E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_232100121516D0A5EA5448DE13D5885E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_07918FBD1C35AF6796DD48DE13D5C0FB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_07918FBD1C35AF6796DD48DE13D5C0FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_07918FBD1C35AF6796DD48DE13D5C0FB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_07918FBD1C35AF6796DD48DE13D5C0FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_07918FBD1C35AF6796DD48DE13D5C0FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_07918FBD1C35AF6796DD48DE13D5C0FB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_07918FBD1C35AF6796DD48DE13D5C0FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DCC4964FC090B7C0749448DE13D55906_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DCC4964FC090B7C0749448DE13D55906" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeitures (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DCC4964FC090B7C0749448DE13D55906_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DCC4964FC090B7C0749448DE13D55906" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DCC4964FC090B7C0749448DE13D55906" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DCC4964FC090B7C0749448DE13D55906" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DCC4964FC090B7C0749448DE13D55906" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A6FB10A0130B5D8264CD48DE13D5A171_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A6FB10A0130B5D8264CD48DE13D5A171" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercises (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A6FB10A0130B5D8264CD48DE13D5A171_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A6FB10A0130B5D8264CD48DE13D5A171" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A6FB10A0130B5D8264CD48DE13D5A171" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A6FB10A0130B5D8264CD48DE13D5A171" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A6FB10A0130B5D8264CD48DE13D5A171" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CFB03DA16141B686321648DE13D6C718_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CFB03DA16141B686321648DE13D6C718" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at year end (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CFB03DA16141B686321648DE13D6C718" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CFB03DA16141B686321648DE13D6C718" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CFB03DA16141B686321648DE13D6C718" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3FA54CE6C7930F5B91C048DE13D6155F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3FA54CE6C7930F5B91C048DE13D6155F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable at year end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3FA54CE6C7930F5B91C048DE13D6155F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3FA54CE6C7930F5B91C048DE13D6155F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3FA54CE6C7930F5B91C048DE13D6155F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3FA54CE6C7930F5B91C048DE13D6155F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3FA54CE6C7930F5B91C048DE13D6155F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_12289C935F67E616ACD2F45222116990_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_12289C935F67E616ACD2F45222116990" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_12289C935F67E616ACD2F45222116990_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_12289C935F67E616ACD2F45222116990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_12289C935F67E616ACD2F45222116990" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_12289C935F67E616ACD2F45222116990" xlink:to="lab_us-gaap_ShareBasedCompensation_12289C935F67E616ACD2F45222116990" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_B9098408E43C43712D0AF44BE344EA8F_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet_B9098408E43C43712D0AF44BE344EA8F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_B9098408E43C43712D0AF44BE344EA8F_label_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet_B9098408E43C43712D0AF44BE344EA8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Amortization and Accretion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_B9098408E43C43712D0AF44BE344EA8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAmortizationAndAccretionNet_B9098408E43C43712D0AF44BE344EA8F" xlink:to="lab_us-gaap_DepreciationAmortizationAndAccretionNet_B9098408E43C43712D0AF44BE344EA8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_493CB2EBE6CA5C490573C9CD1C929E18_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_493CB2EBE6CA5C490573C9CD1C929E18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_493CB2EBE6CA5C490573C9CD1C929E18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_493CB2EBE6CA5C490573C9CD1C929E18" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_493CB2EBE6CA5C490573C9CD1C929E18" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_8DDAAB2A2DCF1B756AE5C9CD1C9208F3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_8DDAAB2A2DCF1B756AE5C9CD1C9208F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_8DDAAB2A2DCF1B756AE5C9CD1C9208F3_label_en-US" xlink:label="lab_us-gaap_StatementTable_8DDAAB2A2DCF1B756AE5C9CD1C9208F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_8DDAAB2A2DCF1B756AE5C9CD1C9208F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_8DDAAB2A2DCF1B756AE5C9CD1C9208F3" xlink:to="lab_us-gaap_StatementTable_8DDAAB2A2DCF1B756AE5C9CD1C9208F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_1203FAE5B547EF230F4AC9CD1C9254DD_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_1203FAE5B547EF230F4AC9CD1C9254DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_1203FAE5B547EF230F4AC9CD1C9254DD_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_1203FAE5B547EF230F4AC9CD1C9254DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1203FAE5B547EF230F4AC9CD1C9254DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1203FAE5B547EF230F4AC9CD1C9254DD" xlink:to="lab_us-gaap_StatementClassOfStockAxis_1203FAE5B547EF230F4AC9CD1C9254DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_3DB7DF2CFB13066EB004C9CD1C92FBDC_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_3DB7DF2CFB13066EB004C9CD1C92FBDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_3DB7DF2CFB13066EB004C9CD1C92FBDC_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_3DB7DF2CFB13066EB004C9CD1C92FBDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3DB7DF2CFB13066EB004C9CD1C92FBDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_3DB7DF2CFB13066EB004C9CD1C92FBDC" xlink:to="lab_us-gaap_ClassOfStockDomain_3DB7DF2CFB13066EB004C9CD1C92FBDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_897A7AE7CABF415085FDC9CD1C92B3FD_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_897A7AE7CABF415085FDC9CD1C92B3FD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series A convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_897A7AE7CABF415085FDC9CD1C92B3FD_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_897A7AE7CABF415085FDC9CD1C92B3FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_897A7AE7CABF415085FDC9CD1C92B3FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_897A7AE7CABF415085FDC9CD1C92B3FD" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_897A7AE7CABF415085FDC9CD1C92B3FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_2C321560D3D515DAFB24C9CD1C92E39B_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_2C321560D3D515DAFB24C9CD1C92E39B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_2C321560D3D515DAFB24C9CD1C92E39B_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_2C321560D3D515DAFB24C9CD1C92E39B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_2C321560D3D515DAFB24C9CD1C92E39B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_2C321560D3D515DAFB24C9CD1C92E39B" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_2C321560D3D515DAFB24C9CD1C92E39B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="lab_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C12A021F10009024D4E7C9CD1C92D3C4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C12A021F10009024D4E7C9CD1C92D3C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C12A021F10009024D4E7C9CD1C92D3C4_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C12A021F10009024D4E7C9CD1C92D3C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C12A021F10009024D4E7C9CD1C92D3C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C12A021F10009024D4E7C9CD1C92D3C4" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C12A021F10009024D4E7C9CD1C92D3C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_CDC56721589EC5C72A0FC9CD1C921905_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_CDC56721589EC5C72A0FC9CD1C921905" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_CDC56721589EC5C72A0FC9CD1C921905_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_CDC56721589EC5C72A0FC9CD1C921905" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_CDC56721589EC5C72A0FC9CD1C921905" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_CDC56721589EC5C72A0FC9CD1C921905" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_CDC56721589EC5C72A0FC9CD1C921905" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_896BFCF723EDC4C33220C9CD1C92BAB5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_896BFCF723EDC4C33220C9CD1C92BAB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_896BFCF723EDC4C33220C9CD1C92BAB5_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_896BFCF723EDC4C33220C9CD1C92BAB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_896BFCF723EDC4C33220C9CD1C92BAB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_896BFCF723EDC4C33220C9CD1C92BAB5" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_896BFCF723EDC4C33220C9CD1C92BAB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4203033638040A923828C9CD1C92EDCF_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4203033638040A923828C9CD1C92EDCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4203033638040A923828C9CD1C92EDCF_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4203033638040A923828C9CD1C92EDCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4203033638040A923828C9CD1C92EDCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4203033638040A923828C9CD1C92EDCF" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4203033638040A923828C9CD1C92EDCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_8B0B9687FC66722908D8C9CD1C929150_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_8B0B9687FC66722908D8C9CD1C929150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net (Note 5)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_8B0B9687FC66722908D8C9CD1C929150_label_en-US" xlink:label="lab_us-gaap_InventoryNet_8B0B9687FC66722908D8C9CD1C929150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_8B0B9687FC66722908D8C9CD1C929150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_8B0B9687FC66722908D8C9CD1C929150" xlink:to="lab_us-gaap_InventoryNet_8B0B9687FC66722908D8C9CD1C929150" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_BB394E1C58DA36EF63FDC9CD1C926703_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_BB394E1C58DA36EF63FDC9CD1C926703" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_BB394E1C58DA36EF63FDC9CD1C926703_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_BB394E1C58DA36EF63FDC9CD1C926703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_BB394E1C58DA36EF63FDC9CD1C926703" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_BB394E1C58DA36EF63FDC9CD1C926703" xlink:to="lab_us-gaap_AssetsCurrent_BB394E1C58DA36EF63FDC9CD1C926703" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8AA29E37755CE9BE5F0FC9CD1C92D3C2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_8AA29E37755CE9BE5F0FC9CD1C92D3C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8AA29E37755CE9BE5F0FC9CD1C92D3C2_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_8AA29E37755CE9BE5F0FC9CD1C92D3C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8AA29E37755CE9BE5F0FC9CD1C92D3C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8AA29E37755CE9BE5F0FC9CD1C92D3C2" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_8AA29E37755CE9BE5F0FC9CD1C92D3C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_1473D06CF139A820CA1CC9CD1C925E98_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_1473D06CF139A820CA1CC9CD1C925E98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset, net (Note 6)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_1473D06CF139A820CA1CC9CD1C925E98_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_1473D06CF139A820CA1CC9CD1C925E98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1473D06CF139A820CA1CC9CD1C925E98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1473D06CF139A820CA1CC9CD1C925E98" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_1473D06CF139A820CA1CC9CD1C925E98" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_91D6D0B1C60D17907B78C9CD1C924D6D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_91D6D0B1C60D17907B78C9CD1C924D6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_91D6D0B1C60D17907B78C9CD1C924D6D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_91D6D0B1C60D17907B78C9CD1C924D6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_91D6D0B1C60D17907B78C9CD1C924D6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_91D6D0B1C60D17907B78C9CD1C924D6D" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_91D6D0B1C60D17907B78C9CD1C924D6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_DF2D5EF62413BACE7D98C9CD1C92BDE4_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_DF2D5EF62413BACE7D98C9CD1C92BDE4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_DF2D5EF62413BACE7D98C9CD1C92BDE4_label_en-US" xlink:label="lab_us-gaap_Assets_DF2D5EF62413BACE7D98C9CD1C92BDE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_DF2D5EF62413BACE7D98C9CD1C92BDE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_DF2D5EF62413BACE7D98C9CD1C92BDE4" xlink:to="lab_us-gaap_Assets_DF2D5EF62413BACE7D98C9CD1C92BDE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_185B9680717D7C84C637C9CD1C9291F3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_185B9680717D7C84C637C9CD1C9291F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_185B9680717D7C84C637C9CD1C9291F3_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_185B9680717D7C84C637C9CD1C9291F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_185B9680717D7C84C637C9CD1C9291F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_185B9680717D7C84C637C9CD1C9291F3" xlink:to="lab_us-gaap_AccountsPayableCurrent_185B9680717D7C84C637C9CD1C9291F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_A43972AFA28B71203473C9CD1C92D600_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_A43972AFA28B71203473C9CD1C92D600" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses (Note 7)</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_A43972AFA28B71203473C9CD1C92D600_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_A43972AFA28B71203473C9CD1C92D600" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_A43972AFA28B71203473C9CD1C92D600" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_A43972AFA28B71203473C9CD1C92D600" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_A43972AFA28B71203473C9CD1C92D600" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_0F4834DA9D267A52E4E8C9CD1C928BBD_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_0F4834DA9D267A52E4E8C9CD1C928BBD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative warrant liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_0F4834DA9D267A52E4E8C9CD1C928BBD_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_0F4834DA9D267A52E4E8C9CD1C928BBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_0F4834DA9D267A52E4E8C9CD1C928BBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_0F4834DA9D267A52E4E8C9CD1C928BBD" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_0F4834DA9D267A52E4E8C9CD1C928BBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeaseObligationsCurrent_3C19B4BBE77D52048AD8C9CD1C92CA72_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent_3C19B4BBE77D52048AD8C9CD1C92CA72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital lease obligations</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsCurrent_3C19B4BBE77D52048AD8C9CD1C92CA72_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent_3C19B4BBE77D52048AD8C9CD1C92CA72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_3C19B4BBE77D52048AD8C9CD1C92CA72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsCurrent_3C19B4BBE77D52048AD8C9CD1C92CA72" xlink:to="lab_us-gaap_CapitalLeaseObligationsCurrent_3C19B4BBE77D52048AD8C9CD1C92CA72" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_D67C531D6B133ADE373BC9CD1C92A23E_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_D67C531D6B133ADE373BC9CD1C92A23E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_D67C531D6B133ADE373BC9CD1C92A23E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_D67C531D6B133ADE373BC9CD1C92A23E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_D67C531D6B133ADE373BC9CD1C92A23E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_D67C531D6B133ADE373BC9CD1C92A23E" xlink:to="lab_us-gaap_LiabilitiesCurrent_D67C531D6B133ADE373BC9CD1C92A23E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_811AAA277DA6C5D75974C9CD1C927E2C_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_811AAA277DA6C5D75974C9CD1C927E2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NON-CURRENT LIABILITIES:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_811AAA277DA6C5D75974C9CD1C927E2C_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_811AAA277DA6C5D75974C9CD1C927E2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_811AAA277DA6C5D75974C9CD1C927E2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_811AAA277DA6C5D75974C9CD1C927E2C" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_811AAA277DA6C5D75974C9CD1C927E2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_E075D58C5268F747DD13C9CD1C921C81_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_E075D58C5268F747DD13C9CD1C921C81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note payable (Note 9)</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_E075D58C5268F747DD13C9CD1C921C81_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_E075D58C5268F747DD13C9CD1C921C81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_E075D58C5268F747DD13C9CD1C921C81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_E075D58C5268F747DD13C9CD1C921C81" xlink:to="lab_us-gaap_LongTermNotesPayable_E075D58C5268F747DD13C9CD1C921C81" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeaseObligationsNoncurrent_22A5C3F34D5AE574175FC9CD1C92A9ED_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsNoncurrent_22A5C3F34D5AE574175FC9CD1C92A9ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital lease obligations &#8212; less current portion</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsNoncurrent_22A5C3F34D5AE574175FC9CD1C92A9ED_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsNoncurrent_22A5C3F34D5AE574175FC9CD1C92A9ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent_22A5C3F34D5AE574175FC9CD1C92A9ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsNoncurrent_22A5C3F34D5AE574175FC9CD1C92A9ED" xlink:to="lab_us-gaap_CapitalLeaseObligationsNoncurrent_22A5C3F34D5AE574175FC9CD1C92A9ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_C7D8BAE11C3D9B3EAFFDC9CD1C92FC3A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_C7D8BAE11C3D9B3EAFFDC9CD1C92FC3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_C7D8BAE11C3D9B3EAFFDC9CD1C92FC3A_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_C7D8BAE11C3D9B3EAFFDC9CD1C92FC3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_C7D8BAE11C3D9B3EAFFDC9CD1C92FC3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_C7D8BAE11C3D9B3EAFFDC9CD1C92FC3A" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_C7D8BAE11C3D9B3EAFFDC9CD1C92FC3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0055424628E42D295352C9CD1C9245AF_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0055424628E42D295352C9CD1C9245AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0055424628E42D295352C9CD1C9245AF_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0055424628E42D295352C9CD1C9245AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0055424628E42D295352C9CD1C9245AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_0055424628E42D295352C9CD1C9245AF" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0055424628E42D295352C9CD1C9245AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:to="lab_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_2EB4B74630F7B2F3F156C9CD1C9253ED_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_2EB4B74630F7B2F3F156C9CD1C9253ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_2EB4B74630F7B2F3F156C9CD1C9253ED_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_2EB4B74630F7B2F3F156C9CD1C9253ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_2EB4B74630F7B2F3F156C9CD1C9253ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_2EB4B74630F7B2F3F156C9CD1C9253ED" xlink:to="lab_us-gaap_PreferredStockValue_2EB4B74630F7B2F3F156C9CD1C9253ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_939E4A4BAF27B68E8120C9CD1C92C4DA_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_939E4A4BAF27B68E8120C9CD1C92C4DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $.01 par value &#8212; 150,000,000 shares authorized, 64,862,904 shares issued and outstanding at March 31, 2017 and December 31, 2016</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_939E4A4BAF27B68E8120C9CD1C92C4DA_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_939E4A4BAF27B68E8120C9CD1C92C4DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_939E4A4BAF27B68E8120C9CD1C92C4DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_939E4A4BAF27B68E8120C9CD1C92C4DA" xlink:to="lab_us-gaap_CommonStockValue_939E4A4BAF27B68E8120C9CD1C92C4DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_F8EC311D9D4637606637C9CD1C92824C_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_F8EC311D9D4637606637C9CD1C92824C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_F8EC311D9D4637606637C9CD1C92824C_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_F8EC311D9D4637606637C9CD1C92824C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_F8EC311D9D4637606637C9CD1C92824C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_F8EC311D9D4637606637C9CD1C92824C" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_F8EC311D9D4637606637C9CD1C92824C" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_A701D0532A4CDE88A3DCC9CD1C924E41_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_A701D0532A4CDE88A3DCC9CD1C924E41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_A701D0532A4CDE88A3DCC9CD1C924E41_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_A701D0532A4CDE88A3DCC9CD1C924E41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_A701D0532A4CDE88A3DCC9CD1C924E41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_A701D0532A4CDE88A3DCC9CD1C924E41" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_A701D0532A4CDE88A3DCC9CD1C924E41" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_446CB8BB3CCBE395BA12C9CD1C92EDCE_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_446CB8BB3CCBE395BA12C9CD1C92EDCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_446CB8BB3CCBE395BA12C9CD1C92EDCE_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_446CB8BB3CCBE395BA12C9CD1C92EDCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_446CB8BB3CCBE395BA12C9CD1C92EDCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_446CB8BB3CCBE395BA12C9CD1C92EDCE" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_446CB8BB3CCBE395BA12C9CD1C92EDCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6D41AFB0FBCD18321B0C9CD1C92A7AB_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6D41AFB0FBCD18321B0C9CD1C92A7AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6D41AFB0FBCD18321B0C9CD1C92A7AB_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6D41AFB0FBCD18321B0C9CD1C92A7AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6D41AFB0FBCD18321B0C9CD1C92A7AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6D41AFB0FBCD18321B0C9CD1C92A7AB" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6D41AFB0FBCD18321B0C9CD1C92A7AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_24A9C75B810ECC42CCE1C9CD1C92E8DA_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_24A9C75B810ECC42CCE1C9CD1C92E8DA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_24A9C75B810ECC42CCE1C9CD1C92E8DA_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_24A9C75B810ECC42CCE1C9CD1C92E8DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_24A9C75B810ECC42CCE1C9CD1C92E8DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_24A9C75B810ECC42CCE1C9CD1C92E8DA" xlink:to="lab_us-gaap_StockholdersEquity_24A9C75B810ECC42CCE1C9CD1C92E8DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_775CC71950C7F6D132C6C9CD1C923CA4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_775CC71950C7F6D132C6C9CD1C923CA4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_775CC71950C7F6D132C6C9CD1C923CA4_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_775CC71950C7F6D132C6C9CD1C923CA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_775CC71950C7F6D132C6C9CD1C923CA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_775CC71950C7F6D132C6C9CD1C923CA4" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_775CC71950C7F6D132C6C9CD1C923CA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_B42A1ADC1CB45D0E413A48DE137C4EC4_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_B42A1ADC1CB45D0E413A48DE137C4EC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_B42A1ADC1CB45D0E413A48DE137C4EC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_B42A1ADC1CB45D0E413A48DE137C4EC4" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_B42A1ADC1CB45D0E413A48DE137C4EC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_6FDFAF6EC918B3197F1848DE137CE3D4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_6FDFAF6EC918B3197F1848DE137CE3D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_6FDFAF6EC918B3197F1848DE137CE3D4_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_6FDFAF6EC918B3197F1848DE137CE3D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_6FDFAF6EC918B3197F1848DE137CE3D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_6FDFAF6EC918B3197F1848DE137CE3D4" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_6FDFAF6EC918B3197F1848DE137CE3D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_65750C46B575C1669C6CD0D7D19D0B35_terseLabel_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_65750C46B575C1669C6CD0D7D19D0B35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Substantial Doubt about Going Concern</link:label>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_65750C46B575C1669C6CD0D7D19D0B35_label_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_65750C46B575C1669C6CD0D7D19D0B35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_65750C46B575C1669C6CD0D7D19D0B35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_65750C46B575C1669C6CD0D7D19D0B35" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_65750C46B575C1669C6CD0D7D19D0B35" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3DA3ACFF93541C4B973D48DE133EDCB2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3DA3ACFF93541C4B973D48DE133EDCB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3DA3ACFF93541C4B973D48DE133EDCB2_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3DA3ACFF93541C4B973D48DE133EDCB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3DA3ACFF93541C4B973D48DE133EDCB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3DA3ACFF93541C4B973D48DE133EDCB2" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3DA3ACFF93541C4B973D48DE133EDCB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_14DBB78563B0239A803B48DE1362E0D8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_14DBB78563B0239A803B48DE1362E0D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_14DBB78563B0239A803B48DE1362E0D8_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_14DBB78563B0239A803B48DE1362E0D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_14DBB78563B0239A803B48DE1362E0D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_14DBB78563B0239A803B48DE1362E0D8" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_14DBB78563B0239A803B48DE1362E0D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6119CE2A30FC8023FE05F446051EA098_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6119CE2A30FC8023FE05F446051EA098" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6119CE2A30FC8023FE05F446051EA098_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6119CE2A30FC8023FE05F446051EA098" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6119CE2A30FC8023FE05F446051EA098" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6119CE2A30FC8023FE05F446051EA098" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6119CE2A30FC8023FE05F446051EA098" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_D61AF0E4E21DDCDF0B0DF446051E42D9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_D61AF0E4E21DDCDF0B0DF446051E42D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_D61AF0E4E21DDCDF0B0DF446051E42D9_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_D61AF0E4E21DDCDF0B0DF446051E42D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_D61AF0E4E21DDCDF0B0DF446051E42D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_D61AF0E4E21DDCDF0B0DF446051E42D9" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_D61AF0E4E21DDCDF0B0DF446051E42D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_A2A60FE73E0D3DE65C99F446051E80C0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_A2A60FE73E0D3DE65C99F446051E80C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_A2A60FE73E0D3DE65C99F446051E80C0_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_A2A60FE73E0D3DE65C99F446051E80C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_A2A60FE73E0D3DE65C99F446051E80C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_A2A60FE73E0D3DE65C99F446051E80C0" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_A2A60FE73E0D3DE65C99F446051E80C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_C19D169E64C9B47B4DB6F446051E8BDB_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_C19D169E64C9B47B4DB6F446051E8BDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_C19D169E64C9B47B4DB6F446051E8BDB_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_C19D169E64C9B47B4DB6F446051E8BDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_C19D169E64C9B47B4DB6F446051E8BDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_C19D169E64C9B47B4DB6F446051E8BDB" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_C19D169E64C9B47B4DB6F446051E8BDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_8D14481FCC9A61FA9C44F446051E4EA5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_8D14481FCC9A61FA9C44F446051E4EA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_8D14481FCC9A61FA9C44F446051E4EA5_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_8D14481FCC9A61FA9C44F446051E4EA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8D14481FCC9A61FA9C44F446051E4EA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8D14481FCC9A61FA9C44F446051E4EA5" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_8D14481FCC9A61FA9C44F446051E4EA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_3CDB716420AAD9F40816F446051E2221_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_3CDB716420AAD9F40816F446051E2221" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_3CDB716420AAD9F40816F446051E2221_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_3CDB716420AAD9F40816F446051E2221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3CDB716420AAD9F40816F446051E2221" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3CDB716420AAD9F40816F446051E2221" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_3CDB716420AAD9F40816F446051E2221" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_E796284D9FF1C4A24839F446051ED12B_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_E796284D9FF1C4A24839F446051ED12B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_SalesMember_E796284D9FF1C4A24839F446051ED12B_label_en-US" xlink:label="lab_us-gaap_SalesMember_E796284D9FF1C4A24839F446051ED12B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_E796284D9FF1C4A24839F446051ED12B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_E796284D9FF1C4A24839F446051ED12B" xlink:to="lab_us-gaap_SalesMember_E796284D9FF1C4A24839F446051ED12B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_FF9A38545D89061EF6A5F446051EE8AE_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_FF9A38545D89061EF6A5F446051EE8AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_FF9A38545D89061EF6A5F446051EE8AE_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_FF9A38545D89061EF6A5F446051EE8AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_FF9A38545D89061EF6A5F446051EE8AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_FF9A38545D89061EF6A5F446051EE8AE" xlink:to="lab_us-gaap_AccountsReceivableMember_FF9A38545D89061EF6A5F446051EE8AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_9B86506938475CFF7349F446051EBE75_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_9B86506938475CFF7349F446051EBE75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_9B86506938475CFF7349F446051EBE75_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_9B86506938475CFF7349F446051EBE75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9B86506938475CFF7349F446051EBE75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9B86506938475CFF7349F446051EBE75" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis_9B86506938475CFF7349F446051EBE75" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B_label_en-US" xlink:label="lab_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B" xlink:to="lab_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B" xlink:type="arc" />
    <link:label id="lab_alim_UnitedStatesSegmentMember_B3F2F97588FA1CE7DD4FF446051E63E2_terseLabel_en-US" xlink:label="lab_alim_UnitedStatesSegmentMember_B3F2F97588FA1CE7DD4FF446051E63E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_alim_UnitedStatesSegmentMember_B3F2F97588FA1CE7DD4FF446051E63E2_label_en-US" xlink:label="lab_alim_UnitedStatesSegmentMember_B3F2F97588FA1CE7DD4FF446051E63E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States Segment [Member]</link:label>
    <link:label id="lab_alim_UnitedStatesSegmentMember_B3F2F97588FA1CE7DD4FF446051E63E2_documentation_en-US" xlink:label="lab_alim_UnitedStatesSegmentMember_B3F2F97588FA1CE7DD4FF446051E63E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">United States Segment [Member]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_UnitedStatesSegmentMember" xlink:label="loc_alim_UnitedStatesSegmentMember_B3F2F97588FA1CE7DD4FF446051E63E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_UnitedStatesSegmentMember_B3F2F97588FA1CE7DD4FF446051E63E2" xlink:to="lab_alim_UnitedStatesSegmentMember_B3F2F97588FA1CE7DD4FF446051E63E2" xlink:type="arc" />
    <link:label id="lab_alim_InternationalSegmentMember_DC439EA1AFF7EE35B5E2F446051E727A_terseLabel_en-US" xlink:label="lab_alim_InternationalSegmentMember_DC439EA1AFF7EE35B5E2F446051E727A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_alim_InternationalSegmentMember_DC439EA1AFF7EE35B5E2F446051E727A_label_en-US" xlink:label="lab_alim_InternationalSegmentMember_DC439EA1AFF7EE35B5E2F446051E727A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">International Segment [Member]</link:label>
    <link:label id="lab_alim_InternationalSegmentMember_DC439EA1AFF7EE35B5E2F446051E727A_documentation_en-US" xlink:label="lab_alim_InternationalSegmentMember_DC439EA1AFF7EE35B5E2F446051E727A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">International Segment [Member]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_InternationalSegmentMember" xlink:label="loc_alim_InternationalSegmentMember_DC439EA1AFF7EE35B5E2F446051E727A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_InternationalSegmentMember_DC439EA1AFF7EE35B5E2F446051E727A" xlink:to="lab_alim_InternationalSegmentMember_DC439EA1AFF7EE35B5E2F446051E727A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_D21185038C6D6E107F72F446051E5962_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember_D21185038C6D6E107F72F446051E5962" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Segments</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_D21185038C6D6E107F72F446051E5962_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember_D21185038C6D6E107F72F446051E5962" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="loc_us-gaap_AllOtherSegmentsMember_D21185038C6D6E107F72F446051E5962" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember_D21185038C6D6E107F72F446051E5962" xlink:to="lab_us-gaap_AllOtherSegmentsMember_D21185038C6D6E107F72F446051E5962" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:type="arc" />
    <link:label id="lab_alim_ConcentrationRiskNumberofCustomers_DA8A9F5319C2421BF230F446051E76DF_terseLabel_en-US" xlink:label="lab_alim_ConcentrationRiskNumberofCustomers_DA8A9F5319C2421BF230F446051E76DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of customers</link:label>
    <link:label id="lab_alim_ConcentrationRiskNumberofCustomers_DA8A9F5319C2421BF230F446051E76DF_label_en-US" xlink:label="lab_alim_ConcentrationRiskNumberofCustomers_DA8A9F5319C2421BF230F446051E76DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number of Customers</link:label>
    <link:label id="lab_alim_ConcentrationRiskNumberofCustomers_DA8A9F5319C2421BF230F446051E76DF_documentation_en-US" xlink:label="lab_alim_ConcentrationRiskNumberofCustomers_DA8A9F5319C2421BF230F446051E76DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number of Customers</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_ConcentrationRiskNumberofCustomers" xlink:label="loc_alim_ConcentrationRiskNumberofCustomers_DA8A9F5319C2421BF230F446051E76DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_ConcentrationRiskNumberofCustomers_DA8A9F5319C2421BF230F446051E76DF" xlink:to="lab_alim_ConcentrationRiskNumberofCustomers_DA8A9F5319C2421BF230F446051E76DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_945826C84DDCE124F28FF446051EA8F2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_945826C84DDCE124F28FF446051EA8F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_945826C84DDCE124F28FF446051EA8F2_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_945826C84DDCE124F28FF446051EA8F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_945826C84DDCE124F28FF446051EA8F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_945826C84DDCE124F28FF446051EA8F2" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_945826C84DDCE124F28FF446051EA8F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_13B2AEACA8F67EA1926DF446051E1395_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_13B2AEACA8F67EA1926DF446051E1395" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NET REVENUE</link:label>
    <link:label id="lab_us-gaap_Revenues_13B2AEACA8F67EA1926DF446051E1395_label_en-US" xlink:label="lab_us-gaap_Revenues_13B2AEACA8F67EA1926DF446051E1395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_13B2AEACA8F67EA1926DF446051E1395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_13B2AEACA8F67EA1926DF446051E1395" xlink:to="lab_us-gaap_Revenues_13B2AEACA8F67EA1926DF446051E1395" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_E8EDF06E274109035DB3F446051E271D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_E8EDF06E274109035DB3F446051E271D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsSold_E8EDF06E274109035DB3F446051E271D_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_E8EDF06E274109035DB3F446051E271D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_E8EDF06E274109035DB3F446051E271D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_E8EDF06E274109035DB3F446051E271D" xlink:to="lab_us-gaap_CostOfGoodsSold_E8EDF06E274109035DB3F446051E271D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_1C4650992C086D179EAEF446051EC55B_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_1C4650992C086D179EAEF446051EC55B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">GROSS PROFIT</link:label>
    <link:label id="lab_us-gaap_GrossProfit_1C4650992C086D179EAEF446051EC55B_label_en-US" xlink:label="lab_us-gaap_GrossProfit_1C4650992C086D179EAEF446051EC55B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1C4650992C086D179EAEF446051EC55B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_1C4650992C086D179EAEF446051EC55B" xlink:to="lab_us-gaap_GrossProfit_1C4650992C086D179EAEF446051EC55B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_41715EB32B0AE1420C7EF446051EC071_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_41715EB32B0AE1420C7EF446051EC071" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_41715EB32B0AE1420C7EF446051EC071_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_41715EB32B0AE1420C7EF446051EC071" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_41715EB32B0AE1420C7EF446051EC071" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_41715EB32B0AE1420C7EF446051EC071" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_41715EB32B0AE1420C7EF446051EC071" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_0C435E24FCFC3BDF9227F446051EF0DE_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0C435E24FCFC3BDF9227F446051EF0DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_0C435E24FCFC3BDF9227F446051EF0DE_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0C435E24FCFC3BDF9227F446051EF0DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0C435E24FCFC3BDF9227F446051EF0DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0C435E24FCFC3BDF9227F446051EF0DE" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0C435E24FCFC3BDF9227F446051EF0DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketingExpense_6C3E1BAF836D87CBA3D9F446051ECFE7_terseLabel_en-US" xlink:label="lab_us-gaap_MarketingExpense_6C3E1BAF836D87CBA3D9F446051ECFE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SALES AND MARKETING EXPENSES</link:label>
    <link:label id="lab_us-gaap_MarketingExpense_6C3E1BAF836D87CBA3D9F446051ECFE7_label_en-US" xlink:label="lab_us-gaap_MarketingExpense_6C3E1BAF836D87CBA3D9F446051ECFE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketing Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaap_MarketingExpense_6C3E1BAF836D87CBA3D9F446051ECFE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketingExpense_6C3E1BAF836D87CBA3D9F446051ECFE7" xlink:to="lab_us-gaap_MarketingExpense_6C3E1BAF836D87CBA3D9F446051ECFE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_41F4D2B8EC52B9DE8245F446051E5CE8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet_41F4D2B8EC52B9DE8245F446051E5CE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DEPRECIATION AND AMORTIZATION</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_41F4D2B8EC52B9DE8245F446051E5CE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAmortizationAndAccretionNet_41F4D2B8EC52B9DE8245F446051E5CE8" xlink:to="lab_us-gaap_DepreciationAmortizationAndAccretionNet_41F4D2B8EC52B9DE8245F446051E5CE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_D1519612BD3CB70BEE1AF446052F57CA_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_D1519612BD3CB70BEE1AF446052F57CA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">OPERATING EXPENSES</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_D1519612BD3CB70BEE1AF446052F57CA_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_D1519612BD3CB70BEE1AF446052F57CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_D1519612BD3CB70BEE1AF446052F57CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_D1519612BD3CB70BEE1AF446052F57CA" xlink:to="lab_us-gaap_OperatingExpenses_D1519612BD3CB70BEE1AF446052F57CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_198B1E9724A368A7090FF446052F531A_netLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_198B1E9724A368A7090FF446052F531A" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">SEGMENT LOSS FROM OPERATIONS</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_198B1E9724A368A7090FF446052F531A_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_198B1E9724A368A7090FF446052F531A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_198B1E9724A368A7090FF446052F531A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_198B1E9724A368A7090FF446052F531A" xlink:to="lab_us-gaap_OperatingIncomeLoss_198B1E9724A368A7090FF446052F531A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_A4670A833DC3D2C20492F446052F83F1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_A4670A833DC3D2C20492F446052F83F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER INCOME AND EXPENSES, NET</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_A4670A833DC3D2C20492F446052F83F1_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_A4670A833DC3D2C20492F446052F83F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_A4670A833DC3D2C20492F446052F83F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_A4670A833DC3D2C20492F446052F83F1" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet_A4670A833DC3D2C20492F446052F83F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_03CB71D2F7EDDADD8472F4460531568D_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_03CB71D2F7EDDADD8472F4460531568D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET LOSS BEFORE TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_03CB71D2F7EDDADD8472F4460531568D_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_03CB71D2F7EDDADD8472F4460531568D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_03CB71D2F7EDDADD8472F4460531568D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_03CB71D2F7EDDADD8472F4460531568D" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_03CB71D2F7EDDADD8472F4460531568D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ACC172FB833E9F9C306E8B8825658D1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ACC172FB833E9F9C306E8B8825658D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ACC172FB833E9F9C306E8B8825658D1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ACC172FB833E9F9C306E8B8825658D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ACC172FB833E9F9C306E8B8825658D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ACC172FB833E9F9C306E8B8825658D1" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ACC172FB833E9F9C306E8B8825658D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_6647BE7361AF447F22CBE8B882565E61_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_6647BE7361AF447F22CBE8B882565E61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_6647BE7361AF447F22CBE8B882565E61_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_6647BE7361AF447F22CBE8B882565E61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6647BE7361AF447F22CBE8B882565E61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_6647BE7361AF447F22CBE8B882565E61" xlink:to="lab_us-gaap_AwardTypeAxis_6647BE7361AF447F22CBE8B882565E61" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_928F1F150267C5F50236E8B882569C4D_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_928F1F150267C5F50236E8B882569C4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_928F1F150267C5F50236E8B882569C4D_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_928F1F150267C5F50236E8B882569C4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_928F1F150267C5F50236E8B882569C4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_928F1F150267C5F50236E8B882569C4D" xlink:to="lab_us-gaap_EmployeeStockOptionMember_928F1F150267C5F50236E8B882569C4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_868BC4AC16D57B4480BEE8B882562D4F_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_868BC4AC16D57B4480BEE8B882562D4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_868BC4AC16D57B4480BEE8B882562D4F_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_868BC4AC16D57B4480BEE8B882562D4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_868BC4AC16D57B4480BEE8B882562D4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_868BC4AC16D57B4480BEE8B882562D4F" xlink:to="lab_us-gaap_EmployeeStockMember_868BC4AC16D57B4480BEE8B882562D4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_1A48D595BD697281E3ECE8C011B1DBAB_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_1A48D595BD697281E3ECE8C011B1DBAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_1A48D595BD697281E3ECE8C011B1DBAB_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_1A48D595BD697281E3ECE8C011B1DBAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1A48D595BD697281E3ECE8C011B1DBAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_1A48D595BD697281E3ECE8C011B1DBAB" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_1A48D595BD697281E3ECE8C011B1DBAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_2254FA9481D279DBD5ECE8B8825650C4_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_2254FA9481D279DBD5ECE8B8825650C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_2254FA9481D279DBD5ECE8B8825650C4_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_2254FA9481D279DBD5ECE8B8825650C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2254FA9481D279DBD5ECE8B8825650C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_2254FA9481D279DBD5ECE8B8825650C4" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_2254FA9481D279DBD5ECE8B8825650C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7F3D41694E07AC638DDAE8B88256C3E7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7F3D41694E07AC638DDAE8B88256C3E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7F3D41694E07AC638DDAE8B88256C3E7_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7F3D41694E07AC638DDAE8B88256C3E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7F3D41694E07AC638DDAE8B88256C3E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7F3D41694E07AC638DDAE8B88256C3E7" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7F3D41694E07AC638DDAE8B88256C3E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1B7FAA7E316645FD66ABE8B88257390F_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1B7FAA7E316645FD66ABE8B88257390F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1B7FAA7E316645FD66ABE8B88257390F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1B7FAA7E316645FD66ABE8B88257390F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1B7FAA7E316645FD66ABE8B88257390F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1B7FAA7E316645FD66ABE8B88257390F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1B7FAA7E316645FD66ABE8B88257390F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_404E5F7BA4D4804BF165E8C0F0C5AC06_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_404E5F7BA4D4804BF165E8C0F0C5AC06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards granted in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_404E5F7BA4D4804BF165E8C0F0C5AC06_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_404E5F7BA4D4804BF165E8C0F0C5AC06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_404E5F7BA4D4804BF165E8C0F0C5AC06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_404E5F7BA4D4804BF165E8C0F0C5AC06" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_404E5F7BA4D4804BF165E8C0F0C5AC06" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_FE3F95A3091A933C2C9BE8C321B94744_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_FE3F95A3091A933C2C9BE8C321B94744" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_FE3F95A3091A933C2C9BE8C321B94744_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_FE3F95A3091A933C2C9BE8C321B94744" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_FE3F95A3091A933C2C9BE8C321B94744" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_FE3F95A3091A933C2C9BE8C321B94744" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_FE3F95A3091A933C2C9BE8C321B94744" xlink:type="arc" />
    <link:label id="lab_alim_CommonStocktobeIssuedValueMaximum_A48D7AFB14972A3CDAF6D0D38EA3DB72_terseLabel_en-US" xlink:label="lab_alim_CommonStocktobeIssuedValueMaximum_A48D7AFB14972A3CDAF6D0D38EA3DB72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum value of common stock to be sold</link:label>
    <link:label id="lab_alim_CommonStocktobeIssuedValueMaximum_A48D7AFB14972A3CDAF6D0D38EA3DB72_label_en-US" xlink:label="lab_alim_CommonStocktobeIssuedValueMaximum_A48D7AFB14972A3CDAF6D0D38EA3DB72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock to be Issued, Value, Maximum</link:label>
    <link:label id="lab_alim_CommonStocktobeIssuedValueMaximum_A48D7AFB14972A3CDAF6D0D38EA3DB72_documentation_en-US" xlink:label="lab_alim_CommonStocktobeIssuedValueMaximum_A48D7AFB14972A3CDAF6D0D38EA3DB72" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock to be Issued, Value, Maximum</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_CommonStocktobeIssuedValueMaximum" xlink:label="loc_alim_CommonStocktobeIssuedValueMaximum_A48D7AFB14972A3CDAF6D0D38EA3DB72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_CommonStocktobeIssuedValueMaximum_A48D7AFB14972A3CDAF6D0D38EA3DB72" xlink:to="lab_alim_CommonStocktobeIssuedValueMaximum_A48D7AFB14972A3CDAF6D0D38EA3DB72" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66C5D37A0164460EA6AA48DE133553A8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66C5D37A0164460EA6AA48DE133553A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66C5D37A0164460EA6AA48DE133553A8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66C5D37A0164460EA6AA48DE133553A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66C5D37A0164460EA6AA48DE133553A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66C5D37A0164460EA6AA48DE133553A8" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66C5D37A0164460EA6AA48DE133553A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_F4A92976164C6EE9D48A48DE13359B5A_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_F4A92976164C6EE9D48A48DE13359B5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_F4A92976164C6EE9D48A48DE13359B5A_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_F4A92976164C6EE9D48A48DE13359B5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F4A92976164C6EE9D48A48DE13359B5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F4A92976164C6EE9D48A48DE13359B5A" xlink:to="lab_us-gaap_TypeOfArrangementAxis_F4A92976164C6EE9D48A48DE13359B5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_300AF2A93ED565568C9948DE13350097_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_300AF2A93ED565568C9948DE13350097" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_300AF2A93ED565568C9948DE13350097_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_300AF2A93ED565568C9948DE13350097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_300AF2A93ED565568C9948DE13350097" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_300AF2A93ED565568C9948DE13350097" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_300AF2A93ED565568C9948DE13350097" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementCopromotionMember_05CF83E61AFFBA9DF7C948DE13363CE2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementCopromotionMember_05CF83E61AFFBA9DF7C948DE13363CE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pSivida</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementCopromotionMember_05CF83E61AFFBA9DF7C948DE13363CE2_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementCopromotionMember_05CF83E61AFFBA9DF7C948DE13363CE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Co-promotion [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementCopromotionMember" xlink:label="loc_us-gaap_CollaborativeArrangementCopromotionMember_05CF83E61AFFBA9DF7C948DE13363CE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementCopromotionMember_05CF83E61AFFBA9DF7C948DE13363CE2" xlink:to="lab_us-gaap_CollaborativeArrangementCopromotionMember_05CF83E61AFFBA9DF7C948DE13363CE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C5319055EB446BD6E90C48DE13362783_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C5319055EB446BD6E90C48DE13362783" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C5319055EB446BD6E90C48DE13362783_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C5319055EB446BD6E90C48DE13362783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C5319055EB446BD6E90C48DE13362783" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C5319055EB446BD6E90C48DE13362783" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C5319055EB446BD6E90C48DE13362783" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F34D80EF790E93F9E74848DE1336934B_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F34D80EF790E93F9E74848DE1336934B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F34D80EF790E93F9E74848DE1336934B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F34D80EF790E93F9E74848DE1336934B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F34D80EF790E93F9E74848DE1336934B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F34D80EF790E93F9E74848DE1336934B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F34D80EF790E93F9E74848DE1336934B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensingAgreementsMember_9D8D5D8910D1AF76F93B48DE13364905_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_9D8D5D8910D1AF76F93B48DE13364905" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_9D8D5D8910D1AF76F93B48DE13364905_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_9D8D5D8910D1AF76F93B48DE13364905" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_9D8D5D8910D1AF76F93B48DE13364905" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember_9D8D5D8910D1AF76F93B48DE13364905" xlink:to="lab_us-gaap_LicensingAgreementsMember_9D8D5D8910D1AF76F93B48DE13364905" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:type="arc" />
    <link:label id="lab_alim_AdditionalMilestonePayment_5A101626C074F00790DF48DE13368DB9_verboseLabel_en-US" xlink:label="lab_alim_AdditionalMilestonePayment_5A101626C074F00790DF48DE13368DB9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment after the first product approved by the FDA</link:label>
    <link:label id="lab_alim_AdditionalMilestonePayment_5A101626C074F00790DF48DE13368DB9_label_en-US" xlink:label="lab_alim_AdditionalMilestonePayment_5A101626C074F00790DF48DE13368DB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_alim_AdditionalMilestonePayment_5A101626C074F00790DF48DE13368DB9_documentation_en-US" xlink:label="lab_alim_AdditionalMilestonePayment_5A101626C074F00790DF48DE13368DB9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_AdditionalMilestonePayment" xlink:label="loc_alim_AdditionalMilestonePayment_5A101626C074F00790DF48DE13368DB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_AdditionalMilestonePayment_5A101626C074F00790DF48DE13368DB9" xlink:to="lab_alim_AdditionalMilestonePayment_5A101626C074F00790DF48DE13368DB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_FF054DCF2B7E3CCD077148DE13369769_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_FF054DCF2B7E3CCD077148DE13369769" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net intangible assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_FF054DCF2B7E3CCD077148DE13369769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_FF054DCF2B7E3CCD077148DE13369769" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_FF054DCF2B7E3CCD077148DE13369769" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_379444018DB15483528848DE13365980_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_379444018DB15483528848DE13365980" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_379444018DB15483528848DE13365980_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_379444018DB15483528848DE13365980" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_379444018DB15483528848DE13365980" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_379444018DB15483528848DE13365980" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_379444018DB15483528848DE13365980" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_78FAD7ECB10545E6E90E48DE13377AE9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_78FAD7ECB10545E6E90E48DE13377AE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_78FAD7ECB10545E6E90E48DE13377AE9_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_78FAD7ECB10545E6E90E48DE13377AE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_78FAD7ECB10545E6E90E48DE13377AE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_78FAD7ECB10545E6E90E48DE13377AE9" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_78FAD7ECB10545E6E90E48DE13377AE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_E43A99A6CE36AFBF26BE48DE1337E8D6_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_E43A99A6CE36AFBF26BE48DE1337E8D6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_E43A99A6CE36AFBF26BE48DE1337E8D6_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_E43A99A6CE36AFBF26BE48DE1337E8D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_E43A99A6CE36AFBF26BE48DE1337E8D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_E43A99A6CE36AFBF26BE48DE1337E8D6" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_E43A99A6CE36AFBF26BE48DE1337E8D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_508EBB2FF8EDDFEA0E6248DE13176E50_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_508EBB2FF8EDDFEA0E6248DE13176E50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_508EBB2FF8EDDFEA0E6248DE13176E50_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_508EBB2FF8EDDFEA0E6248DE13176E50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_508EBB2FF8EDDFEA0E6248DE13176E50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_508EBB2FF8EDDFEA0E6248DE13176E50" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_508EBB2FF8EDDFEA0E6248DE13176E50" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7555EA63FC9EABD0FA0848DE13830576_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7555EA63FC9EABD0FA0848DE13830576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Incentive Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7555EA63FC9EABD0FA0848DE13830576_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7555EA63FC9EABD0FA0848DE13830576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7555EA63FC9EABD0FA0848DE13830576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7555EA63FC9EABD0FA0848DE13830576" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7555EA63FC9EABD0FA0848DE13830576" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_151B75E827362143F766EA0195FC9A41_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_151B75E827362143F766EA0195FC9A41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_151B75E827362143F766EA0195FC9A41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_151B75E827362143F766EA0195FC9A41" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_151B75E827362143F766EA0195FC9A41" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_66C3427C3A27A521E35FEA052702D1AF_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_66C3427C3A27A521E35FEA052702D1AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_66C3427C3A27A521E35FEA052702D1AF_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_66C3427C3A27A521E35FEA052702D1AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_66C3427C3A27A521E35FEA052702D1AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_66C3427C3A27A521E35FEA052702D1AF" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_66C3427C3A27A521E35FEA052702D1AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_613EAEDDD24E8084EE0948DE131C9A71_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_613EAEDDD24E8084EE0948DE131C9A71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_613EAEDDD24E8084EE0948DE131C9A71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_613EAEDDD24E8084EE0948DE131C9A71" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_613EAEDDD24E8084EE0948DE131C9A71" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8D0704EDE7AA5E84496248DE131D59FD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8D0704EDE7AA5E84496248DE131D59FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8D0704EDE7AA5E84496248DE131D59FD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8D0704EDE7AA5E84496248DE131D59FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8D0704EDE7AA5E84496248DE131D59FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8D0704EDE7AA5E84496248DE131D59FD" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8D0704EDE7AA5E84496248DE131D59FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_C812844033F08553D3FDB015E3812329_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_C812844033F08553D3FDB015E3812329" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_C812844033F08553D3FDB015E3812329_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_C812844033F08553D3FDB015E3812329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_C812844033F08553D3FDB015E3812329" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_C812844033F08553D3FDB015E3812329" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_C812844033F08553D3FDB015E3812329" xlink:type="arc" />
    <link:label id="lab_alim_AccruedClinicalInvestigatorExpenses_E45A66C1BFD38F349D1CB015E381D984_terseLabel_en-US" xlink:label="lab_alim_AccruedClinicalInvestigatorExpenses_E45A66C1BFD38F349D1CB015E381D984" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical investigator expenses</link:label>
    <link:label id="lab_alim_AccruedClinicalInvestigatorExpenses_E45A66C1BFD38F349D1CB015E381D984_label_en-US" xlink:label="lab_alim_AccruedClinicalInvestigatorExpenses_E45A66C1BFD38F349D1CB015E381D984" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Investigator Expenses</link:label>
    <link:label id="lab_alim_AccruedClinicalInvestigatorExpenses_E45A66C1BFD38F349D1CB015E381D984_documentation_en-US" xlink:label="lab_alim_AccruedClinicalInvestigatorExpenses_E45A66C1BFD38F349D1CB015E381D984" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued clinical investigator expenses.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_AccruedClinicalInvestigatorExpenses" xlink:label="loc_alim_AccruedClinicalInvestigatorExpenses_E45A66C1BFD38F349D1CB015E381D984" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_AccruedClinicalInvestigatorExpenses_E45A66C1BFD38F349D1CB015E381D984" xlink:to="lab_alim_AccruedClinicalInvestigatorExpenses_E45A66C1BFD38F349D1CB015E381D984" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_A98FC0ED905B250C1C85B015E381CF1F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_A98FC0ED905B250C1C85B015E381CF1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation expenses</link:label>
    <link:label id="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_A98FC0ED905B250C1C85B015E381CF1F_label_en-US" xlink:label="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_A98FC0ED905B250C1C85B015E381CF1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Employee-related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_A98FC0ED905B250C1C85B015E381CF1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_A98FC0ED905B250C1C85B015E381CF1F" xlink:to="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_A98FC0ED905B250C1C85B015E381CF1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_B7F5AFA95F05A49F7C1EB015E381B32A_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent_B7F5AFA95F05A49F7C1EB015E381B32A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued rebate, chargeback and other revenue reserves</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_B7F5AFA95F05A49F7C1EB015E381B32A_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent_B7F5AFA95F05A49F7C1EB015E381B32A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_B7F5AFA95F05A49F7C1EB015E381B32A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent_B7F5AFA95F05A49F7C1EB015E381B32A" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent_B7F5AFA95F05A49F7C1EB015E381B32A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2363D34593402E1B0E5EB015E3819F22_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2363D34593402E1B0E5EB015E3819F22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2363D34593402E1B0E5EB015E3819F22_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2363D34593402E1B0E5EB015E3819F22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2363D34593402E1B0E5EB015E3819F22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2363D34593402E1B0E5EB015E3819F22" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2363D34593402E1B0E5EB015E3819F22" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_207B10ADD14B7027D08FB015E3812639_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_207B10ADD14B7027D08FB015E3812639" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_207B10ADD14B7027D08FB015E3812639" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_207B10ADD14B7027D08FB015E3812639" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_207B10ADD14B7027D08FB015E3812639" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_DE8BF8415CE3C7EEBA2448DE1357480D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_DE8BF8415CE3C7EEBA2448DE1357480D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_DE8BF8415CE3C7EEBA2448DE1357480D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_DE8BF8415CE3C7EEBA2448DE1357480D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_DE8BF8415CE3C7EEBA2448DE1357480D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_DE8BF8415CE3C7EEBA2448DE1357480D" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_DE8BF8415CE3C7EEBA2448DE1357480D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccounting_E9968E6FCB9C9D64E7CD48DE13131864_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccounting_E9968E6FCB9C9D64E7CD48DE13131864" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccounting_E9968E6FCB9C9D64E7CD48DE13131864_label_en-US" xlink:label="lab_us-gaap_BasisOfAccounting_E9968E6FCB9C9D64E7CD48DE13131864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaap_BasisOfAccounting_E9968E6FCB9C9D64E7CD48DE13131864" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccounting_E9968E6FCB9C9D64E7CD48DE13131864" xlink:to="lab_us-gaap_BasisOfAccounting_E9968E6FCB9C9D64E7CD48DE13131864" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5388B8A2581C443F5F46D5403003B8A9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5388B8A2581C443F5F46D5403003B8A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5388B8A2581C443F5F46D5403003B8A9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5388B8A2581C443F5F46D5403003B8A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5388B8A2581C443F5F46D5403003B8A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5388B8A2581C443F5F46D5403003B8A9" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5388B8A2581C443F5F46D5403003B8A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:type="arc" />
    <link:label id="lab_alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_B67A04D6F4B0589DD055D5403004C689_terseLabel_en-US" xlink:label="lab_alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_B67A04D6F4B0589DD055D5403004C689" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum days to require to revert license in case of breaches of contract</link:label>
    <link:label id="lab_alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_B67A04D6F4B0589DD055D5403004C689_label_en-US" xlink:label="lab_alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_B67A04D6F4B0589DD055D5403004C689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Days To Require To Revert License In Case Of Breach Of Contract</link:label>
    <link:label id="lab_alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_B67A04D6F4B0589DD055D5403004C689_documentation_en-US" xlink:label="lab_alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_B67A04D6F4B0589DD055D5403004C689" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum days to require to revert license in case of breach of contract.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract" xlink:label="loc_alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_B67A04D6F4B0589DD055D5403004C689" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_B67A04D6F4B0589DD055D5403004C689" xlink:to="lab_alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_B67A04D6F4B0589DD055D5403004C689" xlink:type="arc" />
    <link:label id="lab_alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_F913F6AE0704CFF672FFD5403004CC16_terseLabel_en-US" xlink:label="lab_alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_F913F6AE0704CFF672FFD5403004CC16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum days to require to revert license in case of breaches of contract</link:label>
    <link:label id="lab_alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_F913F6AE0704CFF672FFD5403004CC16_label_en-US" xlink:label="lab_alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_F913F6AE0704CFF672FFD5403004CC16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Days To Require To Revert License In Case Of Breach Of Contract</link:label>
    <link:label id="lab_alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_F913F6AE0704CFF672FFD5403004CC16_documentation_en-US" xlink:label="lab_alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_F913F6AE0704CFF672FFD5403004CC16" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum days to require to revert license in case of breach of contract.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract" xlink:label="loc_alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_F913F6AE0704CFF672FFD5403004CC16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_F913F6AE0704CFF672FFD5403004CC16" xlink:to="lab_alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_F913F6AE0704CFF672FFD5403004CC16" xlink:type="arc" />
    <link:label id="lab_alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled_8BE8E81DCC19B49F80B1D5403004FDEF_terseLabel_en-US" xlink:label="lab_alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled_8BE8E81DCC19B49F80B1D5403004FDEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of bankruptcy petition proceedings remains undismissed (in days)</link:label>
    <link:label id="lab_alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled_8BE8E81DCC19B49F80B1D5403004FDEF_label_en-US" xlink:label="lab_alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled_8BE8E81DCC19B49F80B1D5403004FDEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bankruptcy Proceedings Period Petitions For Bankruptcy Filed</link:label>
    <link:label id="lab_alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled_8BE8E81DCC19B49F80B1D5403004FDEF_documentation_en-US" xlink:label="lab_alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled_8BE8E81DCC19B49F80B1D5403004FDEF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bankruptcy proceedings period petitions for bankruptcy filed.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled" xlink:label="loc_alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled_8BE8E81DCC19B49F80B1D5403004FDEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled_8BE8E81DCC19B49F80B1D5403004FDEF" xlink:to="lab_alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled_8BE8E81DCC19B49F80B1D5403004FDEF" xlink:type="arc" />
    <link:label id="lab_alim_ShareOfNetProfits_8B1BAFAE2D438CA6C6D9D54030047F62_terseLabel_en-US" xlink:label="lab_alim_ShareOfNetProfits_8B1BAFAE2D438CA6C6D9D54030047F62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of net profits (percent)</link:label>
    <link:label id="lab_alim_ShareOfNetProfits_8B1BAFAE2D438CA6C6D9D54030047F62_label_en-US" xlink:label="lab_alim_ShareOfNetProfits_8B1BAFAE2D438CA6C6D9D54030047F62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Net Profits</link:label>
    <link:label id="lab_alim_ShareOfNetProfits_8B1BAFAE2D438CA6C6D9D54030047F62_documentation_en-US" xlink:label="lab_alim_ShareOfNetProfits_8B1BAFAE2D438CA6C6D9D54030047F62" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of net profits.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_ShareOfNetProfits" xlink:label="loc_alim_ShareOfNetProfits_8B1BAFAE2D438CA6C6D9D54030047F62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_ShareOfNetProfits_8B1BAFAE2D438CA6C6D9D54030047F62" xlink:to="lab_alim_ShareOfNetProfits_8B1BAFAE2D438CA6C6D9D54030047F62" xlink:type="arc" />
    <link:label id="lab_alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien_44C79A7985384E5D2731D54030050854_terseLabel_en-US" xlink:label="lab_alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien_44C79A7985384E5D2731D54030050854" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of any lump sum milestone payments received from a sub-licensee of ILUVIEN (percent)</link:label>
    <link:label id="lab_alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien_44C79A7985384E5D2731D54030050854_label_en-US" xlink:label="lab_alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien_44C79A7985384E5D2731D54030050854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Any Lump Sum Milestone Payments Received From Sub Licensee Of Iluvien</link:label>
    <link:label id="lab_alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien_44C79A7985384E5D2731D54030050854_documentation_en-US" xlink:label="lab_alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien_44C79A7985384E5D2731D54030050854" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of any lump sum milestone payments received from a sub licensee of iluvien.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien" xlink:label="loc_alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien_44C79A7985384E5D2731D54030050854" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien_44C79A7985384E5D2731D54030050854" xlink:to="lab_alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien_44C79A7985384E5D2731D54030050854" xlink:type="arc" />
    <link:label id="lab_alim_PercentageOfRecoveryOfCommercializationCost_EB7D3362B0DAA86A973AD5403005DE3A_terseLabel_en-US" xlink:label="lab_alim_PercentageOfRecoveryOfCommercializationCost_EB7D3362B0DAA86A973AD5403005DE3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recovery of commercialization costs (percent)</link:label>
    <link:label id="lab_alim_PercentageOfRecoveryOfCommercializationCost_EB7D3362B0DAA86A973AD5403005DE3A_label_en-US" xlink:label="lab_alim_PercentageOfRecoveryOfCommercializationCost_EB7D3362B0DAA86A973AD5403005DE3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Recovery Of Commercialization Cost</link:label>
    <link:label id="lab_alim_PercentageOfRecoveryOfCommercializationCost_EB7D3362B0DAA86A973AD5403005DE3A_documentation_en-US" xlink:label="lab_alim_PercentageOfRecoveryOfCommercializationCost_EB7D3362B0DAA86A973AD5403005DE3A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of recovery of commercialization cost.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_PercentageOfRecoveryOfCommercializationCost" xlink:label="loc_alim_PercentageOfRecoveryOfCommercializationCost_EB7D3362B0DAA86A973AD5403005DE3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_PercentageOfRecoveryOfCommercializationCost_EB7D3362B0DAA86A973AD5403005DE3A" xlink:to="lab_alim_PercentageOfRecoveryOfCommercializationCost_EB7D3362B0DAA86A973AD5403005DE3A" xlink:type="arc" />
    <link:label id="lab_alim_CommercializationCosts_66BB602101B4DACD43ADD5403005BB04_terseLabel_en-US" xlink:label="lab_alim_CommercializationCosts_66BB602101B4DACD43ADD5403005BB04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercialization costs owed</link:label>
    <link:label id="lab_alim_CommercializationCosts_66BB602101B4DACD43ADD5403005BB04_label_en-US" xlink:label="lab_alim_CommercializationCosts_66BB602101B4DACD43ADD5403005BB04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercialization Costs</link:label>
    <link:label id="lab_alim_CommercializationCosts_66BB602101B4DACD43ADD5403005BB04_documentation_en-US" xlink:label="lab_alim_CommercializationCosts_66BB602101B4DACD43ADD5403005BB04" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercialization costs.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_CommercializationCosts" xlink:label="loc_alim_CommercializationCosts_66BB602101B4DACD43ADD5403005BB04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_CommercializationCosts_66BB602101B4DACD43ADD5403005BB04" xlink:to="lab_alim_CommercializationCosts_66BB602101B4DACD43ADD5403005BB04" xlink:type="arc" />
    <link:label id="lab_alim_AdditionalMilestonePayment_5DD9C269B26ABD88075FD54030059DAF_terseLabel_en-US" xlink:label="lab_alim_AdditionalMilestonePayment_5DD9C269B26ABD88075FD54030059DAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone payment after the first product approved by the FDA</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_AdditionalMilestonePayment" xlink:label="loc_alim_AdditionalMilestonePayment_5DD9C269B26ABD88075FD54030059DAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_AdditionalMilestonePayment_5DD9C269B26ABD88075FD54030059DAF" xlink:to="lab_alim_AdditionalMilestonePayment_5DD9C269B26ABD88075FD54030059DAF" xlink:type="arc" />
    <link:label id="lab_alim_CommercializationCostsReceivable_6F046B759D5CCE2735FBD5403005D724_terseLabel_en-US" xlink:label="lab_alim_CommercializationCostsReceivable_6F046B759D5CCE2735FBD5403005D724" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercialization costs receivable</link:label>
    <link:label id="lab_alim_CommercializationCostsReceivable_6F046B759D5CCE2735FBD5403005D724_label_en-US" xlink:label="lab_alim_CommercializationCostsReceivable_6F046B759D5CCE2735FBD5403005D724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercialization Costs Receivable</link:label>
    <link:label id="lab_alim_CommercializationCostsReceivable_6F046B759D5CCE2735FBD5403005D724_documentation_en-US" xlink:label="lab_alim_CommercializationCostsReceivable_6F046B759D5CCE2735FBD5403005D724" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercialization Costs Receivable</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_CommercializationCostsReceivable" xlink:label="loc_alim_CommercializationCostsReceivable_6F046B759D5CCE2735FBD5403005D724" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_CommercializationCostsReceivable_6F046B759D5CCE2735FBD5403005D724" xlink:to="lab_alim_CommercializationCostsReceivable_6F046B759D5CCE2735FBD5403005D724" xlink:type="arc" />
    <link:label id="lab_alim_CommercializationCostsReceivablePostAdjustment_FD22786B8807954A7401D5403005530F_terseLabel_en-US" xlink:label="lab_alim_CommercializationCostsReceivablePostAdjustment_FD22786B8807954A7401D5403005530F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercialization cost receivable post adjustment</link:label>
    <link:label id="lab_alim_CommercializationCostsReceivablePostAdjustment_FD22786B8807954A7401D5403005530F_label_en-US" xlink:label="lab_alim_CommercializationCostsReceivablePostAdjustment_FD22786B8807954A7401D5403005530F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercialization Costs Receivable Post Adjustment</link:label>
    <link:label id="lab_alim_CommercializationCostsReceivablePostAdjustment_FD22786B8807954A7401D5403005530F_documentation_en-US" xlink:label="lab_alim_CommercializationCostsReceivablePostAdjustment_FD22786B8807954A7401D5403005530F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercialization Costs Receivable Post Adjustment</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_CommercializationCostsReceivablePostAdjustment" xlink:label="loc_alim_CommercializationCostsReceivablePostAdjustment_FD22786B8807954A7401D5403005530F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_CommercializationCostsReceivablePostAdjustment_FD22786B8807954A7401D5403005530F" xlink:to="lab_alim_CommercializationCostsReceivablePostAdjustment_FD22786B8807954A7401D5403005530F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2AA3D744E69596DAFF7D48DE13ACE057_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2AA3D744E69596DAFF7D48DE13ACE057" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2AA3D744E69596DAFF7D48DE13ACE057_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2AA3D744E69596DAFF7D48DE13ACE057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2AA3D744E69596DAFF7D48DE13ACE057" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2AA3D744E69596DAFF7D48DE13ACE057" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2AA3D744E69596DAFF7D48DE13ACE057" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_858C1CA21D364F51974248DE13AC48B3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_858C1CA21D364F51974248DE13AC48B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_858C1CA21D364F51974248DE13AC48B3_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_858C1CA21D364F51974248DE13AC48B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_858C1CA21D364F51974248DE13AC48B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_858C1CA21D364F51974248DE13AC48B3" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_858C1CA21D364F51974248DE13AC48B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_0C1092799D16F24A911248DE13ACAC55_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_0C1092799D16F24A911248DE13ACAC55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_0C1092799D16F24A911248DE13ACAC55_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_0C1092799D16F24A911248DE13ACAC55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0C1092799D16F24A911248DE13ACAC55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0C1092799D16F24A911248DE13ACAC55" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_0C1092799D16F24A911248DE13ACAC55" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_DA08F051C15AB54E1A8548DE13AC6646_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_DA08F051C15AB54E1A8548DE13AC6646" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_DA08F051C15AB54E1A8548DE13AC6646_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_DA08F051C15AB54E1A8548DE13AC6646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_DA08F051C15AB54E1A8548DE13AC6646" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_DA08F051C15AB54E1A8548DE13AC6646" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_DA08F051C15AB54E1A8548DE13AC6646" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1AAB24272BFCE1D2A42948DE13AC7B3F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1AAB24272BFCE1D2A42948DE13AC7B3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1AAB24272BFCE1D2A42948DE13AC7B3F_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1AAB24272BFCE1D2A42948DE13AC7B3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1AAB24272BFCE1D2A42948DE13AC7B3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1AAB24272BFCE1D2A42948DE13AC7B3F" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1AAB24272BFCE1D2A42948DE13AC7B3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_FD05358DFBF1EA53923948DE13AD2656_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_FD05358DFBF1EA53923948DE13AD2656" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_FD05358DFBF1EA53923948DE13AD2656_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_FD05358DFBF1EA53923948DE13AD2656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_FD05358DFBF1EA53923948DE13AD2656" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_FD05358DFBF1EA53923948DE13AD2656" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_FD05358DFBF1EA53923948DE13AD2656" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_CF96C3F141558E1D838048DE13ADA1E3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_CF96C3F141558E1D838048DE13ADA1E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_CF96C3F141558E1D838048DE13ADA1E3_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_CF96C3F141558E1D838048DE13ADA1E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_CF96C3F141558E1D838048DE13ADA1E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_CF96C3F141558E1D838048DE13ADA1E3" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_CF96C3F141558E1D838048DE13ADA1E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_A8399D2E5A34F5AD7C6048DE13AD3C89_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_A8399D2E5A34F5AD7C6048DE13AD3C89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_A8399D2E5A34F5AD7C6048DE13AD3C89_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_A8399D2E5A34F5AD7C6048DE13AD3C89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_A8399D2E5A34F5AD7C6048DE13AD3C89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_A8399D2E5A34F5AD7C6048DE13AD3C89" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_A8399D2E5A34F5AD7C6048DE13AD3C89" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33B2683B017FFAB84F4548DE13AD0EED_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33B2683B017FFAB84F4548DE13AD0EED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33B2683B017FFAB84F4548DE13AD0EED_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33B2683B017FFAB84F4548DE13AD0EED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33B2683B017FFAB84F4548DE13AD0EED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33B2683B017FFAB84F4548DE13AD0EED" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33B2683B017FFAB84F4548DE13AD0EED" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_8C58B517DF8EE742A94D48DE13AD1F1F_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_8C58B517DF8EE742A94D48DE13AD1F1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_8C58B517DF8EE742A94D48DE13AD1F1F_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_8C58B517DF8EE742A94D48DE13AD1F1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_8C58B517DF8EE742A94D48DE13AD1F1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8C58B517DF8EE742A94D48DE13AD1F1F" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_8C58B517DF8EE742A94D48DE13AD1F1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6E7F133B0C23991B010E48DE13AD0BEE_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6E7F133B0C23991B010E48DE13AD0BEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6E7F133B0C23991B010E48DE13AD0BEE_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6E7F133B0C23991B010E48DE13AD0BEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6E7F133B0C23991B010E48DE13AD0BEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6E7F133B0C23991B010E48DE13AD0BEE" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6E7F133B0C23991B010E48DE13AD0BEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_AEEB1A2E6B0BBF9FD06448DE13AD43FC_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_AEEB1A2E6B0BBF9FD06448DE13AD43FC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_AEEB1A2E6B0BBF9FD06448DE13AD43FC_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_AEEB1A2E6B0BBF9FD06448DE13AD43FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_AEEB1A2E6B0BBF9FD06448DE13AD43FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_AEEB1A2E6B0BBF9FD06448DE13AD43FC" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_AEEB1A2E6B0BBF9FD06448DE13AD43FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_B6D9B67E966D8E1A318848DE13ADC9CD_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_B6D9B67E966D8E1A318848DE13ADC9CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_B6D9B67E966D8E1A318848DE13ADC9CD_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_B6D9B67E966D8E1A318848DE13ADC9CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B6D9B67E966D8E1A318848DE13ADC9CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B6D9B67E966D8E1A318848DE13ADC9CD" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_B6D9B67E966D8E1A318848DE13ADC9CD" xlink:type="arc" />
    <link:label id="lab_alim_DerivativeWarrantLiabilitiesFairValueDisclosure_D284E628CF70DCF6C82A48DE13ADFD71_terseLabel_en-US" xlink:label="lab_alim_DerivativeWarrantLiabilitiesFairValueDisclosure_D284E628CF70DCF6C82A48DE13ADFD71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative warrant liability</link:label>
    <link:label id="lab_alim_DerivativeWarrantLiabilitiesFairValueDisclosure_D284E628CF70DCF6C82A48DE13ADFD71_label_en-US" xlink:label="lab_alim_DerivativeWarrantLiabilitiesFairValueDisclosure_D284E628CF70DCF6C82A48DE13ADFD71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Warrant Liabilities, Fair Value Disclosure</link:label>
    <link:label id="lab_alim_DerivativeWarrantLiabilitiesFairValueDisclosure_D284E628CF70DCF6C82A48DE13ADFD71_documentation_en-US" xlink:label="lab_alim_DerivativeWarrantLiabilitiesFairValueDisclosure_D284E628CF70DCF6C82A48DE13ADFD71" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Warrant Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_DerivativeWarrantLiabilitiesFairValueDisclosure" xlink:label="loc_alim_DerivativeWarrantLiabilitiesFairValueDisclosure_D284E628CF70DCF6C82A48DE13ADFD71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_DerivativeWarrantLiabilitiesFairValueDisclosure_D284E628CF70DCF6C82A48DE13ADFD71" xlink:to="lab_alim_DerivativeWarrantLiabilitiesFairValueDisclosure_D284E628CF70DCF6C82A48DE13ADFD71" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_1E268DAE28811EC921A248DE13AD88A5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_1E268DAE28811EC921A248DE13AD88A5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Liabilities measured at fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_1E268DAE28811EC921A248DE13AD88A5_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_1E268DAE28811EC921A248DE13AD88A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_1E268DAE28811EC921A248DE13AD88A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_1E268DAE28811EC921A248DE13AD88A5" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_1E268DAE28811EC921A248DE13AD88A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_F52C3BA4E07C09E6A637D54852CD27C8_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_F52C3BA4E07C09E6A637D54852CD27C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_F52C3BA4E07C09E6A637D54852CD27C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_F52C3BA4E07C09E6A637D54852CD27C8" xlink:to="lab_us-gaap_SubsequentEventsAbstract_F52C3BA4E07C09E6A637D54852CD27C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_E6228D4D32D75C85A2A9D5487A72818B_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_E6228D4D32D75C85A2A9D5487A72818B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_E6228D4D32D75C85A2A9D5487A72818B_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_E6228D4D32D75C85A2A9D5487A72818B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_E6228D4D32D75C85A2A9D5487A72818B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_E6228D4D32D75C85A2A9D5487A72818B" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_E6228D4D32D75C85A2A9D5487A72818B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8C1EB1D366733530A4136CEB4270BE7E_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8C1EB1D366733530A4136CEB4270BE7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8C1EB1D366733530A4136CEB4270BE7E_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8C1EB1D366733530A4136CEB4270BE7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8C1EB1D366733530A4136CEB4270BE7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8C1EB1D366733530A4136CEB4270BE7E" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8C1EB1D366733530A4136CEB4270BE7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNetAbstract_AE9604C2E2CF2E4EBFCE48DE13492DFD_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_AE9604C2E2CF2E4EBFCE48DE13492DFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory net realizable value</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_AE9604C2E2CF2E4EBFCE48DE13492DFD_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_AE9604C2E2CF2E4EBFCE48DE13492DFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_AE9604C2E2CF2E4EBFCE48DE13492DFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract_AE9604C2E2CF2E4EBFCE48DE13492DFD" xlink:to="lab_us-gaap_InventoryNetAbstract_AE9604C2E2CF2E4EBFCE48DE13492DFD" xlink:type="arc" />
    <link:label id="lab_alim_InventoryComponent_B8BE0CD930EA64478C6E48DE134994AC_terseLabel_en-US" xlink:label="lab_alim_InventoryComponent_B8BE0CD930EA64478C6E48DE134994AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component parts</link:label>
    <link:label id="lab_alim_InventoryComponent_B8BE0CD930EA64478C6E48DE134994AC_label_en-US" xlink:label="lab_alim_InventoryComponent_B8BE0CD930EA64478C6E48DE134994AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Component</link:label>
    <link:label id="lab_alim_InventoryComponent_B8BE0CD930EA64478C6E48DE134994AC_documentation_en-US" xlink:label="lab_alim_InventoryComponent_B8BE0CD930EA64478C6E48DE134994AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory component.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_InventoryComponent" xlink:label="loc_alim_InventoryComponent_B8BE0CD930EA64478C6E48DE134994AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_InventoryComponent_B8BE0CD930EA64478C6E48DE134994AC" xlink:to="lab_alim_InventoryComponent_B8BE0CD930EA64478C6E48DE134994AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcess_1B1EBE433640A2D24E5148DE13494ECA_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_1B1EBE433640A2D24E5148DE13494ECA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_1B1EBE433640A2D24E5148DE13494ECA_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_1B1EBE433640A2D24E5148DE13494ECA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_1B1EBE433640A2D24E5148DE13494ECA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess_1B1EBE433640A2D24E5148DE13494ECA" xlink:to="lab_us-gaap_InventoryWorkInProcess_1B1EBE433640A2D24E5148DE13494ECA" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoods_5CE8825DB5DCA923FADE48DE1349B24E_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_5CE8825DB5DCA923FADE48DE1349B24E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_5CE8825DB5DCA923FADE48DE1349B24E_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_5CE8825DB5DCA923FADE48DE1349B24E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_5CE8825DB5DCA923FADE48DE1349B24E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_5CE8825DB5DCA923FADE48DE1349B24E" xlink:to="lab_us-gaap_InventoryFinishedGoods_5CE8825DB5DCA923FADE48DE1349B24E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryGross_BCB09902282B868B8EFA48DE13495E15_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross_BCB09902282B868B8EFA48DE13495E15" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryGross_BCB09902282B868B8EFA48DE13495E15_label_en-US" xlink:label="lab_us-gaap_InventoryGross_BCB09902282B868B8EFA48DE13495E15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_BCB09902282B868B8EFA48DE13495E15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross_BCB09902282B868B8EFA48DE13495E15" xlink:to="lab_us-gaap_InventoryGross_BCB09902282B868B8EFA48DE13495E15" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryValuationReserves_FF68B1125AEEECFE47D648DE13492B8F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves_FF68B1125AEEECFE47D648DE13492B8F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory reserve</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_FF68B1125AEEECFE47D648DE13492B8F_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves_FF68B1125AEEECFE47D648DE13492B8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_FF68B1125AEEECFE47D648DE13492B8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves_FF68B1125AEEECFE47D648DE13492B8F" xlink:to="lab_us-gaap_InventoryValuationReserves_FF68B1125AEEECFE47D648DE13492B8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_E08BDBB2166FCAAF120748DE1349D2EE_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_E08BDBB2166FCAAF120748DE1349D2EE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventory &#8212; net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_E08BDBB2166FCAAF120748DE1349D2EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_E08BDBB2166FCAAF120748DE1349D2EE" xlink:to="lab_us-gaap_InventoryNet_E08BDBB2166FCAAF120748DE1349D2EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_924534266FA28A16450CE8B8825E06E3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_924534266FA28A16450CE8B8825E06E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_924534266FA28A16450CE8B8825E06E3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_924534266FA28A16450CE8B8825E06E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_924534266FA28A16450CE8B8825E06E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_924534266FA28A16450CE8B8825E06E3" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_924534266FA28A16450CE8B8825E06E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_2FC5FEBDB0C7DEE4E447E8B8825E2589_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_2FC5FEBDB0C7DEE4E447E8B8825E2589" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_2FC5FEBDB0C7DEE4E447E8B8825E2589_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_2FC5FEBDB0C7DEE4E447E8B8825E2589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2FC5FEBDB0C7DEE4E447E8B8825E2589" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2FC5FEBDB0C7DEE4E447E8B8825E2589" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_2FC5FEBDB0C7DEE4E447E8B8825E2589" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_E41628A22DED3B99C5BBE8B8825E7393_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_E41628A22DED3B99C5BBE8B8825E7393" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_E41628A22DED3B99C5BBE8B8825E7393_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_E41628A22DED3B99C5BBE8B8825E7393" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E41628A22DED3B99C5BBE8B8825E7393" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E41628A22DED3B99C5BBE8B8825E7393" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_E41628A22DED3B99C5BBE8B8825E7393" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrivatePlacementMember_5F58BB967C4C772EE7BDE8B8825ED1F8_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember_5F58BB967C4C772EE7BDE8B8825ED1F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_5F58BB967C4C772EE7BDE8B8825ED1F8_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember_5F58BB967C4C772EE7BDE8B8825ED1F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_5F58BB967C4C772EE7BDE8B8825ED1F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_5F58BB967C4C772EE7BDE8B8825ED1F8" xlink:to="lab_us-gaap_PrivatePlacementMember_5F58BB967C4C772EE7BDE8B8825ED1F8" xlink:type="arc" />
    <link:label id="lab_alim_PublicOfferingMember_CD8B28925474C539DF9BE8BE3EFC923B_terseLabel_en-US" xlink:label="lab_alim_PublicOfferingMember_CD8B28925474C539DF9BE8BE3EFC923B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public offering</link:label>
    <link:label id="lab_alim_PublicOfferingMember_CD8B28925474C539DF9BE8BE3EFC923B_label_en-US" xlink:label="lab_alim_PublicOfferingMember_CD8B28925474C539DF9BE8BE3EFC923B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_alim_PublicOfferingMember_CD8B28925474C539DF9BE8BE3EFC923B_documentation_en-US" xlink:label="lab_alim_PublicOfferingMember_CD8B28925474C539DF9BE8BE3EFC923B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_PublicOfferingMember" xlink:label="loc_alim_PublicOfferingMember_CD8B28925474C539DF9BE8BE3EFC923B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_PublicOfferingMember_CD8B28925474C539DF9BE8BE3EFC923B" xlink:to="lab_alim_PublicOfferingMember_CD8B28925474C539DF9BE8BE3EFC923B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_ECFC23A6CB36F4E5E874E8B8825EA745_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_ECFC23A6CB36F4E5E874E8B8825EA745" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_ECFC23A6CB36F4E5E874E8B8825EA745_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_ECFC23A6CB36F4E5E874E8B8825EA745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_ECFC23A6CB36F4E5E874E8B8825EA745" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_ECFC23A6CB36F4E5E874E8B8825EA745" xlink:to="lab_us-gaap_CommonStockMember_ECFC23A6CB36F4E5E874E8B8825EA745" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:to="lab_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E1098E0A5A2B152DF046E8B8825E6923_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E1098E0A5A2B152DF046E8B8825E6923" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E1098E0A5A2B152DF046E8B8825E6923_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E1098E0A5A2B152DF046E8B8825E6923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E1098E0A5A2B152DF046E8B8825E6923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E1098E0A5A2B152DF046E8B8825E6923" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E1098E0A5A2B152DF046E8B8825E6923" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_37B433083D9A1BACA918E8B8825E18A8_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_37B433083D9A1BACA918E8B8825E18A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share purchase price of shares issued (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_37B433083D9A1BACA918E8B8825E18A8_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_37B433083D9A1BACA918E8B8825E18A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_37B433083D9A1BACA918E8B8825E18A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_37B433083D9A1BACA918E8B8825E18A8" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_37B433083D9A1BACA918E8B8825E18A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6B66E2794F48CE927F14E8B8825E73FD_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6B66E2794F48CE927F14E8B8825E73FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6B66E2794F48CE927F14E8B8825E73FD_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6B66E2794F48CE927F14E8B8825E73FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6B66E2794F48CE927F14E8B8825E73FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6B66E2794F48CE927F14E8B8825E73FD" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6B66E2794F48CE927F14E8B8825E73FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_256BE2E5843EE1FD1160E8B8825E52AD_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_256BE2E5843EE1FD1160E8B8825E52AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of stock issuance cost</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_256BE2E5843EE1FD1160E8B8825E52AD_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_256BE2E5843EE1FD1160E8B8825E52AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_256BE2E5843EE1FD1160E8B8825E52AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_256BE2E5843EE1FD1160E8B8825E52AD" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_256BE2E5843EE1FD1160E8B8825E52AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="lab_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_D203232F4296D7183CB6D0A003141145_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_D203232F4296D7183CB6D0A003141145" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET LOSS FROM OPERATIONS</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_D203232F4296D7183CB6D0A003141145" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_D203232F4296D7183CB6D0A003141145" xlink:to="lab_us-gaap_OperatingIncomeLoss_D203232F4296D7183CB6D0A003141145" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_2BEE7E0C195288BCEB74D0A00314CD83_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_2BEE7E0C195288BCEB74D0A00314CD83" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">INTEREST EXPENSE, NET AND OTHER</link:label>
    <link:label id="lab_us-gaap_InterestExpense_2BEE7E0C195288BCEB74D0A00314CD83_label_en-US" xlink:label="lab_us-gaap_InterestExpense_2BEE7E0C195288BCEB74D0A00314CD83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_2BEE7E0C195288BCEB74D0A00314CD83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_2BEE7E0C195288BCEB74D0A00314CD83" xlink:to="lab_us-gaap_InterestExpense_2BEE7E0C195288BCEB74D0A00314CD83" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_8673D8B2F6B72DD5D21BD0A00314719E_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_8673D8B2F6B72DD5D21BD0A00314719E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UNREALIZED FOREIGN CURRENCY (LOSS) GAIN, NET</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_8673D8B2F6B72DD5D21BD0A00314719E_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_8673D8B2F6B72DD5D21BD0A00314719E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_8673D8B2F6B72DD5D21BD0A00314719E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_8673D8B2F6B72DD5D21BD0A00314719E" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_8673D8B2F6B72DD5D21BD0A00314719E" xlink:type="arc" />
    <link:label id="lab_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_ED6B44C90ECB12E185A3D0A00314AC4D_terseLabel_en-US" xlink:label="lab_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_ED6B44C90ECB12E185A3D0A00314AC4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CHANGE IN FAIR VALUE OF DERIVATIVE WARRANT LIABILITY</link:label>
    <link:label id="lab_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_ED6B44C90ECB12E185A3D0A00314AC4D_label_en-US" xlink:label="lab_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_ED6B44C90ECB12E185A3D0A00314AC4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Fair Value Of Preferred Stock Conversion Feature</link:label>
    <link:label id="lab_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_ED6B44C90ECB12E185A3D0A00314AC4D_documentation_en-US" xlink:label="lab_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_ED6B44C90ECB12E185A3D0A00314AC4D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">(INCREASE) DECREASE IN FAIR VALUE OF PREFERRED STOCK CONVERSION FEATURE</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" xlink:label="loc_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_ED6B44C90ECB12E185A3D0A00314AC4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_ED6B44C90ECB12E185A3D0A00314AC4D" xlink:to="lab_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_ED6B44C90ECB12E185A3D0A00314AC4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_22D5828C93DAF8A0722DD0A00314B8F5_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_22D5828C93DAF8A0722DD0A00314B8F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LOSS ON EARLY EXTINGUISHMENT OF DEBT</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_22D5828C93DAF8A0722DD0A00314B8F5_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_22D5828C93DAF8A0722DD0A00314B8F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_22D5828C93DAF8A0722DD0A00314B8F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_22D5828C93DAF8A0722DD0A00314B8F5" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_22D5828C93DAF8A0722DD0A00314B8F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_65317F6B53D67ED1BE6AD0A00315ADF2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_65317F6B53D67ED1BE6AD0A00315ADF2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">PROVISION FOR TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_65317F6B53D67ED1BE6AD0A00315ADF2_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_65317F6B53D67ED1BE6AD0A00315ADF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_65317F6B53D67ED1BE6AD0A00315ADF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_65317F6B53D67ED1BE6AD0A00315ADF2" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_65317F6B53D67ED1BE6AD0A00315ADF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_27DB7105A2AEBB7A8372D0A0031558E4_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_27DB7105A2AEBB7A8372D0A0031558E4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET LOSS</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_27DB7105A2AEBB7A8372D0A0031558E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_27DB7105A2AEBB7A8372D0A0031558E4" xlink:to="lab_us-gaap_NetIncomeLoss_27DB7105A2AEBB7A8372D0A0031558E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_04FE9F3EF7E6E3752C9CD0A0031579C3_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_04FE9F3EF7E6E3752C9CD0A0031579C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">NET LOSS PER SHARE &#8212; Basic and diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_04FE9F3EF7E6E3752C9CD0A0031579C3_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_04FE9F3EF7E6E3752C9CD0A0031579C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_04FE9F3EF7E6E3752C9CD0A0031579C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_04FE9F3EF7E6E3752C9CD0A0031579C3" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_04FE9F3EF7E6E3752C9CD0A0031579C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_321888928B04BC96A33CD0A0031521B7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_321888928B04BC96A33CD0A0031521B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">WEIGHTED AVERAGE SHARES OUTSTANDING &#8212; Basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_321888928B04BC96A33CD0A0031521B7_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_321888928B04BC96A33CD0A0031521B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_321888928B04BC96A33CD0A0031521B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_321888928B04BC96A33CD0A0031521B7" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_321888928B04BC96A33CD0A0031521B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_115A0B37F6DC54E19B3F48DE13DA00E8_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_115A0B37F6DC54E19B3F48DE13DA00E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_115A0B37F6DC54E19B3F48DE13DA00E8_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_115A0B37F6DC54E19B3F48DE13DA00E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_115A0B37F6DC54E19B3F48DE13DA00E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_115A0B37F6DC54E19B3F48DE13DA00E8" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_115A0B37F6DC54E19B3F48DE13DA00E8" xlink:type="arc" />
    <link:label id="lab_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract_19AA719C04CCD58DC44148DE13456597_terseLabel_en-US" xlink:label="lab_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract_19AA719C04CCD58DC44148DE13456597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Stock Options</link:label>
    <link:label id="lab_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract_19AA719C04CCD58DC44148DE13456597_label_en-US" xlink:label="lab_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract_19AA719C04CCD58DC44148DE13456597" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Abstract]</link:label>
    <link:label id="lab_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract_19AA719C04CCD58DC44148DE13456597_documentation_en-US" xlink:label="lab_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract_19AA719C04CCD58DC44148DE13456597" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Abstract]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract" xlink:label="loc_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract_19AA719C04CCD58DC44148DE13456597" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract_19AA719C04CCD58DC44148DE13456597" xlink:to="lab_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract_19AA719C04CCD58DC44148DE13456597" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06606A2E95CEE09CB41948DE13456EEC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06606A2E95CEE09CB41948DE13456EEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06606A2E95CEE09CB41948DE13456EEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06606A2E95CEE09CB41948DE13456EEC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06606A2E95CEE09CB41948DE13456EEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_81F00EEAF0B071FFD98948DE13456C76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_81F00EEAF0B071FFD98948DE13456C76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_81F00EEAF0B071FFD98948DE13456C76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_81F00EEAF0B071FFD98948DE13456C76" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_81F00EEAF0B071FFD98948DE13456C76" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5E2795687B6A3495F04E48DE1345BFB3_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5E2795687B6A3495F04E48DE1345BFB3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5E2795687B6A3495F04E48DE1345BFB3_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5E2795687B6A3495F04E48DE1345BFB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5E2795687B6A3495F04E48DE1345BFB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5E2795687B6A3495F04E48DE1345BFB3" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5E2795687B6A3495F04E48DE1345BFB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8D5A386BD5D62D02833548DE13450910_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8D5A386BD5D62D02833548DE13450910" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8D5A386BD5D62D02833548DE13450910_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8D5A386BD5D62D02833548DE13450910" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8D5A386BD5D62D02833548DE13450910" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8D5A386BD5D62D02833548DE13450910" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8D5A386BD5D62D02833548DE13450910" xlink:type="arc" />
    <link:label id="lab_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract_E9205DB6CA086EEA151448DE134571E4_terseLabel_en-US" xlink:label="lab_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract_E9205DB6CA086EEA151448DE134571E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable Stock Options</link:label>
    <link:label id="lab_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract_E9205DB6CA086EEA151448DE134571E4_label_en-US" xlink:label="lab_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract_E9205DB6CA086EEA151448DE134571E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable [Abstract]</link:label>
    <link:label id="lab_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract_E9205DB6CA086EEA151448DE134571E4_documentation_en-US" xlink:label="lab_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract_E9205DB6CA086EEA151448DE134571E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable [Abstract]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract" xlink:label="loc_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract_E9205DB6CA086EEA151448DE134571E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract_E9205DB6CA086EEA151448DE134571E4" xlink:to="lab_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract_E9205DB6CA086EEA151448DE134571E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4954AFAE25D25E3BAC5D48DE1345A617_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4954AFAE25D25E3BAC5D48DE1345A617" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4954AFAE25D25E3BAC5D48DE1345A617" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4954AFAE25D25E3BAC5D48DE1345A617" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4954AFAE25D25E3BAC5D48DE1345A617" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_175C8D6119373E664EDC48DE13457AF8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_175C8D6119373E664EDC48DE13457AF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_175C8D6119373E664EDC48DE13457AF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_175C8D6119373E664EDC48DE13457AF8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_175C8D6119373E664EDC48DE13457AF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_DA9C455A5C1BD099518548DE1345950E_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_DA9C455A5C1BD099518548DE1345950E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_DA9C455A5C1BD099518548DE1345950E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_DA9C455A5C1BD099518548DE1345950E" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_DA9C455A5C1BD099518548DE1345950E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F79D60B1DA55ABB238D448DE13451347_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F79D60B1DA55ABB238D448DE13451347" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F79D60B1DA55ABB238D448DE13451347_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F79D60B1DA55ABB238D448DE13451347" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F79D60B1DA55ABB238D448DE13451347" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F79D60B1DA55ABB238D448DE13451347" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F79D60B1DA55ABB238D448DE13451347" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_201BE4A05DB7830043C048DE1346CC4E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_201BE4A05DB7830043C048DE1346CC4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_201BE4A05DB7830043C048DE1346CC4E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_201BE4A05DB7830043C048DE1346CC4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_201BE4A05DB7830043C048DE1346CC4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_201BE4A05DB7830043C048DE1346CC4E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_201BE4A05DB7830043C048DE1346CC4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_16DA23866F23EC42B5A548DE1346D593_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_16DA23866F23EC42B5A548DE1346D593" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, vested and expected to vest, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_16DA23866F23EC42B5A548DE1346D593_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_16DA23866F23EC42B5A548DE1346D593" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_16DA23866F23EC42B5A548DE1346D593" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_16DA23866F23EC42B5A548DE1346D593" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_16DA23866F23EC42B5A548DE1346D593" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6DD188CE3F2E15E5928748DE13465275_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6DD188CE3F2E15E5928748DE13465275" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, vested and expected to vest, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6DD188CE3F2E15E5928748DE13465275_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6DD188CE3F2E15E5928748DE13465275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6DD188CE3F2E15E5928748DE13465275" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6DD188CE3F2E15E5928748DE13465275" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6DD188CE3F2E15E5928748DE13465275" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_86FA7B8373E048D4B45A48DE1346D55F_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_86FA7B8373E048D4B45A48DE1346D55F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_86FA7B8373E048D4B45A48DE1346D55F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_86FA7B8373E048D4B45A48DE1346D55F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_86FA7B8373E048D4B45A48DE1346D55F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_86FA7B8373E048D4B45A48DE1346D55F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_86FA7B8373E048D4B45A48DE1346D55F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8D1F4032206F59FEFEA048DE13464D24_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8D1F4032206F59FEFEA048DE13464D24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8D1F4032206F59FEFEA048DE13464D24_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8D1F4032206F59FEFEA048DE13464D24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8D1F4032206F59FEFEA048DE13464D24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8D1F4032206F59FEFEA048DE13464D24" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8D1F4032206F59FEFEA048DE13464D24" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_537606A283D0C2789C5AB015E410D077_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_537606A283D0C2789C5AB015E410D077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_537606A283D0C2789C5AB015E410D077" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_537606A283D0C2789C5AB015E410D077" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_537606A283D0C2789C5AB015E410D077" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDividends_71760BD14BF7B42C269BB015E4106C52_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends_71760BD14BF7B42C269BB015E4106C52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of dividends</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_71760BD14BF7B42C269BB015E4106C52_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends_71760BD14BF7B42C269BB015E4106C52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_71760BD14BF7B42C269BB015E4106C52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends_71760BD14BF7B42C269BB015E4106C52" xlink:to="lab_us-gaap_PaymentsOfDividends_71760BD14BF7B42C269BB015E4106C52" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_71C37644C45C6AB32DA4B015E4109EEA_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_71C37644C45C6AB32DA4B015E4109EEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_71C37644C45C6AB32DA4B015E4109EEA_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_71C37644C45C6AB32DA4B015E4109EEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_71C37644C45C6AB32DA4B015E4109EEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_71C37644C45C6AB32DA4B015E4109EEA" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_71C37644C45C6AB32DA4B015E4109EEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_6E14421942154D9D1FF9B015E4103CEC_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_6E14421942154D9D1FF9B015E4103CEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6E14421942154D9D1FF9B015E4103CEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_6E14421942154D9D1FF9B015E4103CEC" xlink:to="lab_us-gaap_NetIncomeLoss_6E14421942154D9D1FF9B015E4103CEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C2081F4AED99449D07E3B015E41079A5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C2081F4AED99449D07E3B015E41079A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C2081F4AED99449D07E3B015E41079A5_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C2081F4AED99449D07E3B015E41079A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C2081F4AED99449D07E3B015E41079A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C2081F4AED99449D07E3B015E41079A5" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C2081F4AED99449D07E3B015E41079A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_1CF9B687D6C3A6069106B015E4106C86_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_1CF9B687D6C3A6069106B015E4106C86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_1CF9B687D6C3A6069106B015E4106C86_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_1CF9B687D6C3A6069106B015E4106C86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1CF9B687D6C3A6069106B015E4106C86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_1CF9B687D6C3A6069106B015E4106C86" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_1CF9B687D6C3A6069106B015E4106C86" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWriteDown_73EEFD1B47D15588FC6BB015E41098DA_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_73EEFD1B47D15588FC6BB015E41098DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory reserve</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_73EEFD1B47D15588FC6BB015E41098DA_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_73EEFD1B47D15588FC6BB015E41098DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_73EEFD1B47D15588FC6BB015E41098DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown_73EEFD1B47D15588FC6BB015E41098DA" xlink:to="lab_us-gaap_InventoryWriteDown_73EEFD1B47D15588FC6BB015E41098DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_D28A55B7E55F8F96AAF7B015E410B633_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_D28A55B7E55F8F96AAF7B015E410B633" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign currency transaction loss (gain)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_D28A55B7E55F8F96AAF7B015E410B633" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_D28A55B7E55F8F96AAF7B015E410B633" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_D28A55B7E55F8F96AAF7B015E410B633" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_D8CC4E8D97C5F6155271B015E410D46D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_D8CC4E8D97C5F6155271B015E410D46D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_D8CC4E8D97C5F6155271B015E410D46D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_D8CC4E8D97C5F6155271B015E410D46D" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_D8CC4E8D97C5F6155271B015E410D46D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_17DF62E1104F679ABE49B015E4105AC5_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_17DF62E1104F679ABE49B015E4105AC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_17DF62E1104F679ABE49B015E4105AC5_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_17DF62E1104F679ABE49B015E4105AC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_17DF62E1104F679ABE49B015E4105AC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_17DF62E1104F679ABE49B015E4105AC5" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_17DF62E1104F679ABE49B015E4105AC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_F97C459E4FC8DEB47ED7B015E41082E4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_F97C459E4FC8DEB47ED7B015E41082E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_F97C459E4FC8DEB47ED7B015E41082E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_F97C459E4FC8DEB47ED7B015E41082E4" xlink:to="lab_us-gaap_ShareBasedCompensation_F97C459E4FC8DEB47ED7B015E41082E4" xlink:type="arc" />
    <link:label id="lab_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_1F29055DCA9ADC2B830AB015E411E51E_negatedLabel_en-US" xlink:label="lab_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_1F29055DCA9ADC2B830AB015E411E51E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of derivative warrant liability</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" xlink:label="loc_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_1F29055DCA9ADC2B830AB015E411E51E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_1F29055DCA9ADC2B830AB015E411E51E" xlink:to="lab_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_1F29055DCA9ADC2B830AB015E411E51E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8E4FB79417C2C033584CB015E411A96E_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8E4FB79417C2C033584CB015E411A96E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8E4FB79417C2C033584CB015E411A96E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8E4FB79417C2C033584CB015E411A96E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8E4FB79417C2C033584CB015E411A96E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8E4FB79417C2C033584CB015E411A96E" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8E4FB79417C2C033584CB015E411A96E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_22F1BCB010E2D8F9CF35B015E4119BB3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_22F1BCB010E2D8F9CF35B015E4119BB3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_22F1BCB010E2D8F9CF35B015E4119BB3_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_22F1BCB010E2D8F9CF35B015E4119BB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_22F1BCB010E2D8F9CF35B015E4119BB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_22F1BCB010E2D8F9CF35B015E4119BB3" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_22F1BCB010E2D8F9CF35B015E4119BB3" xlink:type="arc" />
    <link:label id="lab_alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_87F503C929F9E2D6440CB015E411CA13_negatedLabel_en-US" xlink:label="lab_alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_87F503C929F9E2D6440CB015E411CA13" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_87F503C929F9E2D6440CB015E411CA13_label_en-US" xlink:label="lab_alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_87F503C929F9E2D6440CB015E411CA13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_87F503C929F9E2D6440CB015E411CA13_documentation_en-US" xlink:label="lab_alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_87F503C929F9E2D6440CB015E411CA13" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="loc_alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_87F503C929F9E2D6440CB015E411CA13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_87F503C929F9E2D6440CB015E411CA13" xlink:to="lab_alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_87F503C929F9E2D6440CB015E411CA13" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4E3B61D2E313F02EA0D0B015E41111E6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_4E3B61D2E313F02EA0D0B015E41111E6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4E3B61D2E313F02EA0D0B015E41111E6_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_4E3B61D2E313F02EA0D0B015E41111E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4E3B61D2E313F02EA0D0B015E41111E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_4E3B61D2E313F02EA0D0B015E41111E6" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_4E3B61D2E313F02EA0D0B015E41111E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_98A361C81C67BE704E21B015E4116838_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_98A361C81C67BE704E21B015E4116838" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_98A361C81C67BE704E21B015E4116838_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_98A361C81C67BE704E21B015E4116838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_98A361C81C67BE704E21B015E4116838" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_98A361C81C67BE704E21B015E4116838" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_98A361C81C67BE704E21B015E4116838" xlink:type="arc" />
    <link:label id="lab_alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_FAA6AFAB82A336ADC3BFB015E4115541_terseLabel_en-US" xlink:label="lab_alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_FAA6AFAB82A336ADC3BFB015E4115541" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_FAA6AFAB82A336ADC3BFB015E4115541_label_en-US" xlink:label="lab_alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_FAA6AFAB82A336ADC3BFB015E4115541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_FAA6AFAB82A336ADC3BFB015E4115541_documentation_en-US" xlink:label="lab_alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_FAA6AFAB82A336ADC3BFB015E4115541" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_FAA6AFAB82A336ADC3BFB015E4115541" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_FAA6AFAB82A336ADC3BFB015E4115541" xlink:to="lab_alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_FAA6AFAB82A336ADC3BFB015E4115541" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3EE49C0DF2F3E267C185B015E411F528_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3EE49C0DF2F3E267C185B015E411F528" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3EE49C0DF2F3E267C185B015E411F528_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3EE49C0DF2F3E267C185B015E411F528" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3EE49C0DF2F3E267C185B015E411F528" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3EE49C0DF2F3E267C185B015E411F528" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3EE49C0DF2F3E267C185B015E411F528" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0E6BC823B57B6FE23361B015E4114AFE_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0E6BC823B57B6FE23361B015E4114AFE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0E6BC823B57B6FE23361B015E4114AFE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0E6BC823B57B6FE23361B015E4114AFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0E6BC823B57B6FE23361B015E4114AFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0E6BC823B57B6FE23361B015E4114AFE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0E6BC823B57B6FE23361B015E4114AFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D7ED73965E59688E34C3B015E411EBE0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D7ED73965E59688E34C3B015E411EBE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D7ED73965E59688E34C3B015E411EBE0_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D7ED73965E59688E34C3B015E411EBE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D7ED73965E59688E34C3B015E411EBE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D7ED73965E59688E34C3B015E411EBE0" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D7ED73965E59688E34C3B015E411EBE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_654F94F0CBC13554983AB015E4161196_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_654F94F0CBC13554983AB015E4161196" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_654F94F0CBC13554983AB015E4161196_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_654F94F0CBC13554983AB015E4161196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_654F94F0CBC13554983AB015E4161196" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_654F94F0CBC13554983AB015E4161196" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_654F94F0CBC13554983AB015E4161196" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_EA28C971899265ADC469B015E41623E6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_EA28C971899265ADC469B015E41623E6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_EA28C971899265ADC469B015E41623E6_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_EA28C971899265ADC469B015E41623E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_EA28C971899265ADC469B015E41623E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_EA28C971899265ADC469B015E41623E6" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_EA28C971899265ADC469B015E41623E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D3624DFB74711CD6151EB015E416AA47_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D3624DFB74711CD6151EB015E416AA47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D3624DFB74711CD6151EB015E416AA47_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D3624DFB74711CD6151EB015E416AA47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D3624DFB74711CD6151EB015E416AA47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D3624DFB74711CD6151EB015E416AA47" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D3624DFB74711CD6151EB015E416AA47" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_F0759F36988180A0E9CFB015E41765F6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_F0759F36988180A0E9CFB015E41765F6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of issuance cost of common stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_F0759F36988180A0E9CFB015E41765F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_F0759F36988180A0E9CFB015E41765F6" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_F0759F36988180A0E9CFB015E41765F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_8180959309CE32B0CD00B015E4171E69_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_8180959309CE32B0CD00B015E4171E69" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of debt costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_8180959309CE32B0CD00B015E4171E69_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_8180959309CE32B0CD00B015E4171E69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8180959309CE32B0CD00B015E4171E69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8180959309CE32B0CD00B015E4171E69" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_8180959309CE32B0CD00B015E4171E69" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_53CCFEC340F04823B7A9B015E4171FC8_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_53CCFEC340F04823B7A9B015E4171FC8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of capital lease obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_53CCFEC340F04823B7A9B015E4171FC8_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_53CCFEC340F04823B7A9B015E4171FC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_53CCFEC340F04823B7A9B015E4171FC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_53CCFEC340F04823B7A9B015E4171FC8" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_53CCFEC340F04823B7A9B015E4171FC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E3DCBEFB9B751E54CFF3B015E4176729_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E3DCBEFB9B751E54CFF3B015E4176729" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E3DCBEFB9B751E54CFF3B015E4176729_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E3DCBEFB9B751E54CFF3B015E4176729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E3DCBEFB9B751E54CFF3B015E4176729" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E3DCBEFB9B751E54CFF3B015E4176729" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E3DCBEFB9B751E54CFF3B015E4176729" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_DAB4F01E8AD30042D809B015E417F279_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_DAB4F01E8AD30042D809B015E417F279" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_DAB4F01E8AD30042D809B015E417F279_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_DAB4F01E8AD30042D809B015E417F279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_DAB4F01E8AD30042D809B015E417F279" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_DAB4F01E8AD30042D809B015E417F279" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_DAB4F01E8AD30042D809B015E417F279" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_A25C0A78B49E3657CB1BB015E4179A64_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_A25C0A78B49E3657CB1BB015E4179A64" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_A25C0A78B49E3657CB1BB015E4179A64_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_A25C0A78B49E3657CB1BB015E4179A64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_A25C0A78B49E3657CB1BB015E4179A64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_A25C0A78B49E3657CB1BB015E4179A64" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_A25C0A78B49E3657CB1BB015E4179A64" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B5E1034471DB87C1151EB015E4186F9A_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B5E1034471DB87C1151EB015E4186F9A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS &#8212; Beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B5E1034471DB87C1151EB015E4186F9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B5E1034471DB87C1151EB015E4186F9A" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B5E1034471DB87C1151EB015E4186F9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_631968A4D5710753895AB015E418577F_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_631968A4D5710753895AB015E418577F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS &#8212; End of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_631968A4D5710753895AB015E418577F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_631968A4D5710753895AB015E418577F" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_631968A4D5710753895AB015E418577F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_42CB04669A2BAB76E38DB015E41888B4_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_42CB04669A2BAB76E38DB015E41888B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_42CB04669A2BAB76E38DB015E41888B4_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_42CB04669A2BAB76E38DB015E41888B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_42CB04669A2BAB76E38DB015E41888B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_42CB04669A2BAB76E38DB015E41888B4" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_42CB04669A2BAB76E38DB015E41888B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_910FEC9CAFB67B3BC1FBB015E41883EE_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_910FEC9CAFB67B3BC1FBB015E41883EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaid_910FEC9CAFB67B3BC1FBB015E41883EE_label_en-US" xlink:label="lab_us-gaap_InterestPaid_910FEC9CAFB67B3BC1FBB015E41883EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_910FEC9CAFB67B3BC1FBB015E41883EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_910FEC9CAFB67B3BC1FBB015E41883EE" xlink:to="lab_us-gaap_InterestPaid_910FEC9CAFB67B3BC1FBB015E41883EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaid_3486B5D2B38D7F573D35B015E41824F0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid_3486B5D2B38D7F573D35B015E41824F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_3486B5D2B38D7F573D35B015E41824F0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid_3486B5D2B38D7F573D35B015E41824F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_3486B5D2B38D7F573D35B015E41824F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_3486B5D2B38D7F573D35B015E41824F0" xlink:to="lab_us-gaap_IncomeTaxesPaid_3486B5D2B38D7F573D35B015E41824F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_797C7E84CEBE3D58B2F4B015E41843FD_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_797C7E84CEBE3D58B2F4B015E41843FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental schedule of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_797C7E84CEBE3D58B2F4B015E41843FD_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_797C7E84CEBE3D58B2F4B015E41843FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_797C7E84CEBE3D58B2F4B015E41843FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_797C7E84CEBE3D58B2F4B015E41843FD" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_797C7E84CEBE3D58B2F4B015E41843FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_D9E4A5048B0FB0013175B015E4185EDB_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred_D9E4A5048B0FB0013175B015E4185EDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment acquired under capital leases</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_D9E4A5048B0FB0013175B015E4185EDB_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred_D9E4A5048B0FB0013175B015E4185EDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations Incurred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred_D9E4A5048B0FB0013175B015E4185EDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsIncurred_D9E4A5048B0FB0013175B015E4185EDB" xlink:to="lab_us-gaap_CapitalLeaseObligationsIncurred_D9E4A5048B0FB0013175B015E4185EDB" xlink:type="arc" />
    <link:label id="lab_alim_DebtInstrumentEndofTermPaymentAccrued_DCEAF0FAB1E8EE1C5AF2B015E418ABD0_terseLabel_en-US" xlink:label="lab_alim_DebtInstrumentEndofTermPaymentAccrued_DCEAF0FAB1E8EE1C5AF2B015E418ABD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note payable end of term payment accrued but unpaid</link:label>
    <link:label id="lab_alim_DebtInstrumentEndofTermPaymentAccrued_DCEAF0FAB1E8EE1C5AF2B015E418ABD0_label_en-US" xlink:label="lab_alim_DebtInstrumentEndofTermPaymentAccrued_DCEAF0FAB1E8EE1C5AF2B015E418ABD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, End of Term Payment Accrued</link:label>
    <link:label id="lab_alim_DebtInstrumentEndofTermPaymentAccrued_DCEAF0FAB1E8EE1C5AF2B015E418ABD0_documentation_en-US" xlink:label="lab_alim_DebtInstrumentEndofTermPaymentAccrued_DCEAF0FAB1E8EE1C5AF2B015E418ABD0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, End of Term Payment Accrued</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentEndofTermPaymentAccrued" xlink:label="loc_alim_DebtInstrumentEndofTermPaymentAccrued_DCEAF0FAB1E8EE1C5AF2B015E418ABD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_DebtInstrumentEndofTermPaymentAccrued_DCEAF0FAB1E8EE1C5AF2B015E418ABD0" xlink:to="lab_alim_DebtInstrumentEndofTermPaymentAccrued_DCEAF0FAB1E8EE1C5AF2B015E418ABD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_AD6C14EE3A13B0D8761948DE135AD6E5_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_AD6C14EE3A13B0D8761948DE135AD6E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_AD6C14EE3A13B0D8761948DE135AD6E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_AD6C14EE3A13B0D8761948DE135AD6E5" xlink:to="lab_us-gaap_DebtDisclosureAbstract_AD6C14EE3A13B0D8761948DE135AD6E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_C54F498CF5C26557003748DE135AFE2C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_C54F498CF5C26557003748DE135AFE2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan Agreements</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_C54F498CF5C26557003748DE135AFE2C_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_C54F498CF5C26557003748DE135AFE2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_C54F498CF5C26557003748DE135AFE2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_C54F498CF5C26557003748DE135AFE2C" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_C54F498CF5C26557003748DE135AFE2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockTable_1B25A705ED56B5A42C2E591B212DA232_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockTable_1B25A705ED56B5A42C2E591B212DA232" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockTable_1B25A705ED56B5A42C2E591B212DA232_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockTable_1B25A705ED56B5A42C2E591B212DA232" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_us-gaap_ConversionOfStockTable_1B25A705ED56B5A42C2E591B212DA232" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockTable_1B25A705ED56B5A42C2E591B212DA232" xlink:to="lab_us-gaap_ConversionOfStockTable_1B25A705ED56B5A42C2E591B212DA232" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_11183F049F3FACCBE2F7591B212DB24B_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_11183F049F3FACCBE2F7591B212DB24B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A convertible preferred stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_11183F049F3FACCBE2F7591B212DB24B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_11183F049F3FACCBE2F7591B212DB24B" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_11183F049F3FACCBE2F7591B212DB24B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_D7314E7C0D39D3E408CF591B212D9D6C_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_D7314E7C0D39D3E408CF591B212D9D6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_D7314E7C0D39D3E408CF591B212D9D6C_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_D7314E7C0D39D3E408CF591B212D9D6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_D7314E7C0D39D3E408CF591B212D9D6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember_D7314E7C0D39D3E408CF591B212D9D6C" xlink:to="lab_us-gaap_OverAllotmentOptionMember_D7314E7C0D39D3E408CF591B212D9D6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="lab_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:type="arc" />
    <link:label id="lab_alim_NumberOfPreferredStockAndWarrants_4C99EB07A5E2BA6AC84D591B212ECD50_terseLabel_en-US" xlink:label="lab_alim_NumberOfPreferredStockAndWarrants_4C99EB07A5E2BA6AC84D591B212ECD50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of preferred stock and warrants (in shares)</link:label>
    <link:label id="lab_alim_NumberOfPreferredStockAndWarrants_4C99EB07A5E2BA6AC84D591B212ECD50_label_en-US" xlink:label="lab_alim_NumberOfPreferredStockAndWarrants_4C99EB07A5E2BA6AC84D591B212ECD50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Preferred Stock and Warrants</link:label>
    <link:label id="lab_alim_NumberOfPreferredStockAndWarrants_4C99EB07A5E2BA6AC84D591B212ECD50_documentation_en-US" xlink:label="lab_alim_NumberOfPreferredStockAndWarrants_4C99EB07A5E2BA6AC84D591B212ECD50" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of preferred stock and warrants.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_NumberOfPreferredStockAndWarrants" xlink:label="loc_alim_NumberOfPreferredStockAndWarrants_4C99EB07A5E2BA6AC84D591B212ECD50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_NumberOfPreferredStockAndWarrants_4C99EB07A5E2BA6AC84D591B212ECD50" xlink:to="lab_alim_NumberOfPreferredStockAndWarrants_4C99EB07A5E2BA6AC84D591B212ECD50" xlink:type="arc" />
    <link:label id="lab_alim_WarrantsToPurchaseAdditionalShares_5658BEC2990679F67A3F591B212E6E1C_terseLabel_en-US" xlink:label="lab_alim_WarrantsToPurchaseAdditionalShares_5658BEC2990679F67A3F591B212E6E1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase additional shares</link:label>
    <link:label id="lab_alim_WarrantsToPurchaseAdditionalShares_5658BEC2990679F67A3F591B212E6E1C_label_en-US" xlink:label="lab_alim_WarrantsToPurchaseAdditionalShares_5658BEC2990679F67A3F591B212E6E1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants To Purchase Additional Shares</link:label>
    <link:label id="lab_alim_WarrantsToPurchaseAdditionalShares_5658BEC2990679F67A3F591B212E6E1C_documentation_en-US" xlink:label="lab_alim_WarrantsToPurchaseAdditionalShares_5658BEC2990679F67A3F591B212E6E1C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants to purchase additional shares.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_WarrantsToPurchaseAdditionalShares" xlink:label="loc_alim_WarrantsToPurchaseAdditionalShares_5658BEC2990679F67A3F591B212E6E1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_WarrantsToPurchaseAdditionalShares_5658BEC2990679F67A3F591B212E6E1C" xlink:to="lab_alim_WarrantsToPurchaseAdditionalShares_5658BEC2990679F67A3F591B212E6E1C" xlink:type="arc" />
    <link:label id="lab_alim_GrossProceedsUnderSecuritiesPurchaseAgreement_39636316BD971BE61872591B212E72F6_terseLabel_en-US" xlink:label="lab_alim_GrossProceedsUnderSecuritiesPurchaseAgreement_39636316BD971BE61872591B212E72F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds under securities purchase agreement</link:label>
    <link:label id="lab_alim_GrossProceedsUnderSecuritiesPurchaseAgreement_39636316BD971BE61872591B212E72F6_label_en-US" xlink:label="lab_alim_GrossProceedsUnderSecuritiesPurchaseAgreement_39636316BD971BE61872591B212E72F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Proceeds Under Securities Purchase Agreement</link:label>
    <link:label id="lab_alim_GrossProceedsUnderSecuritiesPurchaseAgreement_39636316BD971BE61872591B212E72F6_documentation_en-US" xlink:label="lab_alim_GrossProceedsUnderSecuritiesPurchaseAgreement_39636316BD971BE61872591B212E72F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross proceeds under securities purchase agreement.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_GrossProceedsUnderSecuritiesPurchaseAgreement" xlink:label="loc_alim_GrossProceedsUnderSecuritiesPurchaseAgreement_39636316BD971BE61872591B212E72F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_GrossProceedsUnderSecuritiesPurchaseAgreement_39636316BD971BE61872591B212E72F6" xlink:to="lab_alim_GrossProceedsUnderSecuritiesPurchaseAgreement_39636316BD971BE61872591B212E72F6" xlink:type="arc" />
    <link:label id="lab_alim_EstimatedTotalStockIssuanceCost_8D179FEEDE00ACE4664A591B212E044F_terseLabel_en-US" xlink:label="lab_alim_EstimatedTotalStockIssuanceCost_8D179FEEDE00ACE4664A591B212E044F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated total stock issuance cost</link:label>
    <link:label id="lab_alim_EstimatedTotalStockIssuanceCost_8D179FEEDE00ACE4664A591B212E044F_label_en-US" xlink:label="lab_alim_EstimatedTotalStockIssuanceCost_8D179FEEDE00ACE4664A591B212E044F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Total Stock Issuance Cost</link:label>
    <link:label id="lab_alim_EstimatedTotalStockIssuanceCost_8D179FEEDE00ACE4664A591B212E044F_documentation_en-US" xlink:label="lab_alim_EstimatedTotalStockIssuanceCost_8D179FEEDE00ACE4664A591B212E044F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Total Stock Issuance Cost</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_EstimatedTotalStockIssuanceCost" xlink:label="loc_alim_EstimatedTotalStockIssuanceCost_8D179FEEDE00ACE4664A591B212E044F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_EstimatedTotalStockIssuanceCost_8D179FEEDE00ACE4664A591B212E044F" xlink:to="lab_alim_EstimatedTotalStockIssuanceCost_8D179FEEDE00ACE4664A591B212E044F" xlink:type="arc" />
    <link:label id="lab_alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue_5840EA2725D97A606998591B212E95D4_terseLabel_en-US" xlink:label="lab_alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue_5840EA2725D97A606998591B212E95D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion rate of Series A Convertible Preferred Stock issued upon exercise of warrants into common stock (in dollar per share)</link:label>
    <link:label id="lab_alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue_5840EA2725D97A606998591B212E95D4_label_en-US" xlink:label="lab_alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue_5840EA2725D97A606998591B212E95D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Proceeds Under Securities Purchase Agreement Per Value</link:label>
    <link:label id="lab_alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue_5840EA2725D97A606998591B212E95D4_documentation_en-US" xlink:label="lab_alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue_5840EA2725D97A606998591B212E95D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross proceeds under securities purchase agreement per value.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue" xlink:label="loc_alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue_5840EA2725D97A606998591B212E95D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue_5840EA2725D97A606998591B212E95D4" xlink:to="lab_alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue_5840EA2725D97A606998591B212E95D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_53946E113613A0974E40591B212EC012_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_53946E113613A0974E40591B212EC012" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_53946E113613A0974E40591B212EC012_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_53946E113613A0974E40591B212EC012" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_53946E113613A0974E40591B212EC012" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_53946E113613A0974E40591B212EC012" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_53946E113613A0974E40591B212EC012" xlink:type="arc" />
    <link:label id="lab_alim_PreferredStockConvertedToCommonStockPerShare_001A9DA1D206754EC9F8591B212E7319_terseLabel_en-US" xlink:label="lab_alim_PreferredStockConvertedToCommonStockPerShare_001A9DA1D206754EC9F8591B212E7319" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock converted to common stock per share (in dollars per share)</link:label>
    <link:label id="lab_alim_PreferredStockConvertedToCommonStockPerShare_001A9DA1D206754EC9F8591B212E7319_label_en-US" xlink:label="lab_alim_PreferredStockConvertedToCommonStockPerShare_001A9DA1D206754EC9F8591B212E7319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Converted To Common Stock Per Share</link:label>
    <link:label id="lab_alim_PreferredStockConvertedToCommonStockPerShare_001A9DA1D206754EC9F8591B212E7319_documentation_en-US" xlink:label="lab_alim_PreferredStockConvertedToCommonStockPerShare_001A9DA1D206754EC9F8591B212E7319" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred stock converted to common stock per share.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_PreferredStockConvertedToCommonStockPerShare" xlink:label="loc_alim_PreferredStockConvertedToCommonStockPerShare_001A9DA1D206754EC9F8591B212E7319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_PreferredStockConvertedToCommonStockPerShare_001A9DA1D206754EC9F8591B212E7319" xlink:to="lab_alim_PreferredStockConvertedToCommonStockPerShare_001A9DA1D206754EC9F8591B212E7319" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_A6941D3349929AF35C3B591B212EE647_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_A6941D3349929AF35C3B591B212EE647" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of preferred stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_A6941D3349929AF35C3B591B212EE647_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_A6941D3349929AF35C3B591B212EE647" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_A6941D3349929AF35C3B591B212EE647" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_A6941D3349929AF35C3B591B212EE647" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_A6941D3349929AF35C3B591B212EE647" xlink:type="arc" />
    <link:label id="lab_alim_ProportionOfEachUnitOfShares_9831103A75B019217437591B212ECDED_terseLabel_en-US" xlink:label="lab_alim_ProportionOfEachUnitOfShares_9831103A75B019217437591B212ECDED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportion of each unit of shares (in shares)</link:label>
    <link:label id="lab_alim_ProportionOfEachUnitOfShares_9831103A75B019217437591B212ECDED_label_en-US" xlink:label="lab_alim_ProportionOfEachUnitOfShares_9831103A75B019217437591B212ECDED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion Of Each Unit Of Shares</link:label>
    <link:label id="lab_alim_ProportionOfEachUnitOfShares_9831103A75B019217437591B212ECDED_documentation_en-US" xlink:label="lab_alim_ProportionOfEachUnitOfShares_9831103A75B019217437591B212ECDED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proportion of each unit of shares.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_ProportionOfEachUnitOfShares" xlink:label="loc_alim_ProportionOfEachUnitOfShares_9831103A75B019217437591B212ECDED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_ProportionOfEachUnitOfShares_9831103A75B019217437591B212ECDED" xlink:to="lab_alim_ProportionOfEachUnitOfShares_9831103A75B019217437591B212ECDED" xlink:type="arc" />
    <link:label id="lab_alim_ExercisePriceOfWarrants_C02488C215B82DCC5697591B212EF21B_terseLabel_en-US" xlink:label="lab_alim_ExercisePriceOfWarrants_C02488C215B82DCC5697591B212EF21B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
    <link:label id="lab_alim_ExercisePriceOfWarrants_C02488C215B82DCC5697591B212EF21B_label_en-US" xlink:label="lab_alim_ExercisePriceOfWarrants_C02488C215B82DCC5697591B212EF21B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Of Warrants</link:label>
    <link:label id="lab_alim_ExercisePriceOfWarrants_C02488C215B82DCC5697591B212EF21B_documentation_en-US" xlink:label="lab_alim_ExercisePriceOfWarrants_C02488C215B82DCC5697591B212EF21B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price of warrants.</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_ExercisePriceOfWarrants" xlink:label="loc_alim_ExercisePriceOfWarrants_C02488C215B82DCC5697591B212EF21B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_ExercisePriceOfWarrants_C02488C215B82DCC5697591B212EF21B" xlink:to="lab_alim_ExercisePriceOfWarrants_C02488C215B82DCC5697591B212EF21B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_F3AA9D84656CC800084D591B212E3FFA_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_F3AA9D84656CC800084D591B212E3FFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value of derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_F3AA9D84656CC800084D591B212E3FFA_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_F3AA9D84656CC800084D591B212E3FFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Amount Not Offset Against Collateral</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_F3AA9D84656CC800084D591B212E3FFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_F3AA9D84656CC800084D591B212E3FFA" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_F3AA9D84656CC800084D591B212E3FFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_A3C86DD1AD63F57FF9E5591B212EDE0D_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet_A3C86DD1AD63F57FF9E5591B212EDE0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on change in fair value of derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_A3C86DD1AD63F57FF9E5591B212EDE0D_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet_A3C86DD1AD63F57FF9E5591B212EDE0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_A3C86DD1AD63F57FF9E5591B212EDE0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet_A3C86DD1AD63F57FF9E5591B212EDE0D" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet_A3C86DD1AD63F57FF9E5591B212EDE0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_59E046C366E80FA5EB96591B212EDCC1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_59E046C366E80FA5EB96591B212EDCC1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued upon conversion of convertible securities (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_59E046C366E80FA5EB96591B212EDCC1_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_59E046C366E80FA5EB96591B212EDCC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_59E046C366E80FA5EB96591B212EDCC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_59E046C366E80FA5EB96591B212EDCC1" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_59E046C366E80FA5EB96591B212EDCC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_7945A6E51B149735AB9B591B212EE980_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_7945A6E51B149735AB9B591B212EE980" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible securities converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_7945A6E51B149735AB9B591B212EE980_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_7945A6E51B149735AB9B591B212EE980" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_7945A6E51B149735AB9B591B212EE980" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1_7945A6E51B149735AB9B591B212EE980" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1_7945A6E51B149735AB9B591B212EE980" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_CBF13D8C139FEB457394591B21335152_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_CBF13D8C139FEB457394591B21335152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_CBF13D8C139FEB457394591B21335152_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_CBF13D8C139FEB457394591B21335152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_CBF13D8C139FEB457394591B21335152" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_CBF13D8C139FEB457394591B21335152" xlink:to="lab_us-gaap_PreferredStockSharesIssued_CBF13D8C139FEB457394591B21335152" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_2C9A4E44512FFFF21154591B21346A3C_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_2C9A4E44512FFFF21154591B21346A3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_2C9A4E44512FFFF21154591B21346A3C_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_2C9A4E44512FFFF21154591B21346A3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2C9A4E44512FFFF21154591B21346A3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_2C9A4E44512FFFF21154591B21346A3C" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_2C9A4E44512FFFF21154591B21346A3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2224C0256F1CEDB7AEC591B2134129E_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2224C0256F1CEDB7AEC591B2134129E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during period (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2224C0256F1CEDB7AEC591B2134129E_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2224C0256F1CEDB7AEC591B2134129E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2224C0256F1CEDB7AEC591B2134129E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2224C0256F1CEDB7AEC591B2134129E" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2224C0256F1CEDB7AEC591B2134129E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_473A215BE740185DB071591B2134620F_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_473A215BE740185DB071591B2134620F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued upon conversion</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_473A215BE740185DB071591B2134620F_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_473A215BE740185DB071591B2134620F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_473A215BE740185DB071591B2134620F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_473A215BE740185DB071591B2134620F" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_473A215BE740185DB071591B2134620F" xlink:type="arc" />
    <link:label id="lab_alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent_FEC5F0D04E4BA8D5D190591B213408C3_terseLabel_en-US" xlink:label="lab_alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent_FEC5F0D04E4BA8D5D190591B213408C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership interest after conversion (percent)</link:label>
    <link:label id="lab_alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent_FEC5F0D04E4BA8D5D190591B213408C3_label_en-US" xlink:label="lab_alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent_FEC5F0D04E4BA8D5D190591B213408C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Ownership Interest After Conversion, Percent</link:label>
    <link:label id="lab_alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent_FEC5F0D04E4BA8D5D190591B213408C3_documentation_en-US" xlink:label="lab_alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent_FEC5F0D04E4BA8D5D190591B213408C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Ownership Interest After Conversion, Percent</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent" xlink:label="loc_alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent_FEC5F0D04E4BA8D5D190591B213408C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent_FEC5F0D04E4BA8D5D190591B213408C3" xlink:to="lab_alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent_FEC5F0D04E4BA8D5D190591B213408C3" xlink:type="arc" />
    <link:label id="lab_alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature_A2079E28A0524491D149591B2134BA0A_terseLabel_en-US" xlink:label="lab_alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature_A2079E28A0524491D149591B2134BA0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to APIC</link:label>
    <link:label id="lab_alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature_A2079E28A0524491D149591B2134BA0A_label_en-US" xlink:label="lab_alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature_A2079E28A0524491D149591B2134BA0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Preferred Stock Beneficial Feature</link:label>
    <link:label id="lab_alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature_A2079E28A0524491D149591B2134BA0A_documentation_en-US" xlink:label="lab_alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature_A2079E28A0524491D149591B2134BA0A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Preferred Stock Beneficial Feature</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature" xlink:label="loc_alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature_A2079E28A0524491D149591B2134BA0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature_A2079E28A0524491D149591B2134BA0A" xlink:to="lab_alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature_A2079E28A0524491D149591B2134BA0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:to="lab_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_C372B3E9AC583313B572D0A03D4D6975_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_C372B3E9AC583313B572D0A03D4D6975" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_C372B3E9AC583313B572D0A03D4D6975_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_C372B3E9AC583313B572D0A03D4D6975" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_C372B3E9AC583313B572D0A03D4D6975" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_C372B3E9AC583313B572D0A03D4D6975" xlink:to="lab_us-gaap_VariableRateAxis_C372B3E9AC583313B572D0A03D4D6975" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_857E9D77E6699632F4D5D0A03D4DD3DC_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_857E9D77E6699632F4D5D0A03D4DD3DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_857E9D77E6699632F4D5D0A03D4DD3DC_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_857E9D77E6699632F4D5D0A03D4DD3DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_857E9D77E6699632F4D5D0A03D4DD3DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_857E9D77E6699632F4D5D0A03D4DD3DC" xlink:to="lab_us-gaap_VariableRateDomain_857E9D77E6699632F4D5D0A03D4DD3DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrimeRateMember_6C19C1299E16764F9015D0A03D4D7185_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember_6C19C1299E16764F9015D0A03D4D7185" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_6C19C1299E16764F9015D0A03D4D7185_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember_6C19C1299E16764F9015D0A03D4D7185" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_6C19C1299E16764F9015D0A03D4D7185" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember_6C19C1299E16764F9015D0A03D4D7185" xlink:to="lab_us-gaap_PrimeRateMember_6C19C1299E16764F9015D0A03D4D7185" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_DBB2028ADB4BBA933F5BD0A03D4D75D5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_DBB2028ADB4BBA933F5BD0A03D4D75D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_DBB2028ADB4BBA933F5BD0A03D4D75D5_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_DBB2028ADB4BBA933F5BD0A03D4D75D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_DBB2028ADB4BBA933F5BD0A03D4D75D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_DBB2028ADB4BBA933F5BD0A03D4D75D5" xlink:to="lab_us-gaap_DebtInstrumentAxis_DBB2028ADB4BBA933F5BD0A03D4D75D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_D99061EF866BC35EDA41D0A03D4DBF25_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_D99061EF866BC35EDA41D0A03D4DBF25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_D99061EF866BC35EDA41D0A03D4DBF25_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_D99061EF866BC35EDA41D0A03D4DBF25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D99061EF866BC35EDA41D0A03D4DBF25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D99061EF866BC35EDA41D0A03D4DBF25" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_D99061EF866BC35EDA41D0A03D4DBF25" xlink:type="arc" />
    <link:label id="lab_alim_TrancheOneMember_F64400775473302E1CCED0A03D4DE894_terseLabel_en-US" xlink:label="lab_alim_TrancheOneMember_F64400775473302E1CCED0A03D4DE894" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_alim_TrancheOneMember_F64400775473302E1CCED0A03D4DE894_label_en-US" xlink:label="lab_alim_TrancheOneMember_F64400775473302E1CCED0A03D4DE894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche One [Member]</link:label>
    <link:label id="lab_alim_TrancheOneMember_F64400775473302E1CCED0A03D4DE894_documentation_en-US" xlink:label="lab_alim_TrancheOneMember_F64400775473302E1CCED0A03D4DE894" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche One [Member]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_TrancheOneMember" xlink:label="loc_alim_TrancheOneMember_F64400775473302E1CCED0A03D4DE894" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_TrancheOneMember_F64400775473302E1CCED0A03D4DE894" xlink:to="lab_alim_TrancheOneMember_F64400775473302E1CCED0A03D4DE894" xlink:type="arc" />
    <link:label id="lab_alim_TrancheTwoMember_0D683E8A120D5A2E9EBFD0A03D4DDE93_terseLabel_en-US" xlink:label="lab_alim_TrancheTwoMember_0D683E8A120D5A2E9EBFD0A03D4DDE93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_alim_TrancheTwoMember_0D683E8A120D5A2E9EBFD0A03D4DDE93_label_en-US" xlink:label="lab_alim_TrancheTwoMember_0D683E8A120D5A2E9EBFD0A03D4DDE93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche Two [Member]</link:label>
    <link:label id="lab_alim_TrancheTwoMember_0D683E8A120D5A2E9EBFD0A03D4DDE93_documentation_en-US" xlink:label="lab_alim_TrancheTwoMember_0D683E8A120D5A2E9EBFD0A03D4DDE93" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche Two [Member]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_TrancheTwoMember" xlink:label="loc_alim_TrancheTwoMember_0D683E8A120D5A2E9EBFD0A03D4DDE93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_TrancheTwoMember_0D683E8A120D5A2E9EBFD0A03D4DDE93" xlink:to="lab_alim_TrancheTwoMember_0D683E8A120D5A2E9EBFD0A03D4DDE93" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_4D7BD9EA91B89CD98329D0A03D4D42B6_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_4D7BD9EA91B89CD98329D0A03D4D42B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_4D7BD9EA91B89CD98329D0A03D4D42B6_label_en-US" xlink:label="lab_dei_LegalEntityAxis_4D7BD9EA91B89CD98329D0A03D4D42B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4D7BD9EA91B89CD98329D0A03D4D42B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_4D7BD9EA91B89CD98329D0A03D4D42B6" xlink:to="lab_dei_LegalEntityAxis_4D7BD9EA91B89CD98329D0A03D4D42B6" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_931635576EF6E62A8602D0A03D4DEDD4_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_931635576EF6E62A8602D0A03D4DEDD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_931635576EF6E62A8602D0A03D4DEDD4_label_en-US" xlink:label="lab_dei_EntityDomain_931635576EF6E62A8602D0A03D4DEDD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_931635576EF6E62A8602D0A03D4DEDD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_931635576EF6E62A8602D0A03D4DEDD4" xlink:to="lab_dei_EntityDomain_931635576EF6E62A8602D0A03D4DEDD4" xlink:type="arc" />
    <link:label id="lab_alim_AlimeraSciencesIncCompanyMember_8346677F50ADBE675777D0A03D4DF98D_terseLabel_en-US" xlink:label="lab_alim_AlimeraSciencesIncCompanyMember_8346677F50ADBE675777D0A03D4DF98D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alimera Sciences, Inc.(Company)</link:label>
    <link:label id="lab_alim_AlimeraSciencesIncCompanyMember_8346677F50ADBE675777D0A03D4DF98D_label_en-US" xlink:label="lab_alim_AlimeraSciencesIncCompanyMember_8346677F50ADBE675777D0A03D4DF98D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alimera Sciences, Inc.(Company) [Member]</link:label>
    <link:label id="lab_alim_AlimeraSciencesIncCompanyMember_8346677F50ADBE675777D0A03D4DF98D_documentation_en-US" xlink:label="lab_alim_AlimeraSciencesIncCompanyMember_8346677F50ADBE675777D0A03D4DF98D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alimera Sciences, Inc.(Company) [Member]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_AlimeraSciencesIncCompanyMember" xlink:label="loc_alim_AlimeraSciencesIncCompanyMember_8346677F50ADBE675777D0A03D4DF98D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_AlimeraSciencesIncCompanyMember_8346677F50ADBE675777D0A03D4DF98D" xlink:to="lab_alim_AlimeraSciencesIncCompanyMember_8346677F50ADBE675777D0A03D4DF98D" xlink:type="arc" />
    <link:label id="lab_alim_AlimeraSciencesLimitedLimitedMember_19F017263905C6EC710BD0A03D4DECB3_terseLabel_en-US" xlink:label="lab_alim_AlimeraSciencesLimitedLimitedMember_19F017263905C6EC710BD0A03D4DECB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alimera Sciences Limited (Limited)</link:label>
    <link:label id="lab_alim_AlimeraSciencesLimitedLimitedMember_19F017263905C6EC710BD0A03D4DECB3_label_en-US" xlink:label="lab_alim_AlimeraSciencesLimitedLimitedMember_19F017263905C6EC710BD0A03D4DECB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alimera Sciences Limited (Limited) [Member]</link:label>
    <link:label id="lab_alim_AlimeraSciencesLimitedLimitedMember_19F017263905C6EC710BD0A03D4DECB3_documentation_en-US" xlink:label="lab_alim_AlimeraSciencesLimitedLimitedMember_19F017263905C6EC710BD0A03D4DECB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alimera Sciences Limited (Limited) [Member]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_AlimeraSciencesLimitedLimitedMember" xlink:label="loc_alim_AlimeraSciencesLimitedLimitedMember_19F017263905C6EC710BD0A03D4DECB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_AlimeraSciencesLimitedLimitedMember_19F017263905C6EC710BD0A03D4DECB3" xlink:to="lab_alim_AlimeraSciencesLimitedLimitedMember_19F017263905C6EC710BD0A03D4DECB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_97CF78E6E442D6CFC615D0A03D4DBF02_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis_97CF78E6E442D6CFC615D0A03D4DBF02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_97CF78E6E442D6CFC615D0A03D4DBF02_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis_97CF78E6E442D6CFC615D0A03D4DBF02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_97CF78E6E442D6CFC615D0A03D4DBF02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_97CF78E6E442D6CFC615D0A03D4DBF02" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis_97CF78E6E442D6CFC615D0A03D4DBF02" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_8BF8FC722C062451D4A2D0A03D4D581E_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain_8BF8FC722C062451D4A2D0A03D4D581E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_8BF8FC722C062451D4A2D0A03D4D581E_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain_8BF8FC722C062451D4A2D0A03D4D581E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_8BF8FC722C062451D4A2D0A03D4D581E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_8BF8FC722C062451D4A2D0A03D4D581E" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain_8BF8FC722C062451D4A2D0A03D4D581E" xlink:type="arc" />
    <link:label id="lab_alim_HerculesTechnologyGrowthCapitalInc.Member_E4ACF7BEE50590DFBA70D0A03D534CBF_terseLabel_en-US" xlink:label="lab_alim_HerculesTechnologyGrowthCapitalInc.Member_E4ACF7BEE50590DFBA70D0A03D534CBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hercules Technology Growth Capital, Inc.</link:label>
    <link:label id="lab_alim_HerculesTechnologyGrowthCapitalInc.Member_E4ACF7BEE50590DFBA70D0A03D534CBF_label_en-US" xlink:label="lab_alim_HerculesTechnologyGrowthCapitalInc.Member_E4ACF7BEE50590DFBA70D0A03D534CBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hercules Technology Growth Capital, Inc. [Member]</link:label>
    <link:label id="lab_alim_HerculesTechnologyGrowthCapitalInc.Member_E4ACF7BEE50590DFBA70D0A03D534CBF_documentation_en-US" xlink:label="lab_alim_HerculesTechnologyGrowthCapitalInc.Member_E4ACF7BEE50590DFBA70D0A03D534CBF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hercules Technology Growth Capital, Inc. [Member]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_HerculesTechnologyGrowthCapitalInc.Member" xlink:label="loc_alim_HerculesTechnologyGrowthCapitalInc.Member_E4ACF7BEE50590DFBA70D0A03D534CBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_HerculesTechnologyGrowthCapitalInc.Member_E4ACF7BEE50590DFBA70D0A03D534CBF" xlink:to="lab_alim_HerculesTechnologyGrowthCapitalInc.Member_E4ACF7BEE50590DFBA70D0A03D534CBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_BC486F6880CD0B995EB9D0A03D538322_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_BC486F6880CD0B995EB9D0A03D538322" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_BC486F6880CD0B995EB9D0A03D538322_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_BC486F6880CD0B995EB9D0A03D538322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_BC486F6880CD0B995EB9D0A03D538322" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_BC486F6880CD0B995EB9D0A03D538322" xlink:to="lab_us-gaap_CreditFacilityAxis_BC486F6880CD0B995EB9D0A03D538322" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:to="lab_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:type="arc" />
    <link:label id="lab_alim_TwentyFourteenTermLoanMember_641A97B5F66A1490E452D0A03D53DC6B_terseLabel_en-US" xlink:label="lab_alim_TwentyFourteenTermLoanMember_641A97B5F66A1490E452D0A03D53DC6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Term Loan</link:label>
    <link:label id="lab_alim_TwentyFourteenTermLoanMember_641A97B5F66A1490E452D0A03D53DC6B_label_en-US" xlink:label="lab_alim_TwentyFourteenTermLoanMember_641A97B5F66A1490E452D0A03D53DC6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Fourteen Term Loan [Member]</link:label>
    <link:label id="lab_alim_TwentyFourteenTermLoanMember_641A97B5F66A1490E452D0A03D53DC6B_documentation_en-US" xlink:label="lab_alim_TwentyFourteenTermLoanMember_641A97B5F66A1490E452D0A03D53DC6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Fourteen Term Loan [Member]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_TwentyFourteenTermLoanMember" xlink:label="loc_alim_TwentyFourteenTermLoanMember_641A97B5F66A1490E452D0A03D53DC6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_TwentyFourteenTermLoanMember_641A97B5F66A1490E452D0A03D53DC6B" xlink:to="lab_alim_TwentyFourteenTermLoanMember_641A97B5F66A1490E452D0A03D53DC6B" xlink:type="arc" />
    <link:label id="lab_alim_FirstLoanAmendmentMember_B4E5FD3761A879AF73FED0A03D538606_terseLabel_en-US" xlink:label="lab_alim_FirstLoanAmendmentMember_B4E5FD3761A879AF73FED0A03D538606" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Loan Amendment</link:label>
    <link:label id="lab_alim_FirstLoanAmendmentMember_B4E5FD3761A879AF73FED0A03D538606_label_en-US" xlink:label="lab_alim_FirstLoanAmendmentMember_B4E5FD3761A879AF73FED0A03D538606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Loan Amendment [Member]</link:label>
    <link:label id="lab_alim_FirstLoanAmendmentMember_B4E5FD3761A879AF73FED0A03D538606_documentation_en-US" xlink:label="lab_alim_FirstLoanAmendmentMember_B4E5FD3761A879AF73FED0A03D538606" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Loan Amendment [Member]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_FirstLoanAmendmentMember" xlink:label="loc_alim_FirstLoanAmendmentMember_B4E5FD3761A879AF73FED0A03D538606" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_FirstLoanAmendmentMember_B4E5FD3761A879AF73FED0A03D538606" xlink:to="lab_alim_FirstLoanAmendmentMember_B4E5FD3761A879AF73FED0A03D538606" xlink:type="arc" />
    <link:label id="lab_alim_SecondLoanAmendmentMember_F62DD0E7654575D32291D0A03D537135_terseLabel_en-US" xlink:label="lab_alim_SecondLoanAmendmentMember_F62DD0E7654575D32291D0A03D537135" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Loan Amendment</link:label>
    <link:label id="lab_alim_SecondLoanAmendmentMember_F62DD0E7654575D32291D0A03D537135_label_en-US" xlink:label="lab_alim_SecondLoanAmendmentMember_F62DD0E7654575D32291D0A03D537135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second Loan Amendment [Member]</link:label>
    <link:label id="lab_alim_SecondLoanAmendmentMember_F62DD0E7654575D32291D0A03D537135_documentation_en-US" xlink:label="lab_alim_SecondLoanAmendmentMember_F62DD0E7654575D32291D0A03D537135" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second Loan Amendment</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_SecondLoanAmendmentMember" xlink:label="loc_alim_SecondLoanAmendmentMember_F62DD0E7654575D32291D0A03D537135" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_SecondLoanAmendmentMember_F62DD0E7654575D32291D0A03D537135" xlink:to="lab_alim_SecondLoanAmendmentMember_F62DD0E7654575D32291D0A03D537135" xlink:type="arc" />
    <link:label id="lab_alim_ThirdLoanAmendmentMember_4C617DB150C2E2B15FF7D0A03D533ECC_terseLabel_en-US" xlink:label="lab_alim_ThirdLoanAmendmentMember_4C617DB150C2E2B15FF7D0A03D533ECC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Third Loan Amendment</link:label>
    <link:label id="lab_alim_ThirdLoanAmendmentMember_4C617DB150C2E2B15FF7D0A03D533ECC_label_en-US" xlink:label="lab_alim_ThirdLoanAmendmentMember_4C617DB150C2E2B15FF7D0A03D533ECC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third Loan Amendment [Member]</link:label>
    <link:label id="lab_alim_ThirdLoanAmendmentMember_4C617DB150C2E2B15FF7D0A03D533ECC_documentation_en-US" xlink:label="lab_alim_ThirdLoanAmendmentMember_4C617DB150C2E2B15FF7D0A03D533ECC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Third Loan Amendment [Member]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_ThirdLoanAmendmentMember" xlink:label="loc_alim_ThirdLoanAmendmentMember_4C617DB150C2E2B15FF7D0A03D533ECC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_ThirdLoanAmendmentMember_4C617DB150C2E2B15FF7D0A03D533ECC" xlink:to="lab_alim_ThirdLoanAmendmentMember_4C617DB150C2E2B15FF7D0A03D533ECC" xlink:type="arc" />
    <link:label id="lab_alim_July2016WaiverMember_7C7285237E1241EA3442D0A03D531B39_terseLabel_en-US" xlink:label="lab_alim_July2016WaiverMember_7C7285237E1241EA3442D0A03D531B39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">July 2016 Waiver</link:label>
    <link:label id="lab_alim_July2016WaiverMember_7C7285237E1241EA3442D0A03D531B39_label_en-US" xlink:label="lab_alim_July2016WaiverMember_7C7285237E1241EA3442D0A03D531B39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">July 2016 Waiver [Member]</link:label>
    <link:label id="lab_alim_July2016WaiverMember_7C7285237E1241EA3442D0A03D531B39_documentation_en-US" xlink:label="lab_alim_July2016WaiverMember_7C7285237E1241EA3442D0A03D531B39" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">July 2016 Waiver [Member]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_July2016WaiverMember" xlink:label="loc_alim_July2016WaiverMember_7C7285237E1241EA3442D0A03D531B39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_July2016WaiverMember_7C7285237E1241EA3442D0A03D531B39" xlink:to="lab_alim_July2016WaiverMember_7C7285237E1241EA3442D0A03D531B39" xlink:type="arc" />
    <link:label id="lab_alim_FourthLoanAmendmentMember_E6C8C1BDCB5B0B18E802D0A03D53462C_terseLabel_en-US" xlink:label="lab_alim_FourthLoanAmendmentMember_E6C8C1BDCB5B0B18E802D0A03D53462C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fourth Loan Amendment</link:label>
    <link:label id="lab_alim_FourthLoanAmendmentMember_E6C8C1BDCB5B0B18E802D0A03D53462C_label_en-US" xlink:label="lab_alim_FourthLoanAmendmentMember_E6C8C1BDCB5B0B18E802D0A03D53462C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fourth Loan Amendment [Member]</link:label>
    <link:label id="lab_alim_FourthLoanAmendmentMember_E6C8C1BDCB5B0B18E802D0A03D53462C_documentation_en-US" xlink:label="lab_alim_FourthLoanAmendmentMember_E6C8C1BDCB5B0B18E802D0A03D53462C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fourth Loan Amendment [Member]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_FourthLoanAmendmentMember" xlink:label="loc_alim_FourthLoanAmendmentMember_E6C8C1BDCB5B0B18E802D0A03D53462C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_FourthLoanAmendmentMember_E6C8C1BDCB5B0B18E802D0A03D53462C" xlink:to="lab_alim_FourthLoanAmendmentMember_E6C8C1BDCB5B0B18E802D0A03D53462C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="lab_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2F91139318E12902EC65D0A03D53F185_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2F91139318E12902EC65D0A03D53F185" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company entitled to borrow</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2F91139318E12902EC65D0A03D53F185_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2F91139318E12902EC65D0A03D53F185" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2F91139318E12902EC65D0A03D53F185" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2F91139318E12902EC65D0A03D53F185" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2F91139318E12902EC65D0A03D53F185" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_25386C9781535C3F245AD0A03D5395CC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_25386C9781535C3F245AD0A03D5395CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_25386C9781535C3F245AD0A03D5395CC_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_25386C9781535C3F245AD0A03D5395CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_25386C9781535C3F245AD0A03D5395CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_25386C9781535C3F245AD0A03D5395CC" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_25386C9781535C3F245AD0A03D5395CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_B5A276BF118FF03CEE98D0A03D53FCA2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_B5A276BF118FF03CEE98D0A03D53FCA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on term loan (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_B5A276BF118FF03CEE98D0A03D53FCA2_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_B5A276BF118FF03CEE98D0A03D53FCA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_B5A276BF118FF03CEE98D0A03D53FCA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_B5A276BF118FF03CEE98D0A03D53FCA2" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_B5A276BF118FF03CEE98D0A03D53FCA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_F1E16C6B0297E63D677AD0A03D538319_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_F1E16C6B0297E63D677AD0A03D538319" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_F1E16C6B0297E63D677AD0A03D538319_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_F1E16C6B0297E63D677AD0A03D538319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_F1E16C6B0297E63D677AD0A03D538319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_F1E16C6B0297E63D677AD0A03D538319" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_F1E16C6B0297E63D677AD0A03D538319" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9FDF9ACD430CF5C52D7ED0A03D53301A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9FDF9ACD430CF5C52D7ED0A03D53301A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate (percentage)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9FDF9ACD430CF5C52D7ED0A03D53301A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9FDF9ACD430CF5C52D7ED0A03D53301A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9FDF9ACD430CF5C52D7ED0A03D53301A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9FDF9ACD430CF5C52D7ED0A03D53301A" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9FDF9ACD430CF5C52D7ED0A03D53301A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_29DF648A001CD9CAF6E1D0A03D537003_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount_29DF648A001CD9CAF6E1D0A03D537003" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">An upfront fee payment to lenders</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_29DF648A001CD9CAF6E1D0A03D537003_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount_29DF648A001CD9CAF6E1D0A03D537003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_29DF648A001CD9CAF6E1D0A03D537003" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount_29DF648A001CD9CAF6E1D0A03D537003" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount_29DF648A001CD9CAF6E1D0A03D537003" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_3135E044B1BF3F0CF295D0A03D53BAE3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_3135E044B1BF3F0CF295D0A03D53BAE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balloon payment to be paid</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_3135E044B1BF3F0CF295D0A03D53BAE3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_3135E044B1BF3F0CF295D0A03D53BAE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_3135E044B1BF3F0CF295D0A03D53BAE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_3135E044B1BF3F0CF295D0A03D53BAE3" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_3135E044B1BF3F0CF295D0A03D53BAE3" xlink:type="arc" />
    <link:label id="lab_alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal_7B40471ADE1126C796BDD0A03D536DFC_terseLabel_en-US" xlink:label="lab_alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal_7B40471ADE1126C796BDD0A03D536DFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balloon payment, percent of principal</link:label>
    <link:label id="lab_alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal_7B40471ADE1126C796BDD0A03D536DFC_label_en-US" xlink:label="lab_alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal_7B40471ADE1126C796BDD0A03D536DFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid, Percent of Principal</link:label>
    <link:label id="lab_alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal_7B40471ADE1126C796BDD0A03D536DFC_documentation_en-US" xlink:label="lab_alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal_7B40471ADE1126C796BDD0A03D536DFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid, Percent of Principal</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal" xlink:label="loc_alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal_7B40471ADE1126C796BDD0A03D536DFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal_7B40471ADE1126C796BDD0A03D536DFC" xlink:to="lab_alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal_7B40471ADE1126C796BDD0A03D536DFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_2BC4312706EAB9966713D0A03D533658_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_2BC4312706EAB9966713D0A03D533658" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2BC4312706EAB9966713D0A03D533658" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2BC4312706EAB9966713D0A03D533658" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_2BC4312706EAB9966713D0A03D533658" xlink:type="arc" />
    <link:label id="lab_alim_DebtInstrumentCovenantMinimumCashBalance_D3D18BE0A43228DF1EB8D0A03D540FC8_terseLabel_en-US" xlink:label="lab_alim_DebtInstrumentCovenantMinimumCashBalance_D3D18BE0A43228DF1EB8D0A03D540FC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum required cash balance per covenant</link:label>
    <link:label id="lab_alim_DebtInstrumentCovenantMinimumCashBalance_D3D18BE0A43228DF1EB8D0A03D540FC8_label_en-US" xlink:label="lab_alim_DebtInstrumentCovenantMinimumCashBalance_D3D18BE0A43228DF1EB8D0A03D540FC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Minimum Cash Balance</link:label>
    <link:label id="lab_alim_DebtInstrumentCovenantMinimumCashBalance_D3D18BE0A43228DF1EB8D0A03D540FC8_documentation_en-US" xlink:label="lab_alim_DebtInstrumentCovenantMinimumCashBalance_D3D18BE0A43228DF1EB8D0A03D540FC8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Minimum Cash Balance</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentCovenantMinimumCashBalance" xlink:label="loc_alim_DebtInstrumentCovenantMinimumCashBalance_D3D18BE0A43228DF1EB8D0A03D540FC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_DebtInstrumentCovenantMinimumCashBalance_D3D18BE0A43228DF1EB8D0A03D540FC8" xlink:to="lab_alim_DebtInstrumentCovenantMinimumCashBalance_D3D18BE0A43228DF1EB8D0A03D540FC8" xlink:type="arc" />
    <link:label id="lab_alim_DebtInstrumentTickingFeePercent_2363FA43B0C21A54C231D0A03D54F785_terseLabel_en-US" xlink:label="lab_alim_DebtInstrumentTickingFeePercent_2363FA43B0C21A54C231D0A03D54F785" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weekly ticking fee (percent)</link:label>
    <link:label id="lab_alim_DebtInstrumentTickingFeePercent_2363FA43B0C21A54C231D0A03D54F785_label_en-US" xlink:label="lab_alim_DebtInstrumentTickingFeePercent_2363FA43B0C21A54C231D0A03D54F785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Ticking Fee, Percent</link:label>
    <link:label id="lab_alim_DebtInstrumentTickingFeePercent_2363FA43B0C21A54C231D0A03D54F785_documentation_en-US" xlink:label="lab_alim_DebtInstrumentTickingFeePercent_2363FA43B0C21A54C231D0A03D54F785" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Ticking Fee, Percent</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentTickingFeePercent" xlink:label="loc_alim_DebtInstrumentTickingFeePercent_2363FA43B0C21A54C231D0A03D54F785" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_DebtInstrumentTickingFeePercent_2363FA43B0C21A54C231D0A03D54F785" xlink:to="lab_alim_DebtInstrumentTickingFeePercent_2363FA43B0C21A54C231D0A03D54F785" xlink:type="arc" />
    <link:label id="lab_alim_DebtInstrumentTickingFee_F78DCC5780EFE69306F3D0A03D54289B_terseLabel_en-US" xlink:label="lab_alim_DebtInstrumentTickingFee_F78DCC5780EFE69306F3D0A03D54289B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ticking fee</link:label>
    <link:label id="lab_alim_DebtInstrumentTickingFee_F78DCC5780EFE69306F3D0A03D54289B_label_en-US" xlink:label="lab_alim_DebtInstrumentTickingFee_F78DCC5780EFE69306F3D0A03D54289B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Ticking Fee</link:label>
    <link:label id="lab_alim_DebtInstrumentTickingFee_F78DCC5780EFE69306F3D0A03D54289B_documentation_en-US" xlink:label="lab_alim_DebtInstrumentTickingFee_F78DCC5780EFE69306F3D0A03D54289B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Ticking Fee</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentTickingFee" xlink:label="loc_alim_DebtInstrumentTickingFee_F78DCC5780EFE69306F3D0A03D54289B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_DebtInstrumentTickingFee_F78DCC5780EFE69306F3D0A03D54289B" xlink:to="lab_alim_DebtInstrumentTickingFee_F78DCC5780EFE69306F3D0A03D54289B" xlink:type="arc" />
    <link:label id="lab_alim_LineofCreditFacilityIncreaseinBorrowingCapacity_C2971B517BC6002C8C08D0A03D543E46_terseLabel_en-US" xlink:label="lab_alim_LineofCreditFacilityIncreaseinBorrowingCapacity_C2971B517BC6002C8C08D0A03D543E46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in borrowing capacity</link:label>
    <link:label id="lab_alim_LineofCreditFacilityIncreaseinBorrowingCapacity_C2971B517BC6002C8C08D0A03D543E46_label_en-US" xlink:label="lab_alim_LineofCreditFacilityIncreaseinBorrowingCapacity_C2971B517BC6002C8C08D0A03D543E46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Increase in Borrowing Capacity</link:label>
    <link:label id="lab_alim_LineofCreditFacilityIncreaseinBorrowingCapacity_C2971B517BC6002C8C08D0A03D543E46_documentation_en-US" xlink:label="lab_alim_LineofCreditFacilityIncreaseinBorrowingCapacity_C2971B517BC6002C8C08D0A03D543E46" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Increase in Borrowing Capacity</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_LineofCreditFacilityIncreaseinBorrowingCapacity" xlink:label="loc_alim_LineofCreditFacilityIncreaseinBorrowingCapacity_C2971B517BC6002C8C08D0A03D543E46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_LineofCreditFacilityIncreaseinBorrowingCapacity_C2971B517BC6002C8C08D0A03D543E46" xlink:to="lab_alim_LineofCreditFacilityIncreaseinBorrowingCapacity_C2971B517BC6002C8C08D0A03D543E46" xlink:type="arc" />
    <link:label id="lab_alim_DebtInstrumentRevenueRequirement_556E6AB9C1C9132382C8D0A03D546B83_terseLabel_en-US" xlink:label="lab_alim_DebtInstrumentRevenueRequirement_556E6AB9C1C9132382C8D0A03D546B83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue requirement</link:label>
    <link:label id="lab_alim_DebtInstrumentRevenueRequirement_556E6AB9C1C9132382C8D0A03D546B83_label_en-US" xlink:label="lab_alim_DebtInstrumentRevenueRequirement_556E6AB9C1C9132382C8D0A03D546B83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Revenue Requirement</link:label>
    <link:label id="lab_alim_DebtInstrumentRevenueRequirement_556E6AB9C1C9132382C8D0A03D546B83_documentation_en-US" xlink:label="lab_alim_DebtInstrumentRevenueRequirement_556E6AB9C1C9132382C8D0A03D546B83" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Revenue Requirement</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentRevenueRequirement" xlink:label="loc_alim_DebtInstrumentRevenueRequirement_556E6AB9C1C9132382C8D0A03D546B83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_DebtInstrumentRevenueRequirement_556E6AB9C1C9132382C8D0A03D546B83" xlink:to="lab_alim_DebtInstrumentRevenueRequirement_556E6AB9C1C9132382C8D0A03D546B83" xlink:type="arc" />
    <link:label id="lab_alim_DebtInstrumentBasisSpreadonVariableRateReduction_ED2A42019B24FA1CE5FFD0A03D54C550_terseLabel_en-US" xlink:label="lab_alim_DebtInstrumentBasisSpreadonVariableRateReduction_ED2A42019B24FA1CE5FFD0A03D54C550" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in basis spread on variable rate</link:label>
    <link:label id="lab_alim_DebtInstrumentBasisSpreadonVariableRateReduction_ED2A42019B24FA1CE5FFD0A03D54C550_label_en-US" xlink:label="lab_alim_DebtInstrumentBasisSpreadonVariableRateReduction_ED2A42019B24FA1CE5FFD0A03D54C550" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate, Reduction</link:label>
    <link:label id="lab_alim_DebtInstrumentBasisSpreadonVariableRateReduction_ED2A42019B24FA1CE5FFD0A03D54C550_documentation_en-US" xlink:label="lab_alim_DebtInstrumentBasisSpreadonVariableRateReduction_ED2A42019B24FA1CE5FFD0A03D54C550" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate, Reduction</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentBasisSpreadonVariableRateReduction" xlink:label="loc_alim_DebtInstrumentBasisSpreadonVariableRateReduction_ED2A42019B24FA1CE5FFD0A03D54C550" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_DebtInstrumentBasisSpreadonVariableRateReduction_ED2A42019B24FA1CE5FFD0A03D54C550" xlink:to="lab_alim_DebtInstrumentBasisSpreadonVariableRateReduction_ED2A42019B24FA1CE5FFD0A03D54C550" xlink:type="arc" />
    <link:label id="lab_alim_DebitInstrumentPaymentinKindInterestRate_A80ECCDD1B6E4852EF52D0A03D54C40D_terseLabel_en-US" xlink:label="lab_alim_DebitInstrumentPaymentinKindInterestRate_A80ECCDD1B6E4852EF52D0A03D54C40D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment-in-kind interest rate</link:label>
    <link:label id="lab_alim_DebitInstrumentPaymentinKindInterestRate_A80ECCDD1B6E4852EF52D0A03D54C40D_label_en-US" xlink:label="lab_alim_DebitInstrumentPaymentinKindInterestRate_A80ECCDD1B6E4852EF52D0A03D54C40D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debit Instrument, Payment-in-Kind Interest Rate</link:label>
    <link:label id="lab_alim_DebitInstrumentPaymentinKindInterestRate_A80ECCDD1B6E4852EF52D0A03D54C40D_documentation_en-US" xlink:label="lab_alim_DebitInstrumentPaymentinKindInterestRate_A80ECCDD1B6E4852EF52D0A03D54C40D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debit Instrument, Payment-in-Kind Interest Rate</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_DebitInstrumentPaymentinKindInterestRate" xlink:label="loc_alim_DebitInstrumentPaymentinKindInterestRate_A80ECCDD1B6E4852EF52D0A03D54C40D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_DebitInstrumentPaymentinKindInterestRate_A80ECCDD1B6E4852EF52D0A03D54C40D" xlink:to="lab_alim_DebitInstrumentPaymentinKindInterestRate_A80ECCDD1B6E4852EF52D0A03D54C40D" xlink:type="arc" />
    <link:label id="lab_alim_DebtInstrumentPaymentTermsNumberofPayments_E32862D8340405D3F198D0A03D54D9DC_terseLabel_en-US" xlink:label="lab_alim_DebtInstrumentPaymentTermsNumberofPayments_E32862D8340405D3F198D0A03D54D9DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of monthly payments</link:label>
    <link:label id="lab_alim_DebtInstrumentPaymentTermsNumberofPayments_E32862D8340405D3F198D0A03D54D9DC_label_en-US" xlink:label="lab_alim_DebtInstrumentPaymentTermsNumberofPayments_E32862D8340405D3F198D0A03D54D9DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Payment Terms, Number of Payments</link:label>
    <link:label id="lab_alim_DebtInstrumentPaymentTermsNumberofPayments_E32862D8340405D3F198D0A03D54D9DC_documentation_en-US" xlink:label="lab_alim_DebtInstrumentPaymentTermsNumberofPayments_E32862D8340405D3F198D0A03D54D9DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Payment Terms, Number of Payments</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentPaymentTermsNumberofPayments" xlink:label="loc_alim_DebtInstrumentPaymentTermsNumberofPayments_E32862D8340405D3F198D0A03D54D9DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_DebtInstrumentPaymentTermsNumberofPayments_E32862D8340405D3F198D0A03D54D9DC" xlink:to="lab_alim_DebtInstrumentPaymentTermsNumberofPayments_E32862D8340405D3F198D0A03D54D9DC" xlink:type="arc" />
    <link:label id="lab_alim_DebtInstrumentPrepaymentFeePercentageFirst12Months_5FAD954C2C3738CF9732D0A03D548D28_terseLabel_en-US" xlink:label="lab_alim_DebtInstrumentPrepaymentFeePercentageFirst12Months_5FAD954C2C3738CF9732D0A03D548D28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment Fee percentage within the first year</link:label>
    <link:label id="lab_alim_DebtInstrumentPrepaymentFeePercentageFirst12Months_5FAD954C2C3738CF9732D0A03D548D28_label_en-US" xlink:label="lab_alim_DebtInstrumentPrepaymentFeePercentageFirst12Months_5FAD954C2C3738CF9732D0A03D548D28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, First 12 Months</link:label>
    <link:label id="lab_alim_DebtInstrumentPrepaymentFeePercentageFirst12Months_5FAD954C2C3738CF9732D0A03D548D28_documentation_en-US" xlink:label="lab_alim_DebtInstrumentPrepaymentFeePercentageFirst12Months_5FAD954C2C3738CF9732D0A03D548D28" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, First 12 Months</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentPrepaymentFeePercentageFirst12Months" xlink:label="loc_alim_DebtInstrumentPrepaymentFeePercentageFirst12Months_5FAD954C2C3738CF9732D0A03D548D28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_DebtInstrumentPrepaymentFeePercentageFirst12Months_5FAD954C2C3738CF9732D0A03D548D28" xlink:to="lab_alim_DebtInstrumentPrepaymentFeePercentageFirst12Months_5FAD954C2C3738CF9732D0A03D548D28" xlink:type="arc" />
    <link:label id="lab_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months_4E6039E162F9E9F062EFD0A03D54C559_terseLabel_en-US" xlink:label="lab_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months_4E6039E162F9E9F062EFD0A03D54C559" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment fee percentage within the second year</link:label>
    <link:label id="lab_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months_4E6039E162F9E9F062EFD0A03D54C559_label_en-US" xlink:label="lab_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months_4E6039E162F9E9F062EFD0A03D54C559" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Greater than 12 Months, Less than 24 Months</link:label>
    <link:label id="lab_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months_4E6039E162F9E9F062EFD0A03D54C559_documentation_en-US" xlink:label="lab_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months_4E6039E162F9E9F062EFD0A03D54C559" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Greater than 12 Months, Less than 24 Months</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months" xlink:label="loc_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months_4E6039E162F9E9F062EFD0A03D54C559" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months_4E6039E162F9E9F062EFD0A03D54C559" xlink:to="lab_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months_4E6039E162F9E9F062EFD0A03D54C559" xlink:type="arc" />
    <link:label id="lab_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months_E59CE0128FCD2EECABAAD0A03D54CBA3_terseLabel_en-US" xlink:label="lab_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months_E59CE0128FCD2EECABAAD0A03D54CBA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment fee percentage after the second year</link:label>
    <link:label id="lab_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months_E59CE0128FCD2EECABAAD0A03D54CBA3_label_en-US" xlink:label="lab_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months_E59CE0128FCD2EECABAAD0A03D54CBA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Greater than 24 Months</link:label>
    <link:label id="lab_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months_E59CE0128FCD2EECABAAD0A03D54CBA3_documentation_en-US" xlink:label="lab_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months_E59CE0128FCD2EECABAAD0A03D54CBA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Greater than 24 Months</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months" xlink:label="loc_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months_E59CE0128FCD2EECABAAD0A03D54CBA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months_E59CE0128FCD2EECABAAD0A03D54CBA3" xlink:to="lab_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months_E59CE0128FCD2EECABAAD0A03D54CBA3" xlink:type="arc" />
    <link:label id="lab_alim_DebtInstrumentCovenantLiquidityThreshold_8E1D75E61EAF125CE022D0A03D546179_terseLabel_en-US" xlink:label="lab_alim_DebtInstrumentCovenantLiquidityThreshold_8E1D75E61EAF125CE022D0A03D546179" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt covenant liquidity threshold</link:label>
    <link:label id="lab_alim_DebtInstrumentCovenantLiquidityThreshold_8E1D75E61EAF125CE022D0A03D546179_label_en-US" xlink:label="lab_alim_DebtInstrumentCovenantLiquidityThreshold_8E1D75E61EAF125CE022D0A03D546179" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Threshold</link:label>
    <link:label id="lab_alim_DebtInstrumentCovenantLiquidityThreshold_8E1D75E61EAF125CE022D0A03D546179_documentation_en-US" xlink:label="lab_alim_DebtInstrumentCovenantLiquidityThreshold_8E1D75E61EAF125CE022D0A03D546179" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Threshold</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentCovenantLiquidityThreshold" xlink:label="loc_alim_DebtInstrumentCovenantLiquidityThreshold_8E1D75E61EAF125CE022D0A03D546179" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_DebtInstrumentCovenantLiquidityThreshold_8E1D75E61EAF125CE022D0A03D546179" xlink:to="lab_alim_DebtInstrumentCovenantLiquidityThreshold_8E1D75E61EAF125CE022D0A03D546179" xlink:type="arc" />
    <link:label id="lab_alim_DebtInstrumentCovenantCurrentLiquidity_EB5259E9BE3A10700668D0A03D549ED2_terseLabel_en-US" xlink:label="lab_alim_DebtInstrumentCovenantCurrentLiquidity_EB5259E9BE3A10700668D0A03D549ED2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liquidity per covenant</link:label>
    <link:label id="lab_alim_DebtInstrumentCovenantCurrentLiquidity_EB5259E9BE3A10700668D0A03D549ED2_label_en-US" xlink:label="lab_alim_DebtInstrumentCovenantCurrentLiquidity_EB5259E9BE3A10700668D0A03D549ED2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Current Liquidity</link:label>
    <link:label id="lab_alim_DebtInstrumentCovenantCurrentLiquidity_EB5259E9BE3A10700668D0A03D549ED2_documentation_en-US" xlink:label="lab_alim_DebtInstrumentCovenantCurrentLiquidity_EB5259E9BE3A10700668D0A03D549ED2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Current Total Liquidity</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentCovenantCurrentLiquidity" xlink:label="loc_alim_DebtInstrumentCovenantCurrentLiquidity_EB5259E9BE3A10700668D0A03D549ED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_DebtInstrumentCovenantCurrentLiquidity_EB5259E9BE3A10700668D0A03D549ED2" xlink:to="lab_alim_DebtInstrumentCovenantCurrentLiquidity_EB5259E9BE3A10700668D0A03D549ED2" xlink:type="arc" />
    <link:label id="lab_alim_DebtInstrumentCovenantLiquidityRelatedtoCashandCashEquivalents_CBC6955F23035D086FACD0A03D54BD15_terseLabel_en-US" xlink:label="lab_alim_DebtInstrumentCovenantLiquidityRelatedtoCashandCashEquivalents_CBC6955F23035D086FACD0A03D54BD15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current cash and cash equivalents liquidity per covenant</link:label>
    <link:label id="lab_alim_DebtInstrumentCovenantLiquidityRelatedtoCashandCashEquivalents_CBC6955F23035D086FACD0A03D54BD15_label_en-US" xlink:label="lab_alim_DebtInstrumentCovenantLiquidityRelatedtoCashandCashEquivalents_CBC6955F23035D086FACD0A03D54BD15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Related to Cash and Cash Equivalents</link:label>
    <link:label id="lab_alim_DebtInstrumentCovenantLiquidityRelatedtoCashandCashEquivalents_CBC6955F23035D086FACD0A03D54BD15_documentation_en-US" xlink:label="lab_alim_DebtInstrumentCovenantLiquidityRelatedtoCashandCashEquivalents_CBC6955F23035D086FACD0A03D54BD15" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Related to Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentCovenantLiquidityRelatedtoCashandCashEquivalents" xlink:label="loc_alim_DebtInstrumentCovenantLiquidityRelatedtoCashandCashEquivalents_CBC6955F23035D086FACD0A03D54BD15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_DebtInstrumentCovenantLiquidityRelatedtoCashandCashEquivalents_CBC6955F23035D086FACD0A03D54BD15" xlink:to="lab_alim_DebtInstrumentCovenantLiquidityRelatedtoCashandCashEquivalents_CBC6955F23035D086FACD0A03D54BD15" xlink:type="arc" />
    <link:label id="lab_alim_DebtInstrumentCovenantLiquidityRelatedtoAccountsReceivable_17C011E8AED3A6B173BFD0A03D548DEA_terseLabel_en-US" xlink:label="lab_alim_DebtInstrumentCovenantLiquidityRelatedtoAccountsReceivable_17C011E8AED3A6B173BFD0A03D548DEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current accounts receivable liquidity per covenant</link:label>
    <link:label id="lab_alim_DebtInstrumentCovenantLiquidityRelatedtoAccountsReceivable_17C011E8AED3A6B173BFD0A03D548DEA_label_en-US" xlink:label="lab_alim_DebtInstrumentCovenantLiquidityRelatedtoAccountsReceivable_17C011E8AED3A6B173BFD0A03D548DEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Related to Accounts Receivable</link:label>
    <link:label id="lab_alim_DebtInstrumentCovenantLiquidityRelatedtoAccountsReceivable_17C011E8AED3A6B173BFD0A03D548DEA_documentation_en-US" xlink:label="lab_alim_DebtInstrumentCovenantLiquidityRelatedtoAccountsReceivable_17C011E8AED3A6B173BFD0A03D548DEA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Related to Accounts Receivable</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentCovenantLiquidityRelatedtoAccountsReceivable" xlink:label="loc_alim_DebtInstrumentCovenantLiquidityRelatedtoAccountsReceivable_17C011E8AED3A6B173BFD0A03D548DEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_DebtInstrumentCovenantLiquidityRelatedtoAccountsReceivable_17C011E8AED3A6B173BFD0A03D548DEA" xlink:to="lab_alim_DebtInstrumentCovenantLiquidityRelatedtoAccountsReceivable_17C011E8AED3A6B173BFD0A03D548DEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FEA6E40C2D7975FD43A6D0A03D545303_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FEA6E40C2D7975FD43A6D0A03D545303" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares called by warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FEA6E40C2D7975FD43A6D0A03D545303_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FEA6E40C2D7975FD43A6D0A03D545303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FEA6E40C2D7975FD43A6D0A03D545303" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FEA6E40C2D7975FD43A6D0A03D545303" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FEA6E40C2D7975FD43A6D0A03D545303" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3FE461D56301EA11092BD0A03D54D500_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3FE461D56301EA11092BD0A03D54D500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price on warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3FE461D56301EA11092BD0A03D54D500_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3FE461D56301EA11092BD0A03D54D500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3FE461D56301EA11092BD0A03D54D500" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3FE461D56301EA11092BD0A03D54D500" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3FE461D56301EA11092BD0A03D54D500" xlink:type="arc" />
    <link:label id="lab_alim_ClassofWarrantorRightExercisablePercentage_04890CAE64872BB9B068D0A03D54C696_terseLabel_en-US" xlink:label="lab_alim_ClassofWarrantorRightExercisablePercentage_04890CAE64872BB9B068D0A03D54C696" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercisable (percent)</link:label>
    <link:label id="lab_alim_ClassofWarrantorRightExercisablePercentage_04890CAE64872BB9B068D0A03D54C696_label_en-US" xlink:label="lab_alim_ClassofWarrantorRightExercisablePercentage_04890CAE64872BB9B068D0A03D54C696" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercisable, Percentage</link:label>
    <link:label id="lab_alim_ClassofWarrantorRightExercisablePercentage_04890CAE64872BB9B068D0A03D54C696_documentation_en-US" xlink:label="lab_alim_ClassofWarrantorRightExercisablePercentage_04890CAE64872BB9B068D0A03D54C696" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercisable, Percentage</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_ClassofWarrantorRightExercisablePercentage" xlink:label="loc_alim_ClassofWarrantorRightExercisablePercentage_04890CAE64872BB9B068D0A03D54C696" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_ClassofWarrantorRightExercisablePercentage_04890CAE64872BB9B068D0A03D54C696" xlink:to="lab_alim_ClassofWarrantorRightExercisablePercentage_04890CAE64872BB9B068D0A03D54C696" xlink:type="arc" />
    <link:label id="lab_alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage_E606938B4C18AE34F676D0A03D54CF1C_terseLabel_en-US" xlink:label="lab_alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage_E606938B4C18AE34F676D0A03D54CF1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants that will become exercisable upon obtaining additional financing amount (percent)</link:label>
    <link:label id="lab_alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage_E606938B4C18AE34F676D0A03D54CF1C_label_en-US" xlink:label="lab_alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage_E606938B4C18AE34F676D0A03D54CF1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercisable Upon Satisfying Certain Conditions, Percentage</link:label>
    <link:label id="lab_alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage_E606938B4C18AE34F676D0A03D54CF1C_documentation_en-US" xlink:label="lab_alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage_E606938B4C18AE34F676D0A03D54CF1C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercisable Upon Satisfying Certain Conditions, Percentage</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage" xlink:label="loc_alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage_E606938B4C18AE34F676D0A03D54CF1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage_E606938B4C18AE34F676D0A03D54CF1C" xlink:to="lab_alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage_E606938B4C18AE34F676D0A03D54CF1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_DFD79479C0F99D74298548DE132908F5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_DFD79479C0F99D74298548DE132908F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_DFD79479C0F99D74298548DE132908F5_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_DFD79479C0F99D74298548DE132908F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_DFD79479C0F99D74298548DE132908F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_DFD79479C0F99D74298548DE132908F5" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_DFD79479C0F99D74298548DE132908F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_580B53CB8223994B766A48DE13814C3A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_580B53CB8223994B766A48DE13814C3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_580B53CB8223994B766A48DE13814C3A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_580B53CB8223994B766A48DE13814C3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_580B53CB8223994B766A48DE13814C3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_580B53CB8223994B766A48DE13814C3A" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_580B53CB8223994B766A48DE13814C3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8BB437A3371E225BEF148DE13811963_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8BB437A3371E225BEF148DE13811963" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8BB437A3371E225BEF148DE13811963_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8BB437A3371E225BEF148DE13811963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8BB437A3371E225BEF148DE13811963" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8BB437A3371E225BEF148DE13811963" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8BB437A3371E225BEF148DE13811963" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:type="arc" />
    <link:label id="lab_alim_PreferredStockWarrantsMember_DB59C729E4008AEBA9BD48DE13825A03_terseLabel_en-US" xlink:label="lab_alim_PreferredStockWarrantsMember_DB59C729E4008AEBA9BD48DE13825A03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A convertible preferred stock warrants</link:label>
    <link:label id="lab_alim_PreferredStockWarrantsMember_DB59C729E4008AEBA9BD48DE13825A03_label_en-US" xlink:label="lab_alim_PreferredStockWarrantsMember_DB59C729E4008AEBA9BD48DE13825A03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Warrants [Member]</link:label>
    <link:label id="lab_alim_PreferredStockWarrantsMember_DB59C729E4008AEBA9BD48DE13825A03_documentation_en-US" xlink:label="lab_alim_PreferredStockWarrantsMember_DB59C729E4008AEBA9BD48DE13825A03" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock Warrants [Member]</link:label>
    <link:loc xlink:href="alim-20170331.xsd#alim_PreferredStockWarrantsMember" xlink:label="loc_alim_PreferredStockWarrantsMember_DB59C729E4008AEBA9BD48DE13825A03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alim_PreferredStockWarrantsMember_DB59C729E4008AEBA9BD48DE13825A03" xlink:to="lab_alim_PreferredStockWarrantsMember_DB59C729E4008AEBA9BD48DE13825A03" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_28D77D558F211EB9159348DE1382ABCD_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_28D77D558F211EB9159348DE1382ABCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_28D77D558F211EB9159348DE1382ABCD_label_en-US" xlink:label="lab_us-gaap_WarrantMember_28D77D558F211EB9159348DE1382ABCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_28D77D558F211EB9159348DE1382ABCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_28D77D558F211EB9159348DE1382ABCD" xlink:to="lab_us-gaap_WarrantMember_28D77D558F211EB9159348DE1382ABCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E78E48379702E2F2436B48DE13824676_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E78E48379702E2F2436B48DE13824676" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E78E48379702E2F2436B48DE13824676_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E78E48379702E2F2436B48DE13824676" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E78E48379702E2F2436B48DE13824676" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E78E48379702E2F2436B48DE13824676" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E78E48379702E2F2436B48DE13824676" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3B9CF70C3E363066E93048DE138264F8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3B9CF70C3E363066E93048DE138264F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3B9CF70C3E363066E93048DE138264F8_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3B9CF70C3E363066E93048DE138264F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3B9CF70C3E363066E93048DE138264F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3B9CF70C3E363066E93048DE138264F8" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3B9CF70C3E363066E93048DE138264F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_B37FA5EC977502B8E9A7B015E399CEBE_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_B37FA5EC977502B8E9A7B015E399CEBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_B37FA5EC977502B8E9A7B015E399CEBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_B37FA5EC977502B8E9A7B015E399CEBE" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_B37FA5EC977502B8E9A7B015E399CEBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2E6B9BAA48E03997AF2CB015E399DEA2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2E6B9BAA48E03997AF2CB015E399DEA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2E6B9BAA48E03997AF2CB015E399DEA2_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2E6B9BAA48E03997AF2CB015E399DEA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2E6B9BAA48E03997AF2CB015E399DEA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2E6B9BAA48E03997AF2CB015E399DEA2" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2E6B9BAA48E03997AF2CB015E399DEA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F4A81FE91F060E0920C8B015E399F567_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F4A81FE91F060E0920C8B015E399F567" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F4A81FE91F060E0920C8B015E399F567_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F4A81FE91F060E0920C8B015E399F567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F4A81FE91F060E0920C8B015E399F567" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F4A81FE91F060E0920C8B015E399F567" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F4A81FE91F060E0920C8B015E399F567" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C6E9AAF9EEDDCB9F18C2B015E3993760_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C6E9AAF9EEDDCB9F18C2B015E3993760" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C6E9AAF9EEDDCB9F18C2B015E3993760_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C6E9AAF9EEDDCB9F18C2B015E3993760" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C6E9AAF9EEDDCB9F18C2B015E3993760" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C6E9AAF9EEDDCB9F18C2B015E3993760" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C6E9AAF9EEDDCB9F18C2B015E3993760" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_32A7E106A5E132F44B74B015E399646C_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_32A7E106A5E132F44B74B015E399646C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_32A7E106A5E132F44B74B015E399646C_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_32A7E106A5E132F44B74B015E399646C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_32A7E106A5E132F44B74B015E399646C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_32A7E106A5E132F44B74B015E399646C" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_32A7E106A5E132F44B74B015E399646C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ECDADBCD13F3CF488DDEB015E39A1872_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ECDADBCD13F3CF488DDEB015E39A1872" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ECDADBCD13F3CF488DDEB015E39A1872_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ECDADBCD13F3CF488DDEB015E39A1872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ECDADBCD13F3CF488DDEB015E39A1872" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ECDADBCD13F3CF488DDEB015E39A1872" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ECDADBCD13F3CF488DDEB015E39A1872" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_491A73D7283CA274BAC2B015E39A2CC1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_491A73D7283CA274BAC2B015E39A2CC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_491A73D7283CA274BAC2B015E39A2CC1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_491A73D7283CA274BAC2B015E39A2CC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_491A73D7283CA274BAC2B015E39A2CC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_491A73D7283CA274BAC2B015E39A2CC1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_491A73D7283CA274BAC2B015E39A2CC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_72CD7353D600253F1FDAB015E39A9D16_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_72CD7353D600253F1FDAB015E39A9D16" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_72CD7353D600253F1FDAB015E39A9D16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_72CD7353D600253F1FDAB015E39A9D16" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_72CD7353D600253F1FDAB015E39A9D16" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0B3D8EB31750282EEC1F48DE1326720E_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0B3D8EB31750282EEC1F48DE1326720E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0B3D8EB31750282EEC1F48DE1326720E_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0B3D8EB31750282EEC1F48DE1326720E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0B3D8EB31750282EEC1F48DE1326720E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0B3D8EB31750282EEC1F48DE1326720E" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0B3D8EB31750282EEC1F48DE1326720E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_367F3E2EF9545FAB85E848DE13269E89_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_367F3E2EF9545FAB85E848DE13269E89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_367F3E2EF9545FAB85E848DE13269E89_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_367F3E2EF9545FAB85E848DE13269E89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_367F3E2EF9545FAB85E848DE13269E89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_367F3E2EF9545FAB85E848DE13269E89" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_367F3E2EF9545FAB85E848DE13269E89" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_063BAE6AFF7355FCC74348DE13263EDD_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue_063BAE6AFF7355FCC74348DE13263EDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, liquidation preference</link:label>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_063BAE6AFF7355FCC74348DE13263EDD_label_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue_063BAE6AFF7355FCC74348DE13263EDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_063BAE6AFF7355FCC74348DE13263EDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue_063BAE6AFF7355FCC74348DE13263EDD" xlink:to="lab_us-gaap_PreferredStockLiquidationPreferenceValue_063BAE6AFF7355FCC74348DE13263EDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_06D2ACE9BEA2D36317EB48DE13268E83_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_06D2ACE9BEA2D36317EB48DE13268E83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_06D2ACE9BEA2D36317EB48DE13268E83_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_06D2ACE9BEA2D36317EB48DE13268E83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_06D2ACE9BEA2D36317EB48DE13268E83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_06D2ACE9BEA2D36317EB48DE13268E83" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_06D2ACE9BEA2D36317EB48DE13268E83" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0A7D76D2FA16AF3B261748DE13275DC6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0A7D76D2FA16AF3B261748DE13275DC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0A7D76D2FA16AF3B261748DE13275DC6_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0A7D76D2FA16AF3B261748DE13275DC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0A7D76D2FA16AF3B261748DE13275DC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_0A7D76D2FA16AF3B261748DE13275DC6" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0A7D76D2FA16AF3B261748DE13275DC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_A6EA0FC6771517B0BC7548DE1327E78B_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_A6EA0FC6771517B0BC7548DE1327E78B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_A6EA0FC6771517B0BC7548DE1327E78B_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_A6EA0FC6771517B0BC7548DE1327E78B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_A6EA0FC6771517B0BC7548DE1327E78B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_A6EA0FC6771517B0BC7548DE1327E78B" xlink:to="lab_us-gaap_CommonStockSharesIssued_A6EA0FC6771517B0BC7548DE1327E78B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_92386473E92EC0F4BDE148DE132733F3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_92386473E92EC0F4BDE148DE132733F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_92386473E92EC0F4BDE148DE132733F3_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_92386473E92EC0F4BDE148DE132733F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_92386473E92EC0F4BDE148DE132733F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_92386473E92EC0F4BDE148DE132733F3" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_92386473E92EC0F4BDE148DE132733F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_02A54739B50583519CE36CED8C368D1E_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_02A54739B50583519CE36CED8C368D1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Accounting</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_02A54739B50583519CE36CED8C368D1E_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_02A54739B50583519CE36CED8C368D1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_02A54739B50583519CE36CED8C368D1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_02A54739B50583519CE36CED8C368D1E" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_02A54739B50583519CE36CED8C368D1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfOperations_A542D19F5D3F6ACF0BF448DE135E4D55_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations_A542D19F5D3F6ACF0BF448DE135E4D55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_A542D19F5D3F6ACF0BF448DE135E4D55_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations_A542D19F5D3F6ACF0BF448DE135E4D55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_A542D19F5D3F6ACF0BF448DE135E4D55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_A542D19F5D3F6ACF0BF448DE135E4D55" xlink:to="lab_us-gaap_NatureOfOperations_A542D19F5D3F6ACF0BF448DE135E4D55" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>alim-20170331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.alimerasciences.com/role/AccruedExpenses" xlink:href="alim-20170331.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" xlink:href="alim-20170331.xsd#AccruedExpensesSummaryOfAccruedExpensesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/AccruedExpensesTables" xlink:href="alim-20170331.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/BasisOfPresentation" xlink:href="alim-20170331.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/BasisOfPresentationBasisOfPresentationPolicies" xlink:href="alim-20170331.xsd#BasisOfPresentationBasisOfPresentationPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/BasisOfPresentationNarrativeDetails" xlink:href="alim-20170331.xsd#BasisOfPresentationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/CommonStock" xlink:href="alim-20170331.xsd#CommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/CommonStockDetail" xlink:href="alim-20170331.xsd#CommonStockDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/ConsolidatedBalanceSheets" xlink:href="alim-20170331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="alim-20170331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="alim-20170331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="alim-20170331.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/ConsolidatedStatementsOfOperations" xlink:href="alim-20170331.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/DocumentAndEntityInformation" xlink:href="alim-20170331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/FairValue" xlink:href="alim-20170331.xsd#FairValue" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/FairValueDetail" xlink:href="alim-20170331.xsd#FairValueDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/FairValueTables" xlink:href="alim-20170331.xsd#FairValueTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/GoingConcern" xlink:href="alim-20170331.xsd#GoingConcern" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/GoingConcernDetail" xlink:href="alim-20170331.xsd#GoingConcernDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/IncomeTaxes" xlink:href="alim-20170331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/IncomeTaxesDetail" xlink:href="alim-20170331.xsd#IncomeTaxesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/IntangibleAsset" xlink:href="alim-20170331.xsd#IntangibleAsset" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/IntangibleAssetFutureAmortizationDetails" xlink:href="alim-20170331.xsd#IntangibleAssetFutureAmortizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/IntangibleAssetNarrativeDetails" xlink:href="alim-20170331.xsd#IntangibleAssetNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/IntangibleAssetTables" xlink:href="alim-20170331.xsd#IntangibleAssetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/Inventory" xlink:href="alim-20170331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/InventoryDetail" xlink:href="alim-20170331.xsd#InventoryDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/InventoryTables" xlink:href="alim-20170331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LicenseAgreements" xlink:href="alim-20170331.xsd#LicenseAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LicenseAgreementsDetail" xlink:href="alim-20170331.xsd#LicenseAgreementsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LoanAgreements" xlink:href="alim-20170331.xsd#LoanAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LoanAgreementsDetail" xlink:href="alim-20170331.xsd#LoanAgreementsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LossPerShareEps" xlink:href="alim-20170331.xsd#LossPerShareEps" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LossPerShareEpsAntidilutiveSecuritiesExcludedDetail" xlink:href="alim-20170331.xsd#LossPerShareEpsAntidilutiveSecuritiesExcludedDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/LossPerShareEpsTables" xlink:href="alim-20170331.xsd#LossPerShareEpsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/NatureOfOperations" xlink:href="alim-20170331.xsd#NatureOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/NatureOfOperationsDetail" xlink:href="alim-20170331.xsd#NatureOfOperationsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/PreferredStock" xlink:href="alim-20170331.xsd#PreferredStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/PreferredStockDetail" xlink:href="alim-20170331.xsd#PreferredStockDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SegmentInformation" xlink:href="alim-20170331.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SegmentInformationDetails" xlink:href="alim-20170331.xsd#SegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SegmentInformationTables" xlink:href="alim-20170331.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/StockIncentivePlans" xlink:href="alim-20170331.xsd#StockIncentivePlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/StockIncentivePlansAdditionalInformationDetail" xlink:href="alim-20170331.xsd#StockIncentivePlansAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/StockIncentivePlansAdditionalStockOptionTransactionsDetail" xlink:href="alim-20170331.xsd#StockIncentivePlansAdditionalStockOptionTransactionsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/StockIncentivePlansSummaryOfStockOptionTransactionsDetail" xlink:href="alim-20170331.xsd#StockIncentivePlansSummaryOfStockOptionTransactionsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/StockIncentivePlansTables" xlink:href="alim-20170331.xsd#StockIncentivePlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SubsequentEventNotes" xlink:href="alim-20170331.xsd#SubsequentEventNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="alim-20170331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="alim-20170331.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="alim-20170331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_7BFE4C82965647784D2548DE13295CA9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_DFD79479C0F99D74298548DE132908F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7BFE4C82965647784D2548DE13295CA9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_DFD79479C0F99D74298548DE132908F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_A8FC5886213B95B0C645B015E3811079" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_C812844033F08553D3FDB015E3812329" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_A8FC5886213B95B0C645B015E3811079" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_C812844033F08553D3FDB015E3812329" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_AccruedClinicalInvestigatorExpenses" xlink:label="loc_alim_AccruedClinicalInvestigatorExpenses_E45A66C1BFD38F349D1CB015E381D984" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_C812844033F08553D3FDB015E3812329" xlink:to="loc_alim_AccruedClinicalInvestigatorExpenses_E45A66C1BFD38F349D1CB015E381D984" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_A98FC0ED905B250C1C85B015E381CF1F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_C812844033F08553D3FDB015E3812329" xlink:to="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_A98FC0ED905B250C1C85B015E381CF1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_B7F5AFA95F05A49F7C1EB015E381B32A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_C812844033F08553D3FDB015E3812329" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_B7F5AFA95F05A49F7C1EB015E381B32A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2363D34593402E1B0E5EB015E3819F22" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_C812844033F08553D3FDB015E3812329" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2363D34593402E1B0E5EB015E3819F22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_207B10ADD14B7027D08FB015E3812639" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_C812844033F08553D3FDB015E3812329" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_207B10ADD14B7027D08FB015E3812639" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_613EAEDDD24E8084EE0948DE131C9A71" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8D0704EDE7AA5E84496248DE131D59FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_613EAEDDD24E8084EE0948DE131C9A71" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8D0704EDE7AA5E84496248DE131D59FD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/BasisOfPresentation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87DF9C2C8ED85127F3B048DE13125753" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaap_BasisOfAccounting_E9968E6FCB9C9D64E7CD48DE13131864" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87DF9C2C8ED85127F3B048DE13125753" xlink:to="loc_us-gaap_BasisOfAccounting_E9968E6FCB9C9D64E7CD48DE13131864" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/BasisOfPresentationBasisOfPresentationPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AEF88E38A68EA692B2E86CED8C33E096" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_02A54739B50583519CE36CED8C368D1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AEF88E38A68EA692B2E86CED8C33E096" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_02A54739B50583519CE36CED8C368D1E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/BasisOfPresentationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4E79C583388522ED0AC9F44BE344C234" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_12289C935F67E616ACD2F45222116990" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4E79C583388522ED0AC9F44BE344C234" xlink:to="loc_us-gaap_ShareBasedCompensation_12289C935F67E616ACD2F45222116990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_B9098408E43C43712D0AF44BE344EA8F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4E79C583388522ED0AC9F44BE344C234" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_B9098408E43C43712D0AF44BE344EA8F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_39DA93292F33AB77912148DE1378B34F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B23B01F065DF26BEE1E948DE1378456F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_39DA93292F33AB77912148DE1378B34F" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B23B01F065DF26BEE1E948DE1378456F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/CommonStockDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_A6D55004676ABF9D63C2E8B8825DF0D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_924534266FA28A16450CE8B8825E06E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_A6D55004676ABF9D63C2E8B8825DF0D8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_924534266FA28A16450CE8B8825E06E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2FC5FEBDB0C7DEE4E447E8B8825E2589" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_924534266FA28A16450CE8B8825E06E3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2FC5FEBDB0C7DEE4E447E8B8825E2589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E41628A22DED3B99C5BBE8B8825E7393" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2FC5FEBDB0C7DEE4E447E8B8825E2589" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E41628A22DED3B99C5BBE8B8825E7393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_5F58BB967C4C772EE7BDE8B8825ED1F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E41628A22DED3B99C5BBE8B8825E7393" xlink:to="loc_us-gaap_PrivatePlacementMember_5F58BB967C4C772EE7BDE8B8825ED1F8" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_PublicOfferingMember" xlink:label="loc_alim_PublicOfferingMember_CD8B28925474C539DF9BE8BE3EFC923B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E41628A22DED3B99C5BBE8B8825E7393" xlink:to="loc_alim_PublicOfferingMember_CD8B28925474C539DF9BE8BE3EFC923B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A9D62954C8FA4E265D29E8B8825E7BA9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_924534266FA28A16450CE8B8825E06E3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A9D62954C8FA4E265D29E8B8825E7BA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5E6FEFDDBCE4E0791FBEE8B8825E4B7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A9D62954C8FA4E265D29E8B8825E7BA9" xlink:to="loc_us-gaap_ClassOfStockDomain_5E6FEFDDBCE4E0791FBEE8B8825E4B7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_ECFC23A6CB36F4E5E874E8B8825EA745" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5E6FEFDDBCE4E0791FBEE8B8825E4B7C" xlink:to="loc_us-gaap_CommonStockMember_ECFC23A6CB36F4E5E874E8B8825EA745" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_924534266FA28A16450CE8B8825E06E3" xlink:to="loc_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_CommonStocktobeIssuedValueMaximum" xlink:label="loc_alim_CommonStocktobeIssuedValueMaximum_16058BB4D6E58863A3D2E8B8825E7BB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:to="loc_alim_CommonStocktobeIssuedValueMaximum_16058BB4D6E58863A3D2E8B8825E7BB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E1098E0A5A2B152DF046E8B8825E6923" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E1098E0A5A2B152DF046E8B8825E6923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_37B433083D9A1BACA918E8B8825E18A8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_37B433083D9A1BACA918E8B8825E18A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6B66E2794F48CE927F14E8B8825E73FD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6B66E2794F48CE927F14E8B8825E73FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_256BE2E5843EE1FD1160E8B8825E52AD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_686DE283FE33970E76BEE8B8825E2F0A" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_256BE2E5843EE1FD1160E8B8825E52AD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_493CB2EBE6CA5C490573C9CD1C929E18" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_8DDAAB2A2DCF1B756AE5C9CD1C9208F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_493CB2EBE6CA5C490573C9CD1C929E18" xlink:to="loc_us-gaap_StatementTable_8DDAAB2A2DCF1B756AE5C9CD1C9208F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1203FAE5B547EF230F4AC9CD1C9254DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8DDAAB2A2DCF1B756AE5C9CD1C9208F3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1203FAE5B547EF230F4AC9CD1C9254DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3DB7DF2CFB13066EB004C9CD1C92FBDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1203FAE5B547EF230F4AC9CD1C9254DD" xlink:to="loc_us-gaap_ClassOfStockDomain_3DB7DF2CFB13066EB004C9CD1C92FBDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_897A7AE7CABF415085FDC9CD1C92B3FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3DB7DF2CFB13066EB004C9CD1C92FBDC" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_897A7AE7CABF415085FDC9CD1C92B3FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_2C321560D3D515DAFB24C9CD1C92E39B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3DB7DF2CFB13066EB004C9CD1C92FBDC" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_2C321560D3D515DAFB24C9CD1C92E39B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8DDAAB2A2DCF1B756AE5C9CD1C9208F3" xlink:to="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C12A021F10009024D4E7C9CD1C92D3C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C12A021F10009024D4E7C9CD1C92D3C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_CDC56721589EC5C72A0FC9CD1C921905" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_CDC56721589EC5C72A0FC9CD1C921905" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_896BFCF723EDC4C33220C9CD1C92BAB5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_896BFCF723EDC4C33220C9CD1C92BAB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4203033638040A923828C9CD1C92EDCF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4203033638040A923828C9CD1C92EDCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_8B0B9687FC66722908D8C9CD1C929150" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:to="loc_us-gaap_InventoryNet_8B0B9687FC66722908D8C9CD1C929150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_BB394E1C58DA36EF63FDC9CD1C926703" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0B5B7DB9909073C9F511C9CD1C927CF0" xlink:to="loc_us-gaap_AssetsCurrent_BB394E1C58DA36EF63FDC9CD1C926703" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8AA29E37755CE9BE5F0FC9CD1C92D3C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8AA29E37755CE9BE5F0FC9CD1C92D3C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1473D06CF139A820CA1CC9CD1C925E98" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1473D06CF139A820CA1CC9CD1C925E98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_91D6D0B1C60D17907B78C9CD1C924D6D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_91D6D0B1C60D17907B78C9CD1C924D6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_DF2D5EF62413BACE7D98C9CD1C92BDE4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_Assets_DF2D5EF62413BACE7D98C9CD1C92BDE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_185B9680717D7C84C637C9CD1C9291F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:to="loc_us-gaap_AccountsPayableCurrent_185B9680717D7C84C637C9CD1C9291F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_A43972AFA28B71203473C9CD1C92D600" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_A43972AFA28B71203473C9CD1C92D600" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_0F4834DA9D267A52E4E8C9CD1C928BBD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_0F4834DA9D267A52E4E8C9CD1C928BBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_3C19B4BBE77D52048AD8C9CD1C92CA72" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_3C19B4BBE77D52048AD8C9CD1C92CA72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_D67C531D6B133ADE373BC9CD1C92A23E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75E214B721952E815D07C9CD1C921FAA" xlink:to="loc_us-gaap_LiabilitiesCurrent_D67C531D6B133ADE373BC9CD1C92A23E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_811AAA277DA6C5D75974C9CD1C927E2C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_811AAA277DA6C5D75974C9CD1C927E2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_E075D58C5268F747DD13C9CD1C921C81" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_811AAA277DA6C5D75974C9CD1C927E2C" xlink:to="loc_us-gaap_LongTermNotesPayable_E075D58C5268F747DD13C9CD1C921C81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent_22A5C3F34D5AE574175FC9CD1C92A9ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_811AAA277DA6C5D75974C9CD1C927E2C" xlink:to="loc_us-gaap_CapitalLeaseObligationsNoncurrent_22A5C3F34D5AE574175FC9CD1C92A9ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_C7D8BAE11C3D9B3EAFFDC9CD1C92FC3A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_811AAA277DA6C5D75974C9CD1C927E2C" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_C7D8BAE11C3D9B3EAFFDC9CD1C92FC3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0055424628E42D295352C9CD1C9245AF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0055424628E42D295352C9CD1C9245AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_2EB4B74630F7B2F3F156C9CD1C9253ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:to="loc_us-gaap_PreferredStockValue_2EB4B74630F7B2F3F156C9CD1C9253ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_939E4A4BAF27B68E8120C9CD1C92C4DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:to="loc_us-gaap_CommonStockValue_939E4A4BAF27B68E8120C9CD1C92C4DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_F8EC311D9D4637606637C9CD1C92824C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_F8EC311D9D4637606637C9CD1C92824C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_A701D0532A4CDE88A3DCC9CD1C924E41" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_A701D0532A4CDE88A3DCC9CD1C924E41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_446CB8BB3CCBE395BA12C9CD1C92EDCE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_446CB8BB3CCBE395BA12C9CD1C92EDCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6D41AFB0FBCD18321B0C9CD1C92A7AB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6D41AFB0FBCD18321B0C9CD1C92A7AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_24A9C75B810ECC42CCE1C9CD1C92E8DA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_67232A65A7C3BF916E31C9CD1C92F1DF" xlink:to="loc_us-gaap_StockholdersEquity_24A9C75B810ECC42CCE1C9CD1C92E8DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_775CC71950C7F6D132C6C9CD1C923CA4" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_47291FAA5DCF1339B7A7C9CD1C929E27" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_775CC71950C7F6D132C6C9CD1C923CA4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5FB7934C2CE8FF4EAACF48DE1325ECE1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_5910B0A397DA4AE7375F48DE132671F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5FB7934C2CE8FF4EAACF48DE1325ECE1" xlink:to="loc_us-gaap_StatementTable_5910B0A397DA4AE7375F48DE132671F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6AFA87215D5F7C60CB3448DE1326E3E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5910B0A397DA4AE7375F48DE132671F7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6AFA87215D5F7C60CB3448DE1326E3E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A1B3F748D0B02C8C40D348DE13263FE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6AFA87215D5F7C60CB3448DE1326E3E0" xlink:to="loc_us-gaap_ClassOfStockDomain_A1B3F748D0B02C8C40D348DE13263FE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_637F1D73D49D74EA962748DE1326259E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A1B3F748D0B02C8C40D348DE13263FE8" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_637F1D73D49D74EA962748DE1326259E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_DB209E78A51BE82D7B1E48DE1326169A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A1B3F748D0B02C8C40D348DE13263FE8" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_DB209E78A51BE82D7B1E48DE1326169A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5910B0A397DA4AE7375F48DE132671F7" xlink:to="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0B3D8EB31750282EEC1F48DE1326720E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0B3D8EB31750282EEC1F48DE1326720E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_367F3E2EF9545FAB85E848DE13269E89" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_367F3E2EF9545FAB85E848DE13269E89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_FD40DA17FA6BA964985B48DE13260523" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_PreferredStockSharesIssued_FD40DA17FA6BA964985B48DE13260523" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_634F25A30D684335305E48DE13269265" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_634F25A30D684335305E48DE13269265" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_063BAE6AFF7355FCC74348DE13263EDD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_063BAE6AFF7355FCC74348DE13263EDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_06D2ACE9BEA2D36317EB48DE13268E83" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_06D2ACE9BEA2D36317EB48DE13268E83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0A7D76D2FA16AF3B261748DE13275DC6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0A7D76D2FA16AF3B261748DE13275DC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_A6EA0FC6771517B0BC7548DE1327E78B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_CommonStockSharesIssued_A6EA0FC6771517B0BC7548DE1327E78B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_92386473E92EC0F4BDE148DE132733F3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74AEDBA49417B90A3CB648DE132697CF" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_92386473E92EC0F4BDE148DE132733F3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_537606A283D0C2789C5AB015E410D077" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_71760BD14BF7B42C269BB015E4106C52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_537606A283D0C2789C5AB015E410D077" xlink:to="loc_us-gaap_PaymentsOfDividends_71760BD14BF7B42C269BB015E4106C52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_71C37644C45C6AB32DA4B015E4109EEA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_537606A283D0C2789C5AB015E410D077" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_71C37644C45C6AB32DA4B015E4109EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6E14421942154D9D1FF9B015E4103CEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_71C37644C45C6AB32DA4B015E4109EEA" xlink:to="loc_us-gaap_NetIncomeLoss_6E14421942154D9D1FF9B015E4103CEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C2081F4AED99449D07E3B015E41079A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_71C37644C45C6AB32DA4B015E4109EEA" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C2081F4AED99449D07E3B015E41079A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1CF9B687D6C3A6069106B015E4106C86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C2081F4AED99449D07E3B015E41079A5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1CF9B687D6C3A6069106B015E4106C86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_73EEFD1B47D15588FC6BB015E41098DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C2081F4AED99449D07E3B015E41079A5" xlink:to="loc_us-gaap_InventoryWriteDown_73EEFD1B47D15588FC6BB015E41098DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_D28A55B7E55F8F96AAF7B015E410B633" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C2081F4AED99449D07E3B015E41079A5" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_D28A55B7E55F8F96AAF7B015E410B633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_D8CC4E8D97C5F6155271B015E410D46D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C2081F4AED99449D07E3B015E41079A5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_D8CC4E8D97C5F6155271B015E410D46D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_17DF62E1104F679ABE49B015E4105AC5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C2081F4AED99449D07E3B015E41079A5" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_17DF62E1104F679ABE49B015E4105AC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_F97C459E4FC8DEB47ED7B015E41082E4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C2081F4AED99449D07E3B015E41079A5" xlink:to="loc_us-gaap_ShareBasedCompensation_F97C459E4FC8DEB47ED7B015E41082E4" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" xlink:label="loc_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_1F29055DCA9ADC2B830AB015E411E51E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C2081F4AED99449D07E3B015E41079A5" xlink:to="loc_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_1F29055DCA9ADC2B830AB015E411E51E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8E4FB79417C2C033584CB015E411A96E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C2081F4AED99449D07E3B015E41079A5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8E4FB79417C2C033584CB015E411A96E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_22F1BCB010E2D8F9CF35B015E4119BB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8E4FB79417C2C033584CB015E411A96E" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_22F1BCB010E2D8F9CF35B015E4119BB3" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="loc_alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_87F503C929F9E2D6440CB015E411CA13" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8E4FB79417C2C033584CB015E411A96E" xlink:to="loc_alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_87F503C929F9E2D6440CB015E411CA13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4E3B61D2E313F02EA0D0B015E41111E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8E4FB79417C2C033584CB015E411A96E" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4E3B61D2E313F02EA0D0B015E41111E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_98A361C81C67BE704E21B015E4116838" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8E4FB79417C2C033584CB015E411A96E" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_98A361C81C67BE704E21B015E4116838" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_FAA6AFAB82A336ADC3BFB015E4115541" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8E4FB79417C2C033584CB015E411A96E" xlink:to="loc_alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_FAA6AFAB82A336ADC3BFB015E4115541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3EE49C0DF2F3E267C185B015E411F528" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8E4FB79417C2C033584CB015E411A96E" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3EE49C0DF2F3E267C185B015E411F528" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0E6BC823B57B6FE23361B015E4114AFE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_71C37644C45C6AB32DA4B015E4109EEA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0E6BC823B57B6FE23361B015E4114AFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D7ED73965E59688E34C3B015E411EBE0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_537606A283D0C2789C5AB015E410D077" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D7ED73965E59688E34C3B015E411EBE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_654F94F0CBC13554983AB015E4161196" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D7ED73965E59688E34C3B015E411EBE0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_654F94F0CBC13554983AB015E4161196" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_EA28C971899265ADC469B015E41623E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D7ED73965E59688E34C3B015E411EBE0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_EA28C971899265ADC469B015E41623E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D3624DFB74711CD6151EB015E416AA47" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_537606A283D0C2789C5AB015E410D077" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D3624DFB74711CD6151EB015E416AA47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_F0759F36988180A0E9CFB015E41765F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D3624DFB74711CD6151EB015E416AA47" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_F0759F36988180A0E9CFB015E41765F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8180959309CE32B0CD00B015E4171E69" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D3624DFB74711CD6151EB015E416AA47" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8180959309CE32B0CD00B015E4171E69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_53CCFEC340F04823B7A9B015E4171FC8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D3624DFB74711CD6151EB015E416AA47" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_53CCFEC340F04823B7A9B015E4171FC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E3DCBEFB9B751E54CFF3B015E4176729" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D3624DFB74711CD6151EB015E416AA47" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E3DCBEFB9B751E54CFF3B015E4176729" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_DAB4F01E8AD30042D809B015E417F279" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_537606A283D0C2789C5AB015E410D077" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_DAB4F01E8AD30042D809B015E417F279" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_A25C0A78B49E3657CB1BB015E4179A64" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_537606A283D0C2789C5AB015E410D077" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_A25C0A78B49E3657CB1BB015E4179A64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B5E1034471DB87C1151EB015E4186F9A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_537606A283D0C2789C5AB015E410D077" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B5E1034471DB87C1151EB015E4186F9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_631968A4D5710753895AB015E418577F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_537606A283D0C2789C5AB015E410D077" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_631968A4D5710753895AB015E418577F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_42CB04669A2BAB76E38DB015E41888B4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_537606A283D0C2789C5AB015E410D077" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_42CB04669A2BAB76E38DB015E41888B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_910FEC9CAFB67B3BC1FBB015E41883EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_42CB04669A2BAB76E38DB015E41888B4" xlink:to="loc_us-gaap_InterestPaid_910FEC9CAFB67B3BC1FBB015E41883EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_3486B5D2B38D7F573D35B015E41824F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_42CB04669A2BAB76E38DB015E41888B4" xlink:to="loc_us-gaap_IncomeTaxesPaid_3486B5D2B38D7F573D35B015E41824F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_797C7E84CEBE3D58B2F4B015E41843FD" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_537606A283D0C2789C5AB015E410D077" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_797C7E84CEBE3D58B2F4B015E41843FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred_D9E4A5048B0FB0013175B015E4185EDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_797C7E84CEBE3D58B2F4B015E41843FD" xlink:to="loc_us-gaap_CapitalLeaseObligationsIncurred_D9E4A5048B0FB0013175B015E4185EDB" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentEndofTermPaymentAccrued" xlink:label="loc_alim_DebtInstrumentEndofTermPaymentAccrued_DCEAF0FAB1E8EE1C5AF2B015E418ABD0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_797C7E84CEBE3D58B2F4B015E41843FD" xlink:to="loc_alim_DebtInstrumentEndofTermPaymentAccrued_DCEAF0FAB1E8EE1C5AF2B015E418ABD0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_81C4E2226B12DA374E93B015E42115B5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_212E5C26F49C09F09AF6B015E421C9B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_81C4E2226B12DA374E93B015E42115B5" xlink:to="loc_us-gaap_NetIncomeLoss_212E5C26F49C09F09AF6B015E421C9B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_305AEC4DED2C3A7EDFA9B015E421C2D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_81C4E2226B12DA374E93B015E42115B5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_305AEC4DED2C3A7EDFA9B015E421C2D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_E20894E4E7BE9A656643B015E4210170" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_305AEC4DED2C3A7EDFA9B015E421C2D8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_E20894E4E7BE9A656643B015E4210170" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_DEF3F7F5987376BF37BCB015E4218FB3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_305AEC4DED2C3A7EDFA9B015E421C2D8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_DEF3F7F5987376BF37BCB015E4218FB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_65168250D1AF6C5066C7B015E421BB75" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_81C4E2226B12DA374E93B015E42115B5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_65168250D1AF6C5066C7B015E421BB75" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_10AE3996356E4D9AF54DD0A0031274EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="loc_us-gaap_Revenues_10AE3996356E4D9AF54DD0A0031274EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_70472703D647C898887ED0A00314BC92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="loc_us-gaap_CostOfGoodsSold_70472703D647C898887ED0A00314BC92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_98AC03B9B3EF50A5B738D0A003149C70" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="loc_us-gaap_GrossProfit_98AC03B9B3EF50A5B738D0A003149C70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_CE4904C6894FE2317392D0A003145ED2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_CE4904C6894FE2317392D0A003145ED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_A4C4F04974F70FF3DE07D0A0031444B5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_A4C4F04974F70FF3DE07D0A0031444B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaap_MarketingExpense_5072FA30C55ED665CDCFD0A00314F0A2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="loc_us-gaap_MarketingExpense_5072FA30C55ED665CDCFD0A00314F0A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_7FDD655D153F12EEBABFD0A00314DED1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_7FDD655D153F12EEBABFD0A00314DED1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_5A74A1A1937ACDB3E27FD0A00314FCEF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="loc_us-gaap_OperatingExpenses_5A74A1A1937ACDB3E27FD0A00314FCEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_D203232F4296D7183CB6D0A003141145" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="loc_us-gaap_OperatingIncomeLoss_D203232F4296D7183CB6D0A003141145" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_2BEE7E0C195288BCEB74D0A00314CD83" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="loc_us-gaap_InterestExpense_2BEE7E0C195288BCEB74D0A00314CD83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_8673D8B2F6B72DD5D21BD0A00314719E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_8673D8B2F6B72DD5D21BD0A00314719E" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" xlink:label="loc_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_ED6B44C90ECB12E185A3D0A00314AC4D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="loc_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_ED6B44C90ECB12E185A3D0A00314AC4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_22D5828C93DAF8A0722DD0A00314B8F5" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_22D5828C93DAF8A0722DD0A00314B8F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2FF81AF214E1F728BE40D0A00314D2D0" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2FF81AF214E1F728BE40D0A00314D2D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_65317F6B53D67ED1BE6AD0A00315ADF2" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_65317F6B53D67ED1BE6AD0A00315ADF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_27DB7105A2AEBB7A8372D0A0031558E4" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="loc_us-gaap_NetIncomeLoss_27DB7105A2AEBB7A8372D0A0031558E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_04FE9F3EF7E6E3752C9CD0A0031579C3" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_04FE9F3EF7E6E3752C9CD0A0031579C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_321888928B04BC96A33CD0A0031521B7" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04122023CD1891328119D0A0030F02B8" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_321888928B04BC96A33CD0A0031521B7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="alim-20170331.xsd#alim_DocumentAndEntityInformationAbstract" xlink:label="loc_alim_DocumentAndEntityInformationAbstract_D1A1BE1880CFDA23AA5D48DE1393C7A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_7C93A436B4C1F3087BB048DE1393553F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_DocumentAndEntityInformationAbstract_D1A1BE1880CFDA23AA5D48DE1393C7A9" xlink:to="loc_dei_EntityRegistrantName_7C93A436B4C1F3087BB048DE1393553F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6922D9FFAA0C23EBBA3A48DE13934FF5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_DocumentAndEntityInformationAbstract_D1A1BE1880CFDA23AA5D48DE1393C7A9" xlink:to="loc_dei_EntityCentralIndexKey_6922D9FFAA0C23EBBA3A48DE13934FF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_3AE65524962872ECB84948DE1393C7AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_DocumentAndEntityInformationAbstract_D1A1BE1880CFDA23AA5D48DE1393C7A9" xlink:to="loc_dei_DocumentType_3AE65524962872ECB84948DE1393C7AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_6DC7B540A7FD0C15B9A948DE1393B946" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_DocumentAndEntityInformationAbstract_D1A1BE1880CFDA23AA5D48DE1393C7A9" xlink:to="loc_dei_DocumentPeriodEndDate_6DC7B540A7FD0C15B9A948DE1393B946" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_15D14C334D8E40AB46DC48DE13938BB5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_DocumentAndEntityInformationAbstract_D1A1BE1880CFDA23AA5D48DE1393C7A9" xlink:to="loc_dei_AmendmentFlag_15D14C334D8E40AB46DC48DE13938BB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_F10F6FFB940BA504842448DE13943438" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_DocumentAndEntityInformationAbstract_D1A1BE1880CFDA23AA5D48DE1393C7A9" xlink:to="loc_dei_DocumentFiscalYearFocus_F10F6FFB940BA504842448DE13943438" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_38D78B2390B2A41E7C2948DE1394E20A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_DocumentAndEntityInformationAbstract_D1A1BE1880CFDA23AA5D48DE1393C7A9" xlink:to="loc_dei_DocumentFiscalPeriodFocus_38D78B2390B2A41E7C2948DE1394E20A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_71C2624A2DA909C481F248DE1394E28B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_DocumentAndEntityInformationAbstract_D1A1BE1880CFDA23AA5D48DE1393C7A9" xlink:to="loc_dei_CurrentFiscalYearEndDate_71C2624A2DA909C481F248DE1394E28B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_FDCEC096B3A4C094BE2048DE13949A91" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_DocumentAndEntityInformationAbstract_D1A1BE1880CFDA23AA5D48DE1393C7A9" xlink:to="loc_dei_EntityFilerCategory_FDCEC096B3A4C094BE2048DE13949A91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7D743C179813541DA96F48DE1394A945" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_DocumentAndEntityInformationAbstract_D1A1BE1880CFDA23AA5D48DE1393C7A9" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7D743C179813541DA96F48DE1394A945" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_19D2C14724DAB5CCDE4548DE1362A270" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_14DBB78563B0239A803B48DE1362E0D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_19D2C14724DAB5CCDE4548DE1362A270" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_14DBB78563B0239A803B48DE1362E0D8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/FairValueDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_CFC1704E3A1E665AD97948DE13ACF615" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2AA3D744E69596DAFF7D48DE13ACE057" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_CFC1704E3A1E665AD97948DE13ACF615" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2AA3D744E69596DAFF7D48DE13ACE057" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_858C1CA21D364F51974248DE13AC48B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2AA3D744E69596DAFF7D48DE13ACE057" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_858C1CA21D364F51974248DE13AC48B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0C1092799D16F24A911248DE13ACAC55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_858C1CA21D364F51974248DE13AC48B3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0C1092799D16F24A911248DE13ACAC55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_DA08F051C15AB54E1A8548DE13AC6646" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0C1092799D16F24A911248DE13ACAC55" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_DA08F051C15AB54E1A8548DE13AC6646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1AAB24272BFCE1D2A42948DE13AC7B3F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2AA3D744E69596DAFF7D48DE13ACE057" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1AAB24272BFCE1D2A42948DE13AC7B3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1AAB24272BFCE1D2A42948DE13AC7B3F" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_FD05358DFBF1EA53923948DE13AD2656" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_FD05358DFBF1EA53923948DE13AD2656" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_CF96C3F141558E1D838048DE13ADA1E3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_CF96C3F141558E1D838048DE13ADA1E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_A8399D2E5A34F5AD7C6048DE13AD3C89" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F1DCFDA06D423A9A8D1948DE13AD66D8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_A8399D2E5A34F5AD7C6048DE13AD3C89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33B2683B017FFAB84F4548DE13AD0EED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2AA3D744E69596DAFF7D48DE13ACE057" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33B2683B017FFAB84F4548DE13AD0EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_8C58B517DF8EE742A94D48DE13AD1F1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33B2683B017FFAB84F4548DE13AD0EED" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_8C58B517DF8EE742A94D48DE13AD1F1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6E7F133B0C23991B010E48DE13AD0BEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8C58B517DF8EE742A94D48DE13AD1F1F" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6E7F133B0C23991B010E48DE13AD0BEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_AEEB1A2E6B0BBF9FD06448DE13AD43FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8C58B517DF8EE742A94D48DE13AD1F1F" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_AEEB1A2E6B0BBF9FD06448DE13AD43FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B6D9B67E966D8E1A318848DE13ADC9CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33B2683B017FFAB84F4548DE13AD0EED" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B6D9B67E966D8E1A318848DE13ADC9CD" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DerivativeWarrantLiabilitiesFairValueDisclosure" xlink:label="loc_alim_DerivativeWarrantLiabilitiesFairValueDisclosure_D284E628CF70DCF6C82A48DE13ADFD71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B6D9B67E966D8E1A318848DE13ADC9CD" xlink:to="loc_alim_DerivativeWarrantLiabilitiesFairValueDisclosure_D284E628CF70DCF6C82A48DE13ADFD71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_1E268DAE28811EC921A248DE13AD88A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B6D9B67E966D8E1A318848DE13ADC9CD" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_1E268DAE28811EC921A248DE13AD88A5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/FairValueTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1F5F06891E550E16DA4748DE13796061" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A834670DB4109577589D48DE137999B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1F5F06891E550E16DA4748DE13796061" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_A834670DB4109577589D48DE137999B3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/GoingConcern" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_21C74818E304854960C5D0D38EA51B5E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_65750C46B575C1669C6CD0D7D19D0B35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_21C74818E304854960C5D0D38EA51B5E" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_65750C46B575C1669C6CD0D7D19D0B35" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/GoingConcernDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2C7763F27C3B4CA841D6D0D38EA33100" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_138A0F0E289330465E06D0D38EA323A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2C7763F27C3B4CA841D6D0D38EA33100" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_138A0F0E289330465E06D0D38EA323A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A133D30262FD4A2BF0F8D0D38EA38B00" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2C7763F27C3B4CA841D6D0D38EA33100" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A133D30262FD4A2BF0F8D0D38EA38B00" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_CommonStocktobeIssuedValueMaximum" xlink:label="loc_alim_CommonStocktobeIssuedValueMaximum_A48D7AFB14972A3CDAF6D0D38EA3DB72" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2C7763F27C3B4CA841D6D0D38EA33100" xlink:to="loc_alim_CommonStocktobeIssuedValueMaximum_A48D7AFB14972A3CDAF6D0D38EA3DB72" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_05F18D664872E2FD4EF048DE135BE77A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1EB370342CD5B40A5C8148DE135B540F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05F18D664872E2FD4EF048DE135BE77A" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1EB370342CD5B40A5C8148DE135B540F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/IncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_AFD60B18E55C82DC0BB4B015E30787EA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_208CEA5278434B7E899FB015E307FD8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_AFD60B18E55C82DC0BB4B015E30787EA" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_208CEA5278434B7E899FB015E307FD8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_E4263A40940A793DF7D8B015E3086751" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_208CEA5278434B7E899FB015E307FD8A" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_E4263A40940A793DF7D8B015E3086751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_F2C66B71142DEE0F31A0B015E30886D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_E4263A40940A793DF7D8B015E3086751" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_F2C66B71142DEE0F31A0B015E30886D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_9E387820743B077C5019B015E30872EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_F2C66B71142DEE0F31A0B015E30886D4" xlink:to="loc_us-gaap_DomesticCountryMember_9E387820743B077C5019B015E30872EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_6802DB620D6F4AAF09BCB015E3087066" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_F2C66B71142DEE0F31A0B015E30886D4" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_6802DB620D6F4AAF09BCB015E3087066" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_C46E349AD85B218ACB4CB015E3084F7D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_208CEA5278434B7E899FB015E307FD8A" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_C46E349AD85B218ACB4CB015E3084F7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6A38DABA6BDC707147CCB015E308F595" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_C46E349AD85B218ACB4CB015E3084F7D" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6A38DABA6BDC707147CCB015E308F595" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_CumulativeIncomeLossFromForeignOperations" xlink:label="loc_alim_CumulativeIncomeLossFromForeignOperations_98A3DACCFB327311E5F2B087E7BEB55E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_C46E349AD85B218ACB4CB015E3084F7D" xlink:to="loc_alim_CumulativeIncomeLossFromForeignOperations_98A3DACCFB327311E5F2B087E7BEB55E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/IntangibleAsset" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_BDE4078A183C129429CC48DE13B67983" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_AD8E3D8394871EDB898A48DE13B79F00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_BDE4078A183C129429CC48DE13B67983" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_AD8E3D8394871EDB898A48DE13B79F00" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/IntangibleAssetFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_B37FA5EC977502B8E9A7B015E399CEBE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EC56B4F0651EE606AE7EB015E3991D98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_B37FA5EC977502B8E9A7B015E399CEBE" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EC56B4F0651EE606AE7EB015E3991D98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10F2743B228CCEA1C066B015E3995CA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EC56B4F0651EE606AE7EB015E3991D98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10F2743B228CCEA1C066B015E3995CA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_78512CD547B44296534DB015E399FAF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10F2743B228CCEA1C066B015E3995CA5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_78512CD547B44296534DB015E399FAF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_CAE7CCAA38DC76D5B087B015E3998587" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_78512CD547B44296534DB015E399FAF8" xlink:to="loc_us-gaap_LicensingAgreementsMember_CAE7CCAA38DC76D5B087B015E3998587" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A079DEB2077C987EAC8B015E3995744" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EC56B4F0651EE606AE7EB015E3991D98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A079DEB2077C987EAC8B015E3995744" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A079DEB2077C987EAC8B015E3995744" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2E6B9BAA48E03997AF2CB015E399DEA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2E6B9BAA48E03997AF2CB015E399DEA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F4A81FE91F060E0920C8B015E399F567" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F4A81FE91F060E0920C8B015E399F567" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C6E9AAF9EEDDCB9F18C2B015E3993760" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C6E9AAF9EEDDCB9F18C2B015E3993760" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_32A7E106A5E132F44B74B015E399646C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_32A7E106A5E132F44B74B015E399646C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ECDADBCD13F3CF488DDEB015E39A1872" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ECDADBCD13F3CF488DDEB015E39A1872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_491A73D7283CA274BAC2B015E39A2CC1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_491A73D7283CA274BAC2B015E39A2CC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_72CD7353D600253F1FDAB015E39A9D16" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_882C7758F4F9E439DD5FB015E39958F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_72CD7353D600253F1FDAB015E39A9D16" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/IntangibleAssetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_9489673A64E3AD7520CF48DE13357279" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66C5D37A0164460EA6AA48DE133553A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_9489673A64E3AD7520CF48DE13357279" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66C5D37A0164460EA6AA48DE133553A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F4A92976164C6EE9D48A48DE13359B5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66C5D37A0164460EA6AA48DE133553A8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F4A92976164C6EE9D48A48DE13359B5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_300AF2A93ED565568C9948DE13350097" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F4A92976164C6EE9D48A48DE13359B5A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_300AF2A93ED565568C9948DE13350097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementCopromotionMember" xlink:label="loc_us-gaap_CollaborativeArrangementCopromotionMember_05CF83E61AFFBA9DF7C948DE13363CE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_300AF2A93ED565568C9948DE13350097" xlink:to="loc_us-gaap_CollaborativeArrangementCopromotionMember_05CF83E61AFFBA9DF7C948DE13363CE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C5319055EB446BD6E90C48DE13362783" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66C5D37A0164460EA6AA48DE133553A8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C5319055EB446BD6E90C48DE13362783" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F34D80EF790E93F9E74848DE1336934B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C5319055EB446BD6E90C48DE13362783" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F34D80EF790E93F9E74848DE1336934B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_9D8D5D8910D1AF76F93B48DE13364905" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F34D80EF790E93F9E74848DE1336934B" xlink:to="loc_us-gaap_LicensingAgreementsMember_9D8D5D8910D1AF76F93B48DE13364905" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66C5D37A0164460EA6AA48DE133553A8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_AdditionalMilestonePayment" xlink:label="loc_alim_AdditionalMilestonePayment_5A101626C074F00790DF48DE13368DB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:to="loc_alim_AdditionalMilestonePayment_5A101626C074F00790DF48DE13368DB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_FF054DCF2B7E3CCD077148DE13369769" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_FF054DCF2B7E3CCD077148DE13369769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_379444018DB15483528848DE13365980" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_379444018DB15483528848DE13365980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_78FAD7ECB10545E6E90E48DE13377AE9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_78FAD7ECB10545E6E90E48DE13377AE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_E43A99A6CE36AFBF26BE48DE1337E8D6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_33F196B36E18C2859EEB48DE13361B36" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_E43A99A6CE36AFBF26BE48DE1337E8D6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/IntangibleAssetTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6664A8E9458926A11FF548DE133E523A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3DA3ACFF93541C4B973D48DE133EDCB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6664A8E9458926A11FF548DE133E523A" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3DA3ACFF93541C4B973D48DE133EDCB2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_B42A1ADC1CB45D0E413A48DE137C4EC4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_6FDFAF6EC918B3197F1848DE137CE3D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_B42A1ADC1CB45D0E413A48DE137C4EC4" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_6FDFAF6EC918B3197F1848DE137CE3D4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/InventoryDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4C02E5366D8CC42DD1F548DE1349CEC5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_AE9604C2E2CF2E4EBFCE48DE13492DFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4C02E5366D8CC42DD1F548DE1349CEC5" xlink:to="loc_us-gaap_InventoryNetAbstract_AE9604C2E2CF2E4EBFCE48DE13492DFD" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_InventoryComponent" xlink:label="loc_alim_InventoryComponent_B8BE0CD930EA64478C6E48DE134994AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_AE9604C2E2CF2E4EBFCE48DE13492DFD" xlink:to="loc_alim_InventoryComponent_B8BE0CD930EA64478C6E48DE134994AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_1B1EBE433640A2D24E5148DE13494ECA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_AE9604C2E2CF2E4EBFCE48DE13492DFD" xlink:to="loc_us-gaap_InventoryWorkInProcess_1B1EBE433640A2D24E5148DE13494ECA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_5CE8825DB5DCA923FADE48DE1349B24E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_AE9604C2E2CF2E4EBFCE48DE13492DFD" xlink:to="loc_us-gaap_InventoryFinishedGoods_5CE8825DB5DCA923FADE48DE1349B24E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_BCB09902282B868B8EFA48DE13495E15" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_AE9604C2E2CF2E4EBFCE48DE13492DFD" xlink:to="loc_us-gaap_InventoryGross_BCB09902282B868B8EFA48DE13495E15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_FF68B1125AEEECFE47D648DE13492B8F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_AE9604C2E2CF2E4EBFCE48DE13492DFD" xlink:to="loc_us-gaap_InventoryValuationReserves_FF68B1125AEEECFE47D648DE13492B8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_E08BDBB2166FCAAF120748DE1349D2EE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_AE9604C2E2CF2E4EBFCE48DE13492DFD" xlink:to="loc_us-gaap_InventoryNet_E08BDBB2166FCAAF120748DE1349D2EE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_927D8FD62EC1B20D2B5F48DE13577782" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_DE8BF8415CE3C7EEBA2448DE1357480D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_927D8FD62EC1B20D2B5F48DE13577782" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_DE8BF8415CE3C7EEBA2448DE1357480D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/LicenseAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C5E014D12DA187D3E05448DE1317F826" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_508EBB2FF8EDDFEA0E6248DE13176E50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C5E014D12DA187D3E05448DE1317F826" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_508EBB2FF8EDDFEA0E6248DE13176E50" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/LicenseAgreementsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_483AD25A0900FB33CFC8D5403002F2B4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5388B8A2581C443F5F46D5403003B8A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_483AD25A0900FB33CFC8D5403002F2B4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5388B8A2581C443F5F46D5403003B8A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E1E8E8B433D25240D4EFD5403004D1ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5388B8A2581C443F5F46D5403003B8A9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_E1E8E8B433D25240D4EFD5403004D1ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6518C085A30D8C0DBCB8D5403004FC83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E1E8E8B433D25240D4EFD5403004D1ED" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6518C085A30D8C0DBCB8D5403004FC83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementCopromotionMember" xlink:label="loc_us-gaap_CollaborativeArrangementCopromotionMember_027E53BE3A6B0FABD01AD5403004E2EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6518C085A30D8C0DBCB8D5403004FC83" xlink:to="loc_us-gaap_CollaborativeArrangementCopromotionMember_027E53BE3A6B0FABD01AD5403004E2EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5388B8A2581C443F5F46D5403003B8A9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract" xlink:label="loc_alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_B67A04D6F4B0589DD055D5403004C689" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_B67A04D6F4B0589DD055D5403004C689" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract" xlink:label="loc_alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_F913F6AE0704CFF672FFD5403004CC16" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract_F913F6AE0704CFF672FFD5403004CC16" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled" xlink:label="loc_alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled_8BE8E81DCC19B49F80B1D5403004FDEF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled_8BE8E81DCC19B49F80B1D5403004FDEF" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ShareOfNetProfits" xlink:label="loc_alim_ShareOfNetProfits_8B1BAFAE2D438CA6C6D9D54030047F62" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_ShareOfNetProfits_8B1BAFAE2D438CA6C6D9D54030047F62" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien" xlink:label="loc_alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien_44C79A7985384E5D2731D54030050854" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien_44C79A7985384E5D2731D54030050854" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_PercentageOfRecoveryOfCommercializationCost" xlink:label="loc_alim_PercentageOfRecoveryOfCommercializationCost_EB7D3362B0DAA86A973AD5403005DE3A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_PercentageOfRecoveryOfCommercializationCost_EB7D3362B0DAA86A973AD5403005DE3A" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_CommercializationCosts" xlink:label="loc_alim_CommercializationCosts_66BB602101B4DACD43ADD5403005BB04" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_CommercializationCosts_66BB602101B4DACD43ADD5403005BB04" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_AdditionalMilestonePayment" xlink:label="loc_alim_AdditionalMilestonePayment_5DD9C269B26ABD88075FD54030059DAF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_AdditionalMilestonePayment_5DD9C269B26ABD88075FD54030059DAF" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_CommercializationCostsReceivable" xlink:label="loc_alim_CommercializationCostsReceivable_6F046B759D5CCE2735FBD5403005D724" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_CommercializationCostsReceivable_6F046B759D5CCE2735FBD5403005D724" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_CommercializationCostsReceivablePostAdjustment" xlink:label="loc_alim_CommercializationCostsReceivablePostAdjustment_FD22786B8807954A7401D5403005530F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E5BECF0B416C1957891CD5403004F7D8" xlink:to="loc_alim_CommercializationCostsReceivablePostAdjustment_FD22786B8807954A7401D5403005530F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/LoanAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_AD6C14EE3A13B0D8761948DE135AD6E5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_C54F498CF5C26557003748DE135AFE2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_AD6C14EE3A13B0D8761948DE135AD6E5" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_C54F498CF5C26557003748DE135AFE2C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/LoanAgreementsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7B1E7D10B6FA8E28D4CFD0A03D4CAE16" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7B1E7D10B6FA8E28D4CFD0A03D4CAE16" xlink:to="loc_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_C372B3E9AC583313B572D0A03D4D6975" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:to="loc_us-gaap_VariableRateAxis_C372B3E9AC583313B572D0A03D4D6975" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_857E9D77E6699632F4D5D0A03D4DD3DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_C372B3E9AC583313B572D0A03D4D6975" xlink:to="loc_us-gaap_VariableRateDomain_857E9D77E6699632F4D5D0A03D4DD3DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_6C19C1299E16764F9015D0A03D4D7185" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_857E9D77E6699632F4D5D0A03D4DD3DC" xlink:to="loc_us-gaap_PrimeRateMember_6C19C1299E16764F9015D0A03D4D7185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_DBB2028ADB4BBA933F5BD0A03D4D75D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:to="loc_us-gaap_DebtInstrumentAxis_DBB2028ADB4BBA933F5BD0A03D4D75D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D99061EF866BC35EDA41D0A03D4DBF25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_DBB2028ADB4BBA933F5BD0A03D4D75D5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D99061EF866BC35EDA41D0A03D4DBF25" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_TrancheOneMember" xlink:label="loc_alim_TrancheOneMember_F64400775473302E1CCED0A03D4DE894" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D99061EF866BC35EDA41D0A03D4DBF25" xlink:to="loc_alim_TrancheOneMember_F64400775473302E1CCED0A03D4DE894" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_TrancheTwoMember" xlink:label="loc_alim_TrancheTwoMember_0D683E8A120D5A2E9EBFD0A03D4DDE93" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D99061EF866BC35EDA41D0A03D4DBF25" xlink:to="loc_alim_TrancheTwoMember_0D683E8A120D5A2E9EBFD0A03D4DDE93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4D7BD9EA91B89CD98329D0A03D4D42B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:to="loc_dei_LegalEntityAxis_4D7BD9EA91B89CD98329D0A03D4D42B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_931635576EF6E62A8602D0A03D4DEDD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4D7BD9EA91B89CD98329D0A03D4D42B6" xlink:to="loc_dei_EntityDomain_931635576EF6E62A8602D0A03D4DEDD4" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_AlimeraSciencesIncCompanyMember" xlink:label="loc_alim_AlimeraSciencesIncCompanyMember_8346677F50ADBE675777D0A03D4DF98D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_931635576EF6E62A8602D0A03D4DEDD4" xlink:to="loc_alim_AlimeraSciencesIncCompanyMember_8346677F50ADBE675777D0A03D4DF98D" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_AlimeraSciencesLimitedLimitedMember" xlink:label="loc_alim_AlimeraSciencesLimitedLimitedMember_19F017263905C6EC710BD0A03D4DECB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_AlimeraSciencesIncCompanyMember_8346677F50ADBE675777D0A03D4DF98D" xlink:to="loc_alim_AlimeraSciencesLimitedLimitedMember_19F017263905C6EC710BD0A03D4DECB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_97CF78E6E442D6CFC615D0A03D4DBF02" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_97CF78E6E442D6CFC615D0A03D4DBF02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_8BF8FC722C062451D4A2D0A03D4D581E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_97CF78E6E442D6CFC615D0A03D4DBF02" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_8BF8FC722C062451D4A2D0A03D4D581E" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_HerculesTechnologyGrowthCapitalInc.Member" xlink:label="loc_alim_HerculesTechnologyGrowthCapitalInc.Member_E4ACF7BEE50590DFBA70D0A03D534CBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_8BF8FC722C062451D4A2D0A03D4D581E" xlink:to="loc_alim_HerculesTechnologyGrowthCapitalInc.Member_E4ACF7BEE50590DFBA70D0A03D534CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_BC486F6880CD0B995EB9D0A03D538322" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:to="loc_us-gaap_CreditFacilityAxis_BC486F6880CD0B995EB9D0A03D538322" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_BC486F6880CD0B995EB9D0A03D538322" xlink:to="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_TwentyFourteenTermLoanMember" xlink:label="loc_alim_TwentyFourteenTermLoanMember_641A97B5F66A1490E452D0A03D53DC6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:to="loc_alim_TwentyFourteenTermLoanMember_641A97B5F66A1490E452D0A03D53DC6B" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_FirstLoanAmendmentMember" xlink:label="loc_alim_FirstLoanAmendmentMember_B4E5FD3761A879AF73FED0A03D538606" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:to="loc_alim_FirstLoanAmendmentMember_B4E5FD3761A879AF73FED0A03D538606" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_SecondLoanAmendmentMember" xlink:label="loc_alim_SecondLoanAmendmentMember_F62DD0E7654575D32291D0A03D537135" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:to="loc_alim_SecondLoanAmendmentMember_F62DD0E7654575D32291D0A03D537135" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ThirdLoanAmendmentMember" xlink:label="loc_alim_ThirdLoanAmendmentMember_4C617DB150C2E2B15FF7D0A03D533ECC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:to="loc_alim_ThirdLoanAmendmentMember_4C617DB150C2E2B15FF7D0A03D533ECC" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_July2016WaiverMember" xlink:label="loc_alim_July2016WaiverMember_7C7285237E1241EA3442D0A03D531B39" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:to="loc_alim_July2016WaiverMember_7C7285237E1241EA3442D0A03D531B39" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_FourthLoanAmendmentMember" xlink:label="loc_alim_FourthLoanAmendmentMember_E6C8C1BDCB5B0B18E802D0A03D53462C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_AA3856A4AB83A7B8C6E9D0A03D53CC52" xlink:to="loc_alim_FourthLoanAmendmentMember_E6C8C1BDCB5B0B18E802D0A03D53462C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_03D9776D777DFA63493ED0A03D4CC631" xlink:to="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2F91139318E12902EC65D0A03D53F185" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2F91139318E12902EC65D0A03D53F185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_25386C9781535C3F245AD0A03D5395CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_25386C9781535C3F245AD0A03D5395CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_B5A276BF118FF03CEE98D0A03D53FCA2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_B5A276BF118FF03CEE98D0A03D53FCA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_F1E16C6B0297E63D677AD0A03D538319" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_F1E16C6B0297E63D677AD0A03D538319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9FDF9ACD430CF5C52D7ED0A03D53301A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9FDF9ACD430CF5C52D7ED0A03D53301A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_29DF648A001CD9CAF6E1D0A03D537003" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_29DF648A001CD9CAF6E1D0A03D537003" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_3135E044B1BF3F0CF295D0A03D53BAE3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_3135E044B1BF3F0CF295D0A03D53BAE3" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal" xlink:label="loc_alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal_7B40471ADE1126C796BDD0A03D536DFC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal_7B40471ADE1126C796BDD0A03D536DFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_E2FC800A538044BDC1B2D0A03D53340E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_E2FC800A538044BDC1B2D0A03D53340E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2BC4312706EAB9966713D0A03D533658" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2BC4312706EAB9966713D0A03D533658" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentCovenantMinimumCashBalance" xlink:label="loc_alim_DebtInstrumentCovenantMinimumCashBalance_D3D18BE0A43228DF1EB8D0A03D540FC8" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentCovenantMinimumCashBalance_D3D18BE0A43228DF1EB8D0A03D540FC8" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentTickingFeePercent" xlink:label="loc_alim_DebtInstrumentTickingFeePercent_2363FA43B0C21A54C231D0A03D54F785" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentTickingFeePercent_2363FA43B0C21A54C231D0A03D54F785" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentTickingFee" xlink:label="loc_alim_DebtInstrumentTickingFee_F78DCC5780EFE69306F3D0A03D54289B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentTickingFee_F78DCC5780EFE69306F3D0A03D54289B" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_LineofCreditFacilityIncreaseinBorrowingCapacity" xlink:label="loc_alim_LineofCreditFacilityIncreaseinBorrowingCapacity_C2971B517BC6002C8C08D0A03D543E46" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_LineofCreditFacilityIncreaseinBorrowingCapacity_C2971B517BC6002C8C08D0A03D543E46" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentRevenueRequirement" xlink:label="loc_alim_DebtInstrumentRevenueRequirement_556E6AB9C1C9132382C8D0A03D546B83" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentRevenueRequirement_556E6AB9C1C9132382C8D0A03D546B83" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentBasisSpreadonVariableRateReduction" xlink:label="loc_alim_DebtInstrumentBasisSpreadonVariableRateReduction_ED2A42019B24FA1CE5FFD0A03D54C550" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentBasisSpreadonVariableRateReduction_ED2A42019B24FA1CE5FFD0A03D54C550" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebitInstrumentPaymentinKindInterestRate" xlink:label="loc_alim_DebitInstrumentPaymentinKindInterestRate_A80ECCDD1B6E4852EF52D0A03D54C40D" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebitInstrumentPaymentinKindInterestRate_A80ECCDD1B6E4852EF52D0A03D54C40D" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentPaymentTermsNumberofPayments" xlink:label="loc_alim_DebtInstrumentPaymentTermsNumberofPayments_E32862D8340405D3F198D0A03D54D9DC" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentPaymentTermsNumberofPayments_E32862D8340405D3F198D0A03D54D9DC" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentPrepaymentFeePercentageFirst12Months" xlink:label="loc_alim_DebtInstrumentPrepaymentFeePercentageFirst12Months_5FAD954C2C3738CF9732D0A03D548D28" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentPrepaymentFeePercentageFirst12Months_5FAD954C2C3738CF9732D0A03D548D28" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months" xlink:label="loc_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months_4E6039E162F9E9F062EFD0A03D54C559" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months_4E6039E162F9E9F062EFD0A03D54C559" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months" xlink:label="loc_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months_E59CE0128FCD2EECABAAD0A03D54CBA3" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months_E59CE0128FCD2EECABAAD0A03D54CBA3" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentCovenantLiquidityThreshold" xlink:label="loc_alim_DebtInstrumentCovenantLiquidityThreshold_8E1D75E61EAF125CE022D0A03D546179" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentCovenantLiquidityThreshold_8E1D75E61EAF125CE022D0A03D546179" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentCovenantCurrentLiquidity" xlink:label="loc_alim_DebtInstrumentCovenantCurrentLiquidity_EB5259E9BE3A10700668D0A03D549ED2" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentCovenantCurrentLiquidity_EB5259E9BE3A10700668D0A03D549ED2" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentCovenantLiquidityRelatedtoCashandCashEquivalents" xlink:label="loc_alim_DebtInstrumentCovenantLiquidityRelatedtoCashandCashEquivalents_CBC6955F23035D086FACD0A03D54BD15" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentCovenantLiquidityRelatedtoCashandCashEquivalents_CBC6955F23035D086FACD0A03D54BD15" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_DebtInstrumentCovenantLiquidityRelatedtoAccountsReceivable" xlink:label="loc_alim_DebtInstrumentCovenantLiquidityRelatedtoAccountsReceivable_17C011E8AED3A6B173BFD0A03D548DEA" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_DebtInstrumentCovenantLiquidityRelatedtoAccountsReceivable_17C011E8AED3A6B173BFD0A03D548DEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FEA6E40C2D7975FD43A6D0A03D545303" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FEA6E40C2D7975FD43A6D0A03D545303" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3FE461D56301EA11092BD0A03D54D500" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3FE461D56301EA11092BD0A03D54D500" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ClassofWarrantorRightExercisablePercentage" xlink:label="loc_alim_ClassofWarrantorRightExercisablePercentage_04890CAE64872BB9B068D0A03D54C696" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_ClassofWarrantorRightExercisablePercentage_04890CAE64872BB9B068D0A03D54C696" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage" xlink:label="loc_alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage_E606938B4C18AE34F676D0A03D54CF1C" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage_E606938B4C18AE34F676D0A03D54CF1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_4EF4ED11BE8CCCDB6F52D0CA19049ED7" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A364C6BBD614BF368F86D0A03D53A59E" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_4EF4ED11BE8CCCDB6F52D0CA19049ED7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/LossPerShareEps" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_A3A7F6E6F47641C6C33F48DE137D9D7E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_DEBD2BE3255A51F5185648DE137D6607" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_A3A7F6E6F47641C6C33F48DE137D9D7E" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_DEBD2BE3255A51F5185648DE137D6607" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/LossPerShareEpsAntidilutiveSecuritiesExcludedDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_C143EF1DFD58E9B5F57248DE1381C6D2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_580B53CB8223994B766A48DE13814C3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_C143EF1DFD58E9B5F57248DE1381C6D2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_580B53CB8223994B766A48DE13814C3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8BB437A3371E225BEF148DE13811963" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_580B53CB8223994B766A48DE13814C3A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8BB437A3371E225BEF148DE13811963" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8BB437A3371E225BEF148DE13811963" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_AB5DD40080E58875358E48DE13816821" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_AB5DD40080E58875358E48DE13816821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_D010C17E43ABD85C72F948DE1382C332" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_D010C17E43ABD85C72F948DE1382C332" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_PreferredStockWarrantsMember" xlink:label="loc_alim_PreferredStockWarrantsMember_DB59C729E4008AEBA9BD48DE13825A03" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:to="loc_alim_PreferredStockWarrantsMember_DB59C729E4008AEBA9BD48DE13825A03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_28D77D558F211EB9159348DE1382ABCD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:to="loc_us-gaap_WarrantMember_28D77D558F211EB9159348DE1382ABCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C81F8E6435367F25E0CF48DE13827BF0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_33BAC5B4BE4B542B20A448DE1381F331" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C81F8E6435367F25E0CF48DE13827BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E78E48379702E2F2436B48DE13824676" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_580B53CB8223994B766A48DE13814C3A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E78E48379702E2F2436B48DE13824676" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3B9CF70C3E363066E93048DE138264F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E78E48379702E2F2436B48DE13824676" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3B9CF70C3E363066E93048DE138264F8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/LossPerShareEpsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_39D901B0341E6F1F190148DE13580D73" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_190CB2C9AA85B19729D348DE1359D171" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_39D901B0341E6F1F190148DE13580D73" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_190CB2C9AA85B19729D348DE1359D171" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/NatureOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0F0B37D08515A175F0DA48DE135EE3F6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_A542D19F5D3F6ACF0BF448DE135E4D55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0F0B37D08515A175F0DA48DE135EE3F6" xlink:to="loc_us-gaap_NatureOfOperations_A542D19F5D3F6ACF0BF448DE135E4D55" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/NatureOfOperationsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C4EB20B120788F92ECDAD0D38EB2A8B9" xlink:type="locator" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ScheduleNatureOfOperationsTable" xlink:label="loc_alim_ScheduleNatureOfOperationsTable_966477850E80C2374980D0D38EB289A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C4EB20B120788F92ECDAD0D38EB2A8B9" xlink:to="loc_alim_ScheduleNatureOfOperationsTable_966477850E80C2374980D0D38EB289A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_7F8E45ABE6D48D4C2EBAD0D38EB38551" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_ScheduleNatureOfOperationsTable_966477850E80C2374980D0D38EB289A0" xlink:to="loc_us-gaap_ProductOrServiceAxis_7F8E45ABE6D48D4C2EBAD0D38EB38551" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_74D12FB94A09DC1941E7D0D38EB39EF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_7F8E45ABE6D48D4C2EBAD0D38EB38551" xlink:to="loc_us-gaap_ProductsAndServicesDomain_74D12FB94A09DC1941E7D0D38EB39EF1" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_IluvienMember" xlink:label="loc_alim_IluvienMember_08F87BCC806DD243A399D0D38EB397D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_74D12FB94A09DC1941E7D0D38EB39EF1" xlink:to="loc_alim_IluvienMember_08F87BCC806DD243A399D0D38EB397D8" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_NatureOfOperationsLineItems" xlink:label="loc_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_ScheduleNatureOfOperationsTable_966477850E80C2374980D0D38EB289A0" xlink:to="loc_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_PostAuthorizationOpenStudyPeriod" xlink:label="loc_alim_PostAuthorizationOpenStudyPeriod_F7A99C94AC253AB5F7B9D0D38EB3DB6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD" xlink:to="loc_alim_PostAuthorizationOpenStudyPeriod_F7A99C94AC253AB5F7B9D0D38EB3DB6F" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_PlannedDrugStudyNumberofPatients" xlink:label="loc_alim_PlannedDrugStudyNumberofPatients_1884172BADDBC5B4F58DD0D38EB3059D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD" xlink:to="loc_alim_PlannedDrugStudyNumberofPatients_1884172BADDBC5B4F58DD0D38EB3059D" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_PlannedStudyNumberofPatients" xlink:label="loc_alim_PlannedStudyNumberofPatients_B7DF1DC95EEB0BDF2075D0DB455AD02B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_NatureOfOperationsLineItems_2BA3E08BB8360BD99974D0D38EB394AD" xlink:to="loc_alim_PlannedStudyNumberofPatients_B7DF1DC95EEB0BDF2075D0DB455AD02B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/PreferredStock" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_570929CE38DB3841BF2148DE13AFA0D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaap_PreferredStockTextBlock_A0DDA76F52B52A50423448DE13AFA8F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_570929CE38DB3841BF2148DE13AFA0D8" xlink:to="loc_us-gaap_PreferredStockTextBlock_A0DDA76F52B52A50423448DE13AFA8F6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/PreferredStockDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_3AF25AB0388DEF680C9E591B212D17AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_us-gaap_ConversionOfStockTable_1B25A705ED56B5A42C2E591B212DA232" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3AF25AB0388DEF680C9E591B212D17AC" xlink:to="loc_us-gaap_ConversionOfStockTable_1B25A705ED56B5A42C2E591B212DA232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0EF278CFEB309C2113E7591B212D2A79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_1B25A705ED56B5A42C2E591B212DA232" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0EF278CFEB309C2113E7591B212D2A79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8B140EB37DBECAA9A50D591B212D012F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0EF278CFEB309C2113E7591B212D2A79" xlink:to="loc_us-gaap_ClassOfStockDomain_8B140EB37DBECAA9A50D591B212D012F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_11183F049F3FACCBE2F7591B212DB24B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8B140EB37DBECAA9A50D591B212D012F" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_11183F049F3FACCBE2F7591B212DB24B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2BF7226A27CF88FAEBBF591B212D3BB4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8B140EB37DBECAA9A50D591B212D012F" xlink:to="loc_us-gaap_CommonStockMember_2BF7226A27CF88FAEBBF591B212D3BB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_3C35EC7B0303E6B3BCCA591B212D3362" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8B140EB37DBECAA9A50D591B212D012F" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_3C35EC7B0303E6B3BCCA591B212D3362" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_91A528AB170018D9441C591B212D7610" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_1B25A705ED56B5A42C2E591B212DA232" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_91A528AB170018D9441C591B212D7610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9613EE457881F65C42A6591B212D688E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_91A528AB170018D9441C591B212D7610" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9613EE457881F65C42A6591B212D688E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_D7314E7C0D39D3E408CF591B212D9D6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9613EE457881F65C42A6591B212D688E" xlink:to="loc_us-gaap_OverAllotmentOptionMember_D7314E7C0D39D3E408CF591B212D9D6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_1B25A705ED56B5A42C2E591B212DA232" xlink:to="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_NumberOfPreferredStockAndWarrants" xlink:label="loc_alim_NumberOfPreferredStockAndWarrants_4C99EB07A5E2BA6AC84D591B212ECD50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_NumberOfPreferredStockAndWarrants_4C99EB07A5E2BA6AC84D591B212ECD50" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_WarrantsToPurchaseAdditionalShares" xlink:label="loc_alim_WarrantsToPurchaseAdditionalShares_5658BEC2990679F67A3F591B212E6E1C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_WarrantsToPurchaseAdditionalShares_5658BEC2990679F67A3F591B212E6E1C" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_GrossProceedsUnderSecuritiesPurchaseAgreement" xlink:label="loc_alim_GrossProceedsUnderSecuritiesPurchaseAgreement_39636316BD971BE61872591B212E72F6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_GrossProceedsUnderSecuritiesPurchaseAgreement_39636316BD971BE61872591B212E72F6" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_EstimatedTotalStockIssuanceCost" xlink:label="loc_alim_EstimatedTotalStockIssuanceCost_8D179FEEDE00ACE4664A591B212E044F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_EstimatedTotalStockIssuanceCost_8D179FEEDE00ACE4664A591B212E044F" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue" xlink:label="loc_alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue_5840EA2725D97A606998591B212E95D4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue_5840EA2725D97A606998591B212E95D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_53946E113613A0974E40591B212EC012" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_53946E113613A0974E40591B212EC012" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_PreferredStockConvertedToCommonStockPerShare" xlink:label="loc_alim_PreferredStockConvertedToCommonStockPerShare_001A9DA1D206754EC9F8591B212E7319" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_PreferredStockConvertedToCommonStockPerShare_001A9DA1D206754EC9F8591B212E7319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_A6941D3349929AF35C3B591B212EE647" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_A6941D3349929AF35C3B591B212EE647" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ProportionOfEachUnitOfShares" xlink:label="loc_alim_ProportionOfEachUnitOfShares_9831103A75B019217437591B212ECDED" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_ProportionOfEachUnitOfShares_9831103A75B019217437591B212ECDED" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ExercisePriceOfWarrants" xlink:label="loc_alim_ExercisePriceOfWarrants_C02488C215B82DCC5697591B212EF21B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_ExercisePriceOfWarrants_C02488C215B82DCC5697591B212EF21B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_F3AA9D84656CC800084D591B212E3FFA" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_F3AA9D84656CC800084D591B212E3FFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_A3C86DD1AD63F57FF9E5591B212EDE0D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_A3C86DD1AD63F57FF9E5591B212EDE0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_59E046C366E80FA5EB96591B212EDCC1" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_59E046C366E80FA5EB96591B212EDCC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_7945A6E51B149735AB9B591B212EE980" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_7945A6E51B149735AB9B591B212EE980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_CBF13D8C139FEB457394591B21335152" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_PreferredStockSharesIssued_CBF13D8C139FEB457394591B21335152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2C9A4E44512FFFF21154591B21346A3C" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2C9A4E44512FFFF21154591B21346A3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3DD5DD705BB64E352E4D591B21345BD2" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3DD5DD705BB64E352E4D591B21345BD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_0E00EEBE6771911A7A2C591B213462C4" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_0E00EEBE6771911A7A2C591B213462C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2224C0256F1CEDB7AEC591B2134129E" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2224C0256F1CEDB7AEC591B2134129E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_88EDB58AE8F089DFDAC2591B2134FA52" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_88EDB58AE8F089DFDAC2591B2134FA52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_473A215BE740185DB071591B2134620F" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_473A215BE740185DB071591B2134620F" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent" xlink:label="loc_alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent_FEC5F0D04E4BA8D5D190591B213408C3" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent_FEC5F0D04E4BA8D5D190591B213408C3" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature" xlink:label="loc_alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature_A2079E28A0524491D149591B2134BA0A" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_7291431C2FE4C2954038591B212EBFC5" xlink:to="loc_alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature_A2079E28A0524491D149591B2134BA0A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_CEA65DB7C0C8624A76D748DE13561238" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_64E11556AB1F4311485A48DE1356910E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_CEA65DB7C0C8624A76D748DE13561238" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_64E11556AB1F4311485A48DE1356910E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_3C748D51AFC84DFB6DE3F446051E858E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6119CE2A30FC8023FE05F446051EA098" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3C748D51AFC84DFB6DE3F446051E858E" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6119CE2A30FC8023FE05F446051EA098" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_D61AF0E4E21DDCDF0B0DF446051E42D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6119CE2A30FC8023FE05F446051EA098" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_D61AF0E4E21DDCDF0B0DF446051E42D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_A2A60FE73E0D3DE65C99F446051E80C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_D61AF0E4E21DDCDF0B0DF446051E42D9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_A2A60FE73E0D3DE65C99F446051E80C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_C19D169E64C9B47B4DB6F446051E8BDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_A2A60FE73E0D3DE65C99F446051E80C0" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_C19D169E64C9B47B4DB6F446051E8BDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8D14481FCC9A61FA9C44F446051E4EA5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6119CE2A30FC8023FE05F446051EA098" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8D14481FCC9A61FA9C44F446051E4EA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3CDB716420AAD9F40816F446051E2221" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8D14481FCC9A61FA9C44F446051E4EA5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3CDB716420AAD9F40816F446051E2221" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_E796284D9FF1C4A24839F446051ED12B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3CDB716420AAD9F40816F446051E2221" xlink:to="loc_us-gaap_SalesMember_E796284D9FF1C4A24839F446051ED12B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_FF9A38545D89061EF6A5F446051EE8AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3CDB716420AAD9F40816F446051E2221" xlink:to="loc_us-gaap_AccountsReceivableMember_FF9A38545D89061EF6A5F446051EE8AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9B86506938475CFF7349F446051EBE75" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6119CE2A30FC8023FE05F446051EA098" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9B86506938475CFF7349F446051EBE75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9B86506938475CFF7349F446051EBE75" xlink:to="loc_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_UnitedStatesSegmentMember" xlink:label="loc_alim_UnitedStatesSegmentMember_B3F2F97588FA1CE7DD4FF446051E63E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B" xlink:to="loc_alim_UnitedStatesSegmentMember_B3F2F97588FA1CE7DD4FF446051E63E2" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_InternationalSegmentMember" xlink:label="loc_alim_InternationalSegmentMember_DC439EA1AFF7EE35B5E2F446051E727A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B" xlink:to="loc_alim_InternationalSegmentMember_DC439EA1AFF7EE35B5E2F446051E727A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="loc_us-gaap_AllOtherSegmentsMember_D21185038C6D6E107F72F446051E5962" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9D7677818429480523F8F446051EE02B" xlink:to="loc_us-gaap_AllOtherSegmentsMember_D21185038C6D6E107F72F446051E5962" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6119CE2A30FC8023FE05F446051EA098" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_ConcentrationRiskNumberofCustomers" xlink:label="loc_alim_ConcentrationRiskNumberofCustomers_DA8A9F5319C2421BF230F446051E76DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_alim_ConcentrationRiskNumberofCustomers_DA8A9F5319C2421BF230F446051E76DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_945826C84DDCE124F28FF446051EA8F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_945826C84DDCE124F28FF446051EA8F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_13B2AEACA8F67EA1926DF446051E1395" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_Revenues_13B2AEACA8F67EA1926DF446051E1395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_E8EDF06E274109035DB3F446051E271D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_CostOfGoodsSold_E8EDF06E274109035DB3F446051E271D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1C4650992C086D179EAEF446051EC55B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_GrossProfit_1C4650992C086D179EAEF446051EC55B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_41715EB32B0AE1420C7EF446051EC071" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_41715EB32B0AE1420C7EF446051EC071" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0C435E24FCFC3BDF9227F446051EF0DE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0C435E24FCFC3BDF9227F446051EF0DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaap_MarketingExpense_6C3E1BAF836D87CBA3D9F446051ECFE7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_MarketingExpense_6C3E1BAF836D87CBA3D9F446051ECFE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_41F4D2B8EC52B9DE8245F446051E5CE8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_41F4D2B8EC52B9DE8245F446051E5CE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_D1519612BD3CB70BEE1AF446052F57CA" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_OperatingExpenses_D1519612BD3CB70BEE1AF446052F57CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_198B1E9724A368A7090FF446052F531A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_OperatingIncomeLoss_198B1E9724A368A7090FF446052F531A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_A4670A833DC3D2C20492F446052F83F1" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_A4670A833DC3D2C20492F446052F83F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_03CB71D2F7EDDADD8472F4460531568D" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_301DC33953A0E2A554AAF446051E9A51" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_03CB71D2F7EDDADD8472F4460531568D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_95276524943EB58D30E948DE135F34D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_52E5B174B1AAB24626FE48DE135F7ED5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_95276524943EB58D30E948DE135F34D8" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_52E5B174B1AAB24626FE48DE135F7ED5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/StockIncentivePlans" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54E5065DCC8865B8B67748DE138318F3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7555EA63FC9EABD0FA0848DE13830576" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54E5065DCC8865B8B67748DE138318F3" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7555EA63FC9EABD0FA0848DE13830576" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/StockIncentivePlansAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F14A7EFD6C9158F110E0E8B88256AA14" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ACC172FB833E9F9C306E8B8825658D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F14A7EFD6C9158F110E0E8B88256AA14" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ACC172FB833E9F9C306E8B8825658D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6647BE7361AF447F22CBE8B882565E61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ACC172FB833E9F9C306E8B8825658D1" xlink:to="loc_us-gaap_AwardTypeAxis_6647BE7361AF447F22CBE8B882565E61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6647BE7361AF447F22CBE8B882565E61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_928F1F150267C5F50236E8B882569C4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73" xlink:to="loc_us-gaap_EmployeeStockOptionMember_928F1F150267C5F50236E8B882569C4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_868BC4AC16D57B4480BEE8B882562D4F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73" xlink:to="loc_us-gaap_EmployeeStockMember_868BC4AC16D57B4480BEE8B882562D4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1A48D595BD697281E3ECE8C011B1DBAB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92BE6C3C9E17402416A3E8B882569C73" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1A48D595BD697281E3ECE8C011B1DBAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ACC172FB833E9F9C306E8B8825658D1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2254FA9481D279DBD5ECE8B8825650C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2254FA9481D279DBD5ECE8B8825650C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7F3D41694E07AC638DDAE8B88256C3E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7F3D41694E07AC638DDAE8B88256C3E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1B7FAA7E316645FD66ABE8B88257390F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1B7FAA7E316645FD66ABE8B88257390F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_404E5F7BA4D4804BF165E8C0F0C5AC06" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_404E5F7BA4D4804BF165E8C0F0C5AC06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_FE3F95A3091A933C2C9BE8C321B94744" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A43404A8058A44FE3BA4E8B88256D83E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_FE3F95A3091A933C2C9BE8C321B94744" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/StockIncentivePlansAdditionalStockOptionTransactionsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F27CD6FBBF64591EE76948DE13457240" xlink:type="locator" />
    <link:loc xlink:href="alim-20170331.xsd#alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract" xlink:label="loc_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract_19AA719C04CCD58DC44148DE13456597" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F27CD6FBBF64591EE76948DE13457240" xlink:to="loc_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract_19AA719C04CCD58DC44148DE13456597" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06606A2E95CEE09CB41948DE13456EEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract_19AA719C04CCD58DC44148DE13456597" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06606A2E95CEE09CB41948DE13456EEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_81F00EEAF0B071FFD98948DE13456C76" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract_19AA719C04CCD58DC44148DE13456597" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_81F00EEAF0B071FFD98948DE13456C76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5E2795687B6A3495F04E48DE1345BFB3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract_19AA719C04CCD58DC44148DE13456597" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5E2795687B6A3495F04E48DE1345BFB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8D5A386BD5D62D02833548DE13450910" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract_19AA719C04CCD58DC44148DE13456597" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8D5A386BD5D62D02833548DE13450910" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract" xlink:label="loc_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract_E9205DB6CA086EEA151448DE134571E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F27CD6FBBF64591EE76948DE13457240" xlink:to="loc_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract_E9205DB6CA086EEA151448DE134571E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4954AFAE25D25E3BAC5D48DE1345A617" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract_E9205DB6CA086EEA151448DE134571E4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4954AFAE25D25E3BAC5D48DE1345A617" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_175C8D6119373E664EDC48DE13457AF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract_E9205DB6CA086EEA151448DE134571E4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_175C8D6119373E664EDC48DE13457AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_DA9C455A5C1BD099518548DE1345950E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract_E9205DB6CA086EEA151448DE134571E4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_DA9C455A5C1BD099518548DE1345950E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F79D60B1DA55ABB238D448DE13451347" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract_E9205DB6CA086EEA151448DE134571E4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F79D60B1DA55ABB238D448DE13451347" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_201BE4A05DB7830043C048DE1346CC4E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F27CD6FBBF64591EE76948DE13457240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_201BE4A05DB7830043C048DE1346CC4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_16DA23866F23EC42B5A548DE1346D593" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_201BE4A05DB7830043C048DE1346CC4E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_16DA23866F23EC42B5A548DE1346D593" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6DD188CE3F2E15E5928748DE13465275" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_201BE4A05DB7830043C048DE1346CC4E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6DD188CE3F2E15E5928748DE13465275" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_86FA7B8373E048D4B45A48DE1346D55F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_201BE4A05DB7830043C048DE1346CC4E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_86FA7B8373E048D4B45A48DE1346D55F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8D1F4032206F59FEFEA048DE13464D24" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_201BE4A05DB7830043C048DE1346CC4E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8D1F4032206F59FEFEA048DE13464D24" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/StockIncentivePlansSummaryOfStockOptionTransactionsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B880E3710B6C88B565E748DE13D5052E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0FA99FC61230287BDC2B48DE13D57B13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B880E3710B6C88B565E748DE13D5052E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0FA99FC61230287BDC2B48DE13D57B13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_31D4607CD9DDC720812648DE13D500B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0FA99FC61230287BDC2B48DE13D57B13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_31D4607CD9DDC720812648DE13D500B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FED887BF47B09ED8E12D48DE13D5CC61" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0FA99FC61230287BDC2B48DE13D57B13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FED887BF47B09ED8E12D48DE13D5CC61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_933036092485461E719B48DE13D575F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0FA99FC61230287BDC2B48DE13D57B13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_933036092485461E719B48DE13D575F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C475271B32E06DA2431348DE13D5B9AE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0FA99FC61230287BDC2B48DE13D57B13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C475271B32E06DA2431348DE13D5B9AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1254AA4FB4BC8014D79248DE13D580B0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0FA99FC61230287BDC2B48DE13D57B13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1254AA4FB4BC8014D79248DE13D580B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7B978F628F53D95B40FA48DE13D5DA19" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B880E3710B6C88B565E748DE13D5052E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7B978F628F53D95B40FA48DE13D5DA19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EBBB23CCF17E83C655BE48DE13D57D32" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B880E3710B6C88B565E748DE13D5052E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EBBB23CCF17E83C655BE48DE13D57D32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_BF25ACBADC78EE9AAA1348DE13D50E4F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B880E3710B6C88B565E748DE13D5052E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_BF25ACBADC78EE9AAA1348DE13D50E4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_232100121516D0A5EA5448DE13D5885E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_BF25ACBADC78EE9AAA1348DE13D50E4F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_232100121516D0A5EA5448DE13D5885E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_07918FBD1C35AF6796DD48DE13D5C0FB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_BF25ACBADC78EE9AAA1348DE13D50E4F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_07918FBD1C35AF6796DD48DE13D5C0FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DCC4964FC090B7C0749448DE13D55906" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_BF25ACBADC78EE9AAA1348DE13D50E4F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_DCC4964FC090B7C0749448DE13D55906" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A6FB10A0130B5D8264CD48DE13D5A171" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_BF25ACBADC78EE9AAA1348DE13D50E4F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_A6FB10A0130B5D8264CD48DE13D5A171" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CFB03DA16141B686321648DE13D6C718" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_BF25ACBADC78EE9AAA1348DE13D50E4F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CFB03DA16141B686321648DE13D6C718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3FA54CE6C7930F5B91C048DE13D6155F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B880E3710B6C88B565E748DE13D5052E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3FA54CE6C7930F5B91C048DE13D6155F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/StockIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06B25301D6F643788EB848DE134B507D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_C60570F163FF388AC6BB48DE134BD4FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06B25301D6F643788EB848DE134B507D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_C60570F163FF388AC6BB48DE134BD4FB" xlink:type="arc" />
    <link:loc xlink:href="alim-20170331.xsd#alim_AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_alim_AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock_08F23C14571D364343A148DE134C4F9A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06B25301D6F643788EB848DE134B507D" xlink:to="loc_alim_AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock_08F23C14571D364343A148DE134C4F9A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/SubsequentEventNotes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_F52C3BA4E07C09E6A637D54852CD27C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_E6228D4D32D75C85A2A9D5487A72818B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_F52C3BA4E07C09E6A637D54852CD27C8" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_E6228D4D32D75C85A2A9D5487A72818B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_941572903D886638E8D648DE13DA5FE2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_115A0B37F6DC54E19B3F48DE13DA00E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_941572903D886638E8D648DE13DA5FE2" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_115A0B37F6DC54E19B3F48DE13DA00E8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_151B75E827362143F766EA0195FC9A41" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1DA0285DD1FB720F8E68EA0195FD968F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_151B75E827362143F766EA0195FC9A41" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1DA0285DD1FB720F8E68EA0195FD968F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_BA19F3D7DE94F63980D66CDB41138B3F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8C1EB1D366733530A4136CEB4270BE7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_BA19F3D7DE94F63980D66CDB41138B3F" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8C1EB1D366733530A4136CEB4270BE7E" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755049904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>May 10, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ALIMERA SCIENCES INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001267602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,901,636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762369280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 26,737,000<span></span>
</td>
<td class="nump">$ 30,979,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">31,000<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">10,768,000<span></span>
</td>
<td class="nump">13,839,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,112,000<span></span>
</td>
<td class="nump">2,107,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net (Note 5)</a></td>
<td class="nump">802,000<span></span>
</td>
<td class="nump">446,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">40,450,000<span></span>
</td>
<td class="nump">47,402,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,572,000<span></span>
</td>
<td class="nump">1,787,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible asset, net (Note 6)</a></td>
<td class="nump">20,125,000<span></span>
</td>
<td class="nump">20,604,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred tax asset</a></td>
<td class="nump">443,000<span></span>
</td>
<td class="nump">436,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">62,590,000<span></span>
</td>
<td class="nump">70,229,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,963,000<span></span>
</td>
<td class="nump">4,986,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses (Note 7)</a></td>
<td class="nump">2,636,000<span></span>
</td>
<td class="nump">3,758,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative warrant liability</a></td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">188,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease obligations</a></td>
<td class="nump">157,000<span></span>
</td>
<td class="nump">191,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,777,000<span></span>
</td>
<td class="nump">9,123,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable (Note 9)</a></td>
<td class="nump">33,409,000<span></span>
</td>
<td class="nump">33,084,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital lease obligations &#8212; less current portion</a></td>
<td class="nump">184,000<span></span>
</td>
<td class="nump">274,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">2,154,000<span></span>
</td>
<td class="nump">2,162,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.01 par value &#8212; 150,000,000 shares authorized, 64,862,904 shares issued and outstanding at March 31, 2017 and December 31, 2016</a></td>
<td class="nump">649,000<span></span>
</td>
<td class="nump">649,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">331,947,000<span></span>
</td>
<td class="nump">330,781,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Common stock warrants</a></td>
<td class="nump">3,707,000<span></span>
</td>
<td class="nump">3,707,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(383,809,000)<span></span>
</td>
<td class="num">(377,074,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,223,000)<span></span>
</td>
<td class="num">(1,272,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">20,066,000<span></span>
</td>
<td class="nump">25,586,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">62,590,000<span></span>
</td>
<td class="nump">70,229,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">19,227,000<span></span>
</td>
<td class="nump">19,227,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">$ 49,568,000<span></span>
</td>
<td class="nump">$ 49,568,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31917-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761710288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">64,862,904<span></span>
</td>
<td class="nump">64,862,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">64,862,904<span></span>
</td>
<td class="nump">64,862,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred stock, liquidation preference</a></td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="nump">$ 24,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">8,417<span></span>
</td>
<td class="nump">8,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">8,416.251<span></span>
</td>
<td class="nump">8,416.251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">8,416.251<span></span>
</td>
<td class="nump">8,416.251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred stock, liquidation preference</a></td>
<td class="nump">$ 50,750,000<span></span>
</td>
<td class="nump">$ 50,750,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761684752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">NET REVENUE</a></td>
<td class="nump">$ 6,618<span></span>
</td>
<td class="nump">$ 5,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION</a></td>
<td class="num">(587)<span></span>
</td>
<td class="num">(378)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">6,031<span></span>
</td>
<td class="nump">5,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES</a></td>
<td class="nump">2,110<span></span>
</td>
<td class="nump">3,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="nump">3,264<span></span>
</td>
<td class="nump">3,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">SALES AND MARKETING EXPENSES</a></td>
<td class="nump">5,502<span></span>
</td>
<td class="nump">7,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">DEPRECIATION AND AMORTIZATION</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">OPERATING EXPENSES</a></td>
<td class="nump">11,542<span></span>
</td>
<td class="nump">14,213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">NET LOSS FROM OPERATIONS</a></td>
<td class="num">(5,511)<span></span>
</td>
<td class="num">(8,790)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">INTEREST EXPENSE, NET AND OTHER</a></td>
<td class="num">(1,337)<span></span>
</td>
<td class="num">(1,335)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">UNREALIZED FOREIGN CURRENCY (LOSS) GAIN, NET</a></td>
<td class="num">(28)<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature', window );">CHANGE IN FAIR VALUE OF DERIVATIVE WARRANT LIABILITY</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">1,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">LOSS ON EARLY EXTINGUISHMENT OF DEBT</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,564)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">NET LOSS BEFORE TAXES</a></td>
<td class="num">(6,709)<span></span>
</td>
<td class="num">(11,136)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">PROVISION FOR TAXES</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (6,735)<span></span>
</td>
<td class="num">$ (11,145)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">NET LOSS PER SHARE &#8212; Basic and diluted (in USD per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE SHARES OUTSTANDING &#8212; Basic and diluted (in shares)</a></td>
<td class="nump">64,862,904<span></span>
</td>
<td class="nump">45,005,833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>(INCREASE) DECREASE IN FAIR VALUE OF PREFERRED STOCK CONVERSION FEATURE</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749205328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (6,735)<span></span>
</td>
<td class="num">$ (11,145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>OTHER COMPREHENSIVE INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">TOTAL OTHER COMPREHENSIVE INCOME</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE LOSS</a></td>
<td class="num">$ (6,686)<span></span>
</td>
<td class="num">$ (11,026)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569643-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761791600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payments of dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,735,000)<span></span>
</td>
<td class="num">(11,145,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">666,000<span></span>
</td>
<td class="nump">689,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory reserve</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign currency transaction loss (gain)</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="num">(34,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,564,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">343,000<span></span>
</td>
<td class="nump">337,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,166,000<span></span>
</td>
<td class="nump">1,296,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature', window );">Change in fair value of derivative warrant liability</a></td>
<td class="num">(167,000)<span></span>
</td>
<td class="num">(1,519,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">3,090,000<span></span>
</td>
<td class="nump">761,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="num">(67,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(361,000)<span></span>
</td>
<td class="nump">164,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,053,000)<span></span>
</td>
<td class="num">(1,522,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(1,147,000)<span></span>
</td>
<td class="nump">1,704,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="num">(13,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,169,000)<span></span>
</td>
<td class="num">(6,735,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(57,000)<span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(57,000)<span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance cost of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(350,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payment of capital lease obligations</a></td>
<td class="num">(38,000)<span></span>
</td>
<td class="num">(64,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(38,000)<span></span>
</td>
<td class="num">(466,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">22,000<span></span>
</td>
<td class="nump">141,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(4,242,000)<span></span>
</td>
<td class="num">(7,135,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS &#8212; Beginning of period</a></td>
<td class="nump">30,979,000<span></span>
</td>
<td class="nump">31,075,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS &#8212; End of period</a></td>
<td class="nump">26,737,000<span></span>
</td>
<td class="nump">23,940,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">985,000<span></span>
</td>
<td class="nump">996,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Property and equipment acquired under capital leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">56,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DebtInstrumentEndofTermPaymentAccrued', window );">Note payable end of term payment accrued but unpaid</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_DebtInstrumentEndofTermPaymentAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, End of Term Payment Accrued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_DebtInstrumentEndofTermPaymentAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>(INCREASE) DECREASE IN FAIR VALUE OF PREFERRED STOCK CONVERSION FEATURE</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase during the period in capital lease obligations due to entering into new capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4542-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1C<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093883-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093879-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752600640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NATURE OF OPERATIONS</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alimera Sciences, Inc., together with its wholly-owned subsidiaries (the Company), is a pharmaceutical company that specializes in the commercialization, research and development of prescription ophthalmic pharmaceuticals. The Company was formed on June&#160;4, 2003 under the laws of the State of Delaware.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is presently focused on diseases affecting the back of the eye, or retina, because the Company&#8217;s management believes these diseases are not well treated with current therapies and represent a significant market opportunity. The Company&#8217;s only commercial product is ILUVIEN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, which has received marketing authorization in the United States (U.S.), Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the&#160;United Kingdom. In the U.S., ILUVIEN is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries in which ILUVIEN has received marketing authorization, it is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies. As part of the approval process in the EEA, the Company committed to conduct a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year, post-authorization, open label registry study in </font><font style="font-family:inherit;font-size:10pt;">800</font><font style="font-family:inherit;font-size:10pt;"> patients treated with ILUVIEN per the labeled indication. In the fourth quarter of 2016, the Company requested approval to modify its protocol to cap enrollment in the study due to its post market safety surveillance not showing any unexpected safety signals. Although the Company has not received formal regulatory approval, the Medicines &amp; Healthcare products Regulatory Agency (MHRA) has agreed to allow the Company to suspend enrollment, pending approval of the Company&#8217;s protocol amendment.&#160;As of March 31, 2017, </font><font style="font-family:inherit;font-size:10pt;">560</font><font style="font-family:inherit;font-size:10pt;"> patients were enrolled in this study.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company launched ILUVIEN in Germany and the United Kingdom in the second quarter of 2013, in the U.S. and Portugal in the first quarter of 2015 and in Austria in the first quarter of 2017.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the Company has entered into various agreements under which distributors will provide regulatory, reimbursement or sales and marketing support for future commercialization of ILUVIEN in numerous countries in the Middle East, Italy, Spain, Australia, New Zealand and Canada.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=SL51803626-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6920275792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BASIS OF PRESENTATION</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has prepared the accompanying unaudited interim condensed consolidated financial statements and notes thereto (Interim Financial Statements) in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for interim financial information and the instructions to Form 10-Q and Article&#160;10-01 of Regulation&#160;S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of the Company&#8217;s management, the accompanying interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary to present fairly the Company&#8217;s interim financial information.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying interim financial statements and related notes should be read in conjunction with the Company&#8217;s audited financial statements for the year ended December&#160;31, 2016 and related notes included in the Company&#8217;s Annual Report on Form 10-K, which was filed with the SEC on March&#160;3, 2017. The financial results for any interim period are not necessarily indicative of the expected financial results for the full year.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Modification of Segment Footnote</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company modified its segment footnote for the three months ended March 31, 2016 for an immaterial change&#160;and removed, within the segment footnote, certain non-cash expenses including </font><font style="font-family:inherit;font-size:10pt;">$1,296,000</font><font style="font-family:inherit;font-size:10pt;"> of stock-based compensation expense and </font><font style="font-family:inherit;font-size:10pt;">$689,000</font><font style="font-family:inherit;font-size:10pt;"> of depreciation and amortization from the Company&#8217;s U.S. and International segments.&#160;These amounts are appropriately classified as Other within the segment footnote of these interim unaudited condensed consolidated financial statements.&#160;Additionally, in the Company&#8217;s Annual Report on Form 10-K filing for the year ended December 31, 2016, the Company disclosed that the Company&#8217;s chief operating decision maker separately managed and evaluated each segment primarily upon net loss from operations.&#160;The modification made in these financial statements clarifies that the chief operating decision maker manages and evaluates each segment based on net loss from operations adjusted for certain non-cash items, such as stock-based compensation expense and depreciation and amortization.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752622080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accounting policies followed for quarterly financial reporting are the same as those disclosed in the Notes to Financial Statements included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2016. </font></div><div style="line-height:174%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:174%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses were </font><font style="font-family:inherit;font-size:10pt;">$350,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$561,000</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended March 31, 2017 and 2016, respectively.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Adoption of New Accounting Standards</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued Accounting Standards Update (ASU) 2014-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</font><font style="font-family:inherit;font-size:10pt;">. ASU 2014-15 requires management to perform interim and annual assessments of an entity&#8217;s ability to continue as a going concern within one year of the date the financial statements are issued and provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. ASU 2014-15 applies to all entities and is effective for annual and interim reporting periods ending after December 15, 2016, with early adoption permitted. The adoption of this guidance did not have a material impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory (Topic 330): Simplifying the Measurement of Inventory</font><font style="font-family:inherit;font-size:10pt;">. This update requires entities to measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. This ASU is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those years. The adoption of this guidance did not have a material impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718)</font><font style="font-family:inherit;font-size:10pt;">. This standard makes several modifications to Topic 718 related to the accounting for forfeitures, employer tax withholding on share-based compensation and the financial statement presentation of excess tax benefits or deficiencies. ASU 2016-09 also clarifies the statement of cash flows presentation for certain components of share-based awards. The standard is effective for interim and annual reporting periods beginning after December 15, 2016, although early adoption is permitted. The adoption of this guidance did not have a material impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Standards Issued but Not Yet Effective</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">, as subsequently amended. ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. The revenue guidance contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The standard is effective for the first interim period within annual reporting periods beginning after December 15, 2017 for public entities, with early adoption permitted in the annual reporting period beginning after December 15, 2016. The Company has begun its evaluation of the new guidance on its business and, at this time, do not believe there will be a material impact on the Company&#8217;s current direct product sales in international markets. For the U.S. business, the Company continues to evaluate the variable consideration provisions of the new guidance and the impact it will have specifically on the Company&#8217;s gross to net revenue adjustments, including chargebacks and rebates. The Company anticipates adopting the new revenue standard using the modified retrospective transition method.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">. This standard requires all leases with durations greater than twelve months to be recognized on the balance sheet and is effective for interim and annual reporting periods beginning after December 15, 2018, although early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption on its financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6920567520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Substantial Doubt about Going Concern</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GOING CONCERN</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, the Company has incurred recurring losses, negative cash flow from operations and has accumulated a deficit of </font><font style="font-family:inherit;font-size:10pt;">$383,809,000</font><font style="font-family:inherit;font-size:10pt;"> from inception through </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had approximately </font><font style="font-family:inherit;font-size:10pt;">$26,737,000</font><font style="font-family:inherit;font-size:10pt;"> in cash and cash equivalents. The Company&#8217;s ability to achieve profitability and positive cash flow is dependent upon its ability to increase revenue and contain its expenses. Further, the Company must maintain compliance with the debt covenants of its debt agreement (see Note 9). In 2016, in order to continue to fund its operations and meet its debt covenants, the Company raised additional equity and amended its debt agreement. In management&#8217;s opinion, the uncertainty regarding future revenues raises substantial doubt about the Company&#8217;s ability to continue as a going concern without access to additional debt or equity financing, over the course of the next twelve months.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to meet the Company&#8217;s working capital needs through the next twelve months and maintain compliance with its debt covenants, the Company may need to raise additional debt or equity financing. The Company may be able to access capital under the Company&#8217;s current at-the-market offering facility, which has approximately </font><font style="font-family:inherit;font-size:10pt;">$21,504,000</font><font style="font-family:inherit;font-size:10pt;"> of remaining availability. The Company implemented a cost savings program in late 2016 that the Company believes will help decrease cash burn over the next twelve months. While the Company has historically been able to raise additional capital through issuance of equity and/or debt financing, and while the Company has a plan in place to reduce spending in order to satisfy its obligations due within one year from the date of issuance of these financial statements, there can be no guarantees on the Company&#8217;s ability to maintain debt compliance, raise additional equity, or successfully implement its cost reduction plans. Accordingly, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after these financial statements are issued.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=64819266&amp;loc=SL51888449-203568<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=64819266&amp;loc=SL51888443-203568<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752622080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INVENTORY</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory consisted of the following: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Component parts (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process (2)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">389</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total inventory</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">850</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">486</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory reserve </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory &#8212; net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">802</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">446</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Component parts inventory consists of manufactured components of the ILUVIEN applicator.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) Work-in-process primarily consists of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing or stability testing as required by regulatory authorities in Europe and the U.S.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752602704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Asset</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INTANGIBLE ASSET</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the U.S. Food and Drug Administration&#8217;s (FDA) approval of the New Drug Application (NDA) for ILUVIEN in September 2014, the Company was required to pay pSivida US, Inc. (pSivida) a milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$25,000,000</font><font style="font-family:inherit;font-size:10pt;"> (the pSivida Milestone Payment) in October 2014 (see Note 8 License Agreements). The Company had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> intangible assets prior to September 2014. </font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The gross carrying amount of the intangible asset was </font><font style="font-family:inherit;font-size:10pt;">$25,000,000</font><font style="font-family:inherit;font-size:10pt;">, which is being amortized over approximately </font><font style="font-family:inherit;font-size:10pt;">13 years</font><font style="font-family:inherit;font-size:10pt;"> from the payment date. The amortization expense related to the intangible asset was </font><font style="font-family:inherit;font-size:10pt;">$478,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$483,000</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended March 31, 2017 and 2016, respectively. The net book value of the intangible asset was </font><font style="font-family:inherit;font-size:10pt;">$20,125,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$20,604,000</font><font style="font-family:inherit;font-size:10pt;"> as of March 31, 2017 and December 31, 2016, respectively.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated future amortization expense as of March 31, 2017 for the remaining periods in the next five years and thereafter is as follows: </font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Years Ending December&#160;31</font></div></td><td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,940</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,940</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,946</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,940</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,897</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,125</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6920372976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ACCRUED EXPENSES</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consisted of the following: </font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued clinical investigator expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">402</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,020</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued rebate, chargeback and other revenue reserves</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">767</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">807</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accrued expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,636</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,758</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752634896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LICENSE AGREEMENTS</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into an agreement with pSivida for the use of fluocinolone acetonide (FAc) in pSivida&#8217;s proprietary delivery device in February 2005, which was subsequently amended in 2008 (the pSivida Agreement). The pSivida Agreement provides the Company with a worldwide exclusive license to utilize certain underlying technology used in the development and commercialization of ILUVIEN.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s license rights to pSivida&#8217;s proprietary delivery device could revert to pSivida if the Company were to (i)&#160;fail twice to cure its breach of an obligation to make certain payments to pSivida following receipt of written notice thereof; (ii)&#160;fail to cure other breaches of material terms of the pSivida Agreement within </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">30</font><font style="font-family:inherit;font-size:10pt;"> days after notice of such breaches or such longer period (up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">90 days</font><font style="font-family:inherit;font-size:10pt;">) as may be reasonably necessary if the breach cannot be cured within such </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">30</font><font style="font-family:inherit;font-size:10pt;">-day period; (iii)&#160;file for protection under the bankruptcy laws, make an assignment for the benefit of creditors, appoint or suffer appointment of a receiver or trustee over its property, file a petition under any bankruptcy or insolvency act or have any such petition filed against it and such proceeding remains undismissed or unstayed for a period of more than </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60 days</font><font style="font-family:inherit;font-size:10pt;">; or (iv)&#160;notify pSivida in writing of its decision to abandon its license with respect to a certain product using pSivida&#8217;s proprietary delivery device.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company must share </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20%</font><font style="font-family:inherit;font-size:10pt;"> of the net profits of ILUVIEN, determined on a cash basis and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">33%</font><font style="font-family:inherit;font-size:10pt;"> of any lump sum milestone payments received from a sub-licensee of ILUVIEN, as defined by the pSivida Agreement. In connection with this arrangement, the Company is entitled to recover </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20%</font><font style="font-family:inherit;font-size:10pt;"> of commercialization costs of ILUVIEN, as defined in the pSivida Agreement, incurred prior to product profitability out of pSivida&#8217;s share of net profits. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company can reduce future net profit payments to pSivida, as defined in the pSivida Agreement, in the amounts of </font><font style="font-family:inherit;font-size:10pt;">$24,909,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$24,475,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. Due to the uncertainty of future net profits, the Company has fully reserved these amounts in the accompanying Interim Financial Statements. As a result of the FDA&#8217;s approval of the NDA for ILUVIEN in September 2014, the Company made the pSivida Milestone Payment of </font><font style="font-family:inherit;font-size:10pt;">$25,000,000</font><font style="font-family:inherit;font-size:10pt;"> in October 2014.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the second quarter of 2016, pSivida disputed portions of the Company&#8217;s claimed commercialization costs for the year ended December 31, 2014. On May 3, 2017, the Company and pSivida settled this dispute and amended and clarified certain definitions and clauses of the pSivida Agreement. As part of this settlement, the Company and pSivida agreed no additional amounts would be due for the years ended December 31, 2014, 2015 and 2016 and no audits will take place related to the amounts reported for the years ended December 31, 2015 and 2016. As a result of this settlement and amendment, the amount available for the reduction of future net profit payments was reduced from </font><font style="font-family:inherit;font-size:10pt;">$25,828,000</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$24,475,000</font><font style="font-family:inherit;font-size:10pt;"> as of December 31, 2016. Since these amounts are fully reserved, there was no impact to the statements of operations for any period as a result of this settlement and amendment.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752597408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Loan Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LOAN AGREEMENTS</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hercules Loan Agreement</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2014 Loan Agreement</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, Alimera Sciences Limited (Limited), a subsidiary of the Company, entered into a loan and security agreement (2014 Loan Agreement) with Hercules Capital, Inc. (Hercules) providing for a term loan of up to </font><font style="font-family:inherit;font-size:10pt;">$35,000,000</font><font style="font-family:inherit;font-size:10pt;"> (2014 Term Loan), which Limited and Hercules amended in November 2015 (the First Loan Amendment), March 2016 (the Second Loan Amendment), May 2016 (the Third Loan Amendment) and October 2016 (the Fourth Loan Amendment and, collectively with the 2014 Loan Agreement, the First Loan Amendment, the Second Loan Amendment and the Third Loan Amendment, the Term Loan Agreement). Under the 2014 Loan Agreement, Hercules made an advance in the initial principal amount of&#160;</font><font style="font-family:inherit;font-size:10pt;">$10,000,000</font><font style="font-family:inherit;font-size:10pt;">&#160;to Limited at closing to provide Limited with additional working capital for general corporate purposes and to repay a 2013 term loan with Silicon Valley Bank. Hercules made an additional advance of </font><font style="font-family:inherit;font-size:10pt;">$25,000,000</font><font style="font-family:inherit;font-size:10pt;"> to Limited in September 2014, following the approval of ILUVIEN by the FDA to fund the pSivida Milestone Payment. The 2014 Loan Agreement provided for interest only payments through November 2015. Interest on the 2014 Term Loan accrued at a floating per annum rate equal to the greater of (i) </font><font style="font-family:inherit;font-size:10pt;">10.90%</font><font style="font-family:inherit;font-size:10pt;">, or (ii) the sum of (A) </font><font style="font-family:inherit;font-size:10pt;">7.65%</font><font style="font-family:inherit;font-size:10pt;">, plus (B) the prime rate. Following the interest only period the 2014 Term Loan was due and payable to Hercules in equal monthly payments of principal and interest through May 1, 2018. The interest rate on the Term Loan Agreement was </font><font style="font-family:inherit;font-size:10pt;">11.25%</font><font style="font-family:inherit;font-size:10pt;"> as of December 31, 2016.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">First Loan Amendment</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, Limited and Hercules amended the 2014 Loan Agreement to extend the interest only payments through May 2017. In connection with the First Loan Amendment, Limited paid to Hercules an amendment fee of </font><font style="font-family:inherit;font-size:10pt;">$262,500</font><font style="font-family:inherit;font-size:10pt;"> and agreed to make an additional payment of </font><font style="font-family:inherit;font-size:10pt;">$1,050,000</font><font style="font-family:inherit;font-size:10pt;">, equal to </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> of the 2014 Term Loan at the time of the final payment (End of Term Payment).</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Limited and the Company, on a consolidated basis with the Company&#8217;s other subsidiaries (the Consolidated Group), agreed to customary affirmative and negative covenants and events of default in connection with these arrangements. The occurrence of an event of default could result in the acceleration of Limited&#8217;s obligations under the Term Loan Agreement and an increase to the applicable interest rate and would permit Hercules to exercise remedies with respect to the collateral under the Term Loan Agreement. In connection with the First Loan Amendment, Limited agreed to covenants regarding certain revenue thresholds and a liquidity threshold.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Second Loan Amendment</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the revenue threshold covenant was not met by the Consolidated Group and as a result, in March 2016, Limited and Hercules entered into the Second Loan Amendment, which further amended certain terms of the 2014 Loan Agreement. In conjunction with the Second Loan Amendment, Hercules waived this covenant violation.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Second Loan Amendment adjusted the revenue covenant to a rolling three-month calculation, first measured for the three months ended May 31, 2016. In addition, the Second Loan Amendment increased the liquidity covenant. Upon execution of the Second Loan Amendment, Limited paid Hercules an amendment fee of </font><font style="font-family:inherit;font-size:10pt;">$350,000</font><font style="font-family:inherit;font-size:10pt;"> and agreed to increase the End of Term Payment to </font><font style="font-family:inherit;font-size:10pt;">$1,400,000</font><font style="font-family:inherit;font-size:10pt;"> from </font><font style="font-family:inherit;font-size:10pt;">$1,050,000</font><font style="font-family:inherit;font-size:10pt;">, which is payable in May 2018.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company concluded that the Second Loan Amendment resulted in a substantial modification of the terms of debt when considered with the First Loan Amendment in accordance with the guidance in ASC 470-50, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt</font><font style="font-family:inherit;font-size:10pt;">. As a result, the Company accounted for the Second Loan Amendment as an extinguishment and recognized a loss on early extinguishment of debt of approximately </font><font style="font-family:inherit;font-size:10pt;">$2,564,000</font><font style="font-family:inherit;font-size:10pt;"> within the consolidated statement of operations for the year ended December 31, 2016. The loss on early extinguishment consisted primarily of the unamortized debt discount associated with the warrant and debt issuance costs incurred prior to the Second Loan Amendment, the incremental fair value of the warrant as a result of modifying the terms of the warrant and the debt issuance costs of </font><font style="font-family:inherit;font-size:10pt;">$360,000</font><font style="font-family:inherit;font-size:10pt;"> paid to Hercules for the Second Loan Amendment.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Third Loan Amendment and July 2016 Waiver</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016, Limited and Hercules entered into the Third Loan Amendment to expand the definition of liquidity to allow for the inclusion of cash of up to </font><font style="font-family:inherit;font-size:10pt;">$2,000,000</font><font style="font-family:inherit;font-size:10pt;"> in bank accounts outside of the U.S. and the United Kingdom.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2016, Limited obtained a waiver of the requirements of the liquidity covenant (the Waiver) because the Consolidated Group was not in compliance with the liquidity covenant as of June 30, 2016. The Waiver cured the default of the liquidity covenant then existing under the Term Loan Agreement and decreased the liquidity requirement. In addition, the Waiver modified the three-month revenue covenant so that it was not measured at July 31, 2016 and reduced the three-month revenue target to be measured at August 31, 2016. Following execution of the Waiver, Limited incurred a weekly ticking fee equal to </font><font style="font-family:inherit;font-size:10pt;">0.05%</font><font style="font-family:inherit;font-size:10pt;"> multiplied by the outstanding principal amount through the closing of the Company&#8217;s public offering in August 2016 (see Note 12 Common Stock), totaling </font><font style="font-family:inherit;font-size:10pt;">$65,000</font><font style="font-family:inherit;font-size:10pt;">. Further, Limited paid Hercules a fee of </font><font style="font-family:inherit;font-size:10pt;">$350,000</font><font style="font-family:inherit;font-size:10pt;"> associated with the Waiver.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Fourth Loan Amendment</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, Limited entered into the Fourth Loan Amendment with Hercules, which further amended certain terms of the Term Loan Agreement. Pursuant to the terms of the Fourth Loan Amendment, Hercules agreed to provide up to an additional </font><font style="font-family:inherit;font-size:10pt;">$10,000,000</font><font style="font-family:inherit;font-size:10pt;"> to Limited with (i) the first </font><font style="font-family:inherit;font-size:10pt;">$5,000,000</font><font style="font-family:inherit;font-size:10pt;"> available at Limited&#8217;s option through June 30, 2017 subject to (A) the Consolidated Group&#8217;s achievement of </font><font style="font-family:inherit;font-size:10pt;">$12,000,000</font><font style="font-family:inherit;font-size:10pt;"> in trailing three month net product revenue and (B) no event of default having occurred since October 20, 2016 (the Effective Date) and (ii) the second </font><font style="font-family:inherit;font-size:10pt;">$5,000,000</font><font style="font-family:inherit;font-size:10pt;"> available at Limited&#8217;s option through December 31, 2017 subject to (A) the Consolidated Group&#8217;s achievement of </font><font style="font-family:inherit;font-size:10pt;">$15,000,000</font><font style="font-family:inherit;font-size:10pt;"> in trailing three month net product revenue, (B) no event of default having occurred since the Effective Date and (C) the prior </font><font style="font-family:inherit;font-size:10pt;">$5,000,000</font><font style="font-family:inherit;font-size:10pt;"> having been advanced to Limited (the Additional Advances and, together with the 2014 Term Loan, the Term Loan). The Fourth Loan Amendment provides for interest only payments through November 30, 2018 (the Interest-Only Period). Pursuant to the Fourth Loan Amendment, interest on the Term Loan accrues at a floating per annum rate equal the greater of (i) </font><font style="font-family:inherit;font-size:10pt;">11.0%</font><font style="font-family:inherit;font-size:10pt;"> and (ii) the sum of (A) </font><font style="font-family:inherit;font-size:10pt;">11.0%</font><font style="font-family:inherit;font-size:10pt;"> plus (B) the prime rate as reported in The Wall Street Journal, or if not reported, the prime rate most recently reported in The Wall Street Journal, minus </font><font style="font-family:inherit;font-size:10pt;">3.5%</font><font style="font-family:inherit;font-size:10pt;">. In addition to the interest described above, the principal balance of the Term Loan will bear &#8220;payment-in kind&#8221; interest at the rate of </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;"> (PIK Interest), which PIK Interest will be added to the outstanding principal balance of the Term Loan so as to increase the outstanding principal balance of the Term Loan on each payment date for the Term Loan and which amount will be payable when the aggregate outstanding principal amount of the Term Loan is payable. The Term Loan will be due and payable to Hercules in </font><font style="font-family:inherit;font-size:10pt;">24</font><font style="font-family:inherit;font-size:10pt;"> equal monthly payments of principal and interest following the Interest-Only Period beginning on December 1, 2018 and matures in full on November 1, 2020.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Limited paid Hercules a facility charge of </font><font style="font-family:inherit;font-size:10pt;">$337,500</font><font style="font-family:inherit;font-size:10pt;"> and reimbursed Hercules for legal and diligence fees incurred in connection with the Fourth Loan Amendment. If Limited prepays the Term Loan, it will pay Hercules a prepayment penalty (i) if such amounts are prepaid in any of the first 12 months following the Effective Date, equal to </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of the Term Loan being repaid, (ii) if such amounts are prepaid after 12 months but prior to 24 months following the Effective Date, equal to </font><font style="font-family:inherit;font-size:10pt;">2.0%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of the Term Loan being repaid, and (iii) if such amounts are prepaid at any time thereafter, equal to </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of the Term Loan being repaid.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Consolidated Group also agreed to customary affirmative and negative covenants, including, without limitation, covenants relating to minimum liquidity, minimum trailing six-month net revenue and adjusted EBITDA and events of default in connection with these arrangements. The occurrence of an event of default could result in the acceleration of Limited&#8217;s obligations under the Term Loan Agreement, as amended by the Fourth Loan Amendment and an increase to the applicable interest rate and would permit Hercules to exercise remedies with respect to the collateral under the Term Loan Agreement, as amended by the Fourth Loan Amendment. In the event that the Company maintains </font><font style="font-family:inherit;font-size:10pt;">$35,000,000</font><font style="font-family:inherit;font-size:10pt;"> in liquidity, including cash and eligible accounts receivable, at the end of the month and has not been and is not in breach of the amended debt facility, the six-month trailing revenue covenant is waived for such month. As of March 31, 2017, the Company was in compliance with its debt covenants.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">General Discussion of the Term Loan Agreement</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Term Loan Agreement, Limited&#8217;s obligations to Hercules are secured by a first-priority security interest in substantially all of Limited&#8217;s assets, excluding intellectual property. Hercules does, however, maintain a negative pledge on Limited&#8217;s intellectual property requiring Hercules&#8217; consent prior to the sale of such intellectual property. The Company and certain of the Company&#8217;s other subsidiaries are guarantors of the obligations of Limited to Hercules under the Term Loan Agreement pursuant to separate guaranty agreements between Hercules and each of Limited and such subsidiaries (Guaranties). Pursuant to the Guaranties, the Company and these subsidiaries granted Hercules a first-priority security interest in substantially all of their respective assets excluding intellectual property. The Term Loan Agreement also places limitations on the Company&#8217;s ability to declare or pay any dividend or distribution on any shares of capital stock.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2014 Warrant</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with Limited entering into the 2014 Loan Agreement, the Company issued a warrant to Hercules to purchase up to </font><font style="font-family:inherit;font-size:10pt;">285,016</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$6.14</font><font style="font-family:inherit;font-size:10pt;"> per share (the 2014 Warrant). </font><font style="font-family:inherit;font-size:10pt;">Sixty percent</font><font style="font-family:inherit;font-size:10pt;"> of the 2014 Warrant was exercisable at the closing in April 2014 and the remaining </font><font style="font-family:inherit;font-size:10pt;">forty percent</font><font style="font-family:inherit;font-size:10pt;"> became exercisable upon the funding of the additional </font><font style="font-family:inherit;font-size:10pt;">$25,000,000</font><font style="font-family:inherit;font-size:10pt;"> to Limited in September 2014.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company agreed to amend the 2014 Warrant in connection with the First Loan Amendment to increase the number of shares issuable upon exercise to </font><font style="font-family:inherit;font-size:10pt;">660,377</font><font style="font-family:inherit;font-size:10pt;"> and decrease the exercise price to </font><font style="font-family:inherit;font-size:10pt;">$2.65</font><font style="font-family:inherit;font-size:10pt;"> per share. Upon entering into the Second Loan Amendment, the Company agreed to further amend the 2014 Warrant to increase the number of shares issuable upon exercise to </font><font style="font-family:inherit;font-size:10pt;">862,069</font><font style="font-family:inherit;font-size:10pt;"> and decrease the exercise price to </font><font style="font-family:inherit;font-size:10pt;">$2.03</font><font style="font-family:inherit;font-size:10pt;"> per share. In connection with the July 2016 Waiver, the Company agreed to further amend the 2014 Warrant to increase the number of shares issuable upon exercise to </font><font style="font-family:inherit;font-size:10pt;">1,258,993</font><font style="font-family:inherit;font-size:10pt;"> and decrease the exercise price to </font><font style="font-family:inherit;font-size:10pt;">$1.39</font><font style="font-family:inherit;font-size:10pt;"> per share. </font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016 Warrant</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with Limited entering into the Fourth Loan Amendment, the Company agreed to issue a new warrant to Hercules (the 2016 Warrant) to purchase up to </font><font style="font-family:inherit;font-size:10pt;">458,716</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.09</font><font style="font-family:inherit;font-size:10pt;"> per share, which was equal to </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;"> divided by the lowest volume-weighted average sale price for a share of the Company&#8217;s common stock reported over any ten consecutive trading days during the period commencing on and including September 23, 2016 and ending on the earlier to occur of (i) December 30, 2016 (inclusive of such date), and (ii) the second trading day immediately preceding the date of closing of a merger event (as defined in the 2016 Warrant).</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Debt</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average interest rates of the Company&#8217;s notes payable approximate the rate at which the Company could obtain alternative financing and the fair value of the warrants that were issued in connection with the Company&#8217;s notes payable are immaterial. Therefore, the carrying amount of the notes approximated their fair value at March 31, 2017 and December 31, 2016.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752622624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (EPS)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share (EPS)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LOSS PER SHARE (EPS)</font></div><div style="line-height:120%;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic EPS is calculated in accordance with ASC 260, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings per Share</font><font style="font-family:inherit;font-size:10pt;">, by dividing net income or loss attributable to common stockholders by the weighted average common stock outstanding. Diluted EPS is calculated in accordance with ASC 260 by adjusting weighted average common shares outstanding for the dilutive effect of common stock options, warrants and convertible preferred stock. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be anti-dilutive. Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because to do so would have been anti-dilutive, were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,022,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,022,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,416,251</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,416,251</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,511,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,511,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,795,663</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">940,023</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,696,269</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,626,077</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,442,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,516,186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752562160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PREFERRED STOCK</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Series A Convertible Preferred Stock</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October&#160;2, 2012, the Company closed its preferred stock financing in which it sold units consisting of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Convertible Preferred Stock and warrants to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">300,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Convertible Preferred Stock for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$40,000,000</font><font style="font-family:inherit;font-size:10pt;">, prior to the payment of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$560,000</font><font style="font-family:inherit;font-size:10pt;"> of related issuance costs. The powers, preferences and rights of the Series A Convertible Preferred Stock are set forth in the certificate of designation filed by the Company with the Secretary of State of the State of Delaware on October&#160;1, 2012. Each share of Series A Convertible Preferred Stock, including any shares of Series A Convertible Preferred Stock issued upon exercise of the warrants, is convertible into shares of the Company&#8217;s common stock at any time at the option of the holder at the rate equal to </font><font style="font-family:inherit;font-size:10pt;">$40.00</font><font style="font-family:inherit;font-size:10pt;"> divided by </font><font style="font-family:inherit;font-size:10pt;">$2.66</font><font style="font-family:inherit;font-size:10pt;"> (Conversion Price). The initial Conversion Price was subject to adjustment based on certain customary price based anti-dilution adjustments. These adjustment features lapsed in September 2014. Each share of Series A Convertible Preferred Stock shall automatically be converted into shares of common stock at the then-effective Conversion Price upon the occurrence of the later to occur of both (i)&#160;the Company receives and publicly announces the approval by the FDA of the Company&#8217;s NDA for ILUVIEN and (ii)&#160;the date on which the Company consummates an equity financing transaction pursuant to which the Company sells to one or more third party investors either (a)&#160;shares of common stock or (b)&#160;other equity securities that are convertible into shares of common stock and that have rights, preference or privileges, senior to or on a parity with, the Series A Convertible Preferred Stock, in each case having an as-converted per share of common stock price of not less than </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$10.00</font><font style="font-family:inherit;font-size:10pt;"> and that results in total gross proceeds to the Company of at least </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$30,000,000</font><font style="font-family:inherit;font-size:10pt;">. The rights and preferences of Series A Convertible Preferred Stock also place limitations on the Company&#8217;s ability to declare or pay any dividend or distribution on any shares of capital stock.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each unit sold in the preferred stock financing included a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.30</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Convertible Preferred Stock at an exercise price equal to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$44.00</font><font style="font-family:inherit;font-size:10pt;"> per share. At the election of the holder of a warrant, the warrant may be exercised for the number of shares of common stock then issuable upon conversion of the Series A Convertible Preferred Stock that would otherwise be issued upon such exercise at the then-effective Conversion Price. </font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants are considered derivative instruments because the agreements provide for settlement in Series A Convertible Preferred Stock shares or common stock shares at the option of the holder, an adjustment to the warrant exercise price for common shares at some point in the future and contain anti-dilution provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants are subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. Therefore the warrants were recorded as a liability at issuance. The warrant anti-dilution provisions lapsed in September 2014. At </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the fair market value of the warrants was estimated to be </font><font style="font-family:inherit;font-size:10pt;">$21,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$188,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. During the three months ended March 31, 2017 and 2016, the Company recorded gains of </font><font style="font-family:inherit;font-size:10pt;">$167,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,519,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, as a result of the change in fair value of the warrants. The rights to exercise these warrants expire on October 1, 2017.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, </font><font style="font-family:inherit;font-size:10pt;">2,255,639</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock were issued pursuant to the conversion of </font><font style="font-family:inherit;font-size:10pt;">150,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Convertible Preferred Stock held by an investor. In September 2014, </font><font style="font-family:inherit;font-size:10pt;">3,759,398</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock were issued pursuant to the conversion of </font><font style="font-family:inherit;font-size:10pt;">250,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Convertible Preferred Stock held by another investor. As of March 31, 2017, there were </font><font style="font-family:inherit;font-size:10pt;">600,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Convertible Preferred Stock issued and outstanding.</font></div><div style="line-height:120%;padding-top:10px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Series B Convertible Preferred Stock</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December&#160;12, 2014, the Company closed a preferred stock financing in which it sold </font><font style="font-family:inherit;font-size:10pt;">8,291.873</font><font style="font-family:inherit;font-size:10pt;"> shares of Series B Convertible Preferred Stock for a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$6,030</font><font style="font-family:inherit;font-size:10pt;"> per share, or an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$50,000,000</font><font style="font-family:inherit;font-size:10pt;">, prior to the payment of approximately </font><font style="font-family:inherit;font-size:10pt;">$432,000</font><font style="font-family:inherit;font-size:10pt;"> of related issuance costs. The Company issued an additional </font><font style="font-family:inherit;font-size:10pt;">124.378</font><font style="font-family:inherit;font-size:10pt;"> shares of Series B Convertible Preferred Stock as a subscription premium to the purchasers. The powers, preferences and rights of the Series B Convertible Preferred Stock are set forth in the certificate of designation filed by the Company with the Secretary of State of the State of Delaware. Each share of Series B Convertible Preferred Stock is convertible into </font><font style="font-family:inherit;font-size:10pt;">1,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock at any time at the option of the holder, provided that the holder will be prohibited from converting Series B Convertible Preferred Stock into shares of the Company&#8217;s common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than </font><font style="font-family:inherit;font-size:10pt;">9.98%</font><font style="font-family:inherit;font-size:10pt;"> of the total number of shares of the Company&#8217;s common stock then issued and outstanding. The Series B Convertible Preferred Stock ranks junior to the Company&#8217;s existing Series A Convertible Preferred Stock and senior to the Company&#8217;s common stock, with respect to rights upon liquidation. The Series B Convertible Preferred Stock ranks junior to all existing and future indebtedness. Except as otherwise required by law (or with respect to approval of certain actions), the Series B Convertible Preferred Stock do not have voting rights. The Series B Convertible Preferred Stock is not redeemable at the option of the holder. The Series B Convertible Preferred Stock is not subject to any price-based or other anti-dilution protections and does not provide for any accruing dividends.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the conversion option of the Series B Convertible Preferred Stock represented a beneficial conversion feature, as the conversion feature had intrinsic value to the holder on the commitment date as a result of the subscription premium. Therefore, the Company recorded a beneficial conversion feature of </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;"> as an increase in additional paid in capital. Because the Series B Convertible Preferred Stock was immediately convertible into common stock at the option of the holder at issuance, the Company immediately accreted the full value of the beneficial conversion feature to the carrying value of the Series B Convertible Preferred Stock on that date.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761603808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMMON STOCK</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2014, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen) to offer shares of its common stock from time to time through Cowen for the offer and sale of the shares up to an aggregate offering price of </font><font style="font-family:inherit;font-size:10pt;">$35,000,000</font><font style="font-family:inherit;font-size:10pt;">. In 2016, the Company sold a total of </font><font style="font-family:inherit;font-size:10pt;">662,779</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock at a weighted average purchase price of </font><font style="font-family:inherit;font-size:10pt;">$1.83</font><font style="font-family:inherit;font-size:10pt;"> per share, resulting in gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$1,211,000</font><font style="font-family:inherit;font-size:10pt;">, prior to the payment of approximately </font><font style="font-family:inherit;font-size:10pt;">$62,000</font><font style="font-family:inherit;font-size:10pt;"> of underwriter discounts and commissions and related issuance costs. Proceeds from the offering were used for general corporate and working capital purposes. The Company did not sell shares during the three months ended March 31, 2017. As of March 31, 2017, the Company can sell up to approximately </font><font style="font-family:inherit;font-size:10pt;">$21,504,000</font><font style="font-family:inherit;font-size:10pt;"> of its common stock under the terms of the sales agreement with Cowen.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, in August, 2016, pursuant to an underwriting agreement with Cowen, as representative of the several underwriters named therein, the Company closed a public offering in which it sold </font><font style="font-family:inherit;font-size:10pt;">18,900,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock at a price to the public of&#160;</font><font style="font-family:inherit;font-size:10pt;">$1.40</font><font style="font-family:inherit;font-size:10pt;">&#160;per share. The offering resulted in gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$26,460,000</font><font style="font-family:inherit;font-size:10pt;">, prior to the payment of approximately </font><font style="font-family:inherit;font-size:10pt;">$1,309,000</font><font style="font-family:inherit;font-size:10pt;"> of underwriter discounts and commissions and related issuance costs.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6920649120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Incentive Plans</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCK INCENTIVE PLANS</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Option Plans</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended March 31, 2017 and 2016, the Company recorded compensation expense related to stock options of approximately </font><font style="font-family:inherit;font-size:10pt;">$972,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,264,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of March 31, 2017, the total unrecognized compensation cost related to non-vested stock options granted was </font><font style="font-family:inherit;font-size:10pt;">$7,877,000</font><font style="font-family:inherit;font-size:10pt;"> and is expected to be recognized over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">2.40 years</font><font style="font-family:inherit;font-size:10pt;">. The following table presents a summary of stock option activity for the three months ended March 31, 2017 and 2016:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding at beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,804,412</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,475,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,312,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,228,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.46</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeitures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(420,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77,813</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding at period end</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,696,269</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,626,077</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable at period end</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,527,392</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,310,239</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average per share fair value of options granted during the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.86</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides additional information related to outstanding stock options, exercisable stock options and stock options expected to vest as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,696,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.71 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">289</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,527,392</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.52 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, vested and expected to vest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,131,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.58 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides additional information related to outstanding stock options, exercisable stock options and stock options expected to vest as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,804,412</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.45 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,363,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.42 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, vested and expected to vest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,374,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.35 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended March 31, 2017 and 2016, the Company recorded compensation expense related to its employee stock purchase plan of approximately </font><font style="font-family:inherit;font-size:10pt;">$13,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$32,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Units</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the Company granted </font><font style="font-family:inherit;font-size:10pt;">873,900</font><font style="font-family:inherit;font-size:10pt;"> restricted stock units (RSUs) to its employees in lieu of a cash bonus program for 2017. As of March 31, 2017, </font><font style="font-family:inherit;font-size:10pt;">815,700</font><font style="font-family:inherit;font-size:10pt;"> RSUs were outstanding. During the three months ended March 31, 2017, the Company recorded compensation expense related these RSUs of </font><font style="font-family:inherit;font-size:10pt;">$182,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6616239632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCOME TAXES</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC 740, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes,</font><font style="font-family:inherit;font-size:10pt;"> the Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities at the enacted tax rates in effect for the year in which the differences are expected to reverse. The Company records a valuation allowance against its net deferred tax asset to reduce the net carrying value to an amount that is more likely than not to be realized.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the end of each interim period, the Company makes its best estimate of the effective tax rate expected to be applicable for the full fiscal year. This estimate reflects, among other items, the Company&#8217;s best estimate of operating results and foreign currency exchange rates. The Company&#8217;s quarterly income tax rate may differ from its estimated annual effective tax rate because accounting standards require the Company to exclude the actual results of certain entities expected to generate a pretax loss when applying the estimated annual effective tax rate to the Company&#8217;s consolidated pretax results in interim periods. In estimating the annual effective tax rate, the Company does not include the estimated impact of unusual and/or infrequent items, including the reversal of valuation allowances, which may cause significant variations in the customary relationship between income tax expense (benefit) and pretax income (loss) in quarterly periods. The income tax expense (benefit) for such unusual and/or infrequent items is recorded in the quarterly period such items are incurred.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s income tax expense and resulting effective tax rate are based upon the respective estimated annual effective tax rates applicable for the respective periods adjusted for the effects of items required to be treated as discrete to the period, including changes in tax laws, changes in estimated exposures for uncertain tax positions and other items. The Company&#8217;s effective tax rate for the three months ended March 31, 2017 properly excluded tax benefits associated with year-to-date pre-tax losses generated in the U.S. and the Netherlands. Income tax positions are considered for uncertainty in accordance with ASC 740-10. The Company has recorded unrecognized tax benefits related to research and development tax credits. In accordance with ASC 740-10, such attributes are reduced to the amount that is expected to be recognized in the future. The Company has not accrued interest or penalties as no research and development credits have been utilized due to significant net operating losses (NOLs) available. The Company does not expect any decreases to the unrecognized tax benefits within the next twelve months due to any lapses in statute of limitations. Tax years since 2003 remain subject to examination in Georgia, Tennessee and at the federal level. The time period is longer than the standard statutory 3-year period due to NOLs from 2003 being available for utilization. The statute of limitations on these years will close when the NOLs expire or when the statute closes on the years in which the NOLs are utilized. Tax years since 2012 remain subject to examination in the United Kingdom and the Netherlands. Tax years since 2013 remain subject to examination in Germany.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant management judgment is involved in determining the provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. Due to uncertainties with respect to the realization of deferred tax assets due to the history of operating losses, a valuation allowance has been established against the net deferred tax asset balance in the U.S. and the Netherlands. The valuation allowance is based on management&#8217;s estimates of taxable income in the jurisdictions in which the Company operates and the period over which deferred tax assets will be recoverable. In the event that actual results differ from these estimates or the Company adjusts these estimates in future periods, a change in the valuation allowance may be needed, which could materially impact its financial position and results of operations.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, 2016, the Company had federal NOL carry-forwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$104,944,000</font><font style="font-family:inherit;font-size:10pt;"> and state NOL carry-forwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$83,270,000</font><font style="font-family:inherit;font-size:10pt;"> available to reduce future taxable income. The Company&#8217;s federal NOL carry-forwards remain fully reserved as of March 31, 2017. If not utilized, the federal NOL carry-forwards will expire at various dates between 2029 and 2035 and the state NOL carry-forwards will expire at various dates between 2020 and 2035. </font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NOL carry-forwards may be subject to annual limitations under Internal Revenue Code (IRC) Section&#160;382 (Section 382) (or comparable provisions of state law) in the event that certain changes in ownership of the Company were to occur. The Company periodically evaluates its NOL carry-forwards and whether certain changes in ownership have occurred that would limit the Company&#8217;s ability to utilize a portion of its NOL carry-forwards. If it is determined that significant ownership changes have occurred since the Company generated its NOL carry-forwards, it may be subject to annual limitations on the use of these NOL carry-forwards under Section&#160;382 (or comparable provisions of state law). The Company has determined that a Section 382 change in ownership occurred in late 2015.&#160;Therefore, the annual utilization of the Company&#8217;s NOLs are subject to certain limitations under Section 382 and other limitations under state tax laws.&#160;The Company is currently in the process of calculating these limitations. Any reduction to the Company&#8217;s NOL deferred tax asset due to the annual Section 382 limitation and the NOL carryforward period would result in an offsetting reduction in valuation allowance recorded against the NOL deferred tax asset. Therefore, any limitation would not have an impact on the statements of operations for the periods presented. The results of the analysis on the impact to the Company&#8217;s NOLs will be disclosed at a later date.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2016, the Company had cumulative book losses in foreign subsidiaries of </font><font style="font-family:inherit;font-size:10pt;">$92,939,000</font><font style="font-family:inherit;font-size:10pt;">. The Company has not recorded a deferred tax asset for the excess of tax over book basis in the stock of its foreign subsidiaries. The Company anticipates that its foreign subsidiaries will be profitable and have earnings in the future. Once the foreign subsidiaries do have earnings, the Company intends to indefinitely reinvest in its foreign subsidiaries all undistributed earnings of and original investments in such subsidiaries. As a result, the Company has not recorded a deferred tax liability related to excess of book over tax basis in the stock of its foreign subsidiaries in accordance with ASC 740-30-25.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6920614064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FAIR VALUE</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company applies ASC 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:inherit;font-size:10pt;">, in determining the fair value of certain assets and liabilities. Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining fair value, the Company uses various valuation approaches. The hierarchy of those valuation approaches is broken down into three levels based on the reliability of inputs as follows:</font></div><div style="line-height:120%;padding-top:10px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. The valuation under this approach does not entail a significant degree of judgment.</font></div><div style="line-height:120%;padding-top:10px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets, inputs other than quoted prices that are observable for the asset or liability, (e.g., interest rates and yield curves observable at commonly quoted intervals or current market) and contractual prices for the underlying financial instrument, as well as other relevant economic measures.</font></div><div style="line-height:120%;padding-top:10px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no changes in the methodologies used at March 31, 2017 and December 31, 2016.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following fair value table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents (1)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative warrant liability (2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents (1)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative warrant liability (2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:-2px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:-2px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6920301376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SEGMENT INFORMATION</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended March 31, 2017 and 2016, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> customers within the U.S. segment accounted for </font><font style="font-family:inherit;font-size:10pt;">67%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">71%</font><font style="font-family:inherit;font-size:10pt;">, respectively, of the Company&#8217;s consolidated revenues as a result of our sales to large pharmaceutical distributors in the U.S. These </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> customers within the U.S. segment accounted for approximately </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">90%</font><font style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s consolidated accounts receivable at March 31, 2017 and December 31, 2016, respectively. The Company&#8217;s chief operating decision maker is the Chief Executive Officer (CEO). While the CEO is apprised of a variety of financial metrics and information, the business is principally managed and organized based upon geographic and regulatory environment. Each segment is separately managed and is evaluated primarily upon segment loss from operations. Non-cash items including stock-based compensation expense and depreciation and amortization are categorized as Other within the table below.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents a summary of the Company&#8217;s reporting segments for the three months ended March 31, 2017 and 2016:</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/>March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/>March 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">International</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Consolidated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">International</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Consolidated</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="31" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NET REVENUE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,445</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(448</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(139</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(587</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(156</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(378</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">GROSS PROFIT</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,110</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">GENERAL AND ADMINISTRATIVE EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,705</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">918</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">641</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,264</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,921</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">714</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">760</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">SALES AND MARKETING EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,045</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">DEPRECIATION AND AMORTIZATION</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">666</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">666</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">689</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">689</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">OPERATING EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,908</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,802</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,832</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,542</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8,939</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,289</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,985</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,213</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">SEGMENT LOSS FROM OPERATIONS</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,911</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(768</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,832</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5,511</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5,042</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,763</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,985</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8,790</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">OTHER INCOME AND EXPENSES, NET</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NET LOSS BEFORE TAXES</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(11,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8981-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9038-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 33<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8971-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8595-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8380-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 35<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8984-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9031-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8538-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8864-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8924-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752622624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Notes)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUBSEQUENT EVENT</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As disclosed in Note 8 License Agreements, the Company and pSivida settled their dispute and amended and clarified certain definitions and clauses of the pSivida Agreement on May 3, 2017. The specific terms of the settlement and amendment are described in detail within Note 8 License Agreements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6920309104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BASIS OF PRESENTATION</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has prepared the accompanying unaudited interim condensed consolidated financial statements and notes thereto (Interim Financial Statements) in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for interim financial information and the instructions to Form 10-Q and Article&#160;10-01 of Regulation&#160;S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of the Company&#8217;s management, the accompanying interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary to present fairly the Company&#8217;s interim financial information.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying interim financial statements and related notes should be read in conjunction with the Company&#8217;s audited financial statements for the year ended December&#160;31, 2016 and related notes included in the Company&#8217;s Annual Report on Form 10-K, which was filed with the SEC on March&#160;3, 2017. The financial results for any interim period are not necessarily indicative of the expected financial results for the full year.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Modification of Segment Footnote</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company modified its segment footnote for the three months ended March 31, 2016 for an immaterial change&#160;and removed, within the segment footnote, certain non-cash expenses including </font><font style="font-family:inherit;font-size:10pt;">$1,296,000</font><font style="font-family:inherit;font-size:10pt;"> of stock-based compensation expense and </font><font style="font-family:inherit;font-size:10pt;">$689,000</font><font style="font-family:inherit;font-size:10pt;"> of depreciation and amortization from the Company&#8217;s U.S. and International segments.&#160;These amounts are appropriately classified as Other within the segment footnote of these interim unaudited condensed consolidated financial statements.&#160;Additionally, in the Company&#8217;s Annual Report on Form 10-K filing for the year ended December 31, 2016, the Company disclosed that the Company&#8217;s chief operating decision maker separately managed and evaluated each segment primarily upon net loss from operations.&#160;The modification made in these financial statements clarifies that the chief operating decision maker manages and evaluates each segment based on net loss from operations adjusted for certain non-cash items, such as stock-based compensation expense and depreciation and amortization.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6640903104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Adoption of New Accounting Standards</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued Accounting Standards Update (ASU) 2014-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</font><font style="font-family:inherit;font-size:10pt;">. ASU 2014-15 requires management to perform interim and annual assessments of an entity&#8217;s ability to continue as a going concern within one year of the date the financial statements are issued and provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. ASU 2014-15 applies to all entities and is effective for annual and interim reporting periods ending after December 15, 2016, with early adoption permitted. The adoption of this guidance did not have a material impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory (Topic 330): Simplifying the Measurement of Inventory</font><font style="font-family:inherit;font-size:10pt;">. This update requires entities to measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. This ASU is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those years. The adoption of this guidance did not have a material impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718)</font><font style="font-family:inherit;font-size:10pt;">. This standard makes several modifications to Topic 718 related to the accounting for forfeitures, employer tax withholding on share-based compensation and the financial statement presentation of excess tax benefits or deficiencies. ASU 2016-09 also clarifies the statement of cash flows presentation for certain components of share-based awards. The standard is effective for interim and annual reporting periods beginning after December 15, 2016, although early adoption is permitted. The adoption of this guidance did not have a material impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Standards Issued but Not Yet Effective</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">, as subsequently amended. ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. The revenue guidance contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The standard is effective for the first interim period within annual reporting periods beginning after December 15, 2017 for public entities, with early adoption permitted in the annual reporting period beginning after December 15, 2016. The Company has begun its evaluation of the new guidance on its business and, at this time, do not believe there will be a material impact on the Company&#8217;s current direct product sales in international markets. For the U.S. business, the Company continues to evaluate the variable consideration provisions of the new guidance and the impact it will have specifically on the Company&#8217;s gross to net revenue adjustments, including chargebacks and rebates. The Company anticipates adopting the new revenue standard using the modified retrospective transition method.</font></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">. This standard requires all leases with durations greater than twelve months to be recognized on the balance sheet and is effective for interim and annual reporting periods beginning after December 15, 2018, although early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption on its financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6922384672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory consisted of the following: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Component parts (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process (2)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">389</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total inventory</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">850</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">486</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory reserve </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory &#8212; net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">802</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">446</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Component parts inventory consists of manufactured components of the ILUVIEN applicator.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) Work-in-process primarily consists of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing or stability testing as required by regulatory authorities in Europe and the U.S.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6603979328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated future amortization expense as of March 31, 2017 for the remaining periods in the next five years and thereafter is as follows: </font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Years Ending December&#160;31</font></div></td><td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,940</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,940</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,946</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,940</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,897</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,125</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6641451744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consisted of the following: </font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued clinical investigator expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">402</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,020</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued rebate, chargeback and other revenue reserves</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">767</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">807</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accrued expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,636</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,758</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6640991200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (EPS) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because to do so would have been anti-dilutive, were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,022,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,022,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,416,251</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,416,251</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,511,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,511,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,795,663</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">940,023</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,696,269</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,626,077</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,442,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,516,186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749180880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents a summary of stock option activity for the three months ended March 31, 2017 and 2016:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding at beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,804,412</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,475,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,312,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,228,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.46</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeitures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(420,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77,813</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding at period end</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,696,269</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,626,077</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable at period end</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,527,392</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,310,239</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average per share fair value of options granted during the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.86</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of additional stock option transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides additional information related to outstanding stock options, exercisable stock options and stock options expected to vest as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,696,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.71 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">289</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,527,392</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.52 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, vested and expected to vest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,131,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.58 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides additional information related to outstanding stock options, exercisable stock options and stock options expected to vest as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,804,412</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.45 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,363,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.42 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, vested and expected to vest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,374,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.35 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Schedule Of Share-based Compensation Stock Options Activity [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_AdditionalScheduleOfSharebasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6598924160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following fair value table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents (1)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative warrant liability (2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents (1)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative warrant liability (2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:-2px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:-2px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. </font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=SL7498348-110258<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762392592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Reporting Segments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents a summary of the Company&#8217;s reporting segments for the three months ended March 31, 2017 and 2016:</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/>March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/>March 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">International</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Consolidated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">International</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Consolidated</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="31" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NET REVENUE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,445</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(448</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(139</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(587</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(156</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(378</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">GROSS PROFIT</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,110</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">GENERAL AND ADMINISTRATIVE EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,705</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">918</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">641</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,264</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,921</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">714</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">760</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">SALES AND MARKETING EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,045</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">DEPRECIATION AND AMORTIZATION</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">666</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">666</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">689</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">689</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">OPERATING EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,908</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,802</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,832</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,542</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8,939</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,289</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,985</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,213</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">SEGMENT LOSS FROM OPERATIONS</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,911</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(768</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,832</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5,511</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5,042</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,763</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,985</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8,790</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">OTHER INCOME AND EXPENSES, NET</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NET LOSS BEFORE TAXES</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(11,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8813-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6641127552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations (Detail) - ILUVIEN<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>Patient</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_NatureOfOperationsLineItems', window );"><strong>Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_PostAuthorizationOpenStudyPeriod', window );">Post-authorization open study period (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_PlannedDrugStudyNumberofPatients', window );">Planned drug study, number of patients</a></td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_PlannedStudyNumberofPatients', window );">Number of patients</a></td>
<td class="nump">560<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_NatureOfOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_NatureOfOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_PlannedDrugStudyNumberofPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Planned Drug Study, Number of Patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_PlannedDrugStudyNumberofPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_PlannedStudyNumberofPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patients in drug study.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_PlannedStudyNumberofPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_PostAuthorizationOpenStudyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Post-authorization Open Study Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_PostAuthorizationOpenStudyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=alim_IluvienMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=alim_IluvienMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6920562448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expense</a></td>
<td class="nump">$ 1,166<span></span>
</td>
<td class="nump">$ 1,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 666<span></span>
</td>
<td class="nump">$ 689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749180880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761904240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Going Concern (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (383,809)<span></span>
</td>
<td class="num">$ (377,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">26,737<span></span>
</td>
<td class="nump">$ 30,979<span></span>
</td>
<td class="nump">$ 23,940<span></span>
</td>
<td class="nump">$ 31,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_CommonStocktobeIssuedValueMaximum', window );">Maximum value of common stock to be sold</a></td>
<td class="nump">$ 21,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_CommonStocktobeIssuedValueMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock to be Issued, Value, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_CommonStocktobeIssuedValueMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748986672">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Inventory (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory net realizable value</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_InventoryComponent', window );">Component parts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">389<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">127<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total inventory</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">850<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserve</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory &#8212; net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 802<span></span>
</td>
<td class="nump">$ 446<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Component parts inventory consists of manufactured components of the ILUVIEN applicator.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Work-in-process primarily consists of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing or stability testing as required by regulatory authorities in Europe and the U.S.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_InventoryComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_InventoryComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762145056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Aug. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,604,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,604,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 478,000<span></span>
</td>
<td class="nump">$ 483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementCopromotionMember', window );">pSivida</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_AdditionalMilestonePayment', window );">Milestone payment after the first product approved by the FDA</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementCopromotionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementCopromotionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754920752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Asset - Future Amortization (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Aug. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract', window );"><strong>Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 20,125,000<span></span>
</td>
<td class="nump">$ 20,604,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract', window );"><strong>Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2017</a></td>
<td class="nump">1,462,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2018</a></td>
<td class="nump">1,940,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2019</a></td>
<td class="nump">1,940,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2020</a></td>
<td class="nump">1,946,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2021</a></td>
<td class="nump">1,940,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">10,897,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 20,125,000<span></span>
</td>
<td class="nump">$ 20,604,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763084368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Summary of accrued expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_AccruedClinicalInvestigatorExpenses', window );">Accrued clinical investigator expenses</a></td>
<td class="nump">$ 1,119<span></span>
</td>
<td class="nump">$ 1,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Accrued compensation expenses</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Accrued rebate, chargeback and other revenue reserves</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">807<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 2,636<span></span>
</td>
<td class="nump">$ 3,758<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_AccruedClinicalInvestigatorExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical investigator expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_AccruedClinicalInvestigatorExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred for employer-related costs classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750826624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements (Detail) - pSivida - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract', window );">Minimum days to require to revert license in case of breaches of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract', window );">Maximum days to require to revert license in case of breaches of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled', window );">Period of bankruptcy petition proceedings remains undismissed (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_ShareOfNetProfits', window );">Share of net profits (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien', window );">Share of any lump sum milestone payments received from a sub-licensee of ILUVIEN (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_PercentageOfRecoveryOfCommercializationCost', window );">Recovery of commercialization costs (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_CommercializationCosts', window );">Commercialization costs owed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,909,000<span></span>
</td>
<td class="nump">$ 24,475,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_AdditionalMilestonePayment', window );">Additional milestone payment after the first product approved by the FDA</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_CommercializationCostsReceivable', window );">Commercialization costs receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,828,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_CommercializationCostsReceivablePostAdjustment', window );">Commercialization cost receivable post adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,475,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bankruptcy proceedings period petitions for bankruptcy filed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_BankruptcyProceedingsPeriodPetitionsForBankruptcyFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_CommercializationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercialization costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_CommercializationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_CommercializationCostsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercialization Costs Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_CommercializationCostsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_CommercializationCostsReceivablePostAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercialization Costs Receivable Post Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_CommercializationCostsReceivablePostAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum days to require to revert license in case of breach of contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_MaximumDaysToRequireToRevertLicenseInCaseOfBreachOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum days to require to revert license in case of breach of contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_MinimumDaysToRequireToRevertLicenseInCaseOfBreachOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_PercentageOfRecoveryOfCommercializationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of recovery of commercialization cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_PercentageOfRecoveryOfCommercializationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of any lump sum milestone payments received from a sub licensee of iluvien.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_ShareOfAnyLumpSumMilestonePaymentsReceivedFromSubLicenseeOfIluvien</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_ShareOfNetProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of net profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_ShareOfNetProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementCopromotionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementCopromotionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768011984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Agreements (Detail)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>USD ($) </div>
<div>payment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,564,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,707,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,707,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=alim_AlimeraSciencesIncCompanyMember', window );">Alimera Sciences, Inc.(Company) | Hercules Technology Growth Capital, Inc. | 2014 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price on warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_ClassofWarrantorRightExercisablePercentage', window );">Warrants exercisable (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage', window );">Warrants that will become exercisable upon obtaining additional financing amount (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=alim_AlimeraSciencesIncCompanyMember', window );">Alimera Sciences, Inc.(Company) | Hercules Technology Growth Capital, Inc. | First Loan Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price on warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=alim_AlimeraSciencesIncCompanyMember', window );">Alimera Sciences, Inc.(Company) | Hercules Technology Growth Capital, Inc. | Second Loan Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">862,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price on warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=alim_AlimeraSciencesIncCompanyMember', window );">Alimera Sciences, Inc.(Company) | Hercules Technology Growth Capital, Inc. | July 2016 Waiver</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,258,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price on warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=alim_AlimeraSciencesLimitedLimitedMember', window );">Alimera Sciences Limited (Limited) | Hercules Technology Growth Capital, Inc. | 2014 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Company entitled to borrow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on term loan (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=alim_AlimeraSciencesLimitedLimitedMember', window );">Alimera Sciences Limited (Limited) | Hercules Technology Growth Capital, Inc. | First Loan Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">An upfront fee payment to lenders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon payment to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal', window );">Balloon payment, percent of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=alim_AlimeraSciencesLimitedLimitedMember', window );">Alimera Sciences Limited (Limited) | Hercules Technology Growth Capital, Inc. | Second Loan Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">An upfront fee payment to lenders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon payment to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,564,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=alim_AlimeraSciencesLimitedLimitedMember', window );">Alimera Sciences Limited (Limited) | Hercules Technology Growth Capital, Inc. | Third Loan Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DebtInstrumentCovenantMinimumCashBalance', window );">Minimum required cash balance per covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=alim_AlimeraSciencesLimitedLimitedMember', window );">Alimera Sciences Limited (Limited) | Hercules Technology Growth Capital, Inc. | July 2016 Waiver</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">An upfront fee payment to lenders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DebtInstrumentTickingFeePercent', window );">Weekly ticking fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DebtInstrumentTickingFee', window );">Ticking fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=alim_AlimeraSciencesLimitedLimitedMember', window );">Alimera Sciences Limited (Limited) | Hercules Technology Growth Capital, Inc. | Fourth Loan Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on term loan (percent)</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">An upfront fee payment to lenders</a></td>
<td class="nump">$ 338,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_LineofCreditFacilityIncreaseinBorrowingCapacity', window );">Increase in borrowing capacity</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DebitInstrumentPaymentinKindInterestRate', window );">Payment-in-kind interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DebtInstrumentPaymentTermsNumberofPayments', window );">Number of monthly payments | payment</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DebtInstrumentPrepaymentFeePercentageFirst12Months', window );">Prepayment Fee percentage within the first year</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months', window );">Prepayment fee percentage within the second year</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months', window );">Prepayment fee percentage after the second year</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DebtInstrumentCovenantLiquidityThreshold', window );">Debt covenant liquidity threshold</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants | shares</a></td>
<td class="nump">458,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price on warrants (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Common stock warrants</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alim_TrancheOneMember', window );">Tranche One | Alimera Sciences Limited (Limited) | Hercules Technology Growth Capital, Inc. | Fourth Loan Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_LineofCreditFacilityIncreaseinBorrowingCapacity', window );">Increase in borrowing capacity</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DebtInstrumentRevenueRequirement', window );">Revenue requirement</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alim_TrancheTwoMember', window );">Tranche Two | Alimera Sciences Limited (Limited) | Hercules Technology Growth Capital, Inc. | Fourth Loan Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_LineofCreditFacilityIncreaseinBorrowingCapacity', window );">Increase in borrowing capacity</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DebtInstrumentRevenueRequirement', window );">Revenue requirement</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember', window );">Prime Rate | Alimera Sciences Limited (Limited) | Hercules Technology Growth Capital, Inc. | 2014 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember', window );">Prime Rate | Alimera Sciences Limited (Limited) | Hercules Technology Growth Capital, Inc. | Fourth Loan Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (percent)</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DebtInstrumentBasisSpreadonVariableRateReduction', window );">Reduction in basis spread on variable rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_ClassofWarrantorRightExercisablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_ClassofWarrantorRightExercisablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable Upon Satisfying Certain Conditions, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_ClassofWarrantorRightExercisableUponSatisfyingCertainConditionsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_DebitInstrumentPaymentinKindInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debit Instrument, Payment-in-Kind Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_DebitInstrumentPaymentinKindInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_DebtInstrumentBasisSpreadonVariableRateReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Basis Spread on Variable Rate, Reduction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_DebtInstrumentBasisSpreadonVariableRateReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_DebtInstrumentCovenantLiquidityThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Liquidity Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_DebtInstrumentCovenantLiquidityThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_DebtInstrumentCovenantMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Minimum Cash Balance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_DebtInstrumentCovenantMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_DebtInstrumentPaymentTermsNumberofPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Payment Terms, Number of Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_DebtInstrumentPaymentTermsNumberofPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid, Percent of Principal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_DebtInstrumentPeriodicPaymentTermsBalloonPaymenttobePaidPercentofPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_DebtInstrumentPrepaymentFeePercentageFirst12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee Percentage, First 12 Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_DebtInstrumentPrepaymentFeePercentageFirst12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee Percentage, Greater than 12 Months, Less than 24 Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_DebtInstrumentPrepaymentFeePercentageGreaterthan12MonthsLessthan24Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee Percentage, Greater than 24 Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_DebtInstrumentPrepaymentFeePercentageGreaterthan24Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_DebtInstrumentRevenueRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Revenue Requirement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_DebtInstrumentRevenueRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_DebtInstrumentTickingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Ticking Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_DebtInstrumentTickingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_DebtInstrumentTickingFeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Ticking Fee, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_DebtInstrumentTickingFeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_LineofCreditFacilityIncreaseinBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Increase in Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_LineofCreditFacilityIncreaseinBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alim_AlimeraSciencesIncCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alim_AlimeraSciencesIncCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=alim_HerculesTechnologyGrowthCapitalInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=alim_HerculesTechnologyGrowthCapitalInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alim_TwentyFourteenTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alim_TwentyFourteenTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alim_FirstLoanAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alim_FirstLoanAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alim_SecondLoanAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alim_SecondLoanAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alim_July2016WaiverMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alim_July2016WaiverMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alim_AlimeraSciencesLimitedLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alim_AlimeraSciencesLimitedLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alim_ThirdLoanAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alim_ThirdLoanAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alim_FourthLoanAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alim_FourthLoanAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alim_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alim_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alim_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alim_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750958704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (EPS) - AntiDilutive Securities Excluded (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">35,442,018<span></span>
</td>
<td class="nump">33,516,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">9,022,556<span></span>
</td>
<td class="nump">9,022,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">8,416,251<span></span>
</td>
<td class="nump">8,416,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alim_PreferredStockWarrantsMember', window );">Series A convertible preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">4,511,279<span></span>
</td>
<td class="nump">4,511,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,795,663<span></span>
</td>
<td class="nump">940,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">11,696,269<span></span>
</td>
<td class="nump">10,626,077<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alim_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alim_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765492688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 12, 2014</div></th>
<th class="th"><div>Oct. 02, 2012</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Apr. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral', window );">Estimated fair value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on change in fair value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">$ 1,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_NumberOfPreferredStockAndWarrants', window );">Number of preferred stock and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_WarrantsToPurchaseAdditionalShares', window );">Warrants to purchase additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_GrossProceedsUnderSecuritiesPurchaseAgreement', window );">Gross proceeds under securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_EstimatedTotalStockIssuanceCost', window );">Estimated total stock issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue', window );">Conversion rate of Series A Convertible Preferred Stock issued upon exercise of warrants into common stock (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_PreferredStockConvertedToCommonStockPerShare', window );">Preferred stock converted to common stock per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_ProportionOfEachUnitOfShares', window );">Proportion of each unit of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_ExercisePriceOfWarrants', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Convertible securities converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,759,398<span></span>
</td>
<td class="nump">2,255,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,416.251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,416.251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,416.251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,416.251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="nump">8,291.873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share purchase price of shares issued (in dollars per share)</a></td>
<td class="nump">$ 6,030.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period (in shares)</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance cost</a></td>
<td class="nump">$ 432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent', window );">Ownership interest after conversion (percent)</a></td>
<td class="nump">9.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature', window );">Adjustment to APIC</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible preferred stock | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="nump">124.378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Convertible Preferred Stock Beneficial Feature</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_AdjustmentstoAdditionalPaidinCapitalConvertiblePreferredStockBeneficialFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Ownership Interest After Conversion, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_ConvertiblePreferredStockOwnershipInterestAfterConversionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_EstimatedTotalStockIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Total Stock Issuance Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_EstimatedTotalStockIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_ExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_ExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_GrossProceedsUnderSecuritiesPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds under securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_GrossProceedsUnderSecuritiesPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds under securities purchase agreement per value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_GrossProceedsUnderSecuritiesPurchaseAgreementPerValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_NumberOfPreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of preferred stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_NumberOfPreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_PreferredStockConvertedToCommonStockPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock converted to common stock per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_PreferredStockConvertedToCommonStockPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_ProportionOfEachUnitOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proportion of each unit of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_ProportionOfEachUnitOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_WarrantsToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_WarrantsToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after offset of derivative asset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be and before offset against a right to receive collateral under a master netting arrangement. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41678-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226006-175313<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755035328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_CommonStocktobeIssuedValueMaximum', window );">Maximum value of common stock to be sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,504<span></span>
</td>
<td class="nump">$ 21,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">662,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share purchase price of shares issued (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alim_PublicOfferingMember', window );">Public offering | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="nump">18,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share purchase price of shares issued (in dollars per share)</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="nump">$ 26,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance cost</a></td>
<td class="nump">$ 1,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_CommonStocktobeIssuedValueMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock to be Issued, Value, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_CommonStocktobeIssuedValueMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alim_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alim_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755018352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 5 months 3 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 972<span></span>
</td>
<td class="nump">$ 1,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based compensation not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted in period (in shares)</a></td>
<td class="nump">873,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">815,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762340304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Summary of Stock Option Transactions (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of period (in shares)</a></td>
<td class="nump">10,804,412<span></span>
</td>
<td class="nump">9,475,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Grants (in shares)</a></td>
<td class="nump">1,312,500<span></span>
</td>
<td class="nump">1,228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeitures (in shares)</a></td>
<td class="num">(420,643)<span></span>
</td>
<td class="num">(77,813)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at year end (in shares)</a></td>
<td class="nump">11,696,269<span></span>
</td>
<td class="nump">10,626,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at year end (in shares)</a></td>
<td class="nump">7,527,392<span></span>
</td>
<td class="nump">6,310,239<span></span>
</td>
<td class="nump">7,363,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average per share fair value of options granted during the period (in dollars per share)</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">3.22<span></span>
</td>
<td class="nump">3.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Grants (in dollars per share)</a></td>
<td class="nump">1.19<span></span>
</td>
<td class="nump">2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeitures (in dollars per share)</a></td>
<td class="nump">2.79<span></span>
</td>
<td class="nump">3.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercises (in dollars per share)</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at year end (in dollars per share)</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="nump">3.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at year end (in dollars per share)</a></td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
<td class="nump">$ 3.29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751487952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Additional Stock Option Transactions (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract', window );"><strong>Outstanding Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Shares</a></td>
<td class="nump">11,696,269<span></span>
</td>
<td class="nump">10,804,412<span></span>
</td>
<td class="nump">10,626,077<span></span>
</td>
<td class="nump">9,475,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 3.22<span></span>
</td>
<td class="nump">$ 3.32<span></span>
</td>
<td class="nump">$ 3.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 8 months 16 days<span></span>
</td>
<td class="text">6 years 5 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 289<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract', window );"><strong>Exercisable Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Shares</a></td>
<td class="nump">7,527,392<span></span>
</td>
<td class="nump">7,363,400<span></span>
</td>
<td class="nump">6,310,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 6 months 8 days<span></span>
</td>
<td class="text">5 years 5 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Exercisable and expected to vest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Outstanding, vested and expected to vest, Shares</a></td>
<td class="nump">11,131,410<span></span>
</td>
<td class="nump">10,374,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Outstanding, vested and expected to vest, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="nump">$ 3.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Outstanding, vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 6 months 28 days<span></span>
</td>
<td class="text">6 years 4 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Outstanding, vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751521984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_CumulativeIncomeLossFromForeignOperations', window );">Cumulative book losses in foreign subsidiaries</a></td>
<td class="nump">$ 92,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,270<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_CumulativeIncomeLossFromForeignOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative Income (Loss) From Foreign Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_CumulativeIncomeLossFromForeignOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751167008">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Fair Value (Detail) - Recurring basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DerivativeWarrantLiabilitiesFairValueDisclosure', window );">Derivative warrant liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">21<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DerivativeWarrantLiabilitiesFairValueDisclosure', window );">Derivative warrant liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DerivativeWarrantLiabilitiesFairValueDisclosure', window );">Derivative warrant liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">21<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DerivativeWarrantLiabilitiesFairValueDisclosure', window );">Derivative warrant liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_DerivativeWarrantLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Warrant Liabilities, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_DerivativeWarrantLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765476800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>customer</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">NET REVENUE</a></td>
<td class="nump">$ 6,618<span></span>
</td>
<td class="nump">$ 5,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION</a></td>
<td class="num">(587)<span></span>
</td>
<td class="num">(378)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">6,031<span></span>
</td>
<td class="nump">5,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES</a></td>
<td class="nump">2,110<span></span>
</td>
<td class="nump">3,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="nump">3,264<span></span>
</td>
<td class="nump">3,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">SALES AND MARKETING EXPENSES</a></td>
<td class="nump">5,502<span></span>
</td>
<td class="nump">7,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">DEPRECIATION AND AMORTIZATION</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">OPERATING EXPENSES</a></td>
<td class="nump">11,542<span></span>
</td>
<td class="nump">14,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">SEGMENT LOSS FROM OPERATIONS</a></td>
<td class="num">(5,511)<span></span>
</td>
<td class="num">(8,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">OTHER INCOME AND EXPENSES, NET</a></td>
<td class="num">(1,198)<span></span>
</td>
<td class="num">(2,346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">NET LOSS BEFORE TAXES</a></td>
<td class="num">(6,709)<span></span>
</td>
<td class="num">(11,136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=alim_UnitedStatesSegmentMember', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">NET REVENUE</a></td>
<td class="nump">4,445<span></span>
</td>
<td class="nump">4,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION</a></td>
<td class="num">(448)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">3,997<span></span>
</td>
<td class="nump">3,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES</a></td>
<td class="nump">1,158<span></span>
</td>
<td class="nump">1,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="nump">1,705<span></span>
</td>
<td class="nump">1,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">SALES AND MARKETING EXPENSES</a></td>
<td class="nump">4,045<span></span>
</td>
<td class="nump">5,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">DEPRECIATION AND AMORTIZATION</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">OPERATING EXPENSES</a></td>
<td class="nump">6,908<span></span>
</td>
<td class="nump">8,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">SEGMENT LOSS FROM OPERATIONS</a></td>
<td class="num">(2,911)<span></span>
</td>
<td class="num">(5,042)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=alim_InternationalSegmentMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">NET REVENUE</a></td>
<td class="nump">2,173<span></span>
</td>
<td class="nump">1,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION</a></td>
<td class="num">(139)<span></span>
</td>
<td class="num">(156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">2,034<span></span>
</td>
<td class="nump">1,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES</a></td>
<td class="nump">741<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="nump">918<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">SALES AND MARKETING EXPENSES</a></td>
<td class="nump">1,143<span></span>
</td>
<td class="nump">1,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">DEPRECIATION AND AMORTIZATION</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">OPERATING EXPENSES</a></td>
<td class="nump">2,802<span></span>
</td>
<td class="nump">3,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">SEGMENT LOSS FROM OPERATIONS</a></td>
<td class="num">(768)<span></span>
</td>
<td class="num">(1,763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">NET REVENUE</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="nump">641<span></span>
</td>
<td class="nump">760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">SALES AND MARKETING EXPENSES</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">DEPRECIATION AND AMORTIZATION</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">OPERATING EXPENSES</a></td>
<td class="nump">1,832<span></span>
</td>
<td class="nump">1,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">SEGMENT LOSS FROM OPERATIONS</a></td>
<td class="num">(1,832)<span></span>
</td>
<td class="num">(1,985)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">OTHER INCOME AND EXPENSES, NET</a></td>
<td class="num">$ (1,198)<span></span>
</td>
<td class="num">$ (2,346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_ConcentrationRiskNumberofCustomers', window );">Number of customers | customer</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_ConcentrationRiskNumberofCustomers', window );">Number of customers | customer</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_ConcentrationRiskNumberofCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number of Customers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alim_ConcentrationRiskNumberofCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alim_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=alim_UnitedStatesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=alim_UnitedStatesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=alim_InternationalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=alim_InternationalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " "'2:M*^J8G_N\    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+;2L0P$(9?17+?3M/U@*';&\4K!<$%Q;N0S.X&FP/)2+MO;QIW
MNX@^@)>9^?/--S"="D+YB,_1!XQD,%U,=G!)J+!F>Z(@ )+:HY6IS@F7FUL?
MK:3\C#L(4GW('4+;--=@D:26)&$&5F$ALK[32JB(DGP\XK5:\.$S#@6F%>"
M%ATEX#4'UL\3PV$:.C@#9AAAM.F[@'HAENJ?V-(!=DQ.R2RI<1SK<55R>0<.
M;T^/+V7=RKA$TBG,OY(1= BX9J?)KZN[^\T#Z]N&WU3-5<7YIKD5G(OV\GUV
M_>%W%K9>FZWYQ\8GP;Z#7W?1?P%02P,$%     @ ATFK2IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M@0.QZ.1?@:.-"-T"H3.#T-##&3URTR,G/3+T:$;?+ [ 1L1N@8U38&/1DX7
M@-@81#N<,(F3."!NF=@I$ULRVX6,C4C= HE3(+'H>%DJ#LA*K6R=$EN;ORB6
M@P.R4BVI4R*U^=%"(K5^!PEPXA;!@?M6!;;,LJQ&3#S'K!067KF[V%99UI8+
MLUU1<5[@/2:VAW2I8F-(L*+BOL4XM#W@Q4,Q8N9_)H[2 ,?A\MS0[/EK@-],
MIQ!>P>ZM:5,SZ]2-]L0\GW_A0RO[2OFM:H5W9E(]PN:IO#(F0044/*E02M4]
MIT4-5ZFGB9KSH84,"\FZL3VBJ4?G?P!02P,$%     @ ATFK2F?B2(<T!
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M7<XJ?SG+91(?YV9F2<)K%A2]#TV@!5Z*0*6H? %Q&3*6FYDE":]"H"I4OGF
M.BY1W._AT]R2B'<A4!=JWSQ '8<H,\6XAXT*DX:-"+P1@1I1^\L]H*)S#U,<
MU>?!)1-O1*!+4$U\1M>67]S#2<H:C<LZH]\P"/*F16I:[3L-J3^_2 !F+<(G
M3=@AR)L6J6FU[S5D#"I$PJQ&N*36-Y9(R-L6J6TU>5"_>SG*)&\O1S&P>T ]
MJ0-N0=Z3>+\GD?<DWN%)9!Z^,P!N#^..Y)**=R929^K0N'C'H;E_9G@;(;,^
M(S.3DDT;E6EN_^*>Y$057^V@#5N:?^3M:U%WJY>F[YMJW#([-$UO7:OBJYOI
MH\WWEY/2'OKAT+CC=MI*G$[ZYC1OD\:7O=KM_U!+ P04    " "'2:M*+UX?
M,K4"  " "P  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;(V648Z;,!"&
MKX(X0," @:R22$VJJI5:*=JJVV<G<1*T@*EQDNWM:V,687NVD(=@FW_&W]C#
M:%8/QE_;*Z7">ZO*NEW[5R&:IR!HCU=:D7;!&EK+-V?&*R+DE%^"MN&4G#JC
MJ@RB,$R#BA2UOUEU:WN^6;&;*(N:[KG7WJJ*\+];6K+'VD?^^\)S<;D*M1!L
M5@VYT)]4_&KV7,Z"P<NIJ&C=%JSV.#VO_4_H:8<R9= I7@KZ:$=C3X5R8.Q5
M3;Z=UGZHB&A)CT*Y(/)QISM:ELJ3Y/C3._6'/97A>/SN_4L7O SF0%JZ8^7O
MXB2N:S_WO1,]DULIGMGC*^T#PK[71_^=WFDIY8I$[G%D9=O]>\=;*UC5>Y$H
M%7G3SZ+NG@_]!B>]&6P0]0;18(#^;Q#W!K%E$&BR+M3/1)#-BK.'Q_5M-40E
M!7J*Y6$>U6)W=MT[&6TK5^\;G*^"N_+32[9:$HTDD:G8 8IXD 1R_P$B B&B
MSCX90RPM""W).TG=2<)%B"R."9%!$H,DL4.2AA:)EN#1)BC4/XMFAM @2D"B
MQ"6RPMXF<\YF0F208) $NR16(FRQ&S*&#V>.TF!*0:;498HMIM39*4WR-%J&
MB84T0V@092!1YA)9&VVSN40SA 91#A+E[M>5PO9+T'XY_4TLW=N,H5N?UAD\
M*(1K5N@28;MHA>[90433.I/H@RJ*7*+4)D(SB29U)A%<4I%;4]/,)M*:;+13
ME(!?ZQRE20675^365YQ]X $NAPBHAW8V]IKQ">8)RNR8)E0F#5P2$5 3G4S4
MFJ6Y3[J(L%VBYRA-*K@H(J J.MF8SJ::H32IX,*(@,KH9&3FY!D.,PQEY RE
MI@I&K9#J37\0?BGJUCLP(;NJKO<Y,R:H]!HNY U<93L\3$IZ%FJ8R3'7/:&>
M"-;T_6XP--V;?U!+ P04    " "'2:M*67@-ZF$#  #&#0  &    'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;'V7;V^C.!#&OPKB?8O'!F.J)%*3U>I.NI.J
M/>WN:YHX"5K .2#-WK<_\Z=9.C/LFX+-,YZ?)_93>W5SS8_V;&T7_*S*NEV'
MYZZ[/$51NS_;*F\?W<76_LO1-57>^69SBMI+8_/#$%25D11"1U5>U.%F-?2]
M-)N5NW9E4=N7)FBO594W_VUMZ6[K$,+WCB_%Z=SU'=%F=<E/]A_;?;V\-+X5
MW4<Y%)6MV\+506./Z_ 9GG9R"!@4WPI[:V?O03^55^=^](T_#^M0]$2VM/NN
M'R+WCS>[LV79C^0Y_IT&#>\Y^\#Y^_OHGX?)^\F\YJW=N?)[<>C.Z]"$P<$>
M\VO9?7&W/^PTH20,IMG_9=]LZ>4]B<^Q=V4[_ WVU[9SU32*1ZGRG^.SJ(?G
M;?RBS13&!\@I0-X#?.[?!:@I0/T*B(?)CV3#5#_E7;Y9->X6-..O=<G[10%/
MRA=SWW<.M1N^^=FVOO=MH\TJ>NO'F23;42)G$K@K(C_X/8/D,FPE"9<?$^RH
M0F=\!L7.00WQ:A:?"CX^9N/C(3Z>QP.JP2A)!TD](FI A=I146+$0JT2EB2A
M)*A8VU&2S)(\)"9%)(Q(I88GT2R)IB0*D6B21 N%"K>CHB26BB=)69*4DL2(
M)"5))(! )%2DA%Q8)X8E,90D022&)I$:X>X8D<H2GB1C23)*HA%)1@N?"+SS
MJ"@%L;#W0/ &(BA+BAU$T*6B$?".$YDEE@4S \I"W Q(&@"_)C$-(XLE+*Q<
M8*WO&23ER3"/9#9T G@?<3*39@OK%WBC!$5XC, \BB8"I;##+,@65C'PQ@O4
M>0UVWDGS(9'$SLN(5+R PCLO4.LUV'J!VBIH4AA&E,#2.N;-%ZC[&NR^0)T5
M.QXC>9")7BH,;[] _==@_P7JK0\Z%1GF860 H/0"$._"0&W88!L&:K$/DA@.
M(UKZG7@;!NK#!OOPI$D_UD8E&(:1^=K$"QM*\F8LJ1GCL\%VTIAY)O&(_897
MR24<WH\E]6.#_5A2H]6QT3(3^-\FHXP3(1*CL"M'L]-O99O3<%%H@[V[UEU_
MT)SUWB\CS[(_/:/^K;^DC%>*7\.,-YR_\^94U&WPZCI_-A].T$?G.NM!Q:-'
M//M+U;U1VF/7OZ;^O1EO%F.C<Y?IUA3=KVZ;_P%02P,$%     @ ATFK2C\#
M6N@K @  /P8  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6R%55V/FS 0
M_"N(]QZ8[T0$Z4)5M5(K15==^^R034!G8VH[X?KO:QN.H^"T+\%>9G9GUGB3
M]XR_B!I .J^4M&+GUE)V6\\350T4BP?60:O>G!FG6*HMOWBBXX!/AD2)%_A^
MXE'<M&Z1F]B!%SF[2M*T<.".N%**^>\]$-;O7.2^!9Z:2RUUP"OR#E_@.\CG
M[L#5SINRG!H*K6A8ZW X[]Q'M"TSC3> 'PWT8K9VM),C8R]Z\^6T<WTM" A4
M4F? ZG&#$@C1B92,7V-.=RJIB?/U6_9/QKOR<L0"2D9^-B=9[]S,=4YPQE<B
MGUC_&48_L>N,YK_"#8B":R6J1L6(,+].=162T3&+DD+QZ_!L6O/LAS<I&FEV
M0C 2@HF@:O^+$(Z$\)T0&?.#,F/U(Y:XR#GK'3X<5H?U-X&VH6IFI8.F=^:=
M<BM4]%9DF]R[Z3PC9#] @AD$30A/)9\J!+8*^V!%#_XN4*X1R<9>(;1Z" T_
MG/$WOIT?6?F1X4?S'B2+'@R0U$!: _F0I&&\,&)!(82BV"XFMHJ)UV;NM#NQ
M\I.5F<VBW_L!$L]D1HLS+]<0A.Z<26J5D:YEA L9Z?]EK"%W9616&=E:1K20
MD5F.-EE^ *4%A9 ?) LQWNS>4> 7,Z*$4[%K*_4G/HM.4_ QT/=V$=^KZ3@,
ML_<TPVC]AOFE:85S9%)-!7-WSXQ)4"K]!]6J6DWS:4/@+/4R56L^S+1A(UDW
MCFMO^L\H_@!02P,$%     @ ATFK2BA/,@MX!   SA8  !@   !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6R-F%N/XD80A?\*XIVUJ\H7/&*0AHFB1$JDT49)
MGCW0 VAM3&S/L/GW:5^6A:[3SKZ W9SJ/M6XOR[WZE+57YJ#,>WL:UF<FL?Y
MH6W/#T'0; ^FS)M/U=F<["]O55WFK;VM]T%SKDV^ZX/*(N P3((R/Y[FZU7?
M]E*O5]5[6QQ/YJ6>->]EF=?_;DQ171[G-/_6\/FX/[1=0[!>G?.]^<.T?YY?
M:GL77'O9'4MS:H[5:5:;M\?Y$ST\1V$7T"O^.II+<W,]ZU)YK:HOW<VON\=Y
MV#DRA=FV71>Y_?HPSZ8HNIZLCW_&3N?7,;O V^MOO?_<)V^3><T;\UP5?Q]W
M[>%QOIS/=N8M?R_:S]7E%S,F%,]G8_:_F0]36'GGQ(ZQK8JF_YQMWYNV*L=>
MK)4R_SI\'T_]]V7X)4W&,!S 8P!? ^S84P$R!LCW@*A/?G#6I_I3WN;K55U=
M9O7P;YWS[J&@![&3N>T:^[GK?[/9-K;U8YW%J^"CZV>4; 8)WTCHJ@ALY]<1
M&(VP817.]P,\:T62X1$$YB!]O-SFD.#X",9'?7QT&Y\Z<S!(TEYRZB6AD\24
MXLY###W$.H<ECD]@?*)SR)P<!DE\XW"1I!*'H9L*$!)1=*>\LY1"2ZE*B7P=
M+&$'2Y43A>0DM51>DR31*0'9,O/FDT$[&;#C/,J;3(VSU&:TJ)M:CQ<*\;H-
M@1MQ5VZH1F+@!\@6$OD=>4A"P%'D.B(UE'*C)1PG$W8@=IZ(@1V%-E9C221@
MAH!.4K\ES"D28"EQ+8D:B@@]TDC(6>(WA>%'FGX4NO@;1?=(2%)@"@EC\B\U
MPC@DS4,*/4 D3$322*3092)IUDF8A2 Q+4P3\J>%D4BI\L1+UU+Z(PP!JD4R
M\41BPA) +(6N(0W/A=SG/GK20II:N!BSI#DK:I%HA"[LZD8K%REC9J\KQKQE
MP%MR-R,&(+4;)U@G0$EIZ)\KQLQEP%QR]R360+53 #PAG?@M8>XRX"ZY&Q-K
MGBXB2C)@"BC=JN7>%F8OZR+1_C.>+C I&9"2W!V% 0!C]   73J1%<8DQ\"2
MNUA&T?]; KHI2QB[G(")3CU=8$JRIB21BTG6 %0) 4;&$RL?,Y(1(]U]A#7Z
ME!N$T8G"CS$>&92A["*; ?4$[")(-T%LP6P4P$9VV2BHR 26D"Y*_&6-8#(*
M(".[9!10:C*PI&44^?=^P6 4 $9VP2@(C!PA4T"9T@08Q?/R#(I2=LMVT;6F
M+9-2P&NDM/7DA"T,6P&P91>VHB'*=G, ;$-*R2+_ZA,,7 %U*7L.&P0#4D!=
MRF[!+;K<S)9@ST:ZB7< P< 5 %Q5EXJF*8$B$,G\181@YLH23+/O3 AS4@ G
MQ>6D:/ZI?,#;NG^"(TS("!!27$*.HO0.,R%X%_D!X6 JN#D%+$V][P],F]FV
M>C^UW8';3>OU4/:)NU-$IWU##\_#T>KW;H:3WM_S>G\\-;/7JFVKLC])?*NJ
MUEB?X2<[:0>3[ZXWA7EKN\O47M?#">MPTU;G\?0XN!YAK_\#4$L#!!0    (
M (=)JTI^DYD[KP$  -(#   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M?5-A;YPP#/TK47Y <Q=8-YT J==IZJ1-.G7:^CD'!J(FA";AZ/[]G,!1UJ%]
M(;;Q>WYVG&PT]MFU )Z\:M6YG+;>]P?&7-F"%N[&]-#AG]I8+3RZMF&NMR"J
M"-**\=WNEFDA.UID,7:R168&KV0')TO<H+6POX^@S)C3/;T&'F73^A!@1=:+
M!GZ _]F?+'IL8:FDALY)TQ$+=4[O]H=C&O)CPB\)HUO9)'1R-N8Y.%^KG.Z"
M(%!0^L @\+C /2@5B%#&R\Q)EY(!N+:O[%]B[]C+63BX-^I)5K[-Z2=**JC%
MH/RC&1]@[N<#)7/SW^ ""M.#$JQ1&N7BEY2#\T;/+"A%B]?IE%T\QYG_"ML&
M\!G WP'85"@J_RR\*#)K1F*GV?<B7/'^P'$V90C&4<1_*-YA]%+L$YZQ2R":
M<XY3#E_G+!D,V9<2?*O$D?\#Y]OP9%-A$N')7PJ3;8)TDR"-!.E_6]S*2=\5
M8:N9:K!-W"9'2C-T<9-7T65A[WB\D[?T:=N_"]O(SI&S\7BS<?ZU,1Y0RNX&
M5ZC%![8X"FH?S(]HVVG-)L>;?GY!;'G&Q1]02P,$%     @ ATFK2OL'9W^P
M 0  T@,  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6Q]4VUOG# ,_BM1
M?D!S!]>N.@%2KU/529MTZK3U<PX,1,T+3<+1_OLY@:.L0_M";./G\6/'R09C
M7UP+X,F;DMKEM/6^VS/FRA84=U>F XU_:F,5]^C:AKG. J\B2$F6;#8W3'&A
M:9'%V-$6F>F]%!J.EKA>*6[?#R#-D-,MO02>1-/Z$&!%UO$&?H+_U1TM>FQF
MJ80"[831Q$*=T[OM_K +^3'AMX#!+6P2.CD9\Q*<;U5.-T$02"A]8.!XG.$>
MI Q$*.-UXJ1SR0!<VA?VA]@[]G+B#NZ-?!:5;W-Z2TD%->^E?S+#(TS]7%,R
M-?\=SB Q/2C!&J61+GY)V3MOU,2"4A1_&T^AXSE,_!?8.B"9 ,DG !L+1>5?
MN>=%9LU [#C[CH<KWNX3G$T9@G$4\1^*=Q@]%]OT.F/G0#3E',:<9)DS9S!D
MGTLD:R4.R3_P9!V>KBI,(SS]2V&Z3K!;)=A%@MU_6US+N?E4A"UFJL V<9L<
M*4VOXR8OHO/"WB7Q3C[2QVW_P6TCM",GX_%FX_QK8SR@E,T5KE"+#VQV)-0^
MF%_0MN.:C8XWW?2"V/R,BS]02P,$%     @ ATFK2H;HMARU 0  T@,  !@
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MVOF7C?UOM';@I217?H0Z_\$60T#CPO&3/YMIS";#Z7[^063YQN5?4$L#!!0
M   ( (=)JTJ>OP)\KP$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$T
M+GAM;'U386^<, S]*U%^0'/ M9M.@-3K-&W2)ITZ;?V< P-1DY@FX>C^_9+
M4=2B?2&V\7M^=IQ\1/-L.P!'7I74MJ"=<_V!,5MUH+B]P1ZT_].@4=QYU[3,
M]@9X'4%*LG2WNV.*"TW+/,9.ILQQ<%)H.!EB!Z6X^7L$B6-!$WH-/(JV<R'
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MMW+>JV2KF2HP;=PF2RH<=-SD5719V/LTWLE;^K3M/[EIA;;DC,[?;)Q_@^C
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MG8RWV,Q2M@JT;5$3 U5&[[:'8Q+B8\#O%@:[.)-0R1GQ.1C?RHQN@B"04+C
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MI&D6V9::3M,FM5+4:=UO8E_;J'QX@./V[0>8>M9F[0]P+^><^\$E'[5YM1V
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M=V]R:W-H965T<R]S:&5E=#$Y+GAM;'U3VV[;, S]%4$?4"6*FQ:!;:!I473
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M7X?O5A7N(GSWA\+K=8)DE2")!,E_2UR+V?^5A"UZJL#6<9H<*4ROXR0OO//
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M1N=?-O:_1G3@4TFN_ BU_H,MAH+:A>.U/YMIS";#83__(+9\X^(W4$L#!!0
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M_,O&_C=:._"I)%=^A#K_P19#0./"<>_/9AJSR7"ZGW\06;YQ^0%02P,$%
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M12)S5)1P_>M4%RYH.T61*"UZ'9]-IY_#. /AY&9W"":'8'9(_7<=PLDAG!W
M^QG@Y  -!V\L1:]-B03*,T8'AXV?MT=J%X$ME*M?*:->;#TGEX=+ZS4/ IAY
M5Q5HTA2C)EAJ;A6E11'.$D\"S!2!E2+0_N$-160/$%H#A#H O D0WT+N;9K$
M*'74)%K3:4T8&LM1KC4 W(&%5EAH 4D-6)MF8\".FF@)FQJ:<JT!J9TULK)&
M:X[0-SBB=0YS8<NU)HSN;)'8"A);0( !$J^2I)$!6ZXU,(WM((D5)%F! -\X
M#T6R2O()&E^XM&E\.TAJ!4DM*V*"I*N]FIJPY5H#X9T5V1@@-Y/ M]\P_L?G
M;F\3A7?V![ASDX&/C\S>)EH<\#&/M[@\6\S.NC%QIZ*73BC?A75N?GO=JDS[
M9EML+'99[K8 OG4&R)FQ[?U//7;A'XB=FXX[!RID.]"7]HE2@65=_H/<1[5L
M_/. X)-0KXE\9V/W&P>"]E-G]^:_%_D_4$L#!!0    ( (=)JTJ875B?AP(
M !L)   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;(U6:V^;,!3]*X@?
M4&S>B1*D/!IMTB95G;I]=A(G007,;"=T_WY^4!K@ILT7L,TYYYY[;6S/&L9?
MQ8E2Z;R5127F[DG*>NIY8G>B)1$/K*:5^G)@O"12=?G1$S6G9&](9>'Y",5>
M2?+*S69F[(EG,W:615[1)^Z(<UD2_F])"];,7>R^#SSGQY/4 UXVJ\F1_J+R
MI7[BJN=U*ON\I)7(6>5P>IB["SS=X$ 3#.)W3AMQU79T*EO&7G7G^W[N(NV(
M%G0GM011KPM=T:+02LK'WU;4[6)JXG7[77UCDE?);(F@*U;\R??R-'=3U]G3
M SD7\IDUWVB;4.0Z;?8_Z(46"JZ=J!@[5@CS='9G(5G9JB@K)7FS[[PR[\9^
MB?V6!A/\EN!W!!7[,T+0$H)["6%+"#\(X:>$J"5$]Q+BEA /")XMEJG^FDB2
MS3AK'&X74$WT.L736,WO3@^:Z33?U 0(-7K)_"":>1<MU&*6%N/W,'$?LQIC
M<(?PE(/.A@_96/I B&00 L#T$>LQ(I[T(8]0H#YD T%2.)D K&E@!(*>P 06
M"$&!T B$UP(A&E3#8A*#J2P&83]": !\A( Q"D? S1B(8-,1:#H"3-]8 S$H
M$-]?M@042.XHF\5$7Y<M^;IL/4LI:"D%+ U6[2H=1])^;D::@)$F0*3!REY!
MF! .@A&\72! (AKN!6B449BDHQ*O(5P:W,P;W]C!,& IOB$![CX+[-^_]##\
MS^, <)$,-]+@WJGVKO;ODO*C.7V%LV/G2NJ]Z6JT.^$7YM ;C*_P=&W/Z0\9
M>VWX2?@QKX2S95*=+N8,.# FJ3**'M0/<E(WE:Y3T(/4S42UN3VN;4>RNKV*
M>-U]*/L/4$L#!!0    ( (=)JTI93G@F1P(  .T'   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,Y+GAM;(U5;:^:,!3^*X0?<-L"@A@DV=4L6[(EYB[;/E>M
M0FZAK*UR]^_7%F0*1^,7^\+S<LZQI\U:(=]5P9CV/BI>JZ5?:-TL$%*[@E54
MO8B&U>;+0<B*:K.41Z0:R>C>D2J. HQC5-&R]O/,[6UDGHF3YF7--M)3IZJB
M\N\KXZ)=^L2_;+R5QT+;#91G#3VR'TS_;#;2K-"@LB\K5JM2U)YDAZ7_B2S6
M)+ $A_A5LE9=S3V;RE:(=[OXNE_ZV$;$.-MI*T'-<&8KQKE5,G'\Z47]P=,2
MK^<7]<\N>9/,EBJV$OQWN=?%TI_[WIX=Z(GK-]%^87U",]_KL__&SHP;N(W$
M>.P$5^[7VYV4%E6O8D*IZ$<WEK4;VU[_0H,)04\(!@*)'A+"GA ^2XAZ0C0B
MH"X55YLUU33/I&@]V?V]#;6GB"PB4_V=W73%=M],>939/>=!-,_0V0KUF-<.
M$UQC;A$K !'>0M80Y+\1,D$.D09@I($3"&\B36&!$!0(G4!T+3##HU0[3.(P
M=8?!Q,#P"+B"@#&.)L#U%(CAH",PZ&@:=$1@@1DH,'N^;#$H$#N!V6U)DE'=
MIB 2Q<%U-6Z<$M I@9S&AW$*(JDM^QVG.>@TAYS2D=,4]- I!9U2P"D8G[HI
MR#C%=YT(AEL90UYDW,Q3U,.TR)U[@P#=-/$B4R\\3Y/[9G#KD^")UNU!3_0N
MB!PU;Q<6NKI&[4/XG<IC62MO*[2YD=V]>1!",Z.*7TR:A7E[AP5G!VVGB9G+
M[@'J%EHT_>.*AA<^_P=02P,$%     @ ATFK2A(F-"$, @  ^04  !D   !X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL?93;CILP%$5_!?$!8S"W3 1($T95
M*[52-%7;9R<Y"6@,IK83IG]?VQ!$C-L7?&&?[;4-=CXP_BYJ .E]M+03A5]+
MV6\1$L<:6B*>6 ^=>G-FO"52#?D%B9X#.9FBEB(<!"EJ2=/Y96[F]KS,V572
MIH,]]\2U;0G_LP/*AL(/_?O$6W.II9Y 9=Z3"WP'^:/?<S5"L\NI::$3#>L\
M#N?"?PFW5:;U1O"S@4$L^IY.<F#L70^^G H_T$! X2BU U'-#2J@5!LIC-^3
MIS\OJ0N7_;O[)Y-=93D0 16COYJ3K M_XWLG.),KE6]L^ Q3GL3WIO!?X094
MR36)6N/(J#!/[W@5DK63BT)IR<?8-IUIA\G_7N8NP%,!G@O"^+\%T500605H
M)#-17XDD9<[9X/'Q8_5$_Q/A-E*;>=239N_,.Y56J-E;B1.<HYLVFC2[48.7
MFD=%Y5!$LP0I@)D".RFPJ8\>*/YA$#D-(F,0/QC$5HQ1DQE-9S1A&#Y;25PB
MC-THL1,E=J D%LJH21:KQ(&]IVM-&.# 39(X21('26J1)*M5HGACD:PUF^#9
M#9(Z05('2&:!I*M%LM325&O-)LC<()D3)'. 6&EWV>H/P&ED;5NU%D79PFE$
M08M#J"_%;X1?FDYX!R;5>3:G[LR8!&48/*E4M;J'YP&%L]3=3/7Y>!N- \GZ
MZ:)%\VU?_@502P,$%     @ ATFK2CP[FQMH @  =P@  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#$N>&ULC5;;CILP$/T5Q <L8*Z)"%(NJEJIE:*MNGUV
MB!/0&DQM)VS_OK8A+/%.JGT!VYS+C TSY#WCKZ(B1#IO#6W%RJVD[):>)\J*
M-%@\L8ZTZLF)\09+->5G3W2<X*,A-=1#OI]X#:Y;M\C-VIX7.;M(6K=DSQUQ
M:1K,_VX(9?W*#=S;PG-]KJ1>\(J\PV?RD\A?W9ZKF3>I'.N&M*)FK</):>6N
M@^4N"#7!(%YJTHO9V-&I'!A[U9-OQY7KZX@():74$EC=KF1+*-5**HX_HZ@[
M>6KB?'Q3_V*25\D<L"!;1G_71UFMW,QUCN2$+U0^L_XK&1.*76?,_CNY$JK@
M.A+E43(JS-4I+T*R9E11H33X;;C7K;GWH_Z-!A/02$ 307G_CQ".A/"SA&@D
M1.^$R.S6D(K9FQV6N,@YZQT^'&^']5L4+".U^Z5>-)MMGJGM$6KU6J!XD7M7
M+31B-@,&S3%A<H_9?L0$$\)3$4QA("B,#0(L4LL"P-PC=I *'$4(;D9H^.&<
MG_BP0 0*1$8@NA,(K#0@#()-8M D!@1"RP3"1+!) IHD@$!LF4"8!#9)09,4
M$+!/'<)DL$D&FF2 @/6&;P%,^N#@%Z#) A"P#Q[ /,HD\.&/U0=LD/TE#J#4
M@-H!%"W\A>_[UN<"(J,TGB/OPWI00P(@K- N(L%',^WTV RL%.L  6:1G=D
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MR.DC"JL&R&FNL :XW&E46($O@*9FT)0V],6)0$4P@$O#<"G#DRT3<VD-/NX
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M.C%^BAT@TW%DAJ/VHM%3[ "8CGD\C:;8Q=M@.>P-H.F8\DP@<3D G3MB(^P
M38ZC*3SA9D5@ ^L <HXII@3RF4,_JARQ"7: ),>1%!9D3H0V3PY Y#B(7.B(
M$X4CFO5^D5[GY4OW(D4U>2S>-G4[&[V[^Y<UOJCV%^W@_ER>7DOF_HT\7>Q^
M ?]E?O=FR.]9^;+<5)/O15T7Z^['[N>BJ/.F[^*DB8K7/'O:7ZSRY[K]VH9+
MN7LC8W=1%UO_MLEL_\K+Q7]02P,$%     @ ATFK2M9QN7JF @  Y@D  !D
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MN[-GVJW4V4L1X21#%T,T8QXF#%YA,'D/V3L@.%PP2$M8=&"G#FP)R#L=J9N
M. F()8C6!"2X,C)A8HOI+2;%*?FD3>1L$SG:?&)TXR38W&YTZR38.A3@J^O8
M?C :!E$:1>X^L;-/[.A#W 2)DR"YW6GJ)$AO<)I^<)H0' =7;=#J=S#CZ0<5
MI[:7WI$K_6?9[[_F7(%F#.[T#35Z(BX!@UJ9;:SW8IH+4Z#X,(\\M,S=XA]0
M2P,$%     @ ATFK2I+'TB5M P  ,Q$  !D   !X;"]W;W)K<VAE971S+W-H
M965T-3 N>&ULE5CMCILP$'P5Q ,<V'R$1$FD)J>JE5KI=%6OOWV)DZ #3,%)
MKF]?8SB*V<5)_R38GEUF#3/RLKR*ZJT^<2Z=]SPKZI5[DK)<>%Z]._&<U0^B
MY(5:.8@J9U(-JZ-7EQ5G>QV49Q[U_=C+65JXZZ6>>ZK62W&665KPI\JISWG.
MJC\;GHGKRB7NQ\1S>CS)9L);+TMVY#^X_%D^56KD]5GV:<Z+.A6%4_'#ROU$
M%H^!#M"(EY1?Z\&UTY3R*L1;,_BZ7[E^PXAG?">;%$S]7?B69UF32?'XW25U
M^WLV@</KC^R?=?&JF%=6\ZW(?J5[>5JYB>OL^8&=,_DLKE]X5U#D.EWUW_B%
M9PK>,%'WV(FLUK_.[EQ+D7=9%)6<O;?_::'_K^U*''1A> #M F@?D/C6@* +
M"/H $EH#PBX@' 5X;2EZ;QZ99.ME):Y.U3[>DC5O$5F$:O=WS:3>;+VFMJ=6
MLY=U&(1+[](DZC#;%D,'&&HB'A%$T$,\1:!G05$65,<'!HL(3Q"@"0*=(#02
MQ";)#<10.AN5VF)F&E-HC#\JU88PB(8HT1 A.B;18B(+"1O"(!&A)")DNQ,\
M08PFB$$5@_AVMR&$TOFHT!B40<FH4@@AR035&4IUAFSXF,?L-@\(F>21H#R2
M5FADF &/GZ/Q\_LE0GQ<ZOX=(D% 4"4=R/:&6B$FVPEC(G<HI0-9B=@@)A'<
MFPAF3A./GN#N1*#U +T@&"B8#F2MUP8QR>(.13"+ D1N>Y058A+!78I$4#)T
M(@-N4R3^#]'@]D$P_P"B@2!$--!"P);9("9;W&1(<H]HDMM$;!"3".Y6!+.K
M"=%0W*XH="(@&@0#14.A%0%[1S"3_DYQPZ*880$NT(T@%XB9YC)QGJ)0.E,'
M,MRR:'"_="AN)!0SDK%T$!"4#KWM-E:(R19W&QK=(9T.9"5B@YA$<-.BF&E-
M/7[<M"CT(R@=S+/ ZWK;LZP0DRSN613S+$ DN7DPMT),(F//,AL,W(Z".PY&
M&P04AA,L MQ& F@CX+EL$% 8CH^3WJ 'S'EUU/UU[>S$N9!-[&"V[^$WNN,>
MS]/Y8JLV#:ZH@A?;P$=7B%II^_=_-V\_)WQGU3$M:N=52-77ZN[S((3DJC+_
M0;U()\[V_2#C!]E<SM1UU;;Q[4"*LOM$X?7?2=9_ 5!+ P04    " "'2:M*
M8N:Y*H0%  "5'@  &0   'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6R5F5UO
MXD84AO\*XCZ+Y\P9?T0$*1!5K=1*T5;;7CLP"6@-IK:3;/]];>.P^)QW4'H#
MV+PS\_K,\3-?\_>R^EYOO6\F/_;%H;Z;;IOF>#N;U>NMW^?UE_+H#^T_SV6U
MSYOVLGJ9U<?*YYN^T+Z8413%LWV^.TP7\_[>8[68EZ]-L3OXQVI2O^[W>?7O
MTA?E^]W43#]N?-V];)ONQFPQ/^8O_D_??#L^5NW5[%S+9K?WAWI7'B:5?[Z;
MWIO;!Q=W!7K%7SO_7E_\GG2/\E26W[N+WS9WTZASY N_;KHJ\O;KS:]\470U
MM3[^&2J=GMOL"E[^_JC]E_[AVX=YRFN_*HN_=YMF>S=-IY.-?\Y?B^9K^?ZK
M'Q[(32?#T__NWWS1RCLG;1OKLJC[S\GZM6[*_5!+:V6?_SA][P[]]_OIG_BC
M&"Y 0P$Z%Z#L:@$[%+"?+<!# ?Y9@/IHG1ZEC\U#WN2+>56^3ZI3]Q[S+HO,
M+;?17W<W^V#W_[7AJ=N[;PMFFL_>NHH&S?*DH0N-&2L>M(*2Y*R9M0[.-@C9
M6)*J@-F.&UDA#0LC2..P$0OC8?L*[*B"&%? L +N*^"+"A(1K>5)DO220R^)
M8Y.*I]4BET8&.W'0B=-.9,^>).ZBD1N7)L()$-DDQ4YBZ"363D3G+F/52!Q9
M$;B5%CDFBYTDT$FBG8@46B:J$3(F$DZTR$8482<I=))J)TXX274C% N[*R"R
M62#E,^@DTTYBX233@7>12*:5%B4FRK 3$V$:1=I+(FD4Z52)A>$5$J4A+P$R
M&NTEE5Z,:L88)P&Z0C(F$\A< Q%Y;TCY85;!(?!&.R-?)"1+DRR0P :CTEA@
M2$7(ZI:,R23MD(QLB+P&H]=H]J;R[1XTHX;BY")-!S] 9HRQ(4.8P$8CF#F4
MA1B=)O[\@&0P\PR GAR2C 8:7XZ<0U2 JNW,@!O,/0/ IR8<&FHW*K562$5$
M 3>8?0; 3PY-1H/-9ID<)9$JS4*3((P_ OB3"4R:;"UR9&R0*HD"@S9A !(
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M!Y^&XQL:I7+2/PR!OX+6%""@@Q^'5P\C/'D@JN,?&9 _#>_NAI9 42&OM"4
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MAK[*/>7?,>\ 2P&-OB@]]Q.<.!+AX[V8>S^\^33^>#7B(D H@D9*PI:C(#/
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M460(3WN#2M6 "BVK/#$^1\@'PT]WHQ%7&;-IG9,J@0X&K7V3AJ5(K,+[@O7
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MF66VR D[6I=*O-#)*$2DF"A*X+&*_>TE!+Y:4B0@J10'+$LV/0^ZI\T3V'!
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MVT+RWU5?.;)%@+#!S>F5:5=L^CJZ$YX@J5>HL!K>-)L"RG\=O08=%2Y \5[
MW=%:54I--S4<]3KXKRRV&N^R%1K-7L(X:G=?D38_JIR+6YV4#LOS?WMT"Q1Y
MEGC.5C\_U*'PU2/5O,D.V#(O!&KT/?/<Q"_.&R &4"GAM0]'[JC?<?WSP66Y
M6D5(G6RL</ZM^T)D"M.I:L5:"K*FF>HD@(\I.C>/+H?3C\>FN(V)&Q3'YF,Z
M=TK^1G/0CWB2(I<8DYU!$O0"Z0!AMK\\;*ATKBDY-.?F@A3\0^(#]B,WQF43
M7Z^[0LO&3 :#7@Y:G%[CG34I^=",@U3'%%F.4A30/4%%:>:/*6)1C#9.,9##
MN2GH4CIU ]ZQ*LA@53Q!6*N]>%]ZV%*D\]%P^G!,[YVT>F'@YOL_.&%X;$J*
M-B#9H"%>RU-#8XC'),>$VI^B'/8IE<1'&&43P&:F#VHF%8N>VZ&*:!*/,Y2<
M=88%1Q62+QWM57FN_<V1I(=XXT9FSCK8ACZ3=0AMP-K5%*0J2#57?6_,:5D.
M;@OE.9U!<E676%"+JDJ[SAS.1D%_*I8U3351+JW%C7-4WE;/ ES@*<^<JL:E
MTF24B*\1E M";0J["S5 U4C RD4OC9*X"[$IL]A3>A>Y-+!_TJM&3FG5JMWZ
MT=RN/918L%$54>IOB4],]X,!,RVE*UG/@^D,I-X)<&EX%'DFJDI']^D6>$JG
MTSS^'L@N]B9=Z#0ARY6)2S=O21I7P1=%(ZR&MF7 3O1+0EBPC1:A%E5TB*@G
M\4X%K:*Z0M:2!D:$5KY5.JI)J4!?IB[[H_$DS>#,D)? [<XXIDBIF2&7$,>0
M=% F'KD7%4:$TBQ4#X07!Z"(64M%1I_F@BCD[T(<D5!L2Q"QC=X(G0T;N.<2
M-JS@H"UT!36[NAI?3E2L9\8\VGX6;>(";CS".ARNXJTISU"#N@[>ZUX]2J],
M50CY/QB%6:DT 2D>'.Z?-,]"I^**R*V<=^R48A'\/FT-CA76:N;*"8^JKLX:
M6"S5R4RD)ZY^TXYI(+>'81IX @M3JR)4R<D<Z(# Q#ICTF@MM^K ./8 %?3D
M 4JPM>4K3./DH HG;P(KP\?L4IUQ'(<!%->B5S)I[H8G<=17_A0LT&/MSD4U
MN%7\(JP6N(+P%WL?D408WMO9#A4D]?"LKT#8$#NJ/5&QL!*]3?)_#LGURQPB
M_X%$ %)V\#/0,=.-?LR2?8TTHA@9XK>*D25[DRJ1(!'_Y]HL*?C=;_:/ W)E
MYIH>(8!8+6G8(UO5)#"D<XF./CS?+ ;&3'W]5-MK2=,A,++]G0C.:J7=K;(<
M;25546S\O@:Y%&?7]KV5%F65I,+R(N6H<AL$"<ZL.!-)'C5]Y($-2 $:$BLX
MR-6D%_%Z+$N_7@!SDNH2]+MZ&EH.P%B*]:L0&9ARF2+:4B'][)F=X[;%F >W
MD[^(=?%D[$;(Q?!/7ZZD.L/&)"NS\8V%H])<;UTYIB<918_9)%Y1^*^^AJ<T
MO-3^4AS_#3%(\>6:2=^^^M5@0GBEX+"XV,1]B,"*.IHM?E).NS(S \"DF3RB
M .ET4A+5Z$!4S5NB  \F$2HN@<,T\)IA,*KX(%1JM#9B2L!% TL=&:^"D5)L
M&X22V;D2O%BIZ0GEY=*^I*A<G]\'$L5O='8';Y8HHC(SD V^9J=<Q V+<)&,
M)M?1-#DJ9<=FR_@QFGU6)=@>*QGX3FPF8X](H+AL-8'&=9:;B#(0SR8GT [6
MI/)^Z9(*W1(!"NCN9?R8J3HD>X6+=AA<<<:B4-=!MUV5'K34BP1QQ<_3)9@7
M2F-=4AJQR@=TDAFKY<<8U"I'*G^*XYU?:_DFS'3P'F9Z8/RXNHAR.,:"L',8
M\J:43F0QU&IU$Z.GD#.W:C.</<7S@BN$ZJ?KAY&V>.RMVMF^DDK$1C78H.1D
M.%="$04UJBB"3J>+C@1017]*L\\GR>9$00@=WQVT#@_0*,19<TS66^W3H--3
M40M&^A_TFD%WT+<4+TDK"H[8I]!%ZZ_Y59EO\5I^"-!$_2'H=ONTLO)JDS),
MZ C7T:988!Q5)C*JD?H06KJO%J?=4T<$W%9YJ\9_9@\N.E6L>A3BD<F VI)$
MO)HL =Q?DV@2$F?]<HB5"CC6""YN1K=E%TNK0S*=*6.'?!E9Z?V/K[:?,"K@
M.#,="C<J,"]>4T<DR%5,@NN_I"J]% AR$%Y>4D#WR17%WY9' &)YR>EG0]OQ
M-V(787G8>T?Y5?UO[!>U;]%7>LW42%"UMQ2]L-.N%TAI.-U68 %TC*A(X@:X
M_DS/C-A 8MV7\DVAN=&[UNVWB?B@AP1P%SZ>Z8_M)GWLX\>6?'MOIL;R7F>J
MI^<'>"ALM7ME\ PE.UZ@E]<?C[$UE]^I&S-68WY+&J(&GZW@.&8Z1C]9(H*:
M*1%VRD/9:K?-:QZO<AYTR3>% %7/,=,-+69LY1 9<9]H2QYT@+@,0%%@/VM4
MWO]I_Q1^5D=1^1G]K/U.'TEA>-H;'-(#^J!;A#*"IQ.PJ6$A;1N<MKNQW=>9
M]-::^MF_M@?^M3UP?7M@;T'@0XB+4_O5#I4OO1-\6:^^ST%>BO_C-UNYB+_Y
MP^'!'+_6F/VUQNS?N\;L'C2WZI(>BO$UR/TO4NCTUY*UOY:L_;5D[9[TR3K>
M)^'QUU84NO46U<97B1(4$O(5?/#7[(Y_@32$7[,[?LWN^#6[XUMD=U3EJFIZ
MQT$*LLGUD!$.%+E^#0[_-3C\U^#P7X/#_SG!X3>Z>>#$A'H>75 @U'%PHCP$
MY=>NL9:XHBZW\!K0HYJA)\[0_WV%805C3-6I!)7?IOGN1)P"JG;3-D9S4S'7
M99&/@ 60E%S9BDC/E5%7T0:K<\RS8LE#A58CUBVOO?+6S9M/^$.P;Y#_$),1
M(.8(Q8?I17#T 0\"5G^O:*'?S%6?L%1I@;4W=ZGFI7>$>?^2O=S5%<&-:^S\
M;DBNA8&'S0?2JT;(BE]B&F_AQR9WYJZB,@A@Q=JJ".-TWR79 ?NT[7&.OG>Q
MYE5?[*7'1&Z[#LL__W>K<I%*_L#*&^UJH1W'(UH17%S':/UV+ _H&[OX9@[0
M-_;^_Y$O]&3_A2V_WW(DOO*OD]E.WZ?*E1D6R_H?][M;]S* &ZILH]]@2T'%
M@\4Y,Q7Z04$Q;[[]D,>+8L7Z13TK =' RTL<'S%5'7IC.LDMJM"<!+2)'0;Z
MJQZ+[&4U46,J?(F[3EOY+!?# Q#!Y](^ "7>\I3[7.0AJ!JDE[X&6ANJSQLC
M2N+1B\3-_*9#^238XSI^/R&V;>@E1VK=4O:[BFO?\GF*ZQY^E[NX<G&]7F,_
M17_KJ6IZF@UBE3=7BT[GH.M&CZF0I"$JYDN5M0+[H<3MND>">[NPU3ZB<0WG
M@?Q['KWF7%18^KI(RR"T]_ VJ.>UI"-D,1<=(U[ QN3RP)TFC5DG+WSS^<[\
M\]WJ!IB/T>9S5FQW,Q2&=XD*-<16KN1DY["2G.L18N/5F,5E'+5R.'W_;!P6
M ).A9,(5&.'00?9&WVMED':ST6S^MG8,*MM9K+=HV@C699JGZBRHV &T@#R>
M"/!BFR77SM_I^.:_XQK@KTJ80_.]J<G..2:U0Y[7O)"^5)GDT#A7*KO[)12]
M;@VF+L5A;]B%++:4[J.#1*MQ(='&=\\KG+%]L-C0%[(@ /D0?"?]C?G??4)%
MOX:BW*3/6I#OR3-OCKO-C/!_X#N.>ENS%ON9_H'CVEI*W1[_6*S>/2YE*^\?
MUM&!:IZYB!_1[JF,H_N5=76)J<?!XZ[4U+ER"JL$$#0"&2&)N<W3>#-K'(F1
M\SCX6_ #X&^!QNG[>/:TP3IDKP$(=2^8;\%MS?D=>!2WP'X_1-L*;\,?5JD.
M_J]7[:7=-@9;\WW4UN._!7Y :Q>E=)K?F%>(TB([RZQP)]R8.;R*KJ+>M1VM
MM92I[R6V>@P.D^*H>>JY8 ]*R;OIXT[\IY976 *!M5.B?OZN=_YO>K"71"F9
M%JE4^K_KA%.L,3C_1\ZH<D3[P4\1\+ZJR%N:++C"NM?(R>7#-[TKRD]D9\"
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M;-W[_M\!E=\WW_OQ7(MC;;\\UB]+/Z=OH_G>-1]\S&/J4!_<1U^^)NAPHCO
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M6_HF-X6,U$P_VB4VP1@/]KT%#Z;]K%DO$>/!_@HIK?EU4W!H_).?4$L#!!0
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MY_Z1TGG8$L/Q\^2WY3CU*R+\>#U^]PE02P,$%     @ ATFK2A5(7^K* 0
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M9%4HLBH4616*K$,468=7E+4[IK4NF[^2?!BS/,QGW3_ATR]02P$"% ,4
M" "'2:M*'R// \     3 @  "P              @ $     7W)E;',O+G)E
M;'-02P$"% ,4    " "'2:M*9O,+8((   "Q    $               @ 'I
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( (=)JTKZIB?^[P   "L"
M   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( (=)JTJ97)PC$ 8  )PG   3              "  ;<"  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ ATFK2ORG_$-6 @  KP<  !@
M         ( !^ @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( (=)JTIGXDB'- 0  +<5   8              "  80+  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "'2:M*+UX?,K4"  " "P
M&               @ 'N#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ ATFK2EEX#>IA P  Q@T  !@              ( !V1(  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( (=)JTH_ UKH*P(
M #\&   8              "  7 6  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    " "'2:M**$\R"W@$  #.%@  &               @ '1
M&   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ ATFK2GZ3
MF3NO 0  T@,  !@              ( !?QT  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( (=)JTK[!V=_L $  -(#   8
M  "  60?  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "'
M2:M*ANBV'+4!  #2 P  &               @ %*(0  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ ATFK2F#\:]"Q 0  T@,  !D
M         ( !-2,  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    " "'2:M*>K=/?;,!  #2 P  &0              @ $=)0  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( (=)JTK+<\<HM $  -(#
M   9              "  0<G  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ ATFK2K>*DU>U 0  T@,  !D              ( !\B@
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "'2:M*GK\"
M?*\!  #2 P  &0              @ '>*@  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( (=)JTHC<_"<M $  -(#   9
M  "  <0L  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
MATFK2@.!U\:T 0  T@,  !D              ( !KRX  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    " "'2:M*N.]J>;0!  #2 P  &0
M            @ &:,   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( (=)JTI"">/SL@$  -(#   9              "  84R  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ ATFK2I)CK]&U 0
MT@,  !D              ( !;C0  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    " "'2:M*@MTT4+4!  #2 P  &0              @ %:
M-@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( (=)JTKP
MZ7?$LP$  -(#   9              "  48X  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ ATFK2@DQPWFT 0  T@,  !D
M     ( !,#H  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (=)JTJ.>L'=N $  -(#   9              "
M <U#  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ ATFK
M2K.5[7&V 0  T@,  !D              ( !O$4  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    " "'2:M*$*3Z/;,!  #2 P  &0
M        @ &I1P  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( (=)JTHM=RQEQP$  #<$   9              "  9-)  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ ATFK2C34I?BW 0  T@,
M !D              ( !D4L  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    " "'2:M*W^W-GK<!  #2 P  &0              @ %_30
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( (=)JTHEKD]\
MW $  )X$   9              "  6U/  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ ATFK2D]'U]KQ 0  [00  !D
M ( !@%$  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " "'
M2:M*-6A-,]T!  !B!   &0              @ &H4P  >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( (=)JTKS3QN;) (  & &   9
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M970T,"YX;6Q02P$"% ,4    " "'2:M*/#N;&V@"  !W"   &0
M    @ %+8@  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M (=)JTI.[0ZN_04  /XB   9              "  >ID  !X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ ATFK2M9QN7JF @  Y@D  !D
M             ( !'FL  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    " "'2:M*_)\92O\#  #$$P  &0              @ '[;0  >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( (=)JTJH(;@>X0(
M *<*   9              "  3%R  !X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ ATFK2O0)B*"Q @    H  !D              ( !
M274  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " "'2:M*
MYQKI$!P#   "#   &0              @ $Q>   >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( (=)JTK92![,) ,  )P,   9
M      "  81[  !X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ ATFK2HX.2CGO 0  @P4  !D              ( !WWX  'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " "'2:M*DL?2)6T#   S$0
M&0              @ $%@0  >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M 0(4 Q0    ( (=)JTIBYKDJA 4  )4>   9              "  :F$  !X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ ATFK2N]#7Z0,
M5P  0E<! !0              ( !9(H  'AL+W-H87)E9%-T<FEN9W,N>&UL
M4$L! A0#%     @ ATFK2I1P[3]7 @  !0P   T              ( !HN$
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "'2:M*P,R0;=(#  "Q(   #P
M            @ $DY   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ATFK
M2E,Z.%3@ 0  +A\  !H              ( !(^@  'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ ATFK2A5(7^K* 0  $1\  !,
M         ( !.^H  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #P / !6
)$   -NP

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>97</ContextCount>
  <ElementCount>229</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/NatureOfOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/GoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Intangible Asset</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/IntangibleAsset</Role>
      <ShortName>Intangible Asset</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Loan Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/LoanAgreements</Role>
      <ShortName>Loan Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2124100 - Disclosure - Loss Per Share (EPS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/LossPerShareEps</Role>
      <ShortName>Loss Per Share (EPS)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/PreferredStock</Role>
      <ShortName>Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2131100 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2132100 - Disclosure - Stock Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/StockIncentivePlans</Role>
      <ShortName>Stock Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2133100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2134100 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2135100 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2136100 - Disclosure - Subsequent Event (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.alimerasciences.com/role/SubsequentEventNotes</Role>
      <ShortName>Subsequent Event (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/BasisOfPresentationBasisOfPresentationPolicies</Role>
      <ShortName>Basis of Presentation Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2207201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/Inventory</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Intangible Asset (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/IntangibleAssetTables</Role>
      <ShortName>Intangible Asset (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/IntangibleAsset</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/AccruedExpenses</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2324301 - Disclosure - Loss Per Share (EPS) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/LossPerShareEpsTables</Role>
      <ShortName>Loss Per Share (EPS) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/LossPerShareEps</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2332301 - Disclosure - Stock Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/StockIncentivePlansTables</Role>
      <ShortName>Stock Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/StockIncentivePlans</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2334301 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/FairValue</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2335301 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/SegmentInformation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Nature of Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/NatureOfOperationsDetail</Role>
      <ShortName>Nature of Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/NatureOfOperations</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Basis of Presentation Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/BasisOfPresentationNarrativeDetails</Role>
      <ShortName>Basis of Presentation Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Summary of Significant Accounting Policies Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - Going Concern (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/GoingConcernDetail</Role>
      <ShortName>Going Concern (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/GoingConcern</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/InventoryDetail</Role>
      <ShortName>Inventory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/InventoryTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Intangible Asset - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/IntangibleAssetNarrativeDetails</Role>
      <ShortName>Intangible Asset - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Intangible Asset - Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/IntangibleAssetFutureAmortizationDetails</Role>
      <ShortName>Intangible Asset - Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Summary of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2417401 - Disclosure - License Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/LicenseAgreementsDetail</Role>
      <ShortName>License Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/LicenseAgreements</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2418401 - Disclosure - Loan Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/LoanAgreementsDetail</Role>
      <ShortName>Loan Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/LoanAgreements</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2424402 - Disclosure - Loss Per Share (EPS) - AntiDilutive Securities Excluded (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/LossPerShareEpsAntidilutiveSecuritiesExcludedDetail</Role>
      <ShortName>Loss Per Share (EPS) - AntiDilutive Securities Excluded (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/LossPerShareEpsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2428401 - Disclosure - Preferred Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/PreferredStockDetail</Role>
      <ShortName>Preferred Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/PreferredStock</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2431401 - Disclosure - Common Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/CommonStockDetail</Role>
      <ShortName>Common Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/CommonStock</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2432402 - Disclosure - Stock Incentive Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/StockIncentivePlansAdditionalInformationDetail</Role>
      <ShortName>Stock Incentive Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2432403 - Disclosure - Stock Incentive Plans - Summary of Stock Option Transactions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/StockIncentivePlansSummaryOfStockOptionTransactionsDetail</Role>
      <ShortName>Stock Incentive Plans - Summary of Stock Option Transactions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2432404 - Disclosure - Stock Incentive Plans - Additional Stock Option Transactions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/StockIncentivePlansAdditionalStockOptionTransactionsDetail</Role>
      <ShortName>Stock Incentive Plans - Additional Stock Option Transactions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2433401 - Disclosure - Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/IncomeTaxesDetail</Role>
      <ShortName>Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/IncomeTaxes</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2434402 - Disclosure - Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/FairValueDetail</Role>
      <ShortName>Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/FairValueTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="alim-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2435402 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alimerasciences.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alimerasciences.com/role/SegmentInformationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>alim-20170331.xml</File>
    <File>alim-20170331.xsd</File>
    <File>alim-20170331_cal.xml</File>
    <File>alim-20170331_def.xml</File>
    <File>alim-20170331_lab.xml</File>
    <File>alim-20170331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0001267602-17-000037-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001267602-17-000037-xbrl.zip
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M<\JO-$YK[ UZX^Q=[UMV_78 PG3;^]+/S&B4C4?VX=?.?P_SPL8O>3#O@(Q
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M /5+V OWG^]%ZT+6]QS396>75N0+^;6W@^[P+OO<^6XFXZ_#O!I6MY1^,VG
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M+)UQ2$"X'E#T6D2N=.*=M%HJ2=KO%A'9B7=;,&!OCEXX" &O *>)*&>\HUJ
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MZ*K#U0RNBYDU#E1BMJ2F=BX"P(X;QI1*%=2>6A9%Z>\S;G&DJN')RL4:]$=
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MAN(RL4BC#MJ@U[_< #[97WYJ_'CUQC*G%GNC;J?_SZR3A^E,X2U>3@T2U+@
M_Y0<M*UE?/9RCAU]_<M5M51EW9LJ2/RP6T3]TP>FEB?"W]8D(Q<RR=HS@JSV
M:;:0U"9$.Z.#]?'U+[^74*Q\2SL8"<YM@9 ZVF1OL+/"41D%XJH$PHAH[.MB
MN'<;&+.WU(&8PK<#2T X%0B$"/!NA'R:NU&!@*FAKY?FBZ]\4QV,I%JV>'L
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M%5P]3-D+E_L<P"GN0A?7MIK!M>EV\RS].WQYYV(%*3%6H,2EP 8S;Y$I*Y,
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MEHUGC<+M35AN29%&HF%CN!ZH= B,&<;)E7+!:E?=MDHAFY C@=BVD->2#'O
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MU#1B8V"8I-WS5.JJ+P# HTVH,9CZ!B?F .P V09Z6D.]]A(%&0T"H!@V53Q
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M\K@* =X]XP31A_)1%O>S'H,\.SKK8]9-XX7ACTNPM<.Q#Z2;QH9S:@.7+&H
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ME!B$@!52/\OML<SFH&LV2HKA/N=QR!(15BLXI2(&I0EX! /5#+[;'U0Z](D
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MXQ8N4Z[A2;) JNUKOH,&#;622;]'?3^W'U10( )[[P; *@NQ*"96#.G8/OK
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MA?[MT!O2_6Y\-N[&P/-<SS-B=!@7GNV(="=<(8A^;4B[*<J5>NR5V<M* *!
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M]1SHFM>EX[NWW3N]IY?2X\X-O)T<JMT7 UROCQ_I,S1YED@G3B'+$,!(.E1
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MZE2Q-*V/V0O5+I/,=JU(&U3'5B=?/_TC18KT\$G^2SUS)&EVJ+7<'5]+O2A
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MSX[+N[2YO LCZBO:ZL<"K+RGQ'5>=KOAU.JUS7Y[]70G.\DU8)2WJL*.IS
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M+@Z"V5NO#FU;)^Z]3GY>K6C%?,5\Q7S%?'4HM&*^8KZJ0<YZC3S+75JSN3J
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M:.-*;SW@AE8]+O"X'W]H-2L^+9J77]#0'FK<X=6%T6\VS%5N?0Z-Z/(/;@P
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M;@#5LJQCUX_B,)E7@UGZ^K_\D$2GM[:]^#"&8?V*H[IT(\<+</<KNH8%/_>
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MYSV<8A/32;$1W$FN*=9[DQI.&(N9'<YM1R2D+V5?5?]!M8Q="&Q #@-)>UC
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M8FW(M-)G)-\3J 4(J=$)[Y6Q -6L/2?S9/*GM%F*T93 Y#JOJ)04AP,<?T^
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MA;V/R#9J)8Q(4A];WH9T>4P=%^<!=5P4U'$Q.\N)BT%LA(?%GM\==Q/YN I
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MJZH;;DVOJ4U;-9V&JU7,9M.V[ ^_/1J>55GW_1F-29O>DVXX\[;;VY7+IWY
M+R:4:Y:FJW];4RVXZL?/?/S] .QW\ME@FB73BO<GE(S"*?@(>";A8TOF$8WA
M83'Q2)S.9E[T0,(1W)@),.3B)5XF7K@V(@G<(YE$E)(9/&$2$PJ-'9(;+QI,
MB*$IA,F9>,&0_6!]?E;IGI/,"@@#:!^-7B+?-9_Q6)SL]]7'!$P1IT^'8'%C
M(: !G4ZS[_SZ0?W ?P> !_GO^VL&"'GL!Z*17IJ$^0?"XO!/[OUA,H%O@R R
MTP)F8^K-8_HY_^'GQZ9BV>[59;"EN;$V!E@O7TD3;3*UO^TV:!OM<=:G R_7
MW_?QV'GL_.EWOO1KZN\]8]8JQ_V*X1TN=4^!\5_OA5>]#:?#/-I@4<*-B!+<
M]2CA%;$H*N)K%-%&/60!*69U3D.U9!VO\49Z]^*L14GLW/$JXZX4]4N5L3QF
M+<M]H&4[7F4J=CWDC?7M7_P#.GQI1N>-FU>#H?+&]$A;Y_Z@T<"/C[5Y7R-_
M\'S;T)*@6T*W=!K*A&X)W=+IN:7]IE"@\L>T(Z_(!%)FD4F8)G'B!:R5Q$O(
M+1W[0<!^"4=D#E>'SS-T##OVBCI=\W A:ZKBJ*9B:O)>&'_6[Z[#W;1'5)=6
M;E645W&U2^?>N=+J<%$9ESK:+[1?QS+AP=B"7U=53+NB./*.[T8T$4T,+3"T
M>-O0PI3WVN]2*\VA]FO_1,=IY3.^1%Z0[)-@?G$\47"Q2P%9!\70=*6B2HL,
MCF6,B_;QZ,I/F8I+3=I&?@0"@2@_$(JN.XJ*;@*I0"H6U^F7\DY@/!4@<!%U
MBV";832B?I)&M)"9Q[&<:WJXH#Z:NJI8;S#7?]4^[6-1)SQ5^)A<U^G0IU_:
M\LXPPY/RD2UD:^G9;%MQ-'1LZ-@0OG=8/JI(>TG\R3NV<U\ARLN:BYFJO>^.
M:?EH%?&2I1TR.A9%P?SA\?@JY.9TTHC(!?H;]#?(U3%SA=R<CK_!9:O]]OZ)
M[7[LZ,[B/=:&(W9/)RVA:8I5M13=>KLWAYQ\]@(S@Y@9W"LS**^N"=E"MM#_
M[>/_5,72+46UI9VPB/X/&47_MY?_,XK?LWTJ;)W[RE@^'Z1BA8R_X.#]YX.E
M8\Y6*KJM&%5YX.T2T;$H$&8PC\>'E0X;XU)W,'6)0+S;Q.LUPES94[[++K\U
M3Y9BP 1,-]XP^?AR82"3R&1)G92T9,:I ('K:UL$FY\^2SQQSBN;29&8O;"0
MC#P_(G?>-*7L@,TPFWB-V>$5\/UA&K&U./8VO;W/WGP''WCL>8&W>ZOJ(2?U
M',UA/.KE&TY=CUYY,&%[!''$SL/-WU"(91#<T0BK;!J'WA.]YZ'G"SEO]SKR
MHU<>])[H/<OE/>6^X/Z5;Z??]*[[<-3T S^AU_X=';:"Q O&/EQ3BV.:Q,V4
MG3Y2FX4POO_A#W%_L.?1O=]ZKU4:#=>R=+VA5YNFJM?U*_'6>],Q-+UJG.!;
M[VF<^#./3;Q'7(S$6Y$CH4*0Q(O95/W1J^SSE]Y'=.;Y_'T98L(>$S_@?PB@
M\60$0T8>P 3&Q N&[/.(>J.$1L2/V7U'X13T/_Y,GE72YX3V]-TK:^QN>MO]
M"\9FYSU6VQ&$T<R;/AV^Q8TY361 I]/L.[]^4#_PW\$X#/+?]]>JF1>-_4 T
MTDN3,/] 6"#^2?:>:Q4DE?E4,'13;Q[3S_D//S]V@\MV1YN,JKG1K+T\+2::
MY)CO^^;PMWU\25YD6E! Q']=?8T1?\Z0#L*(6YK/X(!IQ) 2C_B3&PQ7U.4W
MZ(#.;FFT=&B&5D0L(#<!_^0]4,[KY.=L$A^_S\=6L!1),@G3&"QL_.*#)C!W
MO>VLH'=^+_;1SVR.XG3WXYGU*J:%A8;%69V3,R[[E/J<[G*RIE1-/'<7??*+
ML=FGF.<,R]VE\H1NZ.3=D+Z/LIRV&\+3KM$-O1B;5Z4>T VA&T(WM'$)(EL.
M*(2J4SLABKU,NUK0CN+3/1RJ,&_FE!Z_,/&FQ:@3E@C)%M]))$MU5=%T>0<6
MGWV1D,22#1E%%FO%&W0\HT'2I7-V43!N^/%@&L9PFWUJ,E2[HC<;CEEI6HY9
M,^WF5</B-1F5NJX[3K/PF@Q)H[UY":_G?KEQVWW2:C<[W9M:O]5I/SOR+RD>
MR6BP'AE8*Z]A6-'DU9H&W91<7M)8[N1()A&E9 9?FL1L,ST=/BXF8;4A\(.E
M/*T#><VSD_M0RGW(((U!F#2*R;V?3++"EF^7O4L2"_4FWF  ]H57T(21G-9;
M]M_DM)Y)5<J=;$U.BQ02T7A.6>$7G3XHK*J("915B'G!P^(@1_OGF)D&'H[R
MXJ2(WM$@I;QBR&/W2*<)WSV41B3VIO"')"13+V(;C29>-/,&-.7^@@S].(G\
MVS0)HT5A$A\_F'K$M.3:YLWG4?B#%W!-'^3TQ:D<F^Y554DM>JFR93*.0<\&
MU+_+SP+98+'RRI3\4VM=O[F2;7[>Q*=L[QMEY2]@)(=TX,>LXF[F?1>E<;RE
M_%ON#SI(V0U)9S3R!_#GCW6W\],E^=?$GU+Q1;?#R^E '?P8>@ ]]<B=%_DT
M>6"_C/S "P8^X#"C0,- U.+YP8C5K3%GKO#;W*8Q.)4X9O>".\$5<V\*B@6N
MTQLSP<!%833V A#LD-RRVDZ2SJ'58QJ.(V\^\0?\.Q$=IU,/B'L 8W_G1V'
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MC.WC6/._72D/3\HJ!2R$D@;KY*/'LCH!"_8;JLZ<X[+J (N 072EAJ< 'H#
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M$HY 6KL)9]V&E1+>1AC[D-VT2]ODD#:FK#N.)YASM?^L_#L**\SV$L%4*:<
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M=7_5/V/.)71/B>@W6 CU?7A4P0C%\%Z;:>J:HK&JWV/HMD*HSZ&CYC@_VU*
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M?V=$&!FJ?/-%?1&:Q57:+%\=*())[R+%RG1KA*YLI5!!NL(1I*WR2+$8TOZ
M0UYH1[B/09K#7UH?[KB,C%$N1KRNY@#-V^IS\/?B]MMN3G1G+"66E-D YE)4
M% 6.85PY)\&$$D2S*)7MYZ+OWVX8Q(K14<K%BY?K,,E/YO):W%MKN"!YKPW<
MWF644D:,1?3(2BJ1#IRC(D:"O*)"*:TL<P,FEYQ6QB"V3 E8+N+<$AFTX&I%
M\ZR>03^T22,NKCKXLBUKB5D@,MH"U*B4B#BMP.(2&,G(O<=@=F.L]K?N]Z1]
MI0U;(D9Q;:UB2!&BD%+!(4X*@501O24LJ%@,F$CS+/:,VX7U!)CEML'?FZMD
M'O:WON]F*"G\*[2AJ/ >M$A:AF &9@Q+B!/84NWU]\2*G3KN$>-[,%(9N7"
M,6#[-+C'9\1H8.7;0;BH%F;V-I@VG-A9BKI)H=8]HE<Z,Y:4*9)L#40U(8@%
M:#;5DJ.(;8KC<?#W<.B6]\CT&!VQ?%9X4WU>;7P_27=T92L-H*@L.)\A IJL
ML!(9#*T%9X,Q:PM*AI@9>6SMD?DQ,EY[UB"]?+.M>4LM-89ITR+KK4'1%Q$I
M[SG"'$8%-5R&,""T*?LT,[XY.@6$6>/A;GN7O0.R-V8JK>!*R5 @H@2'D0(S
MK%,FP&"4"CL;HP[?TZ0S/EE&Q2Z;@JG/SZO%ZJ1^VB6M5R=+POQV'-@FU?)X
MKI)I+[@14!EC#"QS@%![JA!W&/2V)=;' ;9K]LEG J4R*GBYB/*D99X-B%'!
MF#>D0-(: U8ZC4@4 2,,^M,(3:S!9'=:Y-E<FI06HV"6,2KAUAG[;;$L&U*7
MA0-SS4<PMX1P*$KPVBRF!!%9%#(Z9@@;L!Z<9]%C:)<]##T8 ::<,\<ZGG5K
M)-R]I*7G10'VNT3,08-8$!Z)H&&<&!&P@5%BY<$;GB-W_@@895OK^GIF_KVI
M_)OYVDK>$$Z]:=%K:^;2$B.4Q6 H.2J055H@%U1 NI#.&:T!YH.W-$=FQR2H
MY>++;RFT_]K:^9" ;T^6BW35?+K"OX,I7=G*Z!T.7A"D231(,V&0(%@B9T+!
MO(P^Z@$'N/)8F2-S9&2\\H7,+DPU#_Z5:>8@:7OLW/)\N3J\^C+$RE5=_NKV
MS&647 <)'I>.+$++24"$% HQ;1UC45A">NTH[M/P')DIDZ"6<:?E1MB5QWWG
M9NKK*U33E6/OPN(D?C*7W?LO3RFI-,$23+%!'"N#C'($Q8*!069BC$2 VG5V
M=R:)[Y%)TT.8+:BAGI]^"LWYZ@*7];9CU^;^AN0E,9PY[32TCAE4"(R1+[A*
M^PV!85IPSP;XN'D(,NWV_CBHY3LGNLM;!).?Y.OQKD#&$WV;#UB\#TU5@Z'J
MFK1V_C)<_]^Y6]&_F)( 4Z(D#!6* F^\U*A(E,1<1R5<(83O%;(^#2(I3AB:
M\;ZI/U?0![]<_=JFV,#7U1SX _/ML5M4GU<CK ./_H646 G"(G;(%8:"NZ@I
MDHYX9(+G/A 5PY! S#Q+*=-U?YT1UVS+;^9J/?ZO;TAKVV5232_JMO-L;5>V
MTF@:G><%,A);Q#7X"L[:@!@+F&IEBX*.<Q 134BCJ7KW_DK=N$#FI\W+8!=/
M9\V#7"6%H4BLLLC%%)]J(@Q"9CC2LL"%8T7P<9Q3AS\4:<; ,9][?O%5[AOS
M[9%M\4X_O7<I)65,<:$%BEI1\$*$02' C\@#)]AY2\D 153\4)R:%M=<''L$
MK/5=5<,,I@V%E)I'(0N>_(P40P3^!0J%I<BP=$R'Z$#X $<^S_;#O@VF<7#-
M/?-]JH\=H-6$1\]R]9@(MQ=2:IW.!P>**(_@)&.P 2*/"BEAG-,D$BD&,&R_
MQM3@GG]D7IP$UCVKL/6]_<-4V(9"2BVY*:*Q2$8&(YH(P,19,!V(M81)K0L2
M#WV/;-\J;!Q<\P4*7S3!5>OKUR]F8=5G<W_[=:O.@.'MV4N+O0@*O!::0NF9
M+7R"0"(1&&%.&$*+<=16?JTUN+,?!!1/@F=&??5M>;Y;)7U+5RIKHI*>(QYI
M1-)C#ZZMXNFH!67:FH =/W3#*1,_A@*7_<:0WQK [67]I4N)/$Q<>LZBQEPA
MIU;;.N"TPAQ=(%5X3DT@FAW^1)2)$J.@EXL7_S#5O$W<#>W)_-5E@F%9M6?)
M#+M>P.B@R=:\I76$<^<4:,) $ ]&IG/-#&FPXKS#G(IBP%5X;*_V\=BTF0+-
M;%'#Z=6O7\!^\VEG.,S;;6;*Y@PE*RA3RBM$E8-QDJ[8$%+#O*IM(!1K+NV
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MO?-L0X]+D^F0RQ>&=6UM;=<:]U*6S KO(\=(4%Z@HF :14,U4C!5RB@9BWS
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M"FV^A;1[C7F75@;3$F'WJL2$"R39%O2^OON2LZX];\I]E:-[9>=VLM)P**S
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MI[,R-K:;8,UZBX0N_0QH@UY2$^D%T' +KG7-KTGN;9?M_-P:!.K&M+J\B?/
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M[)<DV[E76L^(4 ! 8Z51GKF'N < S?.S>EO'].R6-$3F/)9?5\U,)YN"1&6
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MKXYT[4T=.Z&/**R@E;0*6A3<(DJ<D7Z+7%@ -<\>Z*T\<-=#2(]P#9B<OQH
MR^.*U51X<?6(SKNSSW:G[)_24Z28)-!B3*1$4GE,#=85'HZ1Y@4^>RLHW,,H
MTB]H+<:2["[+JW.KDYN_!I"#S@=7FX?:1%)@" %6G&H )8*<8/ZP5G;-\XE[
M*P#<_5C1&3S-UQ6[*Y?O74_L?CPR !$A#()4"U1>3,WD5EJ/8(OD@=Y*\W:^
MD.@$FN'<PSS]%I?GU'V<KAW9BZN'7WY(XZ^K6Z?71](_9H&85T6R4-<!VB+X
M-K/RSHX\GAWT'KMY1>2Q"M.D((RR\GP, (^B:MC[%F527T/H\<QP#D_(7X/
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MD4* 2X>$ A01(J&%1%;8: 6:;Q:AUQ"3/3^B#VSKMP32Y;K$ROOY59;?KNI
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MOB0%@)<JA5KPBH,3HB#'UWS401+_!S(QA D>O4"ED14S%*WCQP5T"+1#B]U
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M8&2X#HE,%U,*VX?@/-]V7*& K,ZJYNA\>%1*<)]4';&<VZ&3<"JXZWF \7^
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M*?M%O!;3&$FN^ 1&/TUBZM+B>:LO@N<<%3TT]Q$Y/>(RC,QY*,M ']Z^]J:
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M)C;M)(U8H2VT<JS$HF[9*=%5I[J6[(=DCU-P.5D-NYPKS*,3*[CHW'):_7
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MV>HZV5:/)A91EN\_%J7K9+7P,?6I#TEI-<!V$/D&AMU\FE"N^W@Z[6L.K#7
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MKW&>QYMM/Y0%,7V;NJ8?1IY!PL@-?1.U$"+B0>[R::H-:Y:^/5SP6XT7K!O
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M9]P"6%FIK5_GZ3(IC5>_6U@>MBW+\"T2((A1B +HM_:@CX36S^6MZ-[L8R#
M<_FW7^*B_(%AJR2O @S2>I0RZ5MEZW6<%^ YR>N_%55!>:(YA6\4C@6UKJ:Q
M!G4&*EA,[&JA&UG;CO'3)V>#.9V)@@WWXZUH*6*&?Y,O6R;)JHA*W]K<Y.KA
M8"JZ<+'K4M,+[,CV0QJ87@2[2:AGB57L&6Y-^]9?#1"PM@9%L\^^E%YQ4D O
M[[;@F,R*[A >DGJ8 1^N58V]6WB"K]Z-0U5<ST/%%/KS;CM1+5/<JA:_5.7.
MFMEN:SK,BFVQ,)URBFM2Q[<M2F%$('2-UJ1C(C%!&V)(MY;5V/8SS;0=><L2
MGJ".#2*44\+&XE)0O1I8^T6P3L$J:"/K5@])?9*E@MN9J)425]X*E3I^^*^*
ME6E%<KN-M]5)BZY>FF%#TS1,*R30#Z!E^A &Q$ E4T9DF)AWVB+[]?H&4HT(
M=) FK/+W(34]PV<HF?,8.8.]>'>[3 4KO./EZCG)8U;1M#9[P6Z5$].P3,N,
M;#-PB0=]*\1N;0G:$-I"52!DOE\H@HM?M+RD=^#BZO861#=7G\'5-;U!=^=7
ME[?C#I</B.D9*D-HG,<P&>1!IJY3B8:3,D5,BBW]]IQLBF1A8DH]:H0P<$S?
MQR'%GMU:"8EOM?4/^ :'Z+=S#8S7]0X$]U$N[^@-O;T#]&_7]/*6G@$V6- E
M 5=W/](;T<('@MSQAF -I$F&WAH):*",'6]?\= ;9^48FX=P2*-_%U>'L, K
M&%&6)^GC)MSE>;)9OAS<*O@A3C=,J7[:U/6KD]7"=SV+G5^+7.R9A#C$A+B%
MX,% J)2;4L.:Y] _7=Y0=''^ORD!T=4-/?_A$H0_W=S0R_#OX#L6FO\,?D#G
MEY7ZB&F.6OKY!&DRYL74JH$)6IS@ "A@2$OJ2ZQ_/@-[N.,JF@B1/7*GI3WF
MH85Z7,M&Z,]"=<B7Y=<7"4GJ_YYONM?FKAZNR_Z6E,!6U8I"F&V^EO)30HN2
M>,L>H:/$Q;8=!@8-,30I]!UDM7A0:',M0^I'H?M0WH_H\@<*SB]!A,YOP,_H
MXB<*KB) Z,WYS^5DYV<*_HIN;M!E.1$Z1_C\XOSN[T+EO74V4+_HSJMMA)=J
M*KB@Q0W.-X>/9EX]@ Y\LRBZAP\:_+-I)Z&"[3-I+[E;(-^=7X9EPG)+_UR.
MH/JG]V/K^H9&M,QA"+B]NPK_ X17ES_3F]OSJ_*#%-W]=$,'5X.7)_&#:#E>
MP\S@$LHX?F9C=WFQJ0F+W@4+WTEQM:'?V/K)+BV^L/%P]4"2^^W"-(GCFWX8
M6 1%/C*\\A>M7>Q'CLA\9+@US4&R6@(L1R=%-Q=_!_1O=^>7/_QT?OOC9UJ&
MQ2I88L')AP*"^68<XW(K%N0.9A*@C%JOT;'=/H9OW'G%2;IZ)A/JJ)['#$*A
M/YFN3BFSXW<7?VL6=G"R21[2[<)U+.B5TQ+'(JY'"<3418TU!Y'(E"I5*V=*
M8MU6HD[M]<W5S^=UPG%U ^[0W^CQ+0VU3(KLG6IB;\C>:0FI7<(%WS6HCI^7
MU;AY^HZ;DYNG\FS.0XX&>_'AYNE05OC?N=T>[$"9'L$>--@;NA1C#_F69[8V
M')_:(MNF8M\\TH;IV$^@;KFV1N6HFD?WE\3^[F52>09XNSJ-\TT9T8OVX#2.
MBW2)-BN2KG=EN%H8=D2#R**11UUJ>8X9!F%KU0M"2^Q^_%!K(@-"ZK9\=X;@
MFMZ VQ_1#>VJ-E=80;Q9@56-MKJ0\=,MD;Z,,9A[OO@\)NEB<;I%MK^,<79
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M3#^ HC4^-^%WJ@-S(U_>'9&;,V1?>[B9?V^G #@C$ &: 8K2G*5AS*)^@PA
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MLNG-5Y]:J9LE*,ER)K(.#E&*.4H)[$?$##&@-$5V9<MS'N@1RL?X'CN,P7P
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M_=!DIX=*=&GIX>#E.WJHS\9T]-  ^QMZ:,K >WJX+*O95?EEOF+U5M['*^?
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M%M\=,'/UM>!.07['H4U/?]]DS$2 +:C34.!Q*#238+W&IR:]1_T]IKWV!$U
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M7M:+=3G?E%7]^B0NC7 *\@2D.45A&-&,AL-8'K)8_2D UX8]JW,/+:CJ[L8
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MG03-56(<.U[^TF7G22"A[[7Y(I#N[#Z,8D^IU$E$72?8L2/K/^VZB+##E*Q
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M^-V__UO_B?C/Y_FF_/=_^W]02P,$%     @ ATFK2A6B8#P^6P  '7L$ !4
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M2R6^/&L0J'%"(&HUM49)A+VR&[!TE/6R7./M\*4.HIWSY=!ERO,/0ZKW(25
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M _O*ZX]#>G\.D%!6$ZV5Q-A3O9&*VCKTZ&'03),[2VTPST.12N6T=C4)5DK
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M,2YN4G+=/^>W9G"?SP?CN.S^;?^V5;F#X(B*6&GG**"I^*I6'*PDHI@872O
MZ6TPYC0%%QV@W5F&@&,VL"W331LBF&=" &.!EI(Z+4NIXNF@SM;5PX<N36Y=
MM<$\#T4.;E3;/@]*84&9(DH+K+A.%2DVDAE#+ZP*6QW5[F7)26B>[B'],\KZ
MX(O%=)YEDR_9]"Z%31WPENYI$QB!2G)-/6,*DE3,E*)RW-8P?<DL.%9U13N@
MGDP&GT]G\V787%SZ1FGYVT^$7=\'31SU%G,&E>!2>8Z]V\P$!BXM T%C)&@(
MT-/?VV;#8C(Z@@$[&P3/D+7 <48)Y=3&Y4_"<L0<XCH7I#UTG3='@:80/7U'
MN,VGQU!@U_>!Q&,93_7302H/$/_TGI?CQ<[4"<7JH<>CP9V@&4!/)L#_7HP?
MDIGXST'^+9ON5_ZV;P./!RQ!$>8.(@*=PNF8OAXGU+A.AJ0>GA>:4WP#8)Z^
M]2?#X_:8O7]7@^"8$09J:S350$/A!-B,F+!:SRSZ^!R]N<V_(43/$T[UOD(.
MP1TM@L(LKFU:6P:)]I@)+U@IGZ*RVSHZ;\K!T RBYW2-KY-GZ6(Z+?[,)S=F
M<!__9?ZPAT;'=!.0EQ!BB>.L@4@"Y RC)1+^XL)^:_.A@L>\(:C/LTQ%(5+!
M^L76%\2'F@243EM&<@$II@9[1*@J)92TEDG;PW-MTV1J"-;S$.?=) *>S>8I
M$'Y9$6#TF :F,I7V=1(T58@S[2$4W@-LG)-B,WV,JN,_[>&)N5UR-0CT>>BF
M![-\]CDJ;3"ZFCQ]S $KDVUW%\%#!UE$&2#)'<.6<:X>/=6PS@FMAT?S=JG6
M&,SG7]?<]74V3+D?:BYM6_H)TELOE]F,0'HK3I'E&P\F!K!.DK(>.@6Z6]WJ
M8WTF0RP[V@[+-O:"M)X1H0" QDJC/'./GM"HK$L^+S9NAIV(ZGE8L\I>FP_7
MR:[2-=E,#\;CHIB4/RIT]G&0;\M=7+?+@"&F#A"B8<3;Q[F%Y.: HY6KP[L>
M)LAKEW>MP7ZR"_38\<V+K\OQK1?>XOKC-)\,\_O!> OW&OX-@6L""(?*.@@1
M,UPR;4M,F/5U3J(]3+C7%!7/JX6NELS?!OED]KZ8S;+9U<1]G^>3FT4^NTVR
M7%TGZ?>LC0?;!H>\$0"H:,*F.6E3N>"-<4% '6=M]?Q\<L6\27:3SG9?W@P!
MVX*YL_0+ZTS+JT&^F\T6@\DPVY5LMD*K@+0A&"(.F%-:2L8XQ!LY&:U3"JB/
M&?B:)E)ST#:T;YKB6S893.;KLBUF,+N-RVD:5+5=<7?[8+&%0CN@"$9(V'BZ
MUJ7?AH X6^I0Y8)]^6V"W!!ION3#/^(2&,\BZTVV&E=>-0L(,^SCT#4P""I*
M#,+E&89X7N^VYX(]]"U@VS@SCJ5$B&.RQE N@/..20R8+Y<_@H2L%8EZP0[U
M)D$]F01I^,6+>\=WD^$T&\RR?%+ELOB4;H)!DD--(=>& 8!,*BA92H<=J1.W
M"B_8,=X!U@TM)ZDHUV21K8MT[4LD?:A=H)0Y%NTJ XV$&&$112C'SW2]ZK\7
M[-%N ]R&R/'D)J=X=I/S*1LMEMFOJY'E<#_!6:1('(_4B'@%C:/>E_(92D$=
M\ERP"[L+L.N0*7_J6%J=S/+)_\DGHZ<W-GM(5*E]4''S-<9:J)DC@B+G-Z]!
MB"&@5HJ*"_9#MPER4T[G)T[(#XL4^UE<ER?\BD[E/3T$AY%@R I,  '48@\W
M@0_$RGK)47\PKW%S,#=%G6EVOQK XY%M<),M7Q1!]'LQF=]6I5"%G@+URLIT
M!C288V&\Y'@S/81%M7PQ/2S3TB:5FH>[74K]%O?:B/C\=C IQ_<^F\W2?R/2
M -$J]!^(8P"G!+3(2R<]8'%]?K*EUPE@0A?L-3ZG$CHC9=,DW,CKJ#0.0"2\
ML<@YH[12&WFUJI44\L?R/[<&>L.7&._S>"0=Y?.'+['Q[+88;PLK.:I]$ Y:
M3AV#3GF(:)0-;59R!GFME>O'\E W!G+#I#&+Z31[,JSC*/.R=7":H@B(U*ED
M#^  ,+:Q)F4\VM8AS(_EQFX(XK;6F$_9. 4SS(MT'3>8C-(?+O[;M\&X^OGO
MV%Z#T89)2CW" %,+!//*E+)K"VOEO;]TEW>GT+=..S4<ICC0"C4\3^\Q0&X
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MG!,Q[^H0];)"6T)JGL>3P"-HRQ)#^ZI"5>XC4"Q)W*LACD=4!20G\2RY,?0
MK.-X[F&-L@9YUS;4#6487 \HK;!/;E?*= $[HUB/Z",  )6T"EH4S4!*G)%^
M@QS'L$X$1@]KB36]=+4(=8=/[)8+;\I.46[?5]=/IL+V(-CM#^^.Z2DH)@FT
M&!,ID50>4X-UB8=CI$Z-CQY6'VMA]6H7\!IK6'%?3,L4)\/;?TSR>91YKT=@
M7YL@!8808,6I!E BR GFC_X,5^<Y1@^KA36_1C4&[>GGM^WE%7>>V[9_'@Q
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MM=MODQ:C5MR+]ZAMET+M"\AJ9M(D(^!SFY<@-8D)VB.JC%;6<.&<5$H]F,O
M90W0*?":N:=0:URN T-;]Q +"",( $200F:!HDY1LK>O!<T)'+R%BY:+JWE'
M;:;.4X-B8/CBS)LZ9__%H'@Y*@+@$@JO+328*L^X9/;A(@#XG&%=P[[4Z1R(
MG2E!;\#X3#2_*T2>24JPQA#)B#=  LT-X$3NMT<JL_K]%^CHO258-JL)O<%F
MM<C.D7D6(4$QKR%0 &*@J16($;/?*17D.3D0!7J%;PF73>I!,:@<C!=IO ;8
M*L@@@9H)%KV)*K.+&0YS\BR&?_'6.18[48*^@+ _?;^PCTZ[<9'7$@-/M815
M[8AE,*]\[FP0OE_KM2S.C@MKMC.&5X])>B^<"8!I1#& EGE&,!?":;$KCM(4
M<-MAX<PK@Z4/DY;4.,IYMOZQ%?)U%*N.-/UU:L?+?G@P#% ./&38>RR$,DSK
MBG.69 7"AE<04UO-CK>RMN7TTUV>#T9S/:;Y2:'R3RGNQ=\1@/ (&YA:;5D<
MA4*PJOIQ&^*E&E8@MV7][5I<K1ZVFYO5Y-LF/L-]C[^N%NL.S]DC8NJ<H"]]
M)7B*S'9@(> &2,<4P]Q2(N*_+>*FEL_8SBIK'7DO?2<XAI"PQ&)D4^=6JI"2
M:9U<<22@&-A)EB_NXS/J0HQM%[-5F?EL.I]]GHU'T048CQ>;:##/IQ\7=[/X
ME>Y0_)24&CA^^4M!$D@YDM'Y%X(Q+)RPE>.OJ'>UTN :0O(I_M>"=:T'! BI
M AISSZRAQ$&IL:\X (#+B7\5B/%+J,(QRIO@<WF0OQHMEZ/D--\WFAC.%@ I
MU)PZ@3AF"!+L.6-. 2BI-U*16A<QS:ST4Q1L5(0O:GYK)]\G=XN_D^V9VIS,
M5Q/WS_ANL^UN,OZVF46$?9A_7"ZB8%?)9#W!BHRG!AAU%0EJ+?2:(^"%8V+'
M*RN9R(G3]6NSJ*TTBZZ87]X.,CCC02LH/;;<.DD\PU( RYBQFD"(1=S>N]LY
MKB;_.Z![N9C'/\?WEY?;5?RX_UW'C#CW44$8Z'1R11G'.+K&$0V8&:<)XD [
MWFI:9J=[1&WU6+3*\1H;P^Z#]"M%)'[YS[]02P$"% ,4    " "'2:M*:S$'
M_2GI  "L+0T $0              @ $     86QI;2TR,#$W,#,S,2YX;6Q0
M2P$"% ,4    " "'2:M*L:W)ZJ</  ">I0  $0              @ %8Z0
M86QI;2TR,#$W,#,S,2YX<V102P$"% ,4    " "'2:M*5.QO>6X8  !?! $
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E,#$W,#,S,5]P<F4N>&UL4$L%!@     &  8 B@$  'U  @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
